

(19)



(11)

EP 1 476 541 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
16.07.2008 Bulletin 2008/29

(21) Application number: **03729693.6**

(22) Date of filing: **21.01.2003**

(51) Int Cl.:
C12N 5/10 ^(2006.01) **C12N 15/19** ^(2006.01)
C12N 15/62 ^(2006.01) **C12N 15/63** ^(2006.01)
C07K 14/52 ^(2006.01) **C07K 16/24** ^(2006.01)
G01N 33/53 ^(2006.01) **G01N 33/567** ^(2006.01)
A61K 38/19 ^(2006.01) **A61K 39/395** ^(2006.01)
C07K 14/54 ^(2006.01)

(86) International application number:
PCT/US2003/001984

(87) International publication number:
WO 2003/060090 (24.07.2003 Gazette 2003/30)

(54) **CYTOKINE (ZCYTOR17 LIGAND)**
 ZYTOKIN (ZCYTOR17-LIGAND)
 CYTOKINE (LIGAND ZCYTOR17)

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

(30) Priority: **18.01.2002 US 350325 P**
25.04.2002 US 375323 P
19.12.2002 US 435315 P

(43) Date of publication of application:
17.11.2004 Bulletin 2004/47

(60) Divisional application:
08102636.1

(73) Proprietor: **ZymoGenetics, Inc.**
Seattle, WA 98102 (US)

(72) Inventors:
 • **SPRECHER, Cindy A.**
Hereford, AZ 85615 (US)
 • **KUIJPER, Joseph, L.**
Kenmore, WA 98028 (US)
 • **DASOVICH, Maria M.**
Seattle, WA 98144 (US)
 • **GRANT, Francis, J.**
Seattle, WA 98115 (US)
 • **HAMMOND, Angela K.**
Kirkland, WA 98033 (US)
 • **NOVAK, Julia, E.**
Suquamish, WA 98392-9740 (US)
 • **GROSS, Jane A.**
Seattle, WA 98115 (US)

• **DILLON, Stacey, R.**
Seattle, WA 98115 (US)

(74) Representative: **MacLean, Martin Robert et al**
Mathys & Squire LLP
120 Holborn
London EC1N 2SQ (GB)

(56) References cited:
US-A- 5 925 735

• **DATABASE EMBL [Online] 16 April 2000**
(2000-04-16), "Homo sapiens 12 BAC
RP11-512M8 (Roswell Park Cancer Institute
Human BAC Library) complete sequence."
XP002353116 retrieved from EBI accession no.
EM_HUM:AC048338 Database accession no.
AC048338
 • **DATABASE EMBL [Online] 8 February 2001**
(2001-02-08), "Mus musculus adult male testis
cDNA, RIKEN full-length enriched library, clone:
1700013B14 product:hypothetical protein, full
insert sequence." XP002353117 retrieved from
EBI accession no. EM_PRO:AK005939 Database
accession no. AK005939
 • **DATABASE EMBL [Online] 18 April 1997**
(1997-04-18), "EST95118 Activated T-cells I Homo
sapiens cDNA 5' end." XP002353118 retrieved
from EBI accession no. EM_EST:HSZZ87105
Database accession no. AA381907

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 476 541 B1

- **DILLON STACEY R ET AL: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice." NATURE IMMUNOLOGY. JUL 2004, vol. 5, no. 7, July 2004 (2004-07), pages 752-760, XP002353112 ISSN: 1529-2908**

Description

BACKGROUND OF THE INVENTION

5 **[0001]** Proliferation and differentiation of cells of multicellular organisms are controlled by hormones and polypeptide growth factors. These diffusible molecules allow cells to communicate with each other and act in concert to form cells, tissues and organs, and to repair damaged tissue. Examples of hormones and growth factors include the steroid hormones (e.g. estrogen, testosterone), parathyroid hormone, follicle stimulating hormone, the interleukins, platelet derived growth factor (PDGF), epidermal growth factor (EGF), granulocyte-macrophage colony stimulating factor (GM-CSF), erythropoietin (EPO) and calcitonin.

10 **[0002]** Hormones and growth factors influence cellular metabolism by binding to receptors. Receptors may be integral membrane proteins that are linked to signaling pathways within the cell, such as second messenger systems. Other classes of receptors are soluble molecules, such as the transcription factors.

15 **[0003]** Cytokines generally stimulate proliferation or differentiation of cells of the hematopoietic lineage or participate in the immune and inflammatory response mechanisms of the body. Examples of cytokines which affect hematopoiesis are erythropoietin (EPO), which stimulates the development of red blood cells; thrombopoietin (TPO), which stimulates development of cells of the megakaryocyte lineage; and granulocyte-colony stimulating factor (G-CSF), which stimulates development of neutrophils. These cytokines are useful in restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer.

20 **[0004]** The interleukins are a family of cytokines that mediate immunological responses, including inflammation. The interleukins mediate a variety of inflammatory pathologies. Central to an immune response are T cells, which produce many cytokines and adaptive immunity to antigens. Cytokines produced by T cells have been classified as type 1 and type 2 (Kelso, A. Immun. Cell Biol. 76:300-317, 1998). Type 1 cytokines include IL-2, IFN- γ , LT- α , and are involved in inflammatory responses, viral immunity, intracellular parasite immunity and allograft rejection. Type 2 cytokines include IL-4, IL-5, IL-6, IL-10 and IL-13, and are involved in humoral responses, helminth immunity and allergic response. Shared cytokines between Type 1 and 2 include IL-3, GM-CSF and TNF- α . There is some evidence to suggest that Type 1 and Type 2 producing T cell populations preferentially migrate into different types of inflamed tissue.

25 **[0005]** Mature T cells may be activated, i.e., by an antigen or other stimulus, to produce, for example, cytokines, biochemical signaling molecules, or receptors that further influence the fate of the T cell population.

30 **[0006]** B cells can be activated via receptors on their cell surface including B cell receptor and other accessory molecules to perform accessory cell functions, such as production of cytokines.

[0007] Monocytes/macrophages and T-cells can be activated by receptors on their cell surface and play a central role in the immune response by presenting antigen to lymphocytes and also act as accessory cells to lymphocytes by secreting numerous cytokines.

35 **[0008]** Natural killer (NK) cells have a common progenitor cell with T cells and B cells, and play a role in immune surveillance. NK cells, which comprise up to 15% of blood lymphocytes, do not express antigen receptors, and therefore do not use MHC recognition as requirement for binding to a target cell. NK cells are involved in the recognition and killing of certain tumor cells and virally infected cells. *In vivo*, NK cells are believed to require activation, however, *in vitro*, NK cells have been shown to kill some types of tumor cells without activation.

40 **[0009]** Database EMBL [Online] 16 April 2000, XP002353116 retrieved from EBI Acc. No. EM_HUM:AC048338, provides the complete *Homo sapiens* 12 BAC RP11-512M8 sequence.

[0010] Database EMBL [Online] 8 February 2001, XP002353117 retrieved from EBI Acc. No. EM_PRO:AK005939, provides *Mus musculus* adult male testis cDNA clone: 1700013B14.

45 **[0011]** The demonstrated *in vivo* activities of the cytokine family illustrate the enormous clinical potential of, and need for other cytokines, cytokine agonists, and cytokine antagonists. The present invention addresses these needs by providing a new cytokine that stimulates cells of the hematopoietic cell lineage, as well as related compositions and methods.

[0012] The present invention provides an isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to the sequence of amino acid residues selected from the group of: (a) the polypeptide shown from residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO:2; (b) the polypeptide shown from residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2; (c) the polypeptide shown from residues 24 (Ser) to 164 (Thr) as shown in SEQ ID NO: 2; and (d) the polypeptide shown from residues 1 (Met) to 164 (Thr) as shown in SEQ ID NO:2.

[0013] The term zcytor17lig, when used in the present application, is referring to the polypeptide and nucleic acid sequences as defined in the claims.

55 BRIEF DESCRIPTION OF THE DRAWINGS

[0014]

Figure 1 is an illustration of a multiple alignment of human zcytor17lig (SEQ ID NO:2) (zcytor17lig), mouse zcytor17lig (SEQ ID NO:11) (mzcytor17lig), mouse IL-3 (mIL-3) (SEQ ID NO:100), and human IL-3 (hIL-3) (SEQ ID NO: 102).
Figure 2 is an illustration of a multiple alignment of human zcytor17lig (SEQ ID NO:2) (zcytor17lig), and mouse zcytor17lig (SEQ ID NO:11) (mzcytor17lig).

Figure 3 is a Hopp/Woods hydrophilicity plot of human zcytor17lig (SEQ ID NO:2).

DETAILED DESCRIPTION OF THE INVENTION

[0015] Prior to setting forth the invention in detail, it may be helpful to the understanding thereof to define the following terms:

[0016] The term "affinity tag" is used herein to denote a polypeptide segment that can be attached to a second polypeptide to provide for purification or detection of the second polypeptide or provide sites for attachment of the second polypeptide to a substrate. In principal, any peptide or protein for which an antibody or other specific binding agent is available can be used as an affinity tag. Affinity tags include a polyhistidine tract, protein A (Nilsson et al., EMBO J. 4: 1075, 1985; Nilsson et al., Methods Enzymol. 198:3, 1991), glutathione S transferase (Smith and Johnson, Gene 67: 31, 1988), Glu-Glu affinity tag (Grussenmeyer et al., Proc. Natl. Acad. Sci. USA 82:7952-4, 1985), substance P, Flag™ peptide (Hopp et al., Biotechnology 6:1204-10, 1988), streptavidin binding peptide, or other antigenic epitope or binding domain. See, in general, Ford et al., Protein Expression and Purification 2: 95-107, 1991. DNAs encoding affinity tags are available from commercial suppliers (e.g., Pharmacia Biotech, Piscataway, NJ).

[0017] The term "allelic variant" is used herein to denote any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

[0018] The terms "amino-terminal" and "carboxyl-terminal" are used herein to denote positions within polypeptides. Where the context allows, these terms are used with reference to a particular sequence or portion of a polypeptide to denote proximity or relative position. For example, a certain sequence positioned carboxyl-terminal to a reference sequence within a polypeptide is located proximal to the carboxyl terminus of the reference sequence, but is not necessarily at the carboxyl terminus of the complete polypeptide.

[0019] The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair. Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of $<10^9$ M⁻¹.

[0020] The term "complements of a polynucleotide molecule" denotes a polynucleotide molecule having a complementary base sequence and reverse orientation as compared to a reference sequence. For example, the sequence 5' ATGCACGGG 3' is complementary to 5' CCCGTGCAT 3'.

[0021] The term "contig" denotes a polynucleotide that has a contiguous stretch of identical or complementary sequence to another polynucleotide. Contiguous sequences are said to "overlap" a given stretch of polynucleotide sequence either in their entirety or along a partial stretch of the polynucleotide. For example, representative contigs to the polynucleotide sequence 5'-ATGGCTTAGCTT-3' are 5'-TAGCTTgagctt-3' and 3'-gtcgcacTACCGA-5'.

[0022] The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more degenerate codons (as compared to a reference polynucleotide molecule that encodes a polypeptide). Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue (i.e., GAU and GAC triplets each encode Asp).

[0023] The term "expression vector" is used to denote a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may also include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

[0024] The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, Nature 316:774-78, 1985).

[0025] An "isolated" polypeptide or protein is a polypeptide or protein that is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e., greater than 95% pure, more preferably greater than 99% pure. When used in this context, the term "isolated" does not exclude the presence of the same polypeptide in alternative physical forms, such as dimers or alternatively glycosylated or derivatized forms.

[0026] The term "neoplastic", when referring to cells, indicates cells undergoing new and abnormal proliferation, particularly in a tissue where the proliferation is uncontrolled and progressive, resulting in a neoplasm. The neoplastic cells can be either malignant, i.e., invasive and metastatic, or benign.

[0027] The term "operably linked", when referring to DNA segments, indicates that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates in the promoter and proceeds through the coding segment to the terminator.

[0028] The term "ortholog" denotes a polypeptide or protein obtained from one species that is the functional counterpart of a polypeptide or protein from a different species. Sequence differences among orthologs are the result of speciation.

[0029] "Paralogs" are distinct but structurally related proteins made by an organism. Paralogs are believed to arise through gene duplication. For example, α -globin, β -globin, and myoglobin are paralogs of each other.

[0030] A "polynucleotide" is a single- or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized *in vitro*, or prepared from a combination of natural and synthetic molecules. Sizes of polynucleotides are expressed as base pairs (abbreviated "bp"), nucleotides ("nt"), or kilobases ("kb"). Where the context allows, the latter two terms may describe polynucleotides that are single-stranded or double-stranded. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term "base pairs". It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide may differ slightly in length and that the ends thereof may be staggered as a result of enzymatic cleavage; thus all nucleotides within a double-stranded polynucleotide molecule may not be paired.

[0031] A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or synthetically. Polypeptides of less than about 10 amino acid residues are commonly referred to as "peptides".

[0032] The term "promoter" is used herein for its art-recognized meaning to denote a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the 5' non-coding regions of genes.

[0033] A "protein" is a macromolecule comprising one or more polypeptide chains. A protein may also comprise non-peptidic components, such as carbohydrate groups. Carbohydrates and other non-peptidic substituents may be added to a protein by the cell in which the protein is produced, and will vary with the type of cell. Proteins are defined herein in terms of their amino acid backbone structures; substituents such as carbohydrate groups are generally not specified, but may be present nonetheless.

[0034] The term "receptor" denotes a cell-associated protein that binds to a bioactive molecule (i.e., a ligand) and mediates the effect of the ligand on the cell. Membrane-bound receptors are characterized by a multi-peptide structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric (e.g., thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric (e.g., PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).

[0035] The term "secretory signal sequence" denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger polypeptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

[0036] The term "splice variant" is used herein to denote alternative forms of RNA transcribed from a gene. Splice variation arises naturally through use of alternative splicing sites within a transcribed RNA molecule, or less commonly between separately transcribed RNA molecules, and may result in several mRNAs transcribed from the same gene. Splice variants may encode polypeptides having altered amino acid sequence. The term splice variant is also used herein to denote a protein encoded by a splice variant of an mRNA transcribed from a gene.

[0037] Molecular weights and lengths of polymers determined by imprecise analytical methods (e.g., gel electrophoresis) will be understood to be approximate values. When such a value is expressed as "about" X or "approximately" X, the stated value of X will be understood to be accurate to $\pm 10\%$.

[0038] All references cited herein are incorporated by reference in their entirety.

[0039] The present invention is based in part upon the discovery of a novel DNA sequence that encodes a protein having the structure of a four-helical-bundle cytokine. Through processes of cloning, and proliferation assays described in detail herein, a polynucleotide sequence encoding a novel ligand polypeptide has been identified that is a ligand with high specificity for the receptor zcytor17 (SEQ ID NO:5) and at least one additional subunit comprising OncostatinM receptor beta (OSMRbeta) (SEQ ID NO:7) and WSX-1 (SEQ ID NO:9). This polypeptide ligand, designated zcytor17lig, was isolated from a cDNA library generated from activated human peripheral blood cells (hPBCs), which were selected for CD3. CD3 is a cell surface marker unique to cells of lymphoid origin, particularly T cells.

[0040] In the examples which follow, a cell line that is dependent on the OSMRbeta and zcytor17 receptor linked pathway or dependent on the OSMRbeta and WSX-1 and the zcytor17 receptor-linked pathway for survival and growth in the absence of other growth factors was used to screen for a source of the cDNA encoding the zcytor17lig. The preferred growth factor-dependent cell line that was used for transfection and expression of zcytor17 receptor was BaF3 (Palacios and Steinmetz, Cell 41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986). However, other growth factor-dependent cell lines, such as FDC-P1 (Hapel et al., Blood 64: 786-790, 1984), and MO7e (Kiss et al., Leukemia 7: 235-240, 1993) are suitable for this purpose.

[0041] The amino acid sequence for the OSMR, WSX-1 and zcytor17 receptors indicated that the encoded receptors belonged to the Class I cytokine receptor subfamily that includes, but is not limited to, the receptors for IL-2, IL-4, IL-7, Lif, IL-12, IL-15, EPO, TPO, GM-CSF and G-CSF (for a review see, Cosman, "The Hematopoietin Receptor Superfamily" in Cytokine 5(2): 95-106, 1993). The zcytor17 receptor is fully described in commonly-owned PCT Patent Application No. US01/20484 (WIPO publication No. WO 02/00721), and WSX-1 is fully described in US Patent No. 5,925,735. Analysis of the tissue distribution of the mRNA of the zcytor17 receptor revealed expression in activated CD4+ and CD8+ T-cell subsets, CD14+ monocytes, and weaker expression in CD19+ B-cells. Moreover, the mRNA was present in both resting or activated monocytic cell lines THP-1 (ATCC No. TIB-202), U937 (ATCC No. CRL-1593.2) and HL60 (ATCC No. CCL-240).

[0042] The expression of WSX-1 is strongest in thymus, spleen, PBL, and lymph node, as well as increased expression observed for activated T-cells. The tissue distribution for OSMRbeta is described as very broad. The tissue distribution of these three receptors suggests that a target for the predicted Zcytor17lig is hematopoietic lineage cells, in particular T-cells, monocytes/macrophages and lymphoid progenitor cells and lymphoid cells. Other known four-helical-bundle cytokines that act on lymphoid cells include IL-2, IL-4, IL-7, and IL-15. For a review of four-helical-bundle cytokines, see, Nicola et al., Advances in Protein Chemistry 52:1-65, 1999 and Kelso, A., Immunol. Cell Biol. 76:300-317, 1998.

[0043] Conditioned media (CM) from CD3+ selected, PMA/Ionomycin-stimulated human peripheral blood cells supported the growth of BaF3 cells that expressed the zcytor17 receptor, OSMR beta and WSX-1 receptor and were otherwise dependent on IL-3. Conditioned media from cells that were not: 1) PMA/Ionomycin-stimulated; or were not: 2) CD3 selected (with or without PMA/Ionomycin stimulation) did not support the growth of BaF3 cells expressing zcytor17, OSMRbeta and WSX-1 (BaF3/zcytor17/WSX-1/OSMRbeta) receptor-expressing cells. Control experiments demonstrated that this proliferative activity was not attributable to other known growth factors, and that the ability of such conditioned media to stimulate proliferation of zcytor17/WSX-1/OSMRbeta receptor-expressing cells could be neutralized by a soluble form of the zcytor17 receptor.

[0044] Conditioned-media from CD3+ selected cells activated with PMA/Ionomycin also supported growth of BaF3 cells that expressed the zcytor17 receptor and OSMRbeta receptor (zcytor17/OSMRbeta), while BaF3 cells expressing only zcytor17 receptor and WSX-1 receptor (zcytor17/WSX-1), or containing only the OSMRbeta receptor, were not stimulated by this conditioned-media.

[0045] Proliferation of zcytor17/WSX-1/OSMRbeta receptor-expressing BaF3 cells exposed to CM from CD3+ selected, PMA/Ionomycin-stimulated human peripheral blood cells were identified by visual inspection of the cultures and/or by proliferation assay. Many suitable proliferation assays are known in the art, and include assays for reduction of a dye such as AlamarBlue™ (AccuMed International, Inc. Westlake, Ohio), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (Mosman, J. Immunol. Meth. 65: 55-63, 1983); 3-(4,5 dimethyl thiazol-2yl)-5-3-carboxymethoxyphenyl-2H-tetrazolium; 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide; and cyanoditoly-tetrazolium chloride (which are commercially available from Polysciences, Inc., Warrington, PA); mitogenesis assays, such as measurement of incorporation of ³H-thymidine; dye exclusion assays using, for example, naphthalene black or trypan blue; dye uptake using diacetyl fluorescein; and chromium release. See, in general, Freshney, Culture of Animal Cells: A Manual of Basic Technique, 3rd ed., Wiley-Liss, 1994, which is incorporated herein by reference.

[0046] A cDNA library was prepared from CD3+ selected, PMA- and Ionomycin-stimulated primary human peripheral blood cells. The CD3+ selected, PMA- and Ionomycin-stimulated human peripheral blood cells cDNA library was divided into pools containing multiple cDNA molecules and was transfected into a host cell line, for example, BHK 570 cells (ATCC Accession No. 10314). The transfected host cells were cultured in a medium that did not contain exogenous growth factors (e.g., 5% FBS) and conditioned medium was collected. The conditioned media were assayed for the ability to stimulate proliferation of BaF3 cells transfected with the zcytor17, WSX-1, and OSMRbeta receptors. CDNA

pools producing conditioned medium that stimulated BaF3/zcytor17/WSX-1/OSMRbeta receptor cells were identified. This pooled plasmid cDNA was electroporated into *E. coli*. CDNA was isolated from single colonies and transfected individually into BHK 570 cells. Positive clones were identified by a positive result in the BaF3/zcytor17/WSX-1/OSMRbeta receptor proliferation assay, and the activity was confirmed by neutralization of proliferation using the soluble zcytor17 receptor.

[0047] A positive clone was isolated, and sequence analysis revealed that the polynucleotide sequence contained within the plasmid DNA was novel. The secretory signal sequence is comprised of amino acid residues 1 (Met) to 23 (Ala), and the mature polypeptide is comprised of amino acid residues 24 (Ser) to 164 (Thr) (as shown in SEQ ID NO: 2). Further N-terminal sequencing analysis of purified zcytor17lig from 293T cells showed an N-terminus at residue 27 (Leu) as shown in SEQ ID NO:2, with the mature polypeptide comprised of amino acid residues 27 (Leu) to 164 (Thr) (as shown in SEQ ID NO:2).

[0048] In general, cytokines are predicted to have a four-alpha helix structure, with helices A, C and D being most important in ligand-receptor interactions, and are more highly conserved among members of the family. Referring to the human zcytor17lig amino acid sequence shown in SEQ ID NO:2, alignment of human zcytor17lig, human IL-3, and human cytokine amino acid sequences it is predicted that zcytor17lig helix A is defined by amino acid residues 38-52; helix B by amino acid residues 83-98; helix C by amino acid residues 104-117; and helix D by amino acid residues 137-152; as shown in SEQ ID NO:2. Structural analysis suggests that the A/B loop is long, the B/C loop is short and the C/D loop is long. This loop structure results in an up-up-down-down helical organization. Based on 4-helix bundle structure, the cysteine residues within zcytor17lig that are conserved correspond to amino acid residues 72, 133, and 147 of SEQ ID NO:2; and 74, 137, and 151 of SEQ ID NO:11 described herein. Consistent cysteine placement is further confirmation of the four-helical-bundle structure. Also highly conserved in the zcytor17lig is the Glu residue as shown in SEQ ID NO:2 at residue 43.

[0049] Moreover, the predicted amino acid sequence of murine zcytor17lig shows 31% identity to the predicted human protein over the entire length of the sequences (SEQ ID NO:2 and SEQ ID NO:11). Based on comparison between sequences of human and murine zcytor17lig conserved residues were found in the regions predicted to encode alpha helices C and D. The corresponding polynucleotides encoding the human zcytor17lig polypeptide regions, domains, motifs, residues and sequences described herein are as shown in SEQ ID NO: 1.

[0050] While helix D is relatively conserved between human and murine zcytor17lig, helix C is the most conserved. While both species have predominant acidic amino acids in this region, the differences may account for species specificity in interaction between zcytor17lig and its receptor, zcytor17 comprising monomeric, heterodimeric (e.g., zcytor17/OSMRbeta, WSX-1/OSMRbeta, zcytor17/WSX-1) or multimeric (e.g., zcytor17/OSMRbeta/WSX-1) receptors. Loop A/B and helix B of zcytor17lig are marginally conserved, and helix C through Loop C/D into helix D is most conserved between species; conservation through this region suggests that it is functionally significant. The D helices of human and murine zcytor17lig are also conserved. Zcytor17 receptor antagonists may be designed through mutations within zcytor17lig helix D. These may include truncation of the protein from residue Thr156 (SEQ ID NO:2), or conservation of residues that confer binding of the ligand to the receptor, but diminish signaling activity.

[0051] Four-helical bundle cytokines are also grouped by the length of their component helices. "Long-helix" form cytokines generally consist of between 24-30 residue helices, and include IL-6, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and human growth hormone (hGH). "Short-helix" form cytokines generally consist of between 18-21 residue helices and include IL-2, IL-4 and GM-CSF. Zcytor17lig is believed to be a new member of the short-helix form cytokine group. Studies using CNTF and IL-6 demonstrated that a CNTF helix can be exchanged for the equivalent helix in IL-6, conferring CTNF-binding properties to the chimera. Thus, it appears that functional domains of four-helical cytokines are determined on the basis of structural homology, irrespective of sequence identity, and can maintain functional integrity in a chimera (Kallen et al., *J. Biol. Chem.* 274:11859-11867, 1999). Therefore, the helical domains of zcytor17lig will be useful for preparing chimeric fusion molecules, particularly with other short-helix form cytokines to determine and modulate receptor binding specificity. Of particular interest are fusion proteins engineered with helix A and/or helix D, and fusion proteins that combine helical and loop domains from other short-form cytokines such as IL-2, IL-4, IL-15, LIF, IL-12, IL-3 and GM-CSF.

[0052] The polynucleotide sequence for human IL-2 is shown in SEQ ID NO:161 and the corresponding amino acid sequence is shown in SEQ ID NO:162. The secretory signal sequence is comprised of amino acid residues 1 (Met) to 20 (Ser) of SEQ ID NO:162; nucleotides 48 to 107 of SEQ ID NO:161. The mature polypeptide is comprised of amino acid residues 21 (Ala) to 156 (Thr) of SEQ ID NO:162; nucleotides 108 to 515 of SEQ ID NO:161. Helix A of human IL-2 is comprised of amino acid residues 27 (Thr) to 48 (Leu) of SEQ ID NO:162; nucleotides 126 to 191 of SEQ ID NO: 161. Helix B of human IL-2 comprises Helix B1 and Helix B2. Helix B1 of human IL-2 is comprised of amino acid residues 73 (Ala) to 80 (Gln) of SEQ ID NO:162; nucleotides 264 to 287 of SEQ ID NO:161. Helix B2 of human IL-2 is comprised of amino acid residues 83 (Glu) to 92 (Val) of SEQ ID NO:162; nucleotides 294 to 323 of SEQ ID NO: 161. Thus, Helix B (comprising Helices B1 and B2) of IL-2 is represented by the amino acid sequence of SEQ ID NO:168 (nucleotide sequence of SEQ ID NO:167) wherein amino acid residues 9 and 10 can be any amino acid. SEQ ID NO:168 is identical

EP 1 476 541 B1

to amino acids 73 (Ala) to 92 (Val) of SEQ ID NO:162 wherein amino acids 81 and 82 are any amino acid. In a preferred form, Helix B of IL-2 comprises amino acids 73 (Ala) to 92 (Val) of SEQ ID NO:162; nucleotides 264 to 323 of SEQ ID NO:161. Helix C of human IL-2 is comprised of amino acid residues 102 (His) to 116 (Val) of SEQ ID NO:162 nucleotides 351 to 395 of SEQ ID NO:161. Helix D of human IL-2 is comprised of amino acid residues 134 (Thr) to 149 (Gln) of SEQ ID NO:162; nucleotides 447 to 494 of SEQ ID NO: 161.

[0053] The polynucleotide sequence for human IL-4 is shown in SEQ ID NO:163 and the corresponding amino acid sequence is shown in SEQ ID NO:164. The secretory signal sequence is comprised of amino acid residues 1 (Met) to 24 (Gly) of SEQ ID NO:164; nucleotides 64 to 135 of SEQ ID NO:163. The mature polypeptide is comprised of amino acid residues 25 (His) to 153 (Ser) of SEQ ID NO:164; nucleotides 136 to 522 of SEQ ID NO:163. Helix A of human IL-4 is comprised of amino acid residues 30 (Thr) to 42 (Thr) of SEQ ID NO:164; nucleotides 151 to 189 of SEQ ID NO: 163. Helix B of human IL-4 is comprised of amino acid residues 65 (Glu) to 83 (His) of SEQ ID NO:164; nucleotides 256 to 312 of SEQ ID NO:163. Helix C. of human IL-4 is comprised of amino acid residues 94 (Ala) to 118 (Ala) of SEQ ID NO:164; nucleotides 343 to 417 of SEQ ID NO:163. Helix D of human IL-4 is comprised of amino acid residues 133 (Leu) to 151 (Cys) of SEQ ID NO:164; nucleotides 460 to 516 of SEQ ID NO:163.

[0054] The polynucleotide sequence for human GM-CSF is shown in SEQ ID NO:165 and the corresponding amino acid sequence is shown in SEQ ID NO:166. The secretory signal sequence is comprised of amino acid residues 1 (Met) to 17 (Ser) of SEQ ID NO:166; nucleotides 9 to 59 of SEQ ID NO:165. The mature polypeptide is comprised of amino acid residues 18 (Ala) to 144 (Glu) of SEQ ID NO:166; nucleotides 60 to 440 of SEQ ID NO:165. Helix A of human GM-CSF is comprised of amino acid residues 30 (Trp) to 44 (Asn) of SEQ ID NO: 166; nucleotides 96 to 140 of SEQ ID NO: 165. Helix B of human GM-CSF is comprised of amino acid residues 72 (Leu) to 81 (Gln) of SEQ ID NO:166; nucleotides 222 to 251 of SEQ ID NO:165. Helix C of human GM-CSF is comprised of amino acid residues 85 (Gly) to 103 (Gln) of SEQ ID NO:166; nucleotides 261 to 317 of SEQ ID NO:165. Helix D of human GM-CSF is comprised of amino acid residues 120 (Phe) to 131 (Leu) of SEQ ID NO:166; nucleotides 366 to 401 of SEQ ID NO:165.

[0055] The amino acid residues comprising helices A, B, C, and D, for human zcytor17lig, IL-3, IL-2, IL-4, and GM-CSF are shown in Table 1.

Table 1

	Helix A	Helix B	Helix C	Helix D	
zcytor17lig	38-52	83-98	104-117	137-152	of SEQ ID NO:2
IL-3	35-45	73-86	91-103	123-141	of SEQ ID NO: 102
IL-2	27-48	73-92	102-116	134-149	of SEQ ID NO: 162; or Helix B as described in SEQ ID NO: 168
IL-4	30-42	65-83	94-118	133-151	of SEQ ID NO:164
GM-CSF	30-44	72-81	85-103	120-131	of SEQ ID NO:166

[0056] The present invention provides polynucleotide molecules, including DNA and RNA molecules, that encode the zcytor17lig polypeptides disclosed herein. Those skilled in the art will readily recognize that, in view of the degeneracy of the genetic code, considerable sequence variation is possible among these polynucleotide molecules. SEQ ID NO: 3 is a degenerate DNA sequence that encompasses all DNAs that encode the zcytor17lig polypeptide, and fragments thereof, of SEQ ID NO:2. Those skilled in the art will recognize that the degenerate sequence of SEQ ID NO:3 also provides all RNA sequences encoding SEQ ID NO:2 by substituting U for T. Thus, zcytor17lig polypeptide-encoding polynucleotides comprising nucleotide 1 or 70 to nucleotide 492 of SEQ ID NO:3 and their RNA equivalents are contemplated by the present invention. Table 2 sets forth the one-letter codes used within SEQ ID NO:3 to denote degenerate nucleotide positions. "Resolutions" are the nucleotides denoted by a code letter. "Complement" indicates the code for the complementary nucleotide(s). For example, the code Y denotes either C or T, and its complement R denotes A or G, with A being complementary to T, and G being complementary to C.

Table 2

Nucleotide	Resolution	Complement	Resolution
A	A	T	T
C	C	G	G
G	G	C	C
T	T	A	A

EP 1 476 541 B1

(continued)

	Nucleotide	Resolution	Complement	Resolution
	R	A G	Y	C T
5	Y	C T	R	A G
	M	A C	K	G T
	K	G T	M	A C
	S	C G	S	C G
10	W	A T	W	A T
	H	A C T	D	A G T
	B	C G T	V	A C G
	V	A C G	B	C G T
	D	A G T	H	A C T
15	N	A C G T	N	A C G T

[0057] The degenerate codons used in SEQ ID NO:3, encompassing all possible codons for a given amino acid, are set forth in Table 3.

	Amino Acid	One Letter Code	Codons	Degenerate Codon
	Cys	C	TGC TGT	TGY
	Ser	S	AGC AGT TCA TCC TCG TCT	WSN
25	Thr	T	ACA ACC ACG ACT	ACN
	Pro	P	CCA CCC CCG CCT	CCN
	Ala	A	GCA GCC GCG GCT	GCN
	Gly	G	GGA GGC GGG GGT	GGN
	Asn	N	AAC AAT	AAV
30	Asp	D	GAC GAT	GAY
	Glu	E	GAA GAG	GAR
	Gln	Q	CAA CAG	CAR
	His	H	CAC CAT	CAY
35	Arg	R	AGA AGG CGA CGC CGG CGT	MGN
	Lys	K	AAA AAG	AAR
	Met	M	ATG	ATG
	Ile	I	ATA ATC ATT	ATH
	Leu	L	CTA CTC CTG CTT TTA TTG	YTN
40	Val	V	GTA GTC GTG GTT	GTN
	Phe	F	TTC TTT	TTY
	Tyr	Y	TAC TAT	TAY
	Trp	W	TGG	TGG
	Ter	.	TAA TAG TGA	TRR
45	Asn Asp	B		RAY
	Glu Gln	Z		SAR
	Any	X		NNN

[0058] One of ordinary skill in the art will appreciate that some ambiguity is introduced in determining a degenerate codon, representative of all possible codons encoding each amino acid. For example, the degenerate codon for serine (WSN) can, in some circumstances, encode arginine (AGR), and the degenerate codon for arginine (MGN) can, in some circumstances, encode serine (AGY). A similar relationship exists between codons encoding phenylalanine and leucine. Thus, some polynucleotides encompassed by the degenerate sequence may encode variant amino acid sequences, but one of ordinary skill in the art can easily identify such variant sequences by reference to the amino acid sequence of SEQ ID NO:2. Variant sequences can be readily tested for functionality as described herein.

[0059] One of ordinary skill in the art will also appreciate that different species can exhibit "preferential codon usage."

In general, see, Grantham, et al., *Nuc. Acids Res.* 8:1893-912, 1980; Haas, et al. *Curr. Biol.* 6:315-24, 1996; Wain-Hobson, et al., *Gene* 13:355-64, 1981; Grosjean and Fiers, *Gene* 18:199-209, 1982; Holm, *Nuc. Acids Res.* 14:3075-87, 1986; Ikemura, *J. Mol. Biol.* 158:573-97, 1982. As used herein, the term "preferential codon usage" or "preferential codons" is a term of art referring to protein translation codons that are most frequently used in cells of a certain species, thus favoring one or a few representatives of the possible codons encoding each amino acid (See Table 3). For example, the amino acid Threonine (Thr) may be encoded by ACA, ACC, ACG, or ACT, but in mammalian cells ACC is the most commonly used codon; in other species, for example, insect cells, yeast, viruses or bacteria, different Thr codons may be preferential. Preferential codons for a particular species can be introduced into the polynucleotides of the present invention by a variety of methods known in the art. Introduction of preferential codon sequences into recombinant DNA can, for example, enhance production of the protein by making protein translation more efficient within a particular cell type or species. Therefore, the degenerate codon sequence disclosed in SEQ ID NO:3 serves as a template for optimizing expression of polynucleotides in various cell types and species commonly used in the art and disclosed herein. Sequences containing preferential codons can be tested and optimized for expression in various species, and tested for functionality as disclosed herein.

[0060] As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for preparing DNA and RNA are well known in the art. In general, RNA is isolated from a tissue or cell that produces large amounts of zcytor17lig RNA. Such tissues and cells are identified by Northern blotting (Thomas, *Proc. Natl. Acad. Sci. USA* 77:5201, 1980), or by screening conditioned medium from various cell types for activity on target cells or tissue. Once the activity or RNA producing cell or tissue is identified, total RNA can be prepared using guanidinium isothiocyanate extraction followed by isolation by centrifugation in a CsCl gradient (Chirgwin et al., *Biochemistry* 18:52-94, 1979). Poly (A)⁺ RNA is prepared from total RNA using the method of Aviv and Leder (*Proc. Natl. Acad. Sci. USA* 69:1408-12, 1972). Complementary DNA (cDNA) is prepared from poly(A)⁺ RNA using known methods. In the alternative, genomic DNA can be isolated. Polynucleotides encoding zcytor17lig polypeptides are then identified and isolated by, for example, hybridization or PCR.

[0061] A full-length clone encoding zcytor17lig can be obtained by conventional cloning procedures. Complementary DNA (cDNA) clones are preferred, although for some applications (e.g., expression in non human transgenic animals) it may be preferable to use a genomic clone, or to modify a cDNA clone to include at least one genomic intron. Methods for preparing cDNA and genomic clones are well known and within the level of ordinary skill in the art, and include the use of the sequence disclosed herein, or parts thereof, for probing or priming a library. Expression libraries can be probed with antibodies to zcytor17lig fragments, zcytor17-comprising soluble receptors, or other specific binding partners.

[0062] Zcytor17lig polynucleotide sequences disclosed herein can also be used as probes or primers to clone 5' non-coding regions of a zcytor17lig gene. In view of the tissue-specific expression observed for zcytor17lig this gene region is expected to provide for hematopoietic- and lymphoid-specific expression. Promoter elements from a zcytor17lig gene could thus be used to direct the tissue-specific expression of heterologous genes in, for example, non-human transgenic animals or patients treated with gene therapy. Cloning of 5' flanking sequences also facilitates production of zcytor17lig proteins by "gene activation" as disclosed in U.S. Patent No. 5,641,670. Briefly, expression of an endogenous zcytor17lig gene in a cell is altered by introducing into the zcytor17lig locus a DNA construct comprising at least a targeting sequence, a regulatory sequence, an exon, and an unpaired splice donor site. The targeting sequence is a zcytor17lig 5' non-coding sequence that permits homologous recombination of the construct with the endogenous zcytor17lig locus, whereby the sequences within the construct become operably linked with the endogenous zcytor17lig coding sequence. In this way, an endogenous zcytor17lig promoter can be replaced or supplemented with other regulatory sequences to provide enhanced, tissue-specific, or otherwise regulated expression.

[0063] The present invention further provides counterpart polypeptides and polynucleotides from other species (orthologs). These species include, but are not limited to, mammalian, avian, amphibian, reptile, fish, insect and other vertebrate and invertebrate species. Of particular interest are zcytor17lig polypeptides from other mammalian species, including, for example, murine, porcine, ovine, bovine, canine, feline, equine, and other primate polypeptides. Orthologs of human zcytor17lig can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses zcytor17lig as disclosed herein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A zcytor17lig-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one or more sets of degenerate probes based on the disclosed sequences. A cDNA can also be cloned using the polymerase chain reaction, or PCR (Mullis, U.S. Patent No. 4,683,202), using primers designed from the representative human zcytor17lig sequence disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to zcytor17lig polypeptide, binding studies or activity assays. Similar techniques can also be applied to the isolation of genomic clones.

[0064] The polynucleotide sequence for the mouse ortholog of zcytor17lig has been identified and is shown in SEQ

ID NO:10 and SEQ ID NO:90 and the corresponding amino acid sequence shown in SEQ ID NO:11 and SEQ ID NO:91. The degenerate polynucleotide sequence encoding the polypeptide of SEQ ID NO:11 is shown in SEQ ID NO:12. For the zcytor17lig mouse cytokine amino acid sequence it is predicted that helix A is defined by amino acid residues 38-52; helix B by amino acid residues 85-98; helix C by amino acid residues 104-118; and helix D by amino acid residues 141-157; as shown in SEQ ID NO:11 and SEQ ID NO:91. There is 31% identity between the mouse and human sequences over the entire length of the amino acid sequences (SEQ ID NO:2 and SEQ ID NO:11) of zcytor17lig. Mature sequence for the mouse zcytor17lig putatively begins at Met₁, as shown in SEQ ID NO:11, which corresponds to Met₁, as shown in SEQ ID NO:2, in the human sequence. Tissue analysis revealed that expression of mouse zcytor17lig is found in testis, brain, CD90+ cells, prostate cells, salivary gland and skin. Further N-terminal sequencing analysis of purified zcytor17lig from 293T cells showed an N-terminus at residue 31 (Ala) as shown in SEQ ID NO:11 and SEQ ID NO:91, with the mature polypeptide comprised of amino acid residues 31 (Ala) to 163 (Cys) (as shown in SEQ ID NO: 11 and SEQ ID NO:91).

[0065] Those skilled in the art will recognize that the sequence disclosed in SEQ ID NO:1 represents a single allele of human zcytor17lig and that allelic variation and alternative splicing are expected to occur. Allelic variants of this sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the DNA sequence shown in SEQ ID NO:1, including those containing silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NO:2. cDNAs generated from alternatively spliced mRNAs, which retain the properties of the zcytor17lig polypeptide, are included within the scope of the present invention, as are polypeptides encoded by such cDNAs and mRNAs. Allelic variants and splice variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals or tissues according to standard procedures known in the art.

[0066] The present invention also provides reagents which will find use in diagnostic applications. For example, the zcytor17lig gene, a probe comprising zcytor17lig DNA or RNA or a subsequence thereof, can be used to determine if the zcytor17lig gene is present on a human chromosome, such as chromosome 12, or if a gene mutation has occurred. Zcytor17lig is located at the 12q24.31 region of chromosome 12 (Example 13). Detectable chromosomal aberrations at the zcytor17lig gene locus include, but are not limited to, aneuploidy, gene copy number changes, loss of heterozygosity (LOH), translocations, insertions, deletions, restriction site changes and rearrangements. Such aberrations can be detected using polynucleotides of the present invention by employing molecular genetic techniques, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, and other genetic linkage analysis techniques known in the art (Sambrook et al., *ibid*; Ausubel et al., *ibid*; Marian, *Chest* 108:255-65, 1995).

[0067] The precise knowledge of a gene's position can be useful for a number of purposes, including: 1) determining if a sequence is part of an existing contig and obtaining additional surrounding genetic sequences in various forms, such as YACs, BACs or cDNA clones; 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region; and 3) cross-referencing model organisms, such as mouse, which may aid in determining what function a particular gene might have.

[0068] One of skill in the art would recognize that the 12q24 region is frequently involved in gross genomic rearrangements, including translocations, deletions, inversions, and duplications, that are associated with various cancers. The Mitelman Database of Chromosomal Aberrations in Cancer, at the Cancer Genome Anatomy Project, National Institutes of Health, Bethesda, Md located on the Internet lists 199 cases of cancers with genomic rearrangements involving 12q24. Of these, most are part of complex karyotypes with other rearrangements; however, in some cases the rearrangement involving 12q24 is the only genomic alteration. Given the expression of the receptor for zcytor17lig on cells of lymphoid and myeloid lineages, it is particularly significant to note that there are at least 4 cases of myeloid leukemia reported in the literature in which either translocation (2 cases: Yamagata et al, *Cancer Genet Cytogenet* 97:90-93, 1997; Dunphy and Batanian, *Cancer Genet Cytogenet* 114:51-57, 1999) or duplication (2 cases: Bonomi et al, *Cancer Genet Cytogenet* 108:75-78, 1999) are the sole genomic alteration. This suggests that a gene or genes residing within 12q24 could be directly involved in the malignant transformation of these patients' cells. Inappropriate over expression of zcytor17lig could contribute to malignant transformation by promoting aberrant proliferation of receptor-bearing cells, through either autocrine or paracrine mechanisms. Inhibition of zcytor17lig activity could thus inhibit growth of such cells. Alternatively, a genomic rearrangement resulting in inactivation of the zcytor17lig gene may promote malignant transformation and/or metastasis by removing zcytor17lig immunoregulatory functions. Indeed, a gene suppressing metastasis in prostate cancer has been mapped to 12q24-qter (Ichikawa et al, *Asian J Androl* 2:167-171, 2000). If zcytor17lig is the gene within this region responsible for the suppression of metastasis, then zcytor17lig itself may have therapeutic value in the treatment of cancer.

[0069] A diagnostic could assist physicians in determining the type of disease and appropriate associated therapy, or assistance in genetic counseling. As such, the inventive anti-zcytor17lig antibodies, polynucleotides, and polypeptides can be used for the detection of zcytor17lig polypeptide, mRNA or anti-zcytor17lig antibodies, thus serving as markers and be directly used for detecting or genetic diseases or cancers, as described herein, using methods known in the art

and described herein. Further, zcytor17lig polynucleotide probes can be used to detect abnormalities or genotypes associated with chromosome 12q24.3 deletions and translocations associated with human diseases, or other translocations involved with malignant progression of tumors or other 12q24.3 mutations, which are expected to be involved in chromosome rearrangements in malignancy; or in other cancers. Similarly, zcytor17lig polynucleotide probes can be used to detect abnormalities or genotypes associated with chromosome 12 trisomy and chromosome loss associated with human diseases or spontaneous abortion. Thus, zcytor17lig polynucleotide probes can be used to detect abnormalities or genotypes associated with these defects.

[0070] One of skill in the art would recognize that zcytor17lig polynucleotide probes are particularly useful for diagnosis of gross chromosomal abnormalities associated with loss of heterogeneity (LOH), chromosome gain (e.g., trisomy), translocation, DNA amplification, and the like. Translocations within chromosomal locus 12q24.3 wherein the zcytor17lig gene is located are known to be associated with human disease. For example, 12q24 deletions and translocations, duplications and trisomy are associated with cancers as discussed above. Thus, since the zcytor17lig gene maps to this critical region, zcytor17lig polynucleotide probes of the present invention can be used to detect abnormalities or genotypes associated with 12q24 translocation, deletion and trisomy, and the like, described above.

[0071] As discussed above, defects in the zcytor17lig gene itself may result in a heritable human disease state. Molecules of the present invention, such as the polypeptides, antagonists, agonists, polynucleotides and antibodies of the present invention would aid in the detection, diagnosis prevention, and treatment associated with a zcytor17lig genetic defect. In addition, zcytor17lig polynucleotide probes can be used to detect allelic differences between diseased or non-diseased individuals at the zcytor17lig chromosomal locus. As such, the zcytor17lig sequences can be used as diagnostics in forensic DNA profiling.

[0072] In general, the diagnostic methods used in genetic linkage analysis, to detect a genetic abnormality or aberration in a patient, are known in the art. Analytical probes will be generally at least 20 nt in length, although somewhat shorter probes can be used (e.g., 14-17 nt). PCR primers are at least 5 nt in length, preferably 15 or more, more preferably 20-30 nt. For gross analysis of genes, or chromosomal DNA, a zcytor17lig polynucleotide probe may comprise an entire exon or more. Exons are readily determined by one of skill in the art by comparing zcytor17lig sequences (SEQ ID NO: 1) with the genomic DNA for mouse zcytor17lig (SEQ ID NO:76). In general, the diagnostic methods used in genetic linkage analysis, to detect a genetic abnormality or aberration in a patient, are known in the art. Most diagnostic methods comprise the steps of (a) obtaining a genetic sample from a potentially diseased patient, diseased patient or potential non-diseased carrier of a recessive disease allele; (b) producing a first reaction product by incubating the genetic sample with a zcytor17lig polynucleotide probe wherein the polynucleotide will hybridize to complementary polynucleotide sequence, such as in RFLP analysis or by incubating the genetic sample with sense and antisense primers in a PCR reaction under appropriate PCR reaction conditions; (iii) visualizing the first reaction product by gel electrophoresis and/or other known methods such as visualizing the first reaction product with a zcytor17lig polynucleotide probe wherein the polynucleotide will hybridize to the complementary polynucleotide sequence of the first reaction; and (iv) comparing the visualized first reaction product to a second control reaction product of a genetic sample from wild type patient, or a normal or control individual. A difference between the first reaction product and the control reaction product is indicative of a genetic abnormality in the diseased or potentially diseased patient, or the presence of a heterozygous recessive carrier phenotype for a non-diseased patient, or the presence of a genetic defect in a tumor from a diseased patient, or the presence of a genetic abnormality in a fetus or pre-implantation embryo. For example, a difference in restriction fragment pattern, length of PCR products, length of repetitive sequences at the zcytor17lig genetic locus, and the like, are indicative of a genetic abnormality, genetic aberration, or allelic difference in comparison to the normal wild type control. Controls can be from unaffected family members, or unrelated individuals, depending on the test and availability of samples. Genetic samples for use within the present invention include genomic DNA, mRNA, and cDNA isolated from any tissue or other biological sample from a patient, which includes, but is not limited to, blood, saliva, semen, embryonic cells, amniotic fluid, and the like. The polynucleotide probe or primer can be RNA or DNA, and will comprise a portion of SEQ ID NO:1, the complement of SEQ ID NO:1, or an RNA equivalent thereof. Such methods of showing genetic linkage analysis to human disease phenotypes are well known in the art. For reference to PCR based methods in diagnostics see generally, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), White (ed.), *PCR Protocols: Current Methods and Applications* (Humana Press, Inc. 1993), Cotter (ed.), *Molecular Diagnosis of Cancer* (Humana Press, Inc. 1996), Hanausek and Walaszek (eds.), *Tumor Marker Protocols* (Humana Press, Inc. 1998), Lo (ed.), *Clinical Applications of PCR* (Humana Press, Inc. 1998), and Meltzer (ed.), *PCR in Bioanalysis* (Humana Press, Inc. 1998).

[0073] Mutations associated with the zcytor17lig locus can be detected using nucleic acid molecules of the present invention by employing standard methods for direct mutation analysis, such as restriction fragment length polymorphism analysis, short tandem repeat analysis employing PCR techniques, amplification-refractory mutation system analysis, single-strand conformation polymorphism detection, RNase cleavage methods, denaturing gradient gel electrophoresis, fluorescence-assisted mismatch analysis, and other genetic analysis techniques known in the art (see, for example, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), Marian, *Chest* 108:255 (1995),

Coleman and Tsongalis, *Molecular Diagnostics* (Human Press, Inc. 1996), Elles (ed.) *Molecular Diagnosis of Genetic Diseases* (Humana Press, Inc. 1996), Landegren (ed.), *Laboratory Protocols for Mutation Detection* (Oxford University Press 1996), Birren et al. (eds.), *Genome Analysis, Vol. 2: Detecting Genes* (Cold Spring Harbor Laboratory Press 1998), Dracopoli et al. (eds.), *Current Protocols in Human Genetics* (John Wiley & Sons 1998), and Richards and Ward, "Molecular Diagnostic Testing," in *Principles of Molecular Medicine*, pages 83-88 (Humana Press, Inc. 1998). Direct analysis of a zcytor17lig gene for a mutation can be performed using a subject's genomic DNA. Methods for amplifying genomic DNA, obtained for example from peripheral blood lymphocytes, are well-known to those of skill in the art (see, for example, Dracopoli et al. (eds.), *Current Protocols in Human Genetics*, at pages 7.1.6 to 7.1.7 (John Wiley & Sons 1998)).

[0074] Positions of introns in the mouse zcytor17lig gene were determined by identification of genomic clones, followed by analysis the intron/exon junctions. The mouse genomic DNA is shown in SEQ ID NO:76. With reference to SEQ ID NO:76, three coding exons separated by introns are evident: the first coding exon lies between nucleic acid numbers 1104-1119 of SEQ ID NO:76, the second exon between nucleic acid numbers 1300-1451 of SEQ ID NO:76, and the third exon between nucleic acid numbers 2411-2998 of SEQ ID NO:76.

[0075] Within embodiments of the invention, isolated zcytor17lig-encoding nucleic acid molecules can hybridize under stringent conditions to nucleic acid molecules having the nucleotide sequence of SEQ ID NO:1, to nucleic acid molecules having the nucleotide sequence of nucleotides 28 to 519 of SEQ ID NO:1, or to nucleic acid molecules having a nucleotide sequence complementary to SEQ ID NO:1. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe.

[0076] A pair of nucleic acid molecules, such as DNA-DNA, RNA-RNA and DNA-RNA, can hybridize if the nucleotide sequences have some degree of complementarity. Hybrids can tolerate mismatched base pairs in the double helix, but the stability of the hybrid is influenced by the degree of mismatch. The T_m of the mismatched hybrid decreases by 1°C for every 1-1.5% base pair mismatch. Varying the stringency of the hybridization conditions allows control over the degree of mismatch that will be present in the hybrid. The degree of stringency increases as the hybridization temperature increases and the ionic strength of the hybridization buffer decreases.

[0077] It is well within the abilities of one skilled in the art to adapt these conditions for use with a particular polynucleotide hybrid. The T_m for a specific target sequence is the temperature (under defined conditions) at which 50% of the target sequence will hybridize to a perfectly matched probe sequence. Those conditions which influence the T_m include, the size and base pair content of the polynucleotide probe, the ionic strength of the hybridization solution, and the presence of destabilizing agents in the hybridization solution. Numerous equations for calculating T_m are known in the art, and are specific for DNA, RNA and DNA-RNA hybrids and polynucleotide probe sequences of varying length (see, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual, Second Edition* (Cold Spring Harbor Press 1989); Ausubel et al., (eds.), *Current Protocols in Molecular Biology* (John Wiley and Sons, Inc. 1987); Berger and Kimmel (eds.), *Guide to Molecular Cloning Techniques*, (Academic Press, Inc. 1987); and Wetmur, *Crit. Rev. Biochem. Mol. Biol.* 26:227 (1990)). Sequence analysis software such as OLIGO 6.0 (LSR; Long Lake, MN) and *Primer Premier 4.0* (Premier Biosoft International; Palo Alto, CA), as well as sites on the Internet, are available tools for analyzing a given sequence and calculating T_m based on user defined criteria. Such programs can also analyze a given sequence under defined conditions and identify suitable probe sequences. Typically, hybridization of longer polynucleotide sequences, >50 base pairs, is performed at temperatures of about 20-25°C below the calculated T_m . For smaller probes, <50 base pairs, hybridization is typically carried out at the T_m or 5-10°C below the calculated T_m . This allows for the maximum rate of hybridization for DNA-DNA and DNA-RNA hybrids.

[0078] Following hybridization, the nucleic acid molecules can be washed to remove non-hybridized nucleic acid molecules under stringent conditions, or under highly stringent conditions. Typical stringent washing conditions include washing in a solution of 0.5x - 2x SSC with 0.1% sodium dodecyl sulfate (SDS) at 55 - 65°C. That is, nucleic acid molecules encoding a variant zcytor17lig polypeptide hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) under stringent washing conditions, in which the wash stringency is equivalent to 0.5x - 2x SSC with 0.1% SDS at 55 - 65°C, including 0.5x SSC with 0.1% SDS at 55°C, or 2x SSC with 0.1% SDS at 65°C. One of skill in the art can readily devise equivalent conditions, for example, by substituting SSPE for SSC in the wash solution.

[0079] Typical highly stringent washing conditions include washing in a solution of 0.1x - 0.2x SSC with 0.1% sodium dodecyl sulfate (SDS) at 50 - 65°C. In other words, nucleic acid molecules encoding a variant zcytor17lig polypeptide hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1x - 0.2x SSC with 0.1% SDS at 50 - 65°C, including 0.1x SSC with 0.1% SDS at 50°C, or 0.2x SSC with 0.1% SDS at 65°C.

[0080] The present invention also provides isolated zcytor17lig polypeptides that have a substantially similar sequence identity to the polypeptides of SEQ ID NO:2, or their orthologs. The term "substantially similar sequence identity" is used herein to denote polypeptides comprising at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least

97%, at least 98%, at least 99%, or greater than 99% sequence identity to the sequences shown in SEQ ID NO:2, or their orthologs. The present invention also includes polypeptides that comprise an amino acid sequence having at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or greater than 99% sequence identity to the sequence of amino acid residues 1 to 162 or 33 to 162 of SEQ ID NO:2. The present invention further includes nucleic acid molecules that encode such polypeptides. Methods for determining percent identity are described below.

[0081] The present invention also contemplates variant zcytor17lig nucleic acid molecules that can be identified using two criteria: a determination of the similarity between the encoded polypeptide with the amino acid sequence of SEQ ID NO:2, and/or a hybridization assay, as described above. Such zcytor17lig variants include nucleic acid molecules: (1) that hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) under stringent washing conditions, in which the wash stringency is equivalent to 0.5x - 2x SSC with 0.1% SDS at 55 - 65°C; or (2) that encode a polypeptide having at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or greater than 99% identity to the amino acid sequence of SEQ ID NO:2. Alternatively, zcytor17lig variants can be characterized as nucleic acid molecules: (1) that hybridize with a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1 (or its complement) under highly stringent washing conditions, in which the wash stringency is equivalent to 0.1x - 0.2x SSC with 0.1% SDS at 50 - 65°C; and (2) that encode a polypeptide having at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or greater than 99% sequence identity to the amino acid sequence of SEQ ID NO:2.

[0082] Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48:603 (1986), and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM62" scoring matrix of Henikoff and Henikoff (*ibid.*) as shown in Table 4 (amino acids are indicated by the standard one-letter codes).

Total number of identical matches

x 100

[length of the longer sequence plus the number of gaps introduced into the longer

sequence in order to align the two sequences]

Table 4

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
A	4																			
R	-1	5																		
N	-2	0	6																	
D	-2	-2	1	6																
C	0	-3	-3	-3	9															
Q	-1	1	0	0	-3	5														
E	-1	0	0	2	-4	2	5													
G	0	-2	0	-1	-3	-2	-2	6												
H	-2	0	1	-1	-3	0	0	-2	8											
I	-1	-3	-3	-3	-1	-3	-3	-4	-3	4										
L	-1	-2	-3	-4	-1	-2	-3	-4	-3	2	4									
K	-1	2	0	-1	-3	1	1	-2	-1	-3	-2	5								
M	-1	-1	-2	-3	-1	0	-2	-3	-2	1	2	-1	5							

EP 1 476 541 B1

(continued)

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V	
5	F	-2	-3	-3	-3	-2	-3	-3	-3	-1	0	0	-3	0	6						
	P	-1	-2	-2	-1	-3	-1	-1	-2	-2	-3	-3	-1	-2	-4	7					
	S	1	-1	1	0	-1	0	0	0	-1	-2	-2	0	-1	-2	-1	4				
	T	0	-1	0	-1	-1	-1	-1	-2	-2	-1	-1	-1	-1	-2	-1	1	5			
	W	-3	-3	-4	-4	-2	-2	-3	-2	-2	-3	-2	-3	-1	1	-4	-3	-2	11		
	Y	-2	-2	-2	-3	-2	-1	-2	-3	2	-1	-1	-2	-1	3	-3	-2	-2	2	7	
10	V	0	-3	-3	-3	-1	-2	-2	-3	-3	3	1	-2	1	-1	-2	-2	0	-3	-1	4

[0083] Those skilled in the art appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson and Lipman is a suitable protein alignment method for examining the level of identity shared by an amino acid sequence disclosed herein and the amino acid sequence of a putative variant zcytor17lig. The FASTA algorithm is described by Pearson and Lipman, Proc. Nat'l Acad. Sci. USA 85: 2444 (1988), and by Pearson, Meth. Enzymol. 183:63 (1990).

[0084] Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (e.g., SEQ ID NO:2) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence and the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm (Needleman and Wunsch, J. Mol. Biol. 48:444 (1970); Sellers, SIAM J. Appl. Math. 26:787 (1974)), which allows for amino acid insertions and deletions. Preferred parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, Meth. Enzymol. 183: 63 (1990).

[0085] FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons, the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as default.

[0086] Variant zcytor17lig polypeptides or polypeptides with substantially similar sequence identity are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (as shown in Table 5 below) and other substitutions that do not significantly affect the folding or activity of the polypeptide; small deletions, typically of one to about 30 amino acids; and amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an affinity tag. The present invention thus includes polypeptides of from about 108 to 216 amino acid residues that comprise a sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or greater than 99% identical to the corresponding region of SEQ ID NO:2. Polypeptides comprising affinity tags can further comprise a proteolytic cleavage site between the zcytor17lig polypeptide and the affinity tag. Preferred such sites include thrombin cleavage sites and factor Xa cleavage sites.

Table 5

Conservative amino acid substitutions

50	Basic:	arginine
		lysine
		histidine
50	Acidic:	glutamic acid
		aspartic acid
55	Polar:	glutamine
		asparagine
55	Hydrophobic:	leucine
		isoleucine
		valine

EP 1 476 541 B1

Aromatic:	phenylalanine
	tryptophan
	tyrosine
Small:	glycine
	alanine
	serine
	threonine
	methionine

[0087] Determination of amino acid residues that comprise regions or domains that are critical to maintaining structural integrity can be determined. Within these regions one can determine specific residues that will be more or less tolerant of change and maintain the overall tertiary structure of the molecule. Methods for analyzing sequence structure include, but are not limited to, alignment of multiple sequences with high amino acid or nucleotide identity, secondary structure propensities, binary patterns, complementary packing and buried polar interactions (Barton, *Current Opin. Struct. Biol.* 5:372-376, 1995 and Cordes et al., *Current Opin. Struct. Biol.* 6:3-10; 1996). In general, when designing modifications to molecules or identifying specific fragments determination of structure will be accompanied by evaluating activity of modified molecules.

[0088] Amino acid sequence changes are made in zcytor17lig polypeptides so as to minimize disruption of higher order structure essential to biological activity. For example, where the zcytor17lig polypeptide comprises one or more helices, changes in amino acid residues will be made so as not to disrupt the helix geometry and other components of the molecule where changes in conformation abate some critical function, for example, binding of the molecule to its binding partners, e.g., A and D helices, residues 43 (Glu), 44 (Glu), and 136 (Phe) of SEQ ID NO:2. The effects of amino acid sequence changes can be predicted by, for example, computer modeling as disclosed above or determined by analysis of crystal structure (see, e.g., Laphom et al., *Nat. Struct. Biol.* 2:266-268, 1995). Other techniques that are well known in the art compare folding of a variant protein to a standard molecule (e.g., the native protein). For example, comparison of the cysteine pattern in a variant and standard molecules can be made. Mass spectrometry and chemical modification using reduction and alkylation provide methods for determining cysteine residues which are associated with disulfide bonds or are free of such associations (Bean et al., *Anal. Biochem.* 201:216-226, 1992; Gray, *Protein Sci.* 2:1732-1748, 1993; and Patterson et al., *Anal. Chem.* 66:3727-3732, 1994). It is generally believed that if a modified molecule does not have the same cysteine pattern as the standard molecule folding would be affected. Another well known and accepted method for measuring folding is circular dichroism (CD). Measuring and comparing the CD spectra generated by a modified molecule and standard molecule is routine (Johnson, *Proteins* 7:205-214, 1990). Crystallography is another well known method for analyzing folding and structure. Nuclear magnetic resonance (NMR), digestive peptide mapping and epitope mapping are also known methods for analyzing folding and structural similarities between proteins and polypeptides (Schaanan et al., *Science* 257:961-964, 1992).

[0089] A Hopp/Woods hydrophilicity profile of the zcytor17lig protein sequence as shown in SEQ ID NO:2 can be generated (Hopp et al., *Proc. Natl. Acad. Sci.* 78:3824-3828, 1981; Hopp, *J. Immun. Meth.* 88:1-18, 1986 and Triquier et al., *Protein Engineering* 11:153-169, 1998). The profile is based on a sliding six-residue window. Buried G, S, and T residues and exposed H, Y, and W residues were ignored. For example, in human zcytor17lig, hydrophilic regions include amino acid residues 54-59 of SEQ ID NO:2, amino acid residues 129-134 of SEQ ID NO:2, amino acid residues 53-58 of SEQ ID NO:2, amino acid residues 35-40 of SEQ ID NO:2, and amino acid residues 33-38 of SEQ ID NO:2. For example, in mouse zcytor17lig, hydrophilic regions include amino acid residues 34-39 of SEQ ID NO:11, amino acid residues 46-51 of SEQ ID NO:11, amino acid residues 131-136 of SEQ ID NO:11, amino acid residues 158-163 of SEQ ID NO:11, and amino acid residues 157-162 of SEQ ID NO:11.

[0090] Those skilled in the art will recognize that hydrophilicity or hydrophobicity will be taken into account when designing modifications in the amino acid sequence of a zcytor17lig polypeptide, so as not to disrupt the overall structural and biological profile. Of particular interest for replacement are hydrophobic residues selected from the group consisting of Val, Leu and Ile or the group consisting of Met, Gly, Ser, Ala, Tyr and Trp. For example, residues tolerant of substitution could include Val, Leu and Ile or the group consisting of Met, Gly, Ser, Ala, Tyr and Trp residues as shown in SEQ ID NO:2. Conserved cysteine residues at positions within SEQ ID NO:2 and SEQ ID NO: 11, will be relatively intolerant of substitution.

[0091] The identities of essential amino acids can also be inferred from analysis of sequence similarity between IL-3, Lif, IL12, IL-15, IL-2, IL-4 and GM-CSF with zcytor17lig. Using methods such as "FASTA" analysis described previously, regions of high similarity are identified within a family of proteins and used to analyze amino acid sequence for conserved regions. An alternative approach to identifying a variant zcytor17lig polynucleotide on the basis of structure is to determine whether a nucleic acid molecule encoding a potential variant zcytor17lig gene can hybridize to a nucleic acid molecule

having the nucleotide sequence of SEQ ID NO:1, as discussed above.

[0092] Other methods of identifying essential amino acids in the polypeptides of the present invention are procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081 (1989), Bass et al., *Proc. Natl Acad. Sci. USA* 88:4498 (1991), Coombs and Corey, "Site-Directed Mutagenesis and Protein Engineering," in *Proteins: Analysis and Design*, Angeletti (ed.), pages 259-311 (Academic Press, Inc. 1998)). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological or biochemical activity as disclosed below to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., *J. Biol. Chem.* 271:4699 (1996).

[0093] The present invention also includes functional fragments of zcytor17lig polypeptides and nucleic acid molecules encoding such functional fragments. A "functional" zcytor17lig or fragment thereof as defined herein is characterized by its proliferative or differentiating activity, by its ability to induce or inhibit specialized cell functions, or by its ability to bind specifically to an anti-zcytor17lig antibody or zcytor17 receptor antibody or zcytor17, WSX-1, or OSMRbeta receptor or heterodimers (e.g., zcytor17/WSX-1 or zcytor17/OSMRbeta) or multimers (e.g., zcytor17/WSX-1/OSMRbeta) of these receptors (either soluble or immobilized). As previously described herein, zcytor17lig is characterized by a four-helical-bundle structure comprising helix A (amino acid residues 38-52), helix B (amino acid residues 83-98), helix C (amino acid residues 104-117) and helix D (amino acid residues 137-152), as shown in SEQ ID NO:2. Thus, the present invention further provides fusion proteins encompassing: (a) polypeptide molecules comprising one or more of the helices described above; and (b) functional fragments comprising one or more of these helices. The other polypeptide portion of the fusion protein may be contributed by another four-helical-bundle cytokine, such as IL-15, IL-2, IL-4 and GM-CSF, or by a non-native and/or an unrelated secretory signal peptide that facilitates secretion of the fusion protein.

[0094] Thus the present invention provides fusion proteins comprising at least four polypeptides, wherein the order of polypeptides from N-terminus to C-terminus are: a first polypeptide comprises amino acids selected from a group consisting of: (a) IL-2 helix A amino acid residues 27-48 of SEQ ID NO: 162; (b) IL-3 helix A amino acid residues 35-45 of SEQ ID NO:102; (c) IL-4 helix A amino acid residues 30-42 of SEQ ID NO:164; (d) GM-CSF helix A amino acid residues 30-44 of SEQ ID NO:166; and (e) amino acids residues 38 to 52 of SEQ ID NO:2; a first spacer of 6-27 amino acids; and a second polypeptide that comprises amino acid residues selected from the group consisting of: (a) IL-2 helix B amino acid residues of SEQ ID NO:168; (b) IL-4 helix B amino acid residues 65-83 of SEQ ID NO:164; (c) IL-3 helix B amino acid residues 73-86 of SEQ ID NO:102; (d) GM-CSF helix B amino acid residues 72-81 of SEQ ID NO:166; and (e) amino acid residues 83-98 of SEQ ID NO:2; a second spacer of 5-11 amino acid residues; a third polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix C residues 102-116 of SEQ ID NO:162; (b) IL-4 helix C residues 94-118 of SEQ ID NO:164; (c) IL-3 helix C residues 91-103 of SEQ ID NO:102; (d) GM-CSF helix C residues 85-103 of SEQ ID NO:166; and (e) amino acid residues 104-117 of SEQ ID NO:2; a third spacer of 3-29 amino acid residues; and a fourth polypeptide that comprises amino acid residues selected from the group consisting of: (a) IL-2 helix D amino acid residues 134-149 of SEQ ID NO:162; (b) IL-3 helix D amino acid residues 123-141 of SEQ ID NO:102; (c) IL-4 helix D amino acid residues 133-151 of SEQ ID NO:164; (d) GM-CSF helix D amino acid residues 120-131 of SEQ ID NO:166; and (e) amino acid residues 137-152 of SEQ ID NO: 2, wherein at least one of the four polypeptides is from zcytor17lig. In other embodiments that the spacer peptides will be selected from the A/B, B/C and C/D loops of zcytor17lig, and IL-3, as shown in Table 1.

[0095] Routine deletion analyses of nucleic acid molecules can be performed to obtain functional fragments of a nucleic acid molecule that encodes a zcytor17lig polypeptide. As an illustration, DNA molecules having the nucleotide sequence of SEQ ID NO:1 or fragments thereof, can be digested with *Bal31* nuclease to obtain a series of nested deletions. These DNA fragments are then inserted into expression vectors in proper reading frame, and the expressed polypeptides are isolated and tested for zcytor17lig activity, or for the ability to bind anti-zcytor17lig antibodies or zcytor17 receptor. One alternative to exonuclease digestion is to use oligonucleotide-directed mutagenesis to introduce deletions or stop codons to specify production of a desired zcytor17lig fragment. Alternatively, particular fragments of a zcytor17lig gene can be synthesized using the polymerase chain reaction.

[0096] Standard methods for identifying functional domains are well-known to those of skill in the art. For example, studies on the truncation at either or both termini of interferons have been summarized by Horisberger and Di Marco, *Pharmac. Ther.* 66:507 (1995). Moreover, standard techniques for functional analysis of proteins are described by, for example, Treuter et al., *Molec. Gen. Genet.* 240:113 (1993); Content et al., "Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon," in *Biological Interferon Systems*, Proceedings of ISIR-TNO Meeting on Interferon Systems, Cantell (ed.), pages 65-72 (Nijhoff 1987); Herschman, "The EGF Receptor," in *Control of Animal Cell Proliferation 1*, Boynton et al., (eds.) pages 169-199 (Academic Press 1985); Coumilleau et al., *J. Biol. Chem.* 270:29270 (1995); Fukunaga et al., *J. Biol. Chem.* 270:25291 (1995); Yamaguchi et al., *Biochem. Pharmacol.* 50:1295 (1995); and Meisel et al., *Plant Molec. Biol.* 30:1 (1996).

[0097] Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (*Science* 241:53 (1988)) or Bowie and Sauer (*Proc. Nat'l Acad. Sci. USA* 86:2152 (1989)). Briefly, these authors disclose methods for simultaneously randomizing two or more positions

in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., *Biochem.* 30:10832 (1991), Ladner et al., U.S. Patent No. 5,223,409, Huse, international publication No. WO 92/06204), and region-directed mutagenesis (Derbyshire et al., *Gene* 46:145 (1986), and Ner et al., *DNA* 7:127, (1988)).

[0098] Variants of the disclosed zcytor17lig nucleotide and polypeptide sequences can also be generated through DNA shuffling as disclosed by Stemmer, *Nature* 370:389 (1994), Stemmer, *Proc. Natl Acad. Sci. USA* 91:10747 (1994), and international publication No. WO 97/20078. Briefly, variant DNA molecules are generated by *in vitro* homologous recombination by random fragmentation of a parent DNA followed by reassembly using PCR, resulting in randomly introduced point mutations. This technique can be modified by using a family of parent DNA molecules, such as allelic variants or DNA molecules from different species, to introduce additional variability into the process. Selection or screening for the desired activity, followed by additional iterations of mutagenesis and assay provides for rapid "evolution" of sequences by selecting for desirable mutations while simultaneously selecting against detrimental changes.

[0099] Mutagenesis methods as disclosed herein can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides in host cells. Mutagenized DNA molecules that encode biologically active polypeptides, or polypeptides that bind with anti-zcytor17lig antibodies or soluble zcytor17 receptor, or soluble WSX-1 or soluble OSMR or heterodimers or multimers of these soluble receptors as described herein can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

[0100] In addition, the proteins of the present invention (or polypeptide fragments thereof) can be joined to other bioactive molecules, particularly other cytokines, to provide multi-functional molecules. For example, one or more helices from zcytor17lig can be joined to other cytokines to enhance their biological properties or efficiency of production.

[0101] The present invention thus provides a series of novel, hybrid molecules in which a segment comprising one or more of the helices of zcytor17lig is fused to another polypeptide. Fusion is preferably done by splicing at the DNA level to allow expression of chimeric molecules in recombinant production systems. The resultant molecules are then assayed for such properties as improved solubility, improved stability, prolonged clearance half-life, improved expression and secretion levels, and pharmacodynamics. Such hybrid molecules may further comprise additional amino acid residues (e.g., a polypeptide linker) between the component proteins or polypeptides.

[0102] Non-naturally occurring amino acids include, without limitation, *trans*-3-methylproline, 2,4-methanoproline, *cis*-4-hydroxyproline, *trans*-4-hydroxyproline, *N*-methylglycine, *allo*-threonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipercolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4-methylproline, 3,3-dimethylproline, *tert*-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an *in vitro* system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations is typically carried out in a cell-free system comprising an *E. coli* S30 extract and commercially available enzymes and other reagents. Proteins are purified by chromatography. See, for example, Robertson et al., *J. Am. Chem. Soc.* 113:2722 (1991), Ellman et al., *Methods Enzymol.* 202:301 (1991), Chung et al., *Science* 259:806 (1993), and Chung et al., *Proc. Nat'l Acad. Sci. USA* 90:10145 (1993).

[0103] In a second method, translation is carried out in *Xenopus* oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., *J. Biol. Chem.* 271:19991 (1996)). Within a third method, *E. coli* cells are cultured in the absence of a natural amino acid that is to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine). The non-naturally occurring amino acid is incorporated into the protein in place of its natural counterpart. See, Koide et al., *Biochem.* 33:7470 (1994). Naturally occurring amino acid residues can be converted to non-naturally occurring species by *in vitro* chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, *Protein Sci.* 2:395 (1993). It may be advantageous to stabilize zcytor17lig to extend the half-life of the molecule, particularly for extending metabolic persistence in an active state. To achieve extended half-life, zcytor17lig molecules can be chemically modified using methods described herein. PEGylation is one method commonly used that has been demonstrated to increase plasma half-life, increased solubility, and decreased antigenicity and immunogenicity (Nucci et al., *Advanced Drug Delivery Reviews* 6:133-155, 1991 and Lu et al., *Int. J. Peptide Protein Res.* 43:127-138, 1994).

[0104] A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for zcytor17lig amino acid residues.

[0105] The present invention also provides polypeptide fragments or peptides comprising an epitope-bearing portion of a zcytor17lig polypeptide described herein. Such fragments or peptides may comprise an "immunogenic epitope,"

which is a part of a protein that elicits an antibody response when the entire protein is used as an immunogen. Immunogenic epitope-bearing peptides can be identified using standard methods (see, for example, Geysen et al., Proc. Nat'l Acad. Sci. USA 81:3998 (1983)).

5 **[0106]** In contrast, polypeptide fragments or peptides may comprise an "antigenic epitope," which is a region of a protein molecule to which an antibody can specifically bind. Certain epitopes consist of a linear or contiguous stretch of amino acids, and the antigenicity of such an epitope is not disrupted by denaturing agents. It is known in the art that relatively short synthetic peptides that can mimic epitopes of a protein can be used to stimulate the production of antibodies against the protein (see, for example, Sutcliffe et al., Science 219:660 (1983)). Accordingly, antigenic epitope-bearing peptides and polypeptides of the present invention are useful to raise antibodies (e.g., neutralizing antibodies) 10 that bind with the polypeptides described herein. Hopp/Woods hydrophilicity profiles can be used to determine regions that have the most antigenic potential (Hopp et al., 1981, *ibid.* and Hopp, 1986, *ibid.*). For example, in human zcytor17lig, hydrophilic regions include amino acid residues 54-59 of SEQ ID NO:2, amino acid residues 129-134 of SEQ ID NO:2, amino acid residues 53-58 of SEQ ID NO:2, amino acid residues 35-40 of SEQ ID NO:2, and amino acid residues 33-38 of SEQ ID NO:2. For example, in mouse zcytor17lig, hydrophilic regions include amino acid residues 34-39 of SEQ ID NO:11, amino acid residues 46-51 of SEQ ID NO:11, amino acid residues 131-136 of SEQ ID NO:11, amino acid residues 158-163 of SEQ ID NO:11, and amino acid residues 157-162 of SEQ ID NO:11.

[0107] Antigenic epitope-bearing peptides and polypeptides preferably contain at least four to ten amino acids, at least ten to fourteen amino acids, or about fourteen to about thirty amino acids of SEQ ID NO:2 or SEQ ID NO:11. Such epitope-bearing peptides and polypeptides can be produced by fragmenting a zcytor17lig polypeptide, or by chemical peptide synthesis, as described herein. Moreover, epitopes can be selected by phage display of random peptide libraries (see, for example, Lane and Stephen, Curr. Opin. Immunol. 5:268 (1993); and Cortese et al., Curr. Opin. Biotechnol. 7: 616 (1996)). Standard methods for identifying epitopes and producing antibodies from small peptides that comprise an epitope are described, for example, by Mole, "Epitope Mapping," in Methods in Molecular Biology, Vol. 10, Manson (ed.), pages 105-116 (The Humana Press, Inc. 1992); Price, "Production and Characterization of Synthetic Peptide-Derived Antibodies," in Monoclonal Antibodies: Production, Engineering, and Clinical Application, Ritter and Ladyman (eds.), pages 60-84 (Cambridge University Press 1995), and Coligan et al. (eds.), Current Protocols in Immunology, pages 9.3.1 - 9.3.5 and pages 9.4.1 - 9.4.11 (John Wiley & Sons 1997).

20 **[0108]** Regardless of the particular nucleotide sequence of a variant zcytor17lig polynucleotide, the polynucleotide encodes a polypeptide that is characterized by its proliferative or differentiating activity, its ability to induce or inhibit specialized cell functions, or by the ability to bind specifically to an anti-zcytor17lig antibody or zcytor17 receptor. More specifically, variant zcytor17lig polynucleotides will encode polypeptides which exhibit at least 50% and preferably, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or greater than 99%, of the activity of the polypeptide as shown in SEQ ID NO:2.

25 **[0109]** For any zcytor17lig polypeptide, including variants and fusion proteins, one of ordinary skill in the art can readily generate a fully degenerate polynucleotide sequence encoding that variant using the information set forth in Tables 1 and 2 above.

30 **[0110]** The present invention further provides a variety of other polypeptide fusions (and related multimeric proteins comprising one or more polypeptide fusions). For example, a zcytor17lig polypeptide can be prepared as a fusion to a dimerizing protein as disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Preferred dimerizing proteins in this regard include immunoglobulin constant region domains. Immunoglobulin- zcytor17lig polypeptide fusions can be expressed in genetically engineered cells (to produce a variety of multimeric zcytor17lig analogs). Auxiliary domains can be fused to zcytor17lig polypeptides to target them to specific cells, tissues, or macromolecules. For example, a zcytor17lig polypeptide or protein could be targeted to a predetermined cell type by fusing a zcytor17lig polypeptide to a ligand that specifically binds to a receptor on the surface of that target cell. In this way, polypeptides and proteins can be targeted for therapeutic or diagnostic purposes. A zcytor17lig polypeptide can be fused to two or more moieties, such as an affinity tag for purification and a targeting domain. Polypeptide fusions can also comprise one or more cleavage sites, particularly between domains. See, Tuan et al., Connective Tissue Research 34:1-9, 1996.

35 **[0111]** Using the methods discussed herein, one of ordinary skill in the art can identify and/or prepare a variety of polypeptides that have substantially similar sequence identity to residues 1-164 or 24-164 of SEQ ID NO:2. or functional fragments and fusions thereof, such as helices A-D (residues 38-152 of SEQ ID NO:2) wherein such polypeptides or fragments or fusions retain the properties of the wild-type protein such as the ability to stimulate proliferation, differentiation, induce specialized cell function or bind the zcytor17 receptor or zcytor17lig antibodies.

40 **[0112]** The zcytor17lig polypeptides of the present invention, including full-length polypeptides, functional fragments, and fusion polypeptides, can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells. Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., 45

Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989, and Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987.

[0113] In general, a DNA sequence encoding a zcytor17lig polypeptide can be operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

[0114] To direct a zcytor17lig polypeptide into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of zcytor17lig, or may be derived from another secreted protein (e.g., t-PA) or synthesized *de novo*. The secretory signal sequence is operably linked to the zcytor17lig DNA sequence, i.e., the two sequences are joined in the correct reading frame and positioned to direct the newly synthesized polypeptide into the secretory pathway of the host cell. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the polypeptide of interest, although certain secretory signal sequences may be positioned elsewhere in the DNA sequence of interest (see, e.g., Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

[0115] Alternatively, the secretory signal sequence contained in the polypeptides of the present invention is used to direct other polypeptides into the secretory pathway. The present invention provides for such fusion polypeptides. A signal fusion polypeptide can be made wherein a secretory signal sequence derived from amino acid residue 1-23 of SEQ ID NO:2 or residues 1-23 SEQ ID NO:11 is operably linked to a DNA sequence encoding another polypeptide using methods known in the art and disclosed herein. The secretory signal sequence contained in the fusion polypeptides of the present invention is preferably fused amino-terminally to an additional peptide to direct the additional peptide into the secretory pathway. Such constructs have numerous applications known in the art. For example, these novel secretory signal sequence fusion constructs can direct the secretion of an active component of a normally non-secreted protein. Such fusions may be used *in vivo* or *in vitro* to direct peptides through the secretory pathway.

[0116] Cultured mammalian cells are suitable hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphate-mediated transfection (Wigler et al., Cell 14:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 1:841-5, 1982), DEAE-dextran mediated transfection (Ausubel et al., *ibid.*), and liposome-mediated transfection (Hawley-Nelson et al., Focus 15:73, 1993; Ciccarone et al., Focus 15:80, 1993, and viral vectors (Miller and Rosman, BioTechniques 7:980-90, 1989; Wang and Finer, Nature Med. 2:714-6, 1996). The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650), COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No. CRL 10314), 293 (ATCC No. CRL 1573; Graham et al., J. Gen. Virol. 36:59-72, 1977) and Chinese hamster ovary (e.g. CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Manassas, VA. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, e.g., U.S. Patent No. 4,956,288. Other suitable promoters include those from metallothionein genes (U.S. Patent Nos. 4,579,821 and 4,601,978) and the adenovirus major late promoter.

[0117] Drug selection is generally used to select for cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin. Selection is carried out in the presence of a neomycin-type drug, such as G-418 or the like. Selection systems can also be used to increase the expression level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate. Other drug resistance genes (e.g., hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used. Alternative markers that introduce an altered phenotype, such as green fluorescent protein, or cell surface proteins such as CD4, CD8, Class I MHC, placental alkaline phosphatase may be used to sort transfected cells from untransfected cells by such means as FACS sorting or magnetic bead separation technology.

[0118] Other higher eukaryotic cells can also be used as hosts, including plant cells, insect cells and avian cells. The use of *Agrobacterium rhizogenes* as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, 1987. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222 and WIPO publication No. WO 94/06463. Insect cells can be

infected with recombinant baculovirus, commonly derived from *Autographa californica nuclear polyhedrosis virus* (AcNPV). See, King, L.A. and Possee, R.D., *The Baculovirus Expression System: A Laboratory Guide*, London, Chapman & Hall; O'Reilly, D.R. et al., *Baculovirus Expression Vectors: A Laboratory Manual*, New York, Oxford University Press., 1994; and, Richardson, C. D., Ed., *Baculovirus Expression Protocols. Methods in Molecular Biology*, Totowa, NJ, Humana Press, 1995. The second method of making recombinant baculovirus utilizes a transposon-based system described by Luckow (Luckow, V.A, et al., *J Virol* 67:4566-79, 1993). This system is sold in the Bac-to-Bac kit (Life Technologies, Rockville, MD). This system utilizes a transfer vector, pFastBac1™ (Life Technologies) containing a Tn7 transposon to move the DNA encoding the zcytor17lig polypeptide into a baculovirus genome maintained in *E. coli* as a large plasmid called a "bacmid." The pFastBac1™ transfer vector utilizes the AcNPV polyhedrin promoter to drive the expression of the gene of interest, in this case zcytor17lig. However, pFastBac1™ can be modified to a considerable degree. The polyhedrin promoter can be removed and substituted with the baculovirus basic protein promoter (also known as Pcor, p6.9 or MP promoter) which is expressed earlier in the baculovirus infection, and has been shown to be advantageous for expressing secreted proteins. See, Hill-Perkins, M.S. and Possee, R.D., *J. Gen. Virol.* 71:971-6, 1990; Bonning, B.C. et al., *J. Gen. Virol.* 75:1551-6, 1994; and, Chazenbalk, G.D., and Rapoport, B., *J. Biol. Chem.* 270:1543-9, 1995. In such transfer vector constructs, a short or long version of the basic protein promoter can be used. Moreover, transfer vectors can be constructed which replace the native zcytor17lig secretory signal sequences with secretory signal sequences derived from insect proteins. For example, a secretory signal sequence from Ecdysteroid Glucosyltransferase (EGT), honey bee Melittin (Invitrogen, Carlsbad, CA), or baculovirus gp67 (PharMingen, San Diego, CA) can be used in constructs to replace the native zcytor17lig secretory signal sequence. In addition, transfer vectors can include an in-frame fusion with DNA encoding an epitope tag at the C- or N-terminus of the expressed zcytor17lig polypeptide, for example, a Glu-Glu epitope tag (Grussenmeyer, T. et al., *Proc. Natl. Acad. Sci.* 82:7952-4, 1985). Using techniques known in the art, a transfer vector containing zcytor17lig is transformed into *E. Coli*, and screened for bacmids which contain an interrupted lacZ gene indicative of recombinant baculovirus. The bacmid DNA containing the recombinant baculovirus genome is isolated, using common techniques, and used to transfect *Spodoptera frugiperda* cells, e.g., Sf9 cells. Recombinant virus that expresses zcytor17lig is subsequently produced. Recombinant viral stocks are made by methods commonly used the art.

[0119] The recombinant virus is used to infect host cells, typically a cell line derived from the fall armyworm, *Spodoptera frugiperda*. See, in general, Glick and Pasternak, *Molecular Biotechnology: Principles and Applications of Recombinant DNA*, ASM Press, Washington, D.C., 1994. Another suitable cell line is the High Five™ cell line (Invitrogen) derived from *Trichoplusia ni* (U.S. Patent No. 5,300,435).

[0120] Fungal cells, including yeast cells, can also be used within the present invention. Yeast species of particular interest in this regard include *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Pichia methanolica*. Methods for transforming *S. cerevisiae* cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No. 4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient (e.g., leucine). A preferred vector system for use in *Saccharomyces cerevisiae* is the *POT1* vector system disclosed by Kawasaki et al. (U.S. Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media. Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S. Patent No. 4,615,974; and Bitter, U.S. Patent No. 4,977,092) and alcohol dehydrogenase genes. See also U.S. Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454. Transformation systems for other yeasts, including *Hansenula polymorpha*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Kluyveromyces fragilis*, *Ustilago maydis*, *Pichia pastoris*, *Pichia methanolica*, *Pichia guilliermondii* and *Candida maltosa* are known in the art. See, for example, Gleeson et al., *J. Gen. Microbiol.* 132:3459-65, 1986 and Cregg, U.S. Patent No. 4,882,279. *Aspergillus* cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349. Methods for transforming *Acremonium chrysogenum* are disclosed by Sumino et al., U.S. Patent No. 5,162,228. Methods for transforming *Neurospora* are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

[0121] The use of *Pichia methanolica* as host for the production of recombinant proteins is disclosed in WIPO Publication Nos. WO 97/17450, WO 97/17451, WO 98/02536, and WO 98/02565. DNA molecules for use in transforming *P. methanolica* will commonly be prepared as double-stranded, circular plasmids, which are preferably linearized prior to transformation. For polypeptide production in *P. methanolica*, it is preferred that the promoter and terminator in the plasmid be that of a *P. methanolica* gene, such as a *P. methanolica* alcohol utilization gene (*AUG1* or *AUG2*). Other useful promoters include those of the dihydroxyacetone synthase (DHAS), formate dehydrogenase (FMD), and catalase (CAT) genes. To facilitate integration of the DNA into the host chromosome, it is preferred to have the entire expression segment of the plasmid flanked at both ends by host DNA sequences. A preferred selectable marker for use in *Pichia methanolica* is a *P. methanolica* *ADE2* gene, which encodes phosphoribosyl-5-aminoimidazole carboxylase (AIRC; EC 4.1.1.21), which allows *ade2* host cells to grow in the absence of adenine. For large-scale, industrial processes where

it is desirable to minimize the use of methanol, it is preferred to use host cells in which both methanol utilization genes (*AUG1* and *AUG2*) are deleted. For production of secreted proteins, host cells deficient in vacuolar protease genes (*PEP4* and *PRB1*) are preferred. Electroporation is used to facilitate the introduction of a plasmid containing DNA encoding a polypeptide of interest into *P. methanolica* cells. It is preferred to transform *P. methanolica* cells by electro-
5 poration using an exponentially decaying, pulsed electric field having a field strength of from 2.5 to 4.5 kV/cm, preferably about 3.75 kV/cm, and a time constant (Ω) of from 1 to 40 milliseconds, most preferably about 20 milliseconds.

[0122] Prokaryotic host cells, including strains of the bacteria *Escherichia coli*, *Bacillus* and other genera are also useful host cells within the present invention. Techniques for transforming these hosts and expressing foreign DNA sequences cloned therein are well known in the art (see, e.g., Sambrook et al., *ibid.*). When expressing a zcytor17lig polypeptide in bacteria such as *E. coli*, the polypeptide may be retained in the cytoplasm, typically as insoluble granules, or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed, and the granules are recovered and denatured using, for example, guanidine isothiocyanate or urea. The denatured polypeptide can then be refolded and dimerized by diluting the denaturant, such as by dialysis against a solution of urea and a combination of reduced and oxidized glutathione, followed by dialysis against a buffered saline solution. In the
10 latter case, the polypeptide can be recovered from the periplasmic space in a soluble and functional form by disrupting the cells (by, for example, sonication or osmotic shock) to release the contents of the periplasmic space and recovering the protein, thereby obviating the need for denaturation and refolding.

[0123] Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or co-transfected into the host cell. *P. methanolica* cells are cultured in a medium comprising
20 adequate sources of carbon, nitrogen and trace nutrients at a temperature of about 25°C to 35°C. Liquid cultures are provided with sufficient aeration by conventional means, such as shaking of small flasks or sparging of fermentors. A preferred culture medium for *P. methanolica* is YEPD (2% D-glucose, 2% Bacto™ Peptone (Difco Laboratories; Detroit, MI), 1% Bacto™ yeast extract (Difco Laboratories), 0.004% adenine and 0.006% L-leucine).

[0124] It is preferred to purify the polypeptides of the present invention to $\geq 80\%$ purity, more preferably to $\geq 90\%$ purity, even more preferably $\geq 95\%$ purity, and particularly preferred is a pharmaceutically pure state, that is greater than 99.9% pure with respect to contaminating macromolecules, particularly other proteins and nucleic acids, and free of infectious and pyrogenic agents. Preferably, a purified polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin.

[0125] Expressed recombinant zcytor17lig polypeptides (or chimeric zcytor17lig polypeptides) can be purified using fractionation and/or conventional purification methods and media. Ammonium sulfate precipitation and acid or chaotrope extraction may be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable chromatographic media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred. Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose (Pharmacia) and the like; or polyacrylic resins, such as Amberchrom CG 71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties. Examples of coupling chemistries include cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Methods for binding receptor polypeptides to support media are well known in the art. Selection of a particular method is a matter of routine design and is determined in part by the properties of the chosen support. See, for example, Affinity Chromatography: Principles & Methods, Pharmacia LKB Biotechnology, Uppsala, Sweden, 1988.

[0126] The polypeptides of the present invention can be isolated by exploitation of their physical or biochemical properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich proteins, including those comprising polyhistidine tags. Briefly, a gel is first charged with divalent metal ions to form a chelate (Sulkowski, Trends in Biochem. 3:1-7, 1985). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography (Methods in Enzymol., Vol. 182, "Guide to Protein Purification", M. Deutscher,

(ed.), Acad. Press, San Diego, 1990, pp.529-39) and use of the soluble zcytor17 receptor. Within additional embodiments of the invention, a fusion of the polypeptide of interest and an affinity tag (e.g., maltose-binding protein, an immunoglobulin domain) may be constructed to facilitate purification.

5 [0127] Moreover, using methods described in the art, polypeptide fusions, or hybrid zcytor17lig proteins, are constructed using regions or domains of the inventive zcytor17lig in combination with those of other human cytokine family proteins (e.g. interleukins or GM-CSF), or heterologous proteins (Sambrook et al., *ibid.*, Altschul et al., *ibid.*, Picard, *Cur. Opin. Biology*, 5:511-5, 1994, and references therein). These methods allow the determination of the biological importance of larger domains or regions in a polypeptide of interest. Such hybrids may alter reaction kinetics, binding, constrict or expand the substrate specificity, or alter tissue and cellular localization of a polypeptide, and can be applied to polypep-
10 tides of unknown structure.

[0128] Fusion proteins can be prepared by methods known to those skilled in the art by preparing each component of the fusion protein and chemically conjugating them. Alternatively, a polynucleotide encoding both components of the fusion protein in the proper reading frame can be generated using known techniques and expressed by the methods described herein. For example, part or all of a helix conferring a biological function may be swapped between zcytor17lig
15 of the present invention with the functionally equivalent helices from another family member, such as IL-15, IL-2, IL-4 or GM-CSF. Such components include, but are not limited to, the secretory signal sequence; helices A, B, C, D; loops A/B, B/C, C/D; of four-helical-bundle cytokines. Such fusion proteins would be expected to have a biological functional profile that is the same or similar to polypeptides of the present invention or other known four-helical-bundle cytokine family proteins, depending on the fusion constructed. Moreover, such fusion proteins may exhibit other properties as disclosed herein.

[0129] Standard molecular biological and cloning techniques can be used to swap the equivalent domains between the zcytor17lig polypeptide and those polypeptides to which they are fused. Generally, a DNA segment that encodes a domain of interest, e.g., zcytor17lig helices A through D, or other domain described herein, is operably linked in frame
25 to at least one other DNA segment encoding an additional polypeptide (for instance a domain or region from another cytokine, such as the IL-2, or the like), and inserted into an appropriate expression vector, as described herein. Generally DNA constructs are made such that the several DNA segments that encode the corresponding regions of a polypeptide are operably linked in frame to make a single construct that encodes the entire fusion protein, or a functional portion thereof. For example, a DNA construct would encode from N-terminus to C-terminus a fusion protein comprising a signal polypeptide followed by a mature four helical bundle cytokine fusion protein containing helix A, followed by helix B,
30 followed by helix C, followed by helix D. Such fusion proteins can be expressed, isolated, and assayed for activity as described herein.

[0130] Zcytor17lig polypeptides or fragments thereof may also be prepared through chemical synthesis. zcytor17lig polypeptides may be monomers or multimers; glycosylated or non-glycosylated; pegylated or non-pegylated; and may or may not include an initial methionine amino acid residue. For example, the polypeptides can be prepared by solid
35 phase peptide synthesis, for example as described by Merrifield, *J. Am. Chem. Soc.* 85:2149, 1963.

[0131] The activity of molecules of the present invention can be measured using a variety of assays that measure proliferation of and/or binding to cells expressing the zcytor17 receptor. Of particular interest are changes in zcytor17lig-
40 dependent cells. Suitable cell lines to be engineered to be zcytor17lig-dependent include the IL-3-dependent BaF3 cell line (Palacios and Steinmetz, *Cell* 41: 727-734, 1985; Mathey-Prevot et al., *Mol. Cell. Biol.* 6: 4133-4135, 1986), FDC-P1 (Hapel et al., *Blood* 64: 786-790, 1984), and MO7e (Kiss et al., *Leukemia* 7: 235-240, 1993). Growth factor-dependent cell lines can be established according to published methods (e.g. Greenberger et al., *Leukemia Res.* 8: 363-375, 1984; Dexter et al., in Baum et al. Eds., *Experimental Hematology Today*, 8th Ann. Mtg. Int. Soc. Exp. Hematol. 1979, 145-156, 1980).

[0132] Proteins of the present invention are useful for stimulating proliferation, activation, differentiation and/or induc-
45 tion or inhibition of specialized cell function of cells of the involved homeostasis of the hematopoiesis and immune function. In particular, zcytor17lig polypeptides are useful for stimulating proliferation, activation, differentiation, induction or inhibition of specialized cell functions of cells of the hematopoietic lineages, including, but not limited to, T cells, B cells, monocytes/macrophages, NK cells, neutrophils, endothelial cells, fibroblasts, eosinophils, chondrocytes, mast cells, langerhan cells, monocytes, and macrophages, as well as epithelial cells. Epithelial cells include, for example,
50 ameloblasts, chief cells, chromatophores, enterochromaffin cells, enterochromaffin-like cells, goblet cells, granulosa cells, keratinocytes, dendritic cells, labyrinth supporting cells, melanocytes, merkel cells, paneth cells, parietal cells, sertoli cells, and the like. Proliferation and/or differentiation of hematopoietic cells can be measured *in vitro* using cultured cells or *in vivo* by administering molecules of the present invention to the appropriate animal model. Assays measuring cell proliferation or differentiation are well known in the art. For example, assays measuring proliferation include such
55 assays as chemosensitivity to neutral red dye (Cavanaugh et al., *Investigational New Drugs* 8:347-354, 1990, incorporated herein by reference), incorporation of radiolabelled nucleotides (Cook et al., *Analytical Biochem.* 179:1-7, 1989, incorporated herein by reference), incorporation of 5-bromo-2'-deoxyuridine (BrdU) in the DNA of proliferating cells (Porstmann et al., *J. Immunol. Methods* 82:169-179, 1985, incorporated herein by reference), and use of tetrazolium

salts (Mosmann, J. Immunol. Methods 65:55-63, 1983; Alley et al., Cancer Res. 48:589-601, 1988; Marshall et al., Growth Reg. 5:69-84, 1995; and Scudiero et al., Cancer Res. 48:4827-4833, 1988; all incorporated herein by reference). Assays measuring differentiation include, for example, measuring cell-surface markers associated with stage-specific expression of a tissue, enzymatic activity, functional activity or morphological changes (Watt, FASEB, 5:281-284, 1991; Francis, Differentiation 57:63-75, 1994; Raes, Adv. Anim. Cell Biol. Technol. Bioprocesses, 161-171, 1989; all incorporated herein by reference).

[0133] The molecules of the present invention can be assayed *in vivo* using viral delivery systems. Exemplary viruses for this purpose include adenovirus, herpesvirus, retroviruses, vaccinia virus, and adeno-associated virus (AAV). Adenovirus, a double-stranded DNA virus, is currently the best studied gene transfer vector for delivery of heterologous nucleic acid (for review, see T.C. Becker et al., Meth. Cell Biol. 43:161-89, 1994; and J.T. Douglas and D.T. Curiel, Science & Medicine 4:44-53, 1997).

[0134] As a ligand, the activity of zcytor17lig polypeptide can be measured by a silicon-based biosensor microphysiometer which measures the extracellular acidification rate or proton excretion associated with receptor binding and subsequent physiologic cellular responses. An exemplary device is the Cytosensor™ Microphysiometer manufactured by Molecular Devices, Sunnyvale, CA. A variety of cellular responses, such as cell proliferation, ion transport, energy production, inflammatory response, regulatory and receptor activation, and the like, can be measured by this method. See, for example, McConnell, H.M. et al., Science 257:1906-1912, 1992; Pitchford, S. et al., Meth. Enzymol. 228:84-108, 1997; Arimilli, S. et al., J. Immunol. Meth. 212:49-59, 1998; Van Liefde, I. et al., Eur. J. Pharmacol. 346:87-95, 1998.

[0135] Moreover, zcytor17lig can be used to identify cells, tissues, or cell lines which respond to a zcytor17lig-stimulated pathway. The microphysiometer, described above, can be used to rapidly identify ligand-responsive cells, such as cells responsive to zcytor17lig of the present invention. Cells can be cultured in the presence or absence of zcytor17lig polypeptide. Those cells which elicit a measurable change in extracellular acidification in the presence of zcytor17lig are responsive to zcytor17lig. Such cells or cell lines, can be used to identify antagonists and agonists of zcytor17lig polypeptide as described above.

[0136] In view of the tissue distribution observed for zcytor17 receptor agonists (including the natural zcytor17lig/substrate/ cofactor/ etc.) and/or antagonists have enormous potential in both *in vitro* and *in vivo* applications. Compounds identified as zcytor17lig agonists are useful for expansion, proliferation, activation, differentiation, and/or induction or inhibition of specialized cell functions of cells involved in homeostasis of hematopoiesis and immune function. For example, zcytor17lig and agonist compounds are useful as components of defined cell culture media, and may be used alone or in combination with other cytokines and hormones to replace serum that is commonly used in cell culture. Agonists are thus useful in specifically promoting the growth and/or development of T-cells, B-cells, monocytes/macrophages, NK cells, cytotoxic lymphocytes, and other cells of the lymphoid and myeloid lineages in culture.

[0137] Antagonists are also useful as research reagents for characterizing sites of ligand-receptor interaction. Antagonists are useful to inhibit expansion, proliferation, activation, and/or differentiation of cells involved in regulating hematopoiesis. Inhibitors of zcytor17lig activity (zcytor17lig antagonists) include anti-zcytor17lig antibodies and soluble zcytor17lig receptors, as well as other peptidic and non-peptidic agents (including ribozymes).

[0138] Zcytor17lig can also be used to identify inhibitors (antagonists) of its activity. Test compounds are added to the assays disclosed herein to identify compounds that inhibit the activity of zcytor17lig. In addition to those assays disclosed herein, samples can be tested for inhibition of zcytor17lig activity within a variety of assays designed to measure receptor binding, the stimulation/inhibition of zcytor17lig-dependent cellular responses or proliferation of zcytor17 receptor-expressing cells.

[0139] A zcytor17lig polypeptide can be expressed as a fusion with an immunoglobulin heavy chain constant region, typically an F_c fragment, which contains two constant region domains and lacks the variable region. Methods for preparing such fusions are disclosed in U.S. Patents Nos. 5,155,027 and 5,567,584. Such fusions are typically secreted as multimeric molecules wherein the F_c portions are disulfide bonded to each other and two non-Ig polypeptides are arrayed in closed proximity to each other. Fusions of this type can be used for example, for dimerization, increasing stability and *in vivo* half-life, to affinity purify ligand, as *in vitro* assay tool or antagonist. For use in assays, the chimeras are bound to a support via the F_c region and used in an ELISA format.

[0140] A zcytor17lig-binding polypeptide can also be used for purification of ligand. The polypeptide is immobilized on a solid support, such as beads of agarose, cross-linked agarose, glass, cellulosic resins, silica-based resins, polystyrene, cross-linked polyacrylamide, or like materials that are stable under the conditions of use. Methods for linking polypeptides to solid supports are known in the art, and include amine chemistry, cyanogen bromide activation, N-hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, and hydrazide activation. The resulting medium will generally be configured in the form of a column, and fluids containing ligand are passed through the column one or more times to allow ligand to bind to the receptor polypeptide. The ligand is then eluted using changes in salt concentration, chaotropic agents (guanidine HCl), or pH to disrupt ligand-receptor binding.

[0141] An assay system that uses a ligand-binding receptor (or an antibody, one member of a complement/anti-complement pair) or a binding fragment thereof, and a commercially available biosensor instrument (BIAcore, Pharmacia

Biosensor, Piscataway, NJ) may be advantageously employed. Such receptor, antibody, member of a complement/anti-complement pair or fragment is immobilized onto the surface of a receptor chip. Use of this instrument is disclosed by Karlsson, J. *Immunol. Methods* 145:229-40, 1991 and Cunningham and Wells, J. *Mol. Biol.* 234:554-63, 1993. A receptor, antibody, member or fragment is covalently attached, using amine or sulfhydryl chemistry, to dextran fibers that are attached to gold film within the flow cell. A test sample is passed through the cell. If a ligand, epitope, or opposite member of the complement/anti-complement pair is present in the sample, it will bind to the immobilized receptor, antibody or member, respectively, causing a change in the refractive index of the medium, which is detected as a change in surface plasmon resonance of the gold film. This system allows the determination of on- and off-rates, from which binding affinity can be calculated, and assessment of stoichiometry of binding. Alternatively, ligand/receptor binding can be analyzed using SELDI(TM) technology (Ciphergen, Inc., Palo Alto, CA).

[0142] Ligand-binding receptor polypeptides can also be used within other assay systems known in the art. Such systems include Scatchard analysis for determination of binding affinity (see Scatchard, *Ann. NY Acad. Sci.* 51: 660-72, 1949) and calorimetric assays (Cunningham et al., *Science* 253:545-48, 1991; Cunningham et al., *Science* 245:821-25, 1991).

[0143] Zcytor17lig polypeptides can also be used to prepare antibodies that bind to zcytor17lig epitopes, peptides or polypeptides. The zcytor17lig polypeptide or a fragment thereof serves as an antigen (immunogen) to inoculate an animal and elicit an immune response. Such antibodies can be used to block the biological action of pro-inflammatory zcytor17lig and are useful as anti-inflammatory therapeutics in a variety of diseases as described herein. One of skill in the art would recognize that antigenic, epitope-bearing polypeptides contain a sequence of at least 6, preferably at least 9, and more preferably at least 15 to about 30 contiguous amino acid residues of a zcytor17lig polypeptide (e.g., SEQ ID NO:2). Polypeptides comprising a larger portion of a zcytor17lig polypeptide, i.e., from 30 to 100 residues up to the entire length of the amino acid sequence are included. Antigens or immunogenic epitopes can also include attached tags, adjuvants, vehicles and carriers, as described herein. Suitable antigens include the zcytor17lig polypeptide encoded by SEQ ID NO:2 from amino acid number 24 to amino acid number 164, or a contiguous 9 to 141 amino acid fragment thereof. Other suitable antigens include, the full length and the mature zcytor17lig, helices A-D, and individual or multiple helices A, B, C, and D, of the zcytor17lig four-helical-bundle structure, as described herein. Preferred peptides to use as antigens are hydrophilic peptides such as those predicted by one of skill in the art from a hydrophobicity plot, as described herein, for example, amino acid residues 114-119, 101-105, 126-131, 113-118, and 158-162 of SEQ ID NO: 2; and amino acid residues 34-39, 46-51, 131-136, 158-163 and 157-162 of SEQ ID NO:11. Moreover, zcytor17lig antigenic epitopes as predicted by a Jameson-Wolf plot, e.g., using DNASTAR Protean program (DNASTAR, Inc., Madison, WI) serve as preferred antigens, and are readily determined by one of skill in the art.

[0144] Antibodies from an immune response generated by inoculation of an animal with these antigens can be isolated and purified as described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, *Current Protocols in Immunology*, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995; Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, NY, 1989; and Hurrell, J. G. R., Ed., *Monoclonal Hybridoma Antibodies: Techniques and Applications*, CRC Press, Inc., Boca Raton, FL, 1982.

[0145] As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a zcytor17lig polypeptide or a fragment thereof. The immunogenicity of a zcytor17lig polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant. Polypeptides useful for immunization also include fusion polypeptides, such as fusions of zcytor17lig or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a full-length molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

[0146] As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab')₂ and Fab proteolytic fragments. Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigen-binding peptides and polypeptides, are also included. Non-human antibodies may be humanized by grafting non-human CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced. Moreover, human antibodies can be produced in transgenic, non-human animals that have been engineered to contain human immunoglobulin genes as disclosed in WIPO Publication No. WO 98/24893. It is preferred that the endogenous immunoglobulin genes in these animals be inactivated or eliminated, such as by homologous

recombination.

[0147] Antibodies are considered to be specifically binding if: 1) they exhibit a threshold level of binding activity, and 2) they do not significantly cross-react with related polypeptide molecules. A threshold level of binding is determined if anti-zcytor17lig antibodies herein bind to a zcytor17lig polypeptide, peptide or epitope with an affinity at least 10-fold greater than the binding affinity to control (non-zcytor17lig) polypeptide. It is preferred that the antibodies exhibit a binding affinity (K_a) of 10^6 M⁻¹ or greater, preferably 10^7 M⁻¹ or greater, more preferably 10^8 M⁻¹ or greater, and most preferably 10^9 M⁻¹ or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis (Scatchard, G., Ann. NY Acad. Sci. 51: 660-672, 1949).

[0148] Whether anti-zcytor17lig antibodies do not significantly cross-react with related polypeptide molecules is shown, for example, by the antibody detecting zcytor17lig polypeptide but not known related polypeptides using a standard Western blot analysis (Ausubel et al., *ibid.*). Examples of known related polypeptides are those disclosed in the prior art, such as known orthologs, and paralogs, and similar known members of a protein family. Screening can also be done using non-human zcytor17lig, and zcytor17lig mutant polypeptides. Moreover, antibodies can be "screened against" known related polypeptides, to isolate a population that specifically binds to the zcytor17lig polypeptides. For example, antibodies raised to zcytor17lig are adsorbed to related polypeptides adhered to insoluble matrix; antibodies specific to zcytor17lig will flow through the matrix under the proper buffer conditions. Screening allows isolation of polyclonal and monoclonal antibodies non-crossreactive to known closely related polypeptides (Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; Current Protocols in Immunology, Cooligan, et al. (eds.), National Institutes of Health, John Wiley and Sons, Inc., 1995). Screening and isolation of specific antibodies is well known in the art. See, Fundamental Immunology, Paul (eds.), Raven Press, 1993; Getzoff et al., Adv. in Immunol. 43: 1-98, 1988; Monoclonal Antibodies: Principles and Practice, Goding, J.W. (eds.), Academic Press Ltd., 1996; Benjamin et al., Ann. Rev. Immunol. 2: 67-101, 1984. Specifically binding anti-zcytor17lig antibodies can be detected by a number of methods in the art, and disclosed below.

[0149] A variety of assays known to those skilled in the art can be utilized to detect antibodies which bind to zcytor17lig proteins or polypeptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane (Eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: concurrent immunoelectrophoresis, radioimmunoassay, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant zcytor17lig protein or polypeptide.

[0150] Antibodies to zcytor17lig may be used for tagging cells that express zcytor17lig; for isolating zcytor17lig by affinity purification; for diagnostic assays for determining circulating levels of zcytor17lig polypeptides; for detecting or quantitating soluble zcytor17lig as a marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block zcytor17lig activity *in vitro* and *in vivo*. Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates. Antibodies herein may also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for *in vivo* diagnostic or therapeutic applications. Moreover, antibodies to zcytor17lig or fragments thereof may be used *in vitro* to detect denatured zcytor17lig or fragments thereof in assays, for example, Western Blots or other assays known in the art.

[0151] Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria, toxin, saporin, *Pseudomonas* exotoxin, ricin, abrin and the like); as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/anti-complementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/ anticomplementary pair.

[0152] Binding polypeptides can also act as zcytor17lig "antagonists" to block zcytor17lig binding and signal transduction *in vitro* and *in vivo*. These anti-zcytor17lig binding polypeptides would be useful for inhibiting zcytor17lig activity or protein-binding.

[0153] Polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues). Alternatively, if the polypeptide has multiple functional domains (i.e., an activation domain or a receptor binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain only fusion protein includes a complementary

molecule, the anti-complementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting carrier or vehicle for cell/tissue-specific delivery of generic anti-complementary-detectable/ cytotoxic molecule conjugates.

[0154] In another embodiment, zcytor17lig cytokine fusion proteins or antibody-cytokine fusion proteins can be used for *in vivo* killing of target tissues (for example, leukemia, lymphoma, lung cancer, colon cancer, melanoma, pancreatic cancer, ovarian cancer, skin, blood and bone marrow cancers, or other cancers wherein zcytor17lig receptors are expressed) (See, generally, Hornick et al., Blood 89:4437-47, 1997). The described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable zcytor17lig polypeptides or anti-zcytor17lig antibodies target an undesirable cell or tissue (i.e., a tumor or a leukemia), and the fused cytokine mediated improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), for instance.

[0155] In yet another embodiment, if the zcytor17lig polypeptide or anti-zcytor17lig antibody targets vascular cells or tissues, such polypeptide or antibody may be conjugated with a radionuclide, and particularly with a beta-emitting radionuclide, to reduce restenosis. Such therapeutic approaches pose less danger to clinicians who administer the radioactive therapy. For instance, iridium-192 impregnated ribbons placed into stented vessels of patients until the required radiation dose was delivered showed decreased tissue growth in the vessel and greater luminal diameter than the control group, which received placebo ribbons. Further, revascularisation and stent thrombosis were significantly lower in the treatment group. Similar results are predicted with targeting of a bioactive conjugate containing a radionuclide, as described herein.

[0156] The bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.

[0157] Moreover, inflammation is a protective response by an organism to fend off an invading agent. Inflammation is a cascading event that involves many cellular and humoral mediators. On one hand, suppression of inflammatory responses can leave a host immunocompromised; however, if left unchecked, inflammation can lead to serious complications including chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and the like), septic shock and multiple organ failure. Importantly, these diverse disease states share common inflammatory mediators. The collective diseases that are characterized by inflammation have a large impact on human morbidity and mortality. Therefore it is clear that anti-inflammatory antibodies and binding polypeptides, such as anti-zcytor17lig antibodies and binding polypeptides described herein, could have crucial therapeutic potential for a vast number of human and animal diseases, from asthma and allergy to autoimmunity and septic shock. As such, use of anti-inflammatory anti zcytor17lig antibodies and binding polypeptides described herein can be used therapeutically as zcytor17lig antagonists described herein, particularly in diseases such as arthritis, endotoxemia, inflammatory bowel disease, psoriasis, related disease and the like.

1. Arthritis

[0158] Arthritis, including osteoarthritis, rheumatoid arthritis, arthritic joints as a result of injury, and the like, are common inflammatory conditions which would benefit from the therapeutic use of anti-inflammatory antibodies and binding polypeptides, such as anti-zcytor17lig antibodies and binding polypeptides of the present invention. For Example, rheumatoid arthritis (RA) is a systemic disease that affects the entire body and is one of the most common forms of arthritis. It is characterized by the inflammation of the membrane lining the joint, which causes pain, stiffness, warmth, redness and swelling. Inflammatory cells release enzymes that may digest bone and cartilage. As a result of rheumatoid arthritis, the inflamed joint lining, the synovium, can invade and damage bone and cartilage leading to joint deterioration and severe pain amongst other physiologic effects. The involved joint can lose its shape and alignment, resulting in pain and loss of movement.

[0159] Rheumatoid arthritis (RA) is an immune-mediated disease particularly characterized by inflammation and subsequent tissue damage leading to severe disability and increased mortality. A variety of cytokines are produced locally in the rheumatoid joints. Numerous studies have demonstrated that IL-1 and TNF-alpha, two prototypic pro-inflammatory cytokines, play an important role in the mechanisms involved in synovial inflammation and in progressive joint destruction. Indeed, the administration of TNF-alpha and IL-1 inhibitors in patients with RA has led to a dramatic improvement of clinical and biological signs of inflammation and a reduction of radiological signs of bone erosion and cartilage destruction. However, despite these encouraging results, a significant percentage of patients do not respond to these agents, suggesting that other mediators are also involved in the pathophysiology of arthritis (Gabay, Expert. Opin. Biol. Ther. 2(2): 135-149, 2002). One of those mediators could be zcytor17lig, and as such a molecule that binds or inhibits zcytor17lig, such as anti zcytor17lig antibodies or binding partners, could serve as a valuable therapeutic to reduce inflammation in rheumatoid arthritis, and other arthritic diseases.

[0160] There are several animal models for rheumatoid arthritis known in the art. For example, in the collagen-induced arthritis (CIA) model, mice develop chronic inflammatory arthritis that closely resembles human rheumatoid arthritis.

Since CIA shares similar immunological and pathological features with RA, this makes it an ideal model for screening potential human anti-inflammatory compounds. The CIA model is a well-known model in mice that depends on both an immune response, and an inflammatory response, in order to occur. The immune response comprises the interaction of B-cells and CD4+ T-cells in response to collagen, which is given as antigen, and leads to the production of anti-collagen antibodies. The inflammatory phase is the result of tissue responses from mediators of inflammation, as a consequence of some of these antibodies cross-reacting to the mouse's native collagen and activating the complement cascade. An advantage in using the CIA model is that the basic mechanisms of pathogenesis are known. The relevant T-cell and B-cell epitopes on type II collagen have been identified, and various immunological (e.g., delayed-type hypersensitivity and anti-collagen antibody) and inflammatory (e.g., cytokines, chemokines, and matrix-degrading enzymes) parameters relating to immune-mediated arthritis have been determined, and can thus be used to assess test compound efficacy in the CIA model (Wooley, *Curr. Opin. Rheum.* 3:407-20, 1999; Williams et al., *Immunol.* 89:9784-788, 1992; Myers et al., *Life Sci.* 61:1861-78, 1997; and Wang et al., *Immunol.* 92:8955-959, 1995).

[0161] The administration of soluble zcytor17 comprising polypeptides (including heterodimeric and multimeric receptors described herein), such as zcytor17-Fc4 or other zcytor17 soluble and fusion proteins to these CIA model mice was used to evaluate the use of zcytor17 to ameliorate symptoms and alter the course of disease. As a molecule that modulates immune and inflammatory response, zcytor17lig, may induce production of SAA, which is implicated in the pathogenesis of rheumatoid arthritis, zcytor17lig antagonists may reduce SAA activity *in vitro* and *in vivo*, the systemic or local administration of zcytor17lig antagonists such as anti-zcytor17lig antibodies or binding partners, zcytor17 comprising polypeptides (including heterodimeric and multimeric receptors described herein), such as zcytor17-Fc4 or other zcytor17 soluble and fusion proteins can potentially suppress the inflammatory response in RA. Other potential therapeutics include zcytor17 polypeptides, soluble heterodimeric and multimeric receptor polypeptides, or anti zcytor17lig antibodies or binding partners of the present invention, and the like.

2. Endotoxemia

[0162] Endotoxemia is a severe condition commonly resulting from infectious agents such as bacteria and other infectious disease agents, sepsis, toxic shock syndrome, or in immunocompromised patients subjected to opportunistic infections, and the like. Therapeutically useful of anti-inflammatory antibodies and binding polypeptides, such as anti-zcytor17lig antibodies and binding polypeptides of the present invention, could aid in preventing and treating endotoxemia in humans and animals. Other potential therapeutics include zcytor17 polypeptides, soluble heterodimeric and multimeric receptor polypeptides, or anti zcytor17lig antibodies or binding partners of the present invention, and the like, could serve as a valuable therapeutic to reduce inflammation and pathological effects in endotoxemia.

[0163] Lipopolysaccharide (LPS) induced endotoxemia engages many of the proinflammatory mediators that produce pathological effects in the infectious diseases and LPS induced endotoxemia in rodents is a widely used and acceptable model for studying the pharmacological effects of potential pro-inflammatory or immunomodulating agents. LPS, produced in gram-negative bacteria, is a major causative agent in the pathogenesis of septic shock (Glausner et al., *Lancet* 338:732, 1991). A shock-like state can indeed be induced experimentally by a single injection of LPS into animals. Molecules produced by cells responding to LPS can target pathogens directly or indirectly. Although these biological responses protect the host against invading pathogens, they may also cause harm. Thus, massive stimulation of innate immunity, occurring as a result of severe Gram-negative bacterial infection, leads to excess production of cytokines and other molecules, and the development of a fatal syndrome, septic shock syndrome, which is characterized by fever, hypotension, disseminated intravascular coagulation, and multiple organ failure (Dumitru et al. *Cell* 103:1071-1083, 2000).

[0164] These toxic effects of LPS are mostly related to macrophage activation leading to the release of multiple inflammatory mediators. Among these mediators, TNF appears to play a crucial role, as indicated by the prevention of LPS toxicity by the administration of neutralizing anti-TNF antibodies (Beutler et al., *Science* 229:869, 1985). It is well established that i.p. injection of *E. coli* LPS into a C57B1/6 mouse will result in significant increases in circulating IL-6, TNF-alpha, IL-1, and acute phase proteins (for example, SAA) approximately 2 hours post injection. The toxicity of LPS appears to be mediated by these cytokines as passive immunization against these mediators can result in decreased mortality (Beutler et al., *Science* 229:869, 1985). The potential immunointervention strategies for the prevention and/or treatment of septic shock include anti-TNF mAb, IL-1 receptor antagonist, LIF, IL-10, and G-CSF. Since LPS induces the production of pro-inflammatory factors possibly contributing to the pathology of endotoxemia, the neutralization of zcytor17lig activity, SAA or other pro-inflammatory factors by antagonizing zcytor17lig polypeptide can be used to reduce the symptoms of endotoxemia, such as seen in endotoxic shock. Other potential therapeutics include zcytor17 polypeptides, soluble heterodimeric and multimeric receptor polypeptides, or anti-zcytor17lig antibodies or binding partners of the present invention, and the like.

3 Inflammatory Bowel Disease. IBD

[0165] In the United States approximately 500,000 people suffer from Inflammatory Bowel Disease (IBD) which can affect either colon and rectum (Ulcerative colitis) or both, small and large intestine (Crohn's Disease). The pathogenesis of these diseases is unclear, but they involve chronic inflammation of the affected tissues. Potential therapeutics include zcytor17 polypeptides, soluble heterodimeric and multimeric receptor polypeptides, or anti-zcytor17lig antibodies or binding partners of the present invention, and the like., could serve as a valuable therapeutic to reduce inflammation and pathological effects in IBD and related diseases.

[0166] Ulcerative colitis (UC) is an inflammatory disease of the large intestine, commonly called the colon, characterized by inflammation and ulceration of the mucosa or innermost lining of the colon. This inflammation causes the colon to empty frequently, resulting in diarrhea. Symptoms include loosening of the stool and associated abdominal cramping, fever and weight loss. Although the exact cause of UC is unknown, recent research suggests that the body's natural defenses are operating against proteins in the body which the body thinks are foreign (an "autoimmune reaction"). Perhaps because they resemble bacterial proteins in the gut, these proteins may either instigate or stimulate the inflammatory process that begins to destroy the lining of the colon. As the lining of the colon is destroyed, ulcers form releasing mucus, pus and blood. The disease usually begins in the rectal area and may eventually extend through the entire large bowel. Repeated episodes of inflammation lead to thickening of the wall of the intestine and rectum with scar tissue. Death of colon tissue or sepsis may occur with severe disease. The symptoms of ulcerative colitis vary in severity and their onset may be gradual or sudden. Attacks may be provoked by many factors, including respiratory infections or stress.

[0167] Although there is currently no cure for UC available, treatments are focused on suppressing the abnormal inflammatory process in the colon lining. Treatments including corticosteroids immunosuppressives (eg. azathioprine, mercaptopurine, and methotrexate) and aminosalicylates are available to treat the disease. However, the long-term use of immunosuppressives such as corticosteroids and azathioprine can result in serious side effects including thinning of bones, cataracts, infection, and liver and bone marrow effects. In the patients in whom current therapies are not successful, surgery is an option. The surgery involves the removal of the entire colon and the rectum.

[0168] There are several animal models that can partially mimic chronic ulcerative colitis. The most widely used model is the 2,4,6-trinitrobenesulfonic acid/ethanol (TNBS) induced colitis model, which induces chronic inflammation and ulceration in the colon. When TNBS is introduced into the colon of susceptible mice via intra-rectal instillation, it induces T-cell mediated immune response in the colonic mucosa, in this case leading to a massive mucosal inflammation characterized by the dense infiltration of T-cells and macrophages throughout the entire wall of the large bowel. Moreover, this histopathologic picture is accompanied by the clinical picture of progressive weight loss (wasting), bloody diarrhea, rectal prolapse, and large bowel wall thickening (Neurath et al. Intern. Rev. Immunol. 19:51-62, 2000).

[0169] Another colitis model uses dextran sulfate sodium (DSS), which induces an acute colitis manifested by bloody diarrhea, weight loss, shortening of the colon and mucosal ulceration with neutrophil infiltration. DSS-induced colitis is characterized histologically by infiltration of inflammatory cells into the lamina propria, with lymphoid hyperplasia, focal crypt damage, and epithelial ulceration. These changes are thought to develop due to a toxic effect of DSS on the epithelium and by phagocytosis of lamina propria cells and production of TNF-alpha and IFN-gamma. Despite its common use, several issues regarding the mechanisms of DSS about the relevance to the human disease remain unresolved. DSS is regarded as a T cell-independent model because it is observed in T cell-deficient animals such as SCID mice.

[0170] The administration of anti-zcytor17lig antibodies or binding partners, soluble zcytor17 comprising polypeptides (including heterodimeric and multimeric receptors), such as zcytor17-Fc4 or other zcytor17 soluble and fusion proteins to these TNBS or DSS models can be used to evaluate the use of zcytor17lig antagonists to ameliorate symptoms and alter the course of gastrointestinal disease. Zcytor17lig may play a role in the inflammatory response in colitis, and the neutralization of zcytor17lig activity by administering zcytor17lig antagonists is a potential therapeutic approach for IBD. Other potential therapeutics include zcytor17 polypeptides, soluble heterodimeric and multimeric receptor polypeptides, or anti-zcytor17lig antibodies or binding partners of the present invention, and the like.

4. Psoriasis

[0171] Psoriasis is a chronic skin condition that affects more than seven million Americans. Psoriasis occurs when new skin cells grow abnormally, resulting in inflamed, swollen, and scaly patches of skin where the old skin has not shed quickly enough. Plaque psoriasis, the most common form, is characterized by inflamed patches of skin ("lesions") topped with silvery white scales. Psoriasis may be limited to a few plaques or involve moderate to extensive areas of skin, appearing most commonly on the scalp, knees, elbows and trunk. Although it is highly visible, psoriasis is not a contagious disease. The pathogenesis of the diseases involves chronic inflammation of the affected tissues. Zcytor17 polypeptides, soluble heterodimeric and multimeric receptor polypeptides, or anti-zcytor17lig antibodies or binding partners of the present invention, and the like, could serve as a valuable therapeutic to reduce inflammation and pathological effects in psoriasis, other inflammatory skin diseases, skin and mucosal allergies, and related diseases.

[0172] Psoriasis is a T-cell mediated inflammatory disorder of the skin that can cause considerable discomfort. It is a disease for which there is no cure and affects people of all ages. Psoriasis affects approximately two percent of the populations of European and North America. Although individuals with mild psoriasis can often control their disease with topical agents, more than one million patients worldwide require ultraviolet or systemic immunosuppressive therapy. Unfortunately, the inconvenience and risks of ultraviolet radiation and the toxicities of many therapies limit their long-term use. Moreover, patients usually have recurrence of psoriasis, and in some cases rebound, shortly after stopping immunosuppressive therapy.

[0173] Differentiation is a progressive and dynamic process, beginning with pluripotent stem cells and ending with terminally differentiated cells. Pluripotent stem cells that can regenerate without commitment to a lineage express a set of differentiation markers that are lost when commitment to a cell lineage is made. Progenitor cells express a set of differentiation markers that may or may not continue to be expressed as the cells progress down the cell lineage pathway toward maturation. Differentiation markers that are expressed exclusively by mature cells are usually functional properties such as cell products, enzymes to produce cell products, and receptors. The stage of a cell population's differentiation is monitored by identification of markers present in the cell population.

[0174] There is evidence, to suggest that factors that stimulate specific cell types down a pathway towards terminal differentiation or dedifferentiation affect the entire cell population originating from a common precursor or stem cell. Thus, the present invention includes stimulating or inhibiting the proliferation of lymphoid cells, hematopoietic cells and epithelial cells.

[0175] Zcytor17lig was isolated from tissue known to have important immunological function and which contain cells that play a role in the immune system. Zcytor17lig is expressed in CD3+ selected, activated peripheral blood cells, and it has been shown that zcytor17lig expression increases after T cell activation. Moreover, results of experiments described in the Examples section herein suggest that polypeptides of the present invention can have an effect on the growth/expansion of monocytes/macrophages, T-cells, B-cells, NK cells and/or differentiated state of monocytes/macrophages, T-cells, B-cells, NK cells or these cells' progenitors. Factors that both stimulate proliferation of hematopoietic progenitors and activate mature cells are generally known, however, proliferation and activation can also require additional growth factors. For example, it has been shown that IL-7 and Steel Factor (c-kit ligand) were required for colony formation of NK progenitors. IL-15 + IL-2 in combination with IL-7 and Steel Factor was more effective (Mrózek et al., Blood 87: 2632-2640, 1996). However, unidentified cytokines may be necessary for proliferation of specific subsets of NK cells and/or NK progenitors (Robertson et. al., Blood 76:2451-2438, 1990). Similarly, zcytor17lig may act alone or in concert or synergy with other cytokines to enhance growth, proliferation expansion and modification of differentiation of monocytes/macrophages, T-cells, B-cells or NK cells.

[0176] Assays measuring differentiation include, for example, measuring cell markers associated with stage-specific expression of a tissue, enzymatic activity, functional activity or morphological changes (Watt, FASEB, 5:281-284, 1991; Francis, Differentiation 57:63-75, 1994; Raes, Adv. Anim. Cell Biol. Technol. Bioprocesses, 161-171, 1989; all incorporated herein by reference). Alternatively, zcytor17lig polypeptide itself can serve as an additional cell-surface or secreted marker associated with stage-specific expression of a tissue. As such, direct measurement of zcytor17lig polypeptide, or its loss of expression in a tissue as it differentiates, can serve as a marker for differentiation of tissues.

[0177] Similarly, direct measurement of zcytor17lig polypeptide, or its loss of expression in a tissue can be determined in a tissue or in cells as they undergo tumor progression. Increases in invasiveness and motility of cells, or the gain or loss of expression of zcytor17lig in a pre-cancerous or cancerous condition, in comparison to normal tissue, can serve as a diagnostic for transformation, invasion and metastasis in tumor progression. As such, knowledge of a tumor's stage of progression or metastasis will aid the physician in choosing the most proper therapy, or aggressiveness of treatment, for a given individual cancer patient. Methods of measuring gain and loss of expression (of either mRNA or protein) are well known in the art and described herein and can be applied to zcytor17lig expression. For example, appearance or disappearance of polypeptides that regulate cell motility can be used to aid diagnosis and prognosis of prostate cancer (Banyard, J. and Zetter, B.R., Cancer and Metast. Rev. 17:449-458, 1999). As an effector of cell motility, zcytor17lig gain or loss of expression may serve as a diagnostic for lymphoid, B-cell, epithelial, hematopoietic and other cancers.

[0178] Moreover, the activity and effect of zcytor17lig on tumor progression and metastasis can be measured *in vivo*. Several syngeneic mouse models have been developed to study the influence of polypeptides, compounds or other treatments on tumor progression. In these models, tumor cells passaged in culture are implanted into mice of the same strain as the tumor donor. The cells will develop into tumors having similar characteristics in the recipient mice; and metastasis will also occur in some of the models. Appropriate tumor models for our studies include the Lewis lung carcinoma (ATCC No. CRL-1642) and B 16 melanoma (ATCC No. CRL-6323), amongst others. These are both commonly used tumor lines, syngeneic to the C57BL6/J mouse, that are readily cultured and manipulated *in vitro*. Tumors resulting from implantation of either of these cell lines are capable of metastasis to the lung in C57BL6/J mice. The Lewis lung carcinoma model has recently been used in mice to identify an inhibitor of angiogenesis (O'Reilly MS, et al. Cell 79: 315-328, 1994). C57BL6/J mice are treated with an experimental agent either through daily injection of recombinant protein, agonist or antagonist or a one time injection of recombinant adenovirus. Three days following this treatment,

10⁵ to 10⁶ cells are implanted under the dorsal skin. Alternatively, the cells themselves may be infected with recombinant adenovirus, such as one expressing zcytor17lig, before implantation so that the protein is synthesized at the tumor site or intracellularly, rather than systemically. The mice normally develop visible tumors within 5 days. The tumors are allowed to grow for a period of up to 3 weeks, during which time they may reach a size of 1500 - 1800 mm³ in the control treated group. Tumor size and body weight are carefully monitored throughout the experiment. At the time of sacrifice, the tumor is removed and weighed along with the lungs and the liver. The lung weight has been shown to correlate well with metastatic tumor burden. As an additional measure, lung surface metastases are counted. The resected tumor, lungs and liver are prepared for histopathological examination, immunohistochemistry, and in situ hybridization, using methods known in the art and described herein. The influence of the expressed polypeptide in question, e.g., zcytor17lig, on the ability of the tumor to recruit vasculature and undergo metastasis can thus be assessed. In addition, aside from using adenovirus, the implanted cells can be transiently transfected with zcytor17lig. Use of stable zcytor17lig transfectants as well as use of inducible promoters to activate zcytor17lig expression *in vivo* are known in the art and can be used in this system to assess zcytor17lig induction of metastasis. Moreover, purified zcytor17lig or zcytor17lig conditioned media can be directly injected in to this mouse model, and hence be used in this system. For general reference see, O'Reilly MS, et al. Cell 79:315-328. 1994; and Rusciano D, et al. Murine Models of Liver Metastasis. Invasion Metastasis 14:349-361, 1995.

[0179] Zcytor17lig or antibodies thereto will be useful in treating tumorigenesis, and therefore would be useful in the treatment of cancer. Zcytor17lig is expressed in activated T-cells, monocytes and macrophages, and is linked to a region of the human chromosome wherein translocations are common in leukemias. Moreover, the zcytor17lig is shown to act through a cytokine receptor, zcytor17, which is also expressed in activated T-cells, monocytes and macrophages. Over stimulation of activated T-cells, monocytes and macrophages by zcytor17lig could result in a human disease state such as, for instance, an immune cell cancer or other cancers. As such, identifying zcytor17lig expression, polypeptides (e.g., by anti-zcytor17lig antibodies, zcytor17 soluble receptors (e.g., zcytor17 receptor, heterodimers (e.g., zcytor17/OSMR-beta, zcytor17/WSX-1), multimers (e.g., zcytor17/OSMRbeta/WSX-1)), or other zcytor17lig binding partners) can serve as a diagnostic, and can serve as antagonists of zcytor17lig proliferative activity. The ligand could be administered in combination with other agents already in use including both conventional chemotherapeutic agents as well as immune modulators such as interferon alpha. Alpha/beta interferons have been shown to be effective in treating some leukemias and animal disease models, and the growth inhibitory effects of interferon-alpha and zcytor17lig may be additive.

[0180] NK cells are thought to play a major role in elimination of metastatic tumor cells and patients with both metastases and solid tumors have decreased levels of NK cell activity (Whiteside et. al., Curr. Top. Microbiol. Immunol. 230:221-244, 1998). An agent that stimulates NK cells would be useful in the elimination of tumors.

[0181] The present invention provides a method of reducing proliferation of a neoplastic monocytes/macrophages comprising administering to a mammal with a monocyte/macrophage neoplasm an amount of a composition of zcytor17lig or anti-zcytor17lig sufficient to reduce proliferation of the neoplastic monocytes/macrophages. In other embodiments, the composition can comprise at least one other cytokine. A second cytokine may be selected from the group consisting of IL-2, IL-3, IL-12, IL-21, IL-22, IL-15, IL-4, GM-CSF, Flt3 ligand or stem cell factor.

[0182] The present invention, provides a method for inhibiting activation or differentiation of monocytes/macrophages. Monocytes are incompletely differentiated cells that migrate to various tissues where they mature and become macrophages. Macrophages play a central role in the immune response by presenting antigen to lymphocytes and play a supportive role as accessory cells to lymphocytes by secreting numerous cytokines. Macrophages can internalize extracellular molecules and upon activation have an increased ability to kill intracellular microorganisms and tumor cells. Activated macrophages are also involved in stimulating acute or local inflammation.

[0183] In another aspect, the present invention provides a method of reducing proliferation of a neoplastic B or T-cells comprising administering to a mammal with a B or T cell neoplasm an amount of a composition of zcytor17lig antagonist sufficient to reducing proliferation of the neoplastic monocytes/macrophages. In other embodiments, the composition can comprise at least one other cytokine, wherein the cytokine may be selected from the group consisting of IL-2, IL-3, IL-12, IL-21, IL-22, IL-15, IL-4, GM-CSF, Flt3 ligand or stem cell factor. Furthermore, the zcytor17lig antagonist can be a ligand/toxin fusion protein.

[0184] A zcytor17lig-saporin fusion toxin may be employed against a similar set of leukemias and lymphomas, extending the range of leukemias that can be treated with zcytor17lig. For example, such leukemias can be those that over-express zcytor17 receptors (e.g., zcytor17 receptor, heterodimers (e.g., zcytor17/OSMRbeta, zcytor17/WSX-1), multimers (e.g., zcytor17/OSMRbeta/WSX)). Fusion toxin mediated activation of the zcytor17 receptor, zcytor17 receptor heterodimers or multimers (e.g., zcytor19/OSMRbeta, zcytor17/WSX-1 or zcytor19/WSX-1/OSMR) provides two independent means to inhibit the growth of the target cells, the first being identical to the effects seen by the ligand alone, and the second due to delivery of the toxin through receptor internalization. The lymphoid and monocyte restricted expression pattern of the zcytor17 receptor suggests that the ligand-saporin conjugate can be tolerated by patients.

[0185] When treatment for malignancies includes allogeneic bone marrow or stem cell transplantation, zcytor17lig may be valuable in enhancement of the graft-vs-tumor effect. Zcytor17lig may stimulate the generation of lytic NK cells

from marrow progenitors and can stimulate the proliferation of monocytes and macrophages following activation of the antigen receptors. Therefore, when patients receive allogeneic marrow transplants, zcytor17lig will enhance the generation of anti-tumor responses, with or without the infusion of donor lymphocytes.

5 [0186] The tissue distribution of receptors for a given cytokine offers a strong indication of the potential sites of action of that cytokine. Expression of zcytor17 was seen in monocytes and B-cells, with a dramatic increase of expression upon activation for CD3+, CD4+, and CD8+ T-cells. In addition, two monocytic cell lines, THP-1 (Tsuchiya et al., Int. J. Cancer 26:171-176, 1980) and U937 (Sundstrom et al., Int. J. Cancer 17:565-577, 1976), were also positive for zcytor17 expression.

10 [0187] Northern analysis of WSX-1 receptor revealed transcripts in all tissues examined, with increased levels of expression in human spleen, thymus, lymph node, bone marrow, and peripheral blood leukocytes. Also, expression levels of WSX-1 increased upon activation of T-cells.

[0188] Expression of OSMR is reported to be very broad (Mosley et al, JBC 271:32635-32643, 1996). This distribution of zcytor17, WSX-1, and OSM receptors supports a role for zcytor17lig in immune responses, especially expansion of T-cells upon activation or a role in the monocyte/macrophage arm of the immune system.

15 [0189] Thus, particular embodiments of the present invention are directed toward use of soluble zcytor17/WSX-1/OSMR, and zcytor17/OSMR heterodimers as antagonists in inflammatory and immune diseases or conditions such as pancreatitis, type I diabetes (IDDM), pancreatic cancer, pancreatitis, Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, colon and intestinal cancer, diverticulosis, autoimmune disease, sepsis, organ or bone marrow transplant; inflammation due to trauma, surgery or infection; amyloidosis; splenomegaly; graft versus host disease; and where
20 inhibition of inflammation, immune suppression, reduction of proliferation of hematopoietic, immune, inflammatory or lymphoid cells, macrophages, T-cells (including Th1 and Th2 cells, CD4+ and CD8+ cells), suppression of immune response to a pathogen or antigen. Moreover the presence of zcytor17 expression in activated immune cells such as activated CD4+ and CD19+ cells showed that zcytor17 receptor may be involved in the body's immune defensive reactions against foreign invaders: such as microorganisms and cell debris, and could play a role in immune responses
25 during inflammation and cancer formation. As such, antibodies and binding partners of the present invention that are agonistic or antagonistic to zcytor17 receptor function, such as zcytor17lig, can be used to modify immune response and inflammation.

[0190] The zcytor17lig structure and tissue expression suggests a role in early hematopoietic or thymocyte development and immune response regulation or inflammation. These processes involve stimulation of cell proliferation and
30 differentiation in response to the binding of one or more cytokines to their cognate receptors. In view of the tissue distribution observed for this zcytor17lig, agonists (including the natural receptor(s)) and antagonists have enormous potential in both *in vitro* and *in vivo* applications. Compounds identified as zcytor17lig agonists are useful for stimulating proliferation and development of target cells *in vitro* and *in vivo*. For example, agonist compounds, zcytor17lig, or anti-zcytor17lig antibodies, are useful as components of defined cell culture media, and may be used alone or in combination
35 with other cytokines and hormones to replace serum that is commonly used in cell culture. Agonists are thus useful in specifically promoting the growth and/or development or activation of monocytes, T-cells, B-cells, and other cells of the lymphoid and myeloid lineages, and hematopoietic cells in culture.

[0191] Zcytor17lig may be useful in stimulating cell-mediated immunity and for stimulating lymphocyte proliferation, such as in the treatment of infections involving immunosuppression, including certain viral infections. Additional uses
40 include tumor suppression, where malignant transformation results in tumor cells that are antigenic. zcytor17lig could be used to induce cytotoxicity, which may be mediated through activation of effector cells such as T-cells, NK (natural killer) cells, or LAK (lymphoid activated killer) cells, or induced directly through apoptotic pathways. Zcytor17lig may also be useful in treating leukopenias by increasing the levels of the affected cell type, and for enhancing the regeneration of the T-cell repertoire after bone marrow transplantation; or for enhancing monocyte proliferation or activation, and for diagnostic and other uses described herein.

[0192] Zcytor17lig may find utility in the suppression of the immune system, such as in the treatment of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel disease, Crohn's disease, etc. Immune suppression can also be used to reduce rejection of tissue or organ transplants and grafts and to
45 treat T-cell, B-cell or monocyte-specific leukemias or lymphomas, and other cancers, by inhibiting proliferation of the affected cell type. Moreover zcytor17lig can be used to detect monocytes, macrophages, and activated T-cells and aid in the diagnosis of such autoimmune disease, particularly in disease states where monocytes are elevated or activated.

[0193] Zcytor17lig polypeptides, peptides, antibodies, and the like may also be used within diagnostic systems for the detection of circulating levels of zcytor17lig. Within a related embodiment, antibodies or other agents that specifically
50 bind to zcytor17lig polypeptides can be used to detect circulating zcytor17lig polypeptides. Elevated or depressed levels of ligand polypeptides may be indicative of pathological conditions, including cancer. Zcytor17lig polypeptides may contribute to pathologic processes and can be an indirect marker of an underlying disease.

[0194] Also, the zcytor17lig can be used to detect or target its receptor(s) in certain disease states. For example, elevated levels of soluble IL-2 receptor in human serum have been associated with a wide variety of inflammatory and

neoplastic conditions, such as myocardial infarction, asthma, myasthenia gravis, rheumatoid arthritis, acute T-cell leukemia, B-cell lymphomas, chronic lymphocytic leukemia, colon cancer, breast cancer, and ovarian cancer (Heaney et al., Blood 87:847-857, 1996). Similarly, zcytor17 receptor is elevated in activated monocytes, and hence zcytor17 receptor and/or its soluble receptors may be associated with or serve as a marker for inflammatory and neoplastic conditions associated therewith. The zcytor17lig, including cytotoxic conjugates, hence can be used to detect or target such tissues, and disease states.

[0195] The molecules of the present invention have particular use in the monocyte/macrophage arm of the immune system. Methods are known that can assess such activity. For example, interferon gamma (IFN γ) is a potent activator of mononuclear phagocytes. For example, an increase in expression of zcytor17 upon activation of THP-1 cells (ATCC No. TIB-202) with interferon gamma could suggest that this receptor is involved in monocyte activation. Monocytes are incompletely differentiated cells that migrate to various tissues where they mature and become macrophages. Macrophages play a central role in the immune response by presenting antigen to lymphocytes and play a supportive role as accessory cells to lymphocytes by secreting numerous cytokines. Macrophages can internalize extracellular molecules and upon activation have an increased ability to kill intracellular microorganisms and tumor cells. Activated macrophages are also involved in stimulating acute or local inflammation. Moreover, monocyte-macrophage function has been shown to be abnormal in a variety of diseased states. For example see, Johnston, RB, New Eng. J. Med. 318:747-752, 1998.

[0196] One of skill in the art would recognize that agonists of zcytor17 receptor, such as zcytor17lig, are useful. For example, depressed migration of monocytes has been reported in populations with a predisposition to infection, such as newborn infants, patients receiving corticosteroid or other immunosuppressive therapy, and patients with diabetes mellitus, burns, or AIDS. Agonists for zcytor17, such as zcytor17lig, could result in an increase in the ability of monocytes to migrate and possibly prevent infection in these populations. There is also a profound defect of phagocytic killing by mononuclear phagocytes from patients with chronic granulomatous disease. This results in the formation of subcutaneous abscesses, as well as abscesses in the liver, lungs, spleen, and lymph nodes. An agonist of zcytor17 receptor such as zcytor17lig, could correct or improve this phagocytic defect. In addition, defective monocyte cytotoxicity has been reported in patients with cancer and Wiskott-Aldrich syndrome (eczema, thrombocytopenia, and recurrent infections). Activation of monocytes by agonists of zcytor17 receptor such as zcytor17lig, could aid in treatment of these conditions. The monocyte-macrophage system is prominently involved in several lipid-storage diseases (sphingolipidoses) such as Gaucher's disease. Resistance to infection can be impaired because of a defect in macrophage function, which could be treated by agonists to zcytor17 receptor such as zcytor17lig.

[0197] Moreover, one of skill in the art would recognize that antagonists of zcytor17lig are useful. For example, in atherosclerotic lesions, one of the first abnormalities is localization of monocyte/macrophages to endothelial cells. These lesions could be prevented by use of antagonists to zcytor17lig. Anti-zcytor17lig antibodies (e.g., zcytor17lig neutralizing antibody), zcytor17 soluble receptors, heterodimers and multimers, and zcytor17lig binding partners can also be used as antagonists to the zcytor17lig. Moreover, monocytic leukemia is associated with a variety of clinical abnormalities that reflect the release of the biologic products of the macrophage, examples include high levels of lysozyme in the serum and urine and high fevers. Moreover, such leukemias exhibit an abnormal increase of monocytic cells. These effects could possibly be prevented by antagonists to zcytor17lig, such as described herein. Moreover, anti-zcytor17lig can be conjugated to molecules such as toxic moieties and cytokines, as described herein to direct the killing of leukemia monocytic cells.

[0198] Using methods known in the art, and disclosed herein, one of skill could readily assess the activity of zcytor17lig agonists and antagonists in the disease states disclosed herein, inflammation, immune (e.g., autoimmune), cancer, or infection as well as other disease states involving monocytic cells. In addition, as zcytor17lig is expressed in a T-cell, macrophage and monocyte-specific manner, and these diseases involve abnormalities in monocytic cells, such as cell proliferation, function, localization, and activation, the polynucleotides, polypeptides, and antibodies of the present invention can be used to as diagnostics to detect such monocytic cell abnormalities, and indicate the presence of disease. Such methods involve taking a biological sample from a patient, such as blood, saliva, or biopsy, and comparing it to a normal control sample. Histological, cytological, flow cytometric, biochemical and other methods can be used to determine the relative levels or localization of zcytor17lig, or cells expressing zcytor17lig, i.e., monocytes, in the patient sample compared to the normal control. A change in the level (increase or decrease) of zcytor17lig expression, or a change in number or localization of monocytes (e.g., increase or infiltration of monocytic cells in tissues where they are not normally present) compared to a control would be indicative of disease. Such diagnostic methods can also include using radio-metric, fluorescent, and colorimetric tags attached to polynucleotides, polypeptides or antibodies of the present invention. Such methods are well known in the art and disclosed herein.

[0199] Amino acid sequences having zcytor17lig activity can be used to modulate the immune system by binding zcytor17 receptor, and thus, preventing the binding of zcytor17lig with endogenous zcytor17lig receptor. Zcytor17lig antagonists, such as anti-zcytor17lig antibodies, can also be used to modulate the immune system by inhibiting the binding of Zcytor17lig with the endogenous zcytor17lig receptor. Accordingly, the present invention includes the use of proteins, polypeptides, and peptides having zcytor17lig activity (such as zcytor17lig polypeptides, zcytor17lig analogs

(e.g., anti-zcytor17lig anti-idiotypic antibodies), and zcytor17lig fusion proteins) to a subject which lacks an adequate amount of this polypeptide, or which produces an excess of zcytor17 comprising receptor(s). Zcytor17 antagonists (e.g., anti-Zcytor17 antibodies) can be also used to treat a subject which produces an excess of either zcytor17lig or Zcytor17 comprising receptor(s). Suitable subjects include mammals, such as humans.

[0200] Zcytor17lig has been shown to be expressed in activated mononuclear cells, and may be involved in regulating inflammation. As such, polypeptides of the present invention can be assayed and used for their ability to modify inflammation, or can be used as a marker for inflammation. Methods to determine proinflammatory and antiinflammatory qualities of zcytor17lig are known in the art and discussed herein. Moreover, it may be involved in up-regulating the production of acute phase reactants, such as serum amyloid A (SAA), α 1-antichymotrypsin, and haptoglobin, and that expression of zcytor17 receptor ligand may be increased upon injection of lipopolysaccharide (LPS) *in vivo* that are involved in inflammatory response (Dumoutier, L. et al., Proc. Nat'l. Acad. Sci. 97:10144-10149, 2000). Production of acute phase proteins, such as SAA, is considered a short-term survival mechanism where inflammation is beneficial; however, maintenance of acute phase proteins for longer periods contributes to chronic inflammation and can be harmful to human health. For review, see Uhlar, CM and Whitehead, AS, Eur. J. Biochem. 265:501-523, 1999, and Baumann H. and Gauldie, J. Immunology Today 15:74-80, 1994. Moreover, the acute phase protein SAA is implicated in the pathogenesis of several chronic inflammatory diseases, is implicated in atherosclerosis and rheumatoid arthritis, and is the precursor to the amyloid A protein deposited in amyloidosis (Uhlar, CM and Whitehead, *supra.*). Thus, where a ligand such as zcytor17lig that acts as a pro-inflammatory molecule and induces production of SAA, antagonists would be useful in treating inflammatory disease and other diseases associated with acute phase response proteins induced by the ligand. Such antagonists are provided by the present invention. For example, a method of reducing inflammation comprises administering to a mammal with inflammation an amount of a composition of zcytor17lig, or anti-zcytor17lig antibody (e.g., neutralizing antibody) that is sufficient to reduce inflammation. Moreover, a method of suppressing an inflammatory response in a mammal with inflammation can comprise: (1) determining a level of serum amyloid A protein; (2) administering a composition comprising a zcytor17lig polypeptide or anti-zcytor17lig antibody as described herein in an acceptable pharmaceutical carrier; (3) determining a post administration level of serum amyloid A protein; (4) comparing the level of serum amyloid A protein in step (1) to the level of serum amyloid A protein in step (3), wherein a lack of increase or a decrease in serum amyloid A protein level is indicative of suppressing an inflammatory response.

[0201] The receptors that bind zcytor17lig of the present invention include at least one zcytor17 receptor subunit. A second receptor polypeptide included in the heterodimeric soluble receptor belongs to the receptor subfamily that includes class I cytokine receptor subunits, and more specifically OSMRbeta and WSX-1. According to the present invention, in addition to a monomeric or homodimeric zcytor17 receptor polypeptide, a heterodimeric soluble zcytor17 receptor, as exemplified by an embodiment comprising a soluble zcytor17 receptor + soluble Class I receptor heterodimeric component, such as OSMRbeta or WSX-1, can act as an antagonist of the zcytor17lig. Other embodiments include soluble multimeric receptors comprising zcytor17, such as zcytor17 receptor + soluble Class I receptor multimeric component, such as OSMRbeta and WSX-1.

[0202] Like zcytor17lig, analysis of the tissue distribution of the mRNA corresponding to its zcytor17 receptor cDNA showed that mRNA level was highest in monocytes and prostate cells, and is elevated in activated monocytes, and activated CD4+, activated CD8+, and activated CD3+ cells. Hence, zcytor17 receptor is also implicated in inducing inflammatory and immune response. Thus, particular embodiments of the present invention are directed toward use of zcytor17lig-antibodies, and zcytor17lig, as well as soluble zcytor17 receptor heterodimers as antagonists in inflammatory and immune diseases or conditions such as, pancreatitis, type I diabetes (EDDM), pancreatic cancer, pancreatitis, Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, colon and intestinal cancer, diverticulosis, autoimmune disease, sepsis, organ or bone marrow transplant; inflammation due to trauma, surgery or infection; amyloidosis; splenomegaly; graft versus host disease; and where inhibition of inflammation, immune suppression, reduction of proliferation of hematopoietic, immune, inflammatory or lymphoid cells, macrophages, T-cells (including Th1 and Th2 cells, CD4+ and CD8+ cells), suppression of immune response to a pathogen or antigen. Moreover the presence of zcytor17 receptor and zcytor17lig expression in activated immune cells such as activated CD3+, monocytes, CD4+ and CD19+ cells showed that zcytor17 receptor may be involved in the body's immune defensive reactions against foreign invaders: such as microorganisms and cell debris, and could play a role in immune responses during inflammation and cancer formation. As such, zcytor17lig and zcytor17lig-antibodies of the present invention that are agonistic or antagonistic to zcytor17 receptor function, can be used to modify immune response and inflammation.

[0203] Moreover, zcytor17lig polypeptides that bind zcytor17 receptor polypeptides, and antibodies thereto are useful to:

- 1) Antagonize or block signaling via zcytor17-comprising receptors in the treatment of acute inflammation, inflammation as a result of trauma, tissue injury, surgery, sepsis or infection, and chronic inflammatory diseases such as asthma, inflammatory bowel disease (IBD), chronic colitis, splenomegaly, rheumatoid arthritis, recurrent acute inflammatory episodes (e.g., tuberculosis), and treatment of amyloidosis, and atherosclerosis, Castleman's Disease,

asthma, and other diseases associated with the induction of acute-phase response.

2) Antagonize or block signaling via the zcytor17 receptor receptors in the treatment of autoimmune diseases such as IDDM, multiple sclerosis (MS), systemic Lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, and IBD to prevent or inhibit signaling in immune cells (e.g. lymphocytes, monocytes, leukocytes) via zcytor17 receptor (Hughes C et al., J. Immunol 153: 3319-3325, 1994). Alternatively antibodies, such as monoclonal antibodies (MAb) to zcytor17lig, can also be used as an antagonist to deplete unwanted immune cells to treat autoimmune disease. Asthma, allergy and other atopic disease may be treated with an MAb against, for example, anti-zcytor17lig antibodies, soluble zcytor17 receptor soluble receptors or zcytor17/CRF2-4 heterodimers, to inhibit the immune response or to deplete offending cells. Blocking or inhibiting signaling via zcytor17, using the polypeptides and antibodies of the present invention, may also benefit diseases of the pancreas, kidney, pituitary and neuronal cells. IDDM, NIDDM, pancreatitis, and pancreatic carcinoma may benefit. Zcytor17 may serve as a target for MAb therapy of cancer where an antagonizing MAb inhibits cancer growth and targets immune-mediated killing. (Holliger P, and Hoogenboom, H: Nature Biotech. 16: 1015-1016, 1998). Mabs to soluble zcytor17 receptor monomers, homodimers, heterodimers and multimers may also be useful to treat nephropathies such as glomerulosclerosis, membranous neuropathy, amyloidosis (which also affects the kidney among other tissues), renal arteriosclerosis, glomerulonephritis of various origins, fibroproliferative diseases of the kidney, as well as kidney dysfunction associated with SLE, IDDM, type II diabetes (NIDDM), renal tumors and other diseases.

3) Agonize or initiate signaling via the zcytor17 receptors in the treatment of autoimmune diseases such as IDDM, MS, SLE, myasthenia gravis, rheumatoid arthritis, and IBD. zcytor17lig may signal lymphocytes or other immune cells to differentiate, alter proliferation, or change production of cytokines or cell surface proteins that ameliorate autoimmunity. Specifically, modulation of a T-helper cell response to an alternate pattern of cytokine secretion may deviate an autoimmune response to ameliorate disease (Smith JA et al., J. Immunol. 160:4841-4849, 1998). Similarly, zcytor17lig may be used to signal, deplete and deviate immune cells involved in asthma, allergy and atopic disease. Signaling via zcytor17 receptor may also benefit diseases of the pancreas, kidney; pituitary and neuronal cells. IDDM, NIDDM, pancreatitis, and pancreatic carcinoma may benefit. Zcytor17 may serve as a target for MAb therapy of pancreatic cancer where a signaling MAb inhibits cancer growth and targets immune-mediated killing (Tutt, AL et al., J Immunol. 161: 3175-3185. 1998). Similarly T-cell specific leukemias, lymphomas, plasma cell dyscrasia (e.g., multiple myeloma), and carcinoma may be treated with monoclonal antibodies (e.g., neutralizing antibody) to zcytor17-comprising soluble receptors of the present invention.

[0204] Anti-zcytor17lig antibodies, soluble zcytor17 receptor monomeric, homodimeric, heterodimeric and multimeric polypeptides described herein can be used to neutralize/block zcytor17 receptor ligand activity in the treatment of autoimmune disease, atopic disease, NIDDM, pancreatitis and kidney dysfunction as described above. A soluble form of zcytor17 receptor may be used to promote an antibody response mediated by T cells and/or to promote the production of IL-4 or other cytokines by lymphocytes or other immune cells.

[0205] Anti-zcytor17lig antibodies, and soluble zcytor17-comprising receptors are useful as antagonists of zcytor17lig. Such antagonistic effects can be achieved by direct neutralization or binding of its natural ligand. In addition to antagonistic uses, the soluble receptors can bind zcytor17lig and act as carrier or carrier proteins, in order to transport zcytor17lig to different tissues, organs, and cells within the body. As such, the soluble receptors can be fused or coupled to molecules, polypeptides or chemical moieties that direct the soluble-receptor-Ligand complex to a specific site, such as a tissue, specific immune cell, monocytes, or tumor. For example, in acute infection or some cancers, benefit may result from induction of inflammation and local acute phase response proteins. Thus, the soluble receptors described herein or antibodies of the present invention can be used to specifically, direct the action of a pro-inflammatory zcytor17lig ligand. See, Cosman, D. Cytokine 5: 95-106, 1993; and Fernandez-Botran, R. Exp. Opin. Invest. Drugs 9:497-513, 2000.

[0206] Moreover, the soluble receptors can be used to stabilize the zcytor17lig, to increase the bioavailability, therapeutic longevity, and/or efficacy of the Ligand by stabilizing the Ligand from degradation or clearance, or by targeting the ligand to a site of action within the body. For example the naturally occurring IL-6/soluble IL-6R complex stabilizes IL-6 and can signal through the gp130 receptor. See, Cosman, D. *supra.*, and Fernandez-Botran, R. *supra.* Moreover, Zcytor17 may be combined with a cognate ligand such as its ligand to comprise a ligand/soluble receptor complex. Such complexes may be used to stimulate responses from cells presenting a companion receptor subunit. The cell specificity of zcytor17 receptor/zcytor17lig complexes may differ from that seen for the ligand administered alone. Furthermore the complexes may have distinct pharmacokinetic properties such as affecting half-life, dose/response and organ or tissue specificity. Zcytor17/ligand complexes thus may have agonist activity to enhance an immune response or stimulate mesangial cells or to stimulate hepatic cells. Alternatively only tissues expressing a signaling subunit the heterodimerizes with the complex may be affected analogous to the response to IL6/IL6R complexes (Hirota H. et al., Proc. Nat'l. Acad. Sci. 92:4862-4866, 1995; Hirano, T. in Thomason, A. (Ed.) "The Cytokine Handbook", 3rd Ed., p. 208-209). Soluble receptor/cytokine complexes for IL12 and CNTF display similar activities.

[0207] Zcytor17lig may also be used within diagnostic systems for the detection of circulating levels of ligand, and in

the detection of acute phase inflammatory response. Within a related embodiment, antibodies or other agents that specifically bind to zcytor17lig can be used to detect circulating zcytor17lig polypeptides; conversely, zcytor17lig itself can be used to detect circulating or locally-acting receptor polypeptides. Elevated or depressed levels of ligand or receptor polypeptides may be indicative of pathological conditions, including inflammation or cancer. Moreover, detection of acute phase proteins or molecules such as zcytor17lig can be indicative of a chronic inflammatory condition in certain disease states (e.g., rheumatoid arthritis). Detection of such conditions serves to aid in disease diagnosis as well as help a physician in choosing proper therapy.

[0208] The polypeptides and proteins of the present invention can also be used *ex vivo*, such as in autologous marrow culture. Briefly, bone marrow is removed from a patient prior to chemotherapy or organ transplant and treated with zcytor17lig, optionally in combination with one or more other cytokines. The treated marrow is then returned to the patient after chemotherapy to speed the recovery of the marrow or after transplant to suppress graft vs. host disease. In addition, the proteins of the present invention can also be used for the *ex vivo* expansion of monocytes/macrophages marrow or peripheral blood progenitor (PBPC) cells. Prior to treatment, marrow can be stimulated with stem cell factor (SCF) to release early progenitor cells into peripheral circulation. These progenitors can be collected and concentrated from peripheral blood and then treated in culture with zcytor17lig, optionally in combination with one or more other cytokines, including but not limited to SCF, IL-2, IL-4, IL-7, Lif, IL-3, IL-12, IL-21, or IL-15, to differentiate and proliferate into high-density lymphoid cultures, which can then be returned to the patient following chemotherapy or transplantation.

[0209] The present invention provides a method for expansion of hematopoietic cells and hematopoietic cell progenitors comprising culturing bone marrow or peripheral blood cells with a composition comprising an amount of zcytor17lig sufficient to produce an increase in the number of lymphoid cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of zcytor17lig. In other embodiments, the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells. In another embodiment, the lymphoid cells are NK cells or cytotoxic T cells. Furthermore, the composition can also comprise at least one other cytokine selected from the group consisting of IL-2, IL-15, IL-4, Lif, IL-3, IL-12, IL-21, GM-CSF, Flt3 ligand and stem cell factor.

[0210] Alternatively, zcytor17lig may activate the immune system which would be important in boosting immunity to infectious diseases, treating immunocompromised patients, such as HIV+ patients, cancer patients, or in improving vaccines. In particular, zcytor17lig stimulation or expansion of monocytes/macrophages, T-cells, B-cells, NK cells, or their progenitors, would provide therapeutic value in treatment of viral infection, and as an anti-neoplastic factor. Similarly, zcytor17lig stimulation of the immune response against viral and non-viral pathogenic agents (including bacteria, protozoa, and fungi) would provide therapeutic value in treatment of such infections by inhibiting the growth of such infectious agents. Determining directly or indirectly the levels of a pathogen or antigen, such as a tumor cell, present in the body can be achieved by a number of methods known in the art and described herein.

[0211] The present invention include a method of stimulating an immune response in a mammal exposed to an antigen or pathogen comprising the steps of: (1) determining directly or indirectly the level of antigen or pathogen present in said mammal; (2) administering a composition comprising zcytor17lig polypeptide in an acceptable pharmaceutical carrier; (3) determining directly or indirectly the level of antigen or pathogen in said mammal; and (4) comparing the level of the antigen or pathogen in step 1 to the antigen or pathogen level in step 3, wherein a change in the level is indicative of stimulating an immune response. In another embodiment the zcytor17lig composition is re-administered. In other embodiments, the antigen is a B cell tumor; a virus; a parasite or a bacterium.

[0212] In another aspect, the present invention provides a method of stimulating an immune response in a mammal exposed to an antigen or pathogen comprising: (1) determining a level of an antigen- or pathogen-specific antibody; (2) administering a composition comprising zcytor17lig polypeptide in an acceptable pharmaceutical carrier; (3) determining a post administration level of antigen- or pathogen-specific antibody; (4) comparing the level of antibody in step (1) to the level of antibody in step (3), wherein an increase in antibody level is indicative of stimulating an immune response.

[0213] Polynucleotides encoding zcytor17lig polypeptides are useful within gene therapy applications where it is desired to increase or inhibit zcytor17lig activity. If a mammal has a mutated or absent zcytor17lig gene, the zcytor17lig gene can be introduced into the cells of the mammal. In one embodiment, a gene encoding a zcytor17lig polypeptide is introduced *in vivo* in a viral vector. Such vectors include an attenuated or defective DNA virus, such as, but not limited to, herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. A defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Examples of particular vectors include, but are not limited to, a defective herpes simplex virus 1 (HSV1) vector (Kapliitt et al., *Molec. Cell. Neurosci.* 2:320-30, 1991); an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al., *J. Clin. Invest.* 90:626-30, 1992; and a defective adeno-associated virus vector (Samulski et al., *J. Virol.* 61:3096-101, 1987; Samulski et al., *J. Virol.* 63:3822-8, 1989).

[0214] A zcytor17lig gene can be introduced in a retroviral vector, e.g., as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al. *Cell* 33:153, 1983; Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No.

4,980,289; Markowitz et al., J. Virol. 62:1120, 1988; Temin et al., U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995 by Dougherty et al.; and Kuo et al., Blood 82:845, 1993. Alternatively, the vector can be introduced by lipofection *in vivo* using liposomes. Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker (Folgnier et al., Proc. Natl. Acad. Sci. USA 84:7413-7, 1987; Mackey et al., Proc. Natl. Acad. Sci. USA 85:8027-31, 1988). The use of lipofection to introduce exogenous genes into specific organs *in vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. More particularly, directing transfection to particular cells represents one area of benefit. For instance, directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as the immune system, pancreas, liver, kidney, and brain. Lipids may be chemically coupled to other molecules for the purpose of targeting. Targeted peptides (e.g., hormones or neurotransmitters), proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically.

[0215] It is possible to remove the target cells from the body; to introduce the vector as a naked DNA plasmid; and then to re-implant the transformed cells into the body. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter. See, e.g., Wu et al., J. Biol. Chem. 267:963-7, 1992; Wu et al., J. Biol. Chem. 263:14621-4, 1988.

[0216] Antisense methodology can be used to inhibit zcytor17lig gene transcription, such as to inhibit cell proliferation *in vivo*. Polynucleotides that are complementary to a segment of a zcytor17lig-encoding polynucleotide (e.g., a polynucleotide as set forth in SEQ ID NO:1) are designed to bind to zcytor17lig-encoding mRNA and to inhibit translation of such mRNA. Such antisense polynucleotides are used to inhibit expression of zcytor17lig polypeptide-encoding genes in cell culture or in a subject.

[0217] Mice engineered to express the zcytor17lig gene, referred to as "transgenic mice," and mice that exhibit a complete absence of zcytor17lig gene function, referred to as "knockout mice," may also be generated (Snouwaert et al., Science 257:1083, 1992; Lowell et al., Nature 366:740-42, 1993; Capecchi, M.R., Science 244: 1288-1292, 1989; Palmiter, R.D. et al. Annu Rev Genet. 20: 465-499, 1986). For example, transgenic mice that over-express zcytor17lig, either ubiquitously or under a tissue-specific or tissue-restricted promoter can be used to ask whether over-expression causes a phenotype. For example, over-expression of a wild-type zcytor17lig polypeptide, polypeptide fragment or a mutant thereof may alter normal cellular processes, resulting in a phenotype that identifies a tissue in which zcytor17lig expression is functionally relevant and may indicate a therapeutic target for the zcytor17lig, its agonists or antagonists. For example, a preferred transgenic mouse to engineer is one that over-expresses the zcytor17lig (amino acid residues 23-164 of SEQ ID NO:2; or 24-163 of SEQ ID NO:11). Moreover, such over-expression may result in a phenotype that shows similarity with human diseases. Similarly, knockout zcytor17lig mice can be used to determine where zcytor17lig is absolutely required *in vivo*. The phenotype of knockout mice is predictive of the *in vivo* effects of that a zcytor17lig antagonist, such as those described herein, may have. The human or mouse zcytor17lig cDNA described herein can be used to generate knockout mice. These mice may be employed to study the zcytor17lig gene and the protein encoded thereby in an *in vivo* system, and can be used as *in vivo* models for corresponding human diseases. Moreover, transgenic mice expression of zcytor17lig antisense polynucleotides or ribozymes directed against zcytor17lig, described herein, can be used analogously to transgenic mice described above. Studies may be carried out by administration of purified zcytor17lig protein, as well.

[0218] Experimental evidence suggests a role for zcytor17lig in the progression of diseases that involve the skin or epithelium of internal surfaces, such as, for instance, large intestine, small intestine, pancreas, lung, prostate, uterus, and the like. First, as disclosed herein, zcytor17 receptors, including both OSM receptor beta and zcytor17, are expressed in several cell types located in epithelial surfaces including cell lines derived from lung epithelium, lung fibroblast, prostate, colon, breast, liver epithelium, bone and skin epithelium, bone fibroblast, and the like. Moreover, as disclosed herein, examples from each of these cell types also responded to zcytor17lig activation of a STAT reporter construct. In addition, several cell lines responded to zcytor17lig stimulation by producing increased levels of IL-6, IL-8, MCP-1 (a chemotactic factor) as described herein. In whole, these data suggest a role for zcytor17lig in diseases that involve the epithelium such as, for instance, atopic dermatitis; dermatitis; psoriasis; psoriatic arthritis; eczema; gingivitis; periodontal disease; inflammatory bowel diseases (IBD) (e.g., ulcerative colitis, Crohn's disease); reproductive disorders, such as, for instance, cervical dysplasia, cervical cancer; other skin diseases like cancers: sarcomas; carcinomas; melanoma, etc. i.e., not just inflammatory diseases, since immune system is involved in activating/curing cancers; diseases involving barrier dysfunction, such as, for instance, graft-versus-host disease (GVHD) and irritable bowel syndrome (IBS); and diseases that involve lung epithelium, such as asthma, emphysema, and the like. In addition, the release of cytokines IL-6, IL-8, and MCP-1 by cells exposed to zcytor17lig suggests that zcytor17lig is involved in inflammation. Therefore, regulation of zcytor17lig can be useful in the treatment of autoimmune, inflammatory, or cancerous diseases associated with the tissues that express receptor. These diseases include, for example, prostatitis, hepatitis, osteoarthritis, and the like. Zcytor17lig may positively or negatively directly or indirectly regulate these diseases. Therefore, the administration of zcytor17lig can be used to treat diseases as described herein directly or with molecules that inhibit zcytor17lig activity

including, for example, both monoclonal antibodies to zcytor17lig or monoclonal antibodies to zcytor17, or monoclonal antibodies that recognize the zcytor17 and OSM receptor beta complex.

[0219] Data also suggests that zcytor17lig may be involved in the regulation of TH2 T cell mediated diseases. First, zcytor17lig is made by the TH2 subset of activated T cells. TH2 cells express more zcytor17lig as compared to TH1 cells. In addition, at least two lung epithelial cell lines (SK-LU-1, A549) were stimulated to increase IL13 receptor alpha-2 mRNA in response to zcyto17 ligand stimulation as described herein. There is an association of IL-13 receptor alpha2 chain and tumorigenicity of human breast and pancreatic tumors. This suggests that zcytor17lig may play a role in regulating tumorigenicity of these types of cancers, as well as other cancers. Therefore, the administration of a zcytor17lig antagonist or direct use of zcytor17lig may be useful in treatment of these types of cancers, benign or malignant and at various grades (grades I-IV) and stages (e.g., TNM or AJC staging methods) of tumor development, in mammals, preferably humans.

[0220] It is well-known in the art that IL13 is involved in the generation of activated TH2 cells and in TH2 mediated diseases, such as asthma, atopic dermatitis, and the like. Zcytor17lig or zcytor17lig antagonists may be useful in the treatment of diseases that involved TH2 T cells. This would include diseases such as, for instance, atopic dermatitis, asthma, as well as other diseases that are exacerbated by activated TH2 cells. The involvement of zcytor17lig in diseases, such as, for instance, atopic dermatitis, is also supported by the phenotype of the transgenic mice that overexpress zcytor17lig and develop symptoms of atopic dermatitis as described herein.

[0221] Despite the preferential expression of zcytor17lig by TH2 cells, there is still some expression of zcytor17lig in TH1 cells and in CD8+ T cells. Therefore, zcytor17lig or its antagonists may be useful in treating diseases that involve immune modulation of activated T cells including, for example, viral infection, cancers, graft rejection, and the like.

[0222] Zcytor17lig may also be involved in the development of cancer. There is expression of the zcytor17 and OSM receptor beta receptors in human bone fibroblast osteosarcomas, human skin fibroblast melanoma, colon epithelial carcinoma, adenocarcinoma, breast epithelial adenocarcinoma, prostate epithelial adenocarcinoma, and lung epithelial adenocarcinoma and carcinoma. Therefore, it may be useful to treat tumors of epithelial origin with either zcytor17lig, fragments thereof, or zcytor17lig antagonists which include, but are not limited to, carcinoma, adenocarcinoma, and melanoma. Notwithstanding, zcytor17lig or a zcytor17lig antagonist may be used to treat a cancer, or reduce one or more symptoms of a cancer, from a cancer including but not limited to squamous cell or epidermoid carcinoma, basal cell carcinoma, adenocarcinoma, papillary carcinoma, cystadenocarcinoma, bronchogenic carcinoma, bronchial adenoma, melanoma, renal cell carcinoma, hepatocellular carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, malignant mixed tumor of salivary gland origin, Wilms' tumor, immature teratoma, teratocarcinoma, and other tumors comprising at least some cells of epithelial origin.

[0223] Generally, the dosage of administered zcytor17lig polypeptide (or zcytor17 analog or fusion protein) will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history. Typically, it is desirable to provide the recipient with a dosage of zcytor17lig polypeptide which is in the range of from about 1 pg/kg to 10 mg/kg (amount of agent/body weight of patient), although a lower or higher dosage also may be administered as circumstances dictate. One skilled in the art can readily determine such dosages, and adjustments thereto, using methods known in the art.

[0224] Administration of a Zcytor17lig polypeptide to a subject can be topical, inhalant, intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, by perfusion through a regional catheter, or by direct intralesional injection. When administering therapeutic proteins by injection, the administration may be by continuous infusion or by single or multiple boluses.

[0225] Additional routes of administration include oral, mucosal-membrane, pulmonary, and transcutaneous. Oral delivery is suitable for polyester microspheres, zein microspheres, proteinoid microspheres, polycyanoacrylate microspheres, and lipid-based systems (see, for example, DiBase and Morrel, "Oral Delivery of Microencapsulated Proteins," in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 255-288 (Plenum Press 1997)). The feasibility of an intranasal delivery is exemplified by such a mode of insulin administration (see, for example, Hinchcliffe and Illum, Adv. Drug Deliv. Rev. 35:199 (1999)). Dry or liquid particles comprising Zcytor17lig can be prepared and inhaled with the aid of dry-powder dispersers, liquid aerosol generators, or nebulizers (e.g., Pettit and Gombotz, TIBTECH 16:343 (1998); Patton et al., Adv. Drug Deliv. Rev. 35:235 (1999)). This approach is illustrated by the AERX diabetes management system, which is a hand-held electronic inhaler that delivers aerosolized insulin into the lungs. Studies have shown that proteins as large as 48,000 kDa have been delivered across skin at therapeutic concentrations with the aid of low-frequency ultrasound, which illustrates the feasibility of transcutaneous administration (Mitrugotri et al., Science 269: 850 (1995)). Transdermal delivery using electroporation provides another means to administer a molecule having Zcytor17lig binding activity (Potts et al., Pharm. Biotechnol. 10:213 (1997)).

[0226] A pharmaceutical composition comprising a protein, polypeptide, or peptide having Zcytor17lig binding activity can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the therapeutic proteins are combined in a mixture with a pharmaceutically acceptable carrier. A composition is said to be a "pharmaceutically acceptable carrier" if its administration can be tolerated by a recipient patient. Sterile phosphate-buffered

saline is one example of a pharmaceutically acceptable carrier. Other suitable carriers are well-known to those in the art. See, for example, Gennaro (ed.), Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company 1995).

5 [0227] For purposes of therapy, molecules having Zcytor17lig binding activity and a pharmaceutically acceptable carrier are administered to a patient in a therapeutically effective amount. A combination of a protein, polypeptide, or peptide having Zcytor17lig binding activity and a pharmaceutically acceptable carrier is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient. For example, an agent used to treat inflammation is physiologically significant if its presence alleviates at least a portion of the inflammatory response.

10 [0228] A pharmaceutical composition comprising Zcytor17lig (or Zcytor17lig analog or fusion protein) can be furnished in liquid form, in an aerosol, or in solid form. Liquid forms, are illustrated by injectable solutions, aerosols, droplets, topological solutions and oral suspensions. Exemplary solid forms include capsules, tablets, and controlled-release forms. The latter form is illustrated by miniosmotic pumps and implants (Bremer et al., Pharm. Biotechnol. 10:239-(1997); Ranade, "Implants in Drug Delivery," in Drug Delivery Systems, Ranade and Hollinger (eds.), pages 95-123 (CRC Press 1995); Bremer et al., "Protein Delivery with Infusion Pumps," in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 239-254 (Plenum Press 1997); Yewey et al., "Delivery of Proteins from a Controlled Release Injectable Implant," in Protein Delivery: Physical Systems, Sanders and Hendren (eds.), pages 93-117 (Plenum Press 1997)). Other solid forms include creams, pastes, other topological applications, and the like.

20 [0229] Liposomes provide one means to deliver therapeutic polypeptides to a subject intravenously, intraperitoneally, intrathecally, intramuscularly, subcutaneously, or via oral administration, inhalation, or intranasal administration. Liposomes are microscopic vesicles that consist of one or more lipid bilayers surrounding aqueous compartments (see, generally, Bakker-Woudenberg et al., Eur. J. Clin. Microbiol. Infect. Dis. 12 (Suppl. 1):S61 (1993), Kim, Drugs 46:618 (1993), and Ranade, "Site-Specific Drug Delivery Using Liposomes as Carriers," in Drug Delivery Systems, Ranade and Hollinger (eds.), pages 3-24 (CRC Press 1995)). Liposomes are similar in composition to cellular membranes and as a result, liposomes can be administered safely and are biodegradable. Depending on the method of preparation, liposomes may be unilamellar or multilamellar, and liposomes can vary in size with diameters ranging from 0.02 μm to greater than 10 μm . A variety of agents can be encapsulated in liposomes: hydrophobic agents partition in the bilayers and hydrophilic agents partition within the inner aqueous space(s) (see, for example, Machy et al., Liposomes In Cell Biology And Pharmacology (John Libbey 1987), and Ostro et al., American J. Hosp. Pharm. 46:1576 (1989)). Moreover, it is possible to control the therapeutic availability of the encapsulated agent by varying liposome size, the number of bilayers, lipid composition, as well as the charge and surface characteristics of the liposomes.

30 [0230] Liposomes can adsorb to virtually any type of cell and then slowly release the encapsulated agent. Alternatively, an absorbed liposome may be endocytosed by cells that are phagocytic. Endocytosis is followed by intralysosomal degradation of liposomal lipids and release of the encapsulated agents (Scherphof et al., Ann. N.Y. Acad. Sci. 446:368 (1985)). After intravenous administration, small liposomes (0.1 to 1.0 μm) are typically taken up by cells of the reticuloendothelial system, located principally in the liver and spleen, whereas liposomes larger than 3.0 μm are deposited in the lung. This preferential uptake of smaller liposomes by the cells of the reticuloendothelial system has been used to deliver chemotherapeutic agents to macrophages and to tumors of the liver.

40 [0231] The reticuloendothelial system can be circumvented by several methods including saturation with large doses of liposome particles, or selective macrophage inactivation by pharmacological means (Claassen et al., Biochim. Biophys. Acta 802:428 (1984)). In addition, incorporation of glycolipid- or polyethelene glycol-derivatized phospholipids into liposome membranes has been shown to result in a significantly reduced uptake by the reticuloendothelial system (Allen et al., Biochim. Biophys. Acta 1068:133 (1991); Allen et al., Biochim. Biophys. Acta 1150:9 (1993)).

45 [0232] Liposomes can also be prepared to target particular cells or organs by varying phospholipid composition or by inserting receptors or ligands into the liposomes. For example, liposomes, prepared with a high content of a nonionic surfactant, have been used to target the liver (Hayakawa et al., Japanese Patent 04-244,018; Kato et al., Biol. Pharm. Bull. 16:960 (1993)). These formulations were prepared by mixing soybean phosphatidylcholine, α -tocopherol, and ethoxylated hydrogenated castor oil (HCO-60) in methanol, concentrating the mixture under vacuum, and then reconstituting the mixture with water. A liposomal formulation of dipalmitoylphosphatidylcholine (DPPC) with a soybean-derived sterylglucoside mixture (SG) and cholesterol (Ch) has also been shown to target the liver (Shimizu et al., Biol. Pharm. Bull. 20:881 (1997)).

50 [0233] Alternatively, various targeting ligands can be bound to the surface of the liposome, such as antibodies, antibody fragments, carbohydrates, vitamins, and transport proteins. For example, liposomes can be modified with branched type galactosyllipid derivatives to target asialoglycoprotein (galactose) receptors, which are exclusively expressed on the surface of liver cells (Kato and Sugiyama, Crit. Rev. Ther. Drug Carrier Syst. 14:287 (1997); Murahashi et al., Biol. Pharm. Bull. 20:259 (1997)). Similarly, Wu et al., Hepatology 27:772 (1998), have shown that labeling liposomes with asialofetuin led to a shortened liposome plasma half-life and greatly enhanced uptake of asialofetuin-labeled liposome

by hepatocytes. On the other hand, hepatic accumulation of liposomes comprising branched type galactosyllipid derivatives can be inhibited by preinjection of asialofetuin (Murahashi et al., *Biol. Pharm. Bull.* 20:259 (1997)). Polyaconitylated human serum albumin liposomes provide another approach for targeting liposomes to liver cells (Kamps et al., *Proc. Nat'l Acad. Sci. USA* 94:11681 (1997)). Moreover, Geho, et al. U.S. Patent No. 4,603,044, describe a hepatocyte-directed liposome vesicle delivery system, which has specificity for hepatobiliary receptors associated with the specialized metabolic cells of the liver.

[0234] In a more general approach to tissue targeting, target cells are prelabeled with biotinylated antibodies specific for a ligand expressed by the target cell (Harasym et al., *Adv. Drug Deliv. Rev.* 32:99 (1998)). After plasma elimination of free antibody, streptavidin-conjugated liposomes are administered. In another approach, targeting antibodies are directly attached to liposomes (Harasym, et al., *Adv. Drug Deliv. Rev.* 32:99 (1998)).

[0235] Polypeptides having Zcytor17lig binding activity can be encapsulated within liposomes using standard techniques of protein microencapsulation (see, for example, Anderson et al., *Infect. Immun.* 31:1099 (1981), Anderson et al., *Cancer Res.* 50:1853 (1990), and Cohen et al., *Biochim. Biophys. Acta* 1063:95 (1991), Alving et al. "Preparation and Use of Liposomes in Immunological Studies," in *Liposome Technology*, 2nd Edition, Vol. III, Gregoriadis (ed.), page 317 (CRC Press 1993), Wassef et al., *Meth. Enzymol.* 149:124 (1987)). As noted above, therapeutically useful liposomes may contain a variety of components. For example, liposomes may comprise lipid derivatives of poly(ethylene glycol) (Allen et al., *Biochim. Biophys. Acta* 1150:9 (1993)).

[0236] Degradable polymer microspheres have been designed to maintain high systemic levels of therapeutic proteins. Microspheres are prepared from degradable polymers such as poly(lactide-co-glycolide) (PLG), polyanhydrides, poly(ortho esters), nonbiodegradable ethylvinyl acetate polymers, in which proteins are entrapped in the polymer (Gombotz and Pettit, *Bioconjugate Chem.* 6:332 (1995); Ranade, "Role of Polymers in Drug Delivery," in *Drug Delivery Systems*, Ranade and Hollinger (eds.), pages 51-93 (CRC Press 1995); Roskos and Maskiewicz, "Degradable Controlled Release Systems Useful for Protein Delivery," in *Protein Delivery: Physical Systems*, Sanders and Hendren (eds.), pages 45-92 (Plenum Press 1997); Bartus et al., *Science* 281:1161 (1998); Putney and Burke, *Nature Biotechnology* 16:153 (1998); Putney, *Curr. Opin. Chem. Biol.* 2:548 (1998)). Polyethylene glycol (PEG)-coated nanospheres can also provide carriers for intravenous administration of therapeutic proteins (see, for example, Gref et al., *Pharm. Biotechnol.* 10: 167 (1997)).

[0237] The present invention also contemplates chemically modified polypeptides having zcytor17lig activity, such as a zcytor17lig polypeptide, zcytor17lig agonists, and Zcytor17lig antagonists, for example anti-zcytor17lig antibodies, which a polypeptide is linked with a polymer, as discussed above.

[0238] Other dosage forms can be devised by those skilled in the art, as shown, for example, by Ansel and Popovich, *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 5th Edition (Lea & Febiger 1990), Gennaro (ed.), *Remington's Pharmaceutical Sciences*, 19th Edition (Mack Publishing Company 1995), and by Ranade and Hollinger, *Drug Delivery Systems* (CRC Press 1996).

[0239] As an illustration, pharmaceutical compositions may be supplied as a kit comprising a container that comprises a zcytor17lig polypeptide or a zcytor17lig antagonist (e.g., an antibody or antibody fragment that binds a Zcytor17lig polypeptide). Therapeutic polypeptides can be provided in the form of an injectable solution for single or multiple doses, or as a sterile powder that will be reconstituted before injection. Alternatively, such a kit can include a dry-powder disperser, liquid aerosol generator, or nebulizer for administration of a therapeutic polypeptide. Such a kit may further comprise written information on indications and usage of the pharmaceutical composition. Moreover, such information may include a statement that the Zcytor17lig composition is contraindicated in patients with known hypersensitivity to Zcytor17lig.

[0240] Within one aspect the present invention provides an isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to the sequence of amino acid residues selected from the group consisting of: (a) the polypeptide shown from residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO:2; (b) the polypeptide shown from residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2; (c) the polypeptide shown from residues 24 (Thr) to 164 (Thr) as shown in SEQ ID NO:2; and (d) the polypeptide shown from residues 1 (Met) to 164 (Thr) as shown in SEQ ID NO: 2. In one embodiment, the isolated polypeptide is as disclosed above, wherein amino acid residues 73, 133 and 147 are cysteine. In another embodiment, the isolated polypeptide is as disclosed above, wherein the polypeptide binds the zcytor17 receptor as shown in SEQ ID NO:5 or SEQ ID NO:71. In another embodiment, the isolated polypeptide comprises at least 14 contiguous amino acid residues of SEQ ID NO:2 or SEQ ID NO:11. In another embodiment, the isolated polypeptide is as disclosed above, wherein the amino acid residues are selected from the group consisting of: (a) amino acid residues 38-52 of SEQ ID NO:2; (b) amino acid residues 83-98 of SEQ ID NO:2; (c) amino acid residues 104-117 of SEQ ID NO:2; and (d) amino acid residues 137-152 of SEQ ID NO:2.

[0241] Within a second aspect the present invention provides a fusion protein comprising at least four polypeptides, wherein the order of polypeptides from N-terminus to C-terminus are: a first polypeptide that comprises a sequence of amino acid residues from 38-52 of SEQ ID NO:2; a first spacer of 6-27 amino acid residues; a second polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix B amino acid residues of SEQ ID NO:168; (b) IL-4 helix B residues 65-83 of SEQ ID NO:164; (c) IL-3 helix B residues 73-86 of SEQ ID NO:

102; (d) GM-CSF helix B residues 72-81 of SEQ ID NO:166; and (e) amino acid residues 83-98 of SEQ ED NO:2; a second spacer of 5-11 amino acid residues; a third polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix C residues 102-116 of SEQ ID NO:162; (b) IL-4 helix C residues 94-118 of SEQ ID NO:164; (c) IL-3 helix C residues 91-103 of SEQ ID NO:102; (d) GM-CSF helix C residues 85-103 of SEQ ID NO:166; and (e) amino acid residues 104-117 of SEQ ID NO:2; a third spacer of 3-29 amino acid residues; and a fourth polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix D residues 134-149 of SEQ ID NO:162; (b) IL-3 helix D residues 123-141 of SEQ ID NO:102; (c) IL-4 helix D residues 133-151 of SEQ ID NO:164; (d) GM-CSF helix D residues 120-131 of SEQ ID NO:166; and (e) amino acid residues 137-152 of SEQ ID NO:2.

[0242] Within a third aspect the present invention provides a fusion protein comprising at least four polypeptides, wherein the order of polypeptides from N-terminus to C-terminus are: a first polypeptide that comprises a sequence of amino acid residues selected from a group consisting of: (a) IL-2 helix A residues 27-48 of SEQ ID NO:162; (b) IL-4 helix A residues 30-42 of SEQ ID NO:164; (c) IL-3 helix A residues 35-45 of SEQ ID NO:102; (d) GM-CSF helix A residues 30-44 of SEQ ID NO:166; and (e) amino acids residues 38-52 of SEQ ID NO:2; a first spacer of 6-27 amino acid residues; a second polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix B amino acid residues of SEQ ID NO:168; (b) IL-4 helix B residues 65-83 of SEQ ID NO:164; (c) IL-3 helix B residues 73-86 of SEQ ID NO: 102; (d) GM-CSF helix B residues 72-81 of SEQ ID NO: 166; and (e) amino acid residues 83-98 of SEQ ID NO:2; a second spacer of 5-11 amino acid residues; a third polypeptide that comprises a sequence of amino acid residues selected from the group consisting of: (a) IL-2 helix C residues 102-116 of SEQ ID NO:162; (b) IL-4 helix C residues 94-118 of SEQ ID NO:164; (c) IL-3 helix C residues 91-103 of SEQ ID NO:102; (d) GM-CSF helix C residues 85-103 of SEQ ID NO:166; and (e) amino acid residues 104-117 of SEQ ID NO:2; a third spacer of 3-29 amino acid residues; and a fourth polypeptide that comprises a sequence of amino acid residues from 137-152 of SEQ ID NO:2. In another embodiment, the fusion protein is as disclosed above, wherein the fourth polypeptide comprises amino acid residues 137-152 of SEQ ID NO:2.

[0243] Within another aspect the present invention provides an isolated polynucleotide molecule comprising a sequence of nucleotides that encode the polypeptide as disclosed above. In one embodiment, the isolated polynucleotide is as disclosed above, wherein the nucleotides are selected from the group consisting of: (a) a polynucleotide as shown in SEQ ID NO: 1 from nucleotide 139 to nucleotide 483; (b) a polynucleotide as shown in SEQ ID NO: 1 from nucleotide 106 to nucleotide 519; (c) a polynucleotide as shown in SEQ ID NO: 1 from nucleotide 97 to nucleotide 519; and (d) a polynucleotide as shown in SEQ ID NO: 1 from nucleotide 28 to nucleotide 519.

[0244] Within another aspect the present invention provides an isolated polynucleotide molecule comprising a sequence of nucleotides that encode for the polypeptide as disclosed herein.

[0245] Within another aspect the present invention provides an expression vector comprising the following operably linked elements: (a) a transcription promoter; (b) a DNA segment encoding a polypeptide comprising a sequence of amino acid residues selected from the group consisting of: (i) amino acid residues 38-52 of SEQ ID NO:2; (ii) amino acid residues 83-98 of SEQ ID NO:2; (iii) amino acid residues 104-117 of SEQ ID NO:2; (iv) amino acid residues 137-152 of SEQ ID NO:2; and (v) combinations thereof; and (c) a transcription terminator.

[0246] Within another aspect the present invention provides an expression vector comprising the following operably linked elements: (a) a transcription promoter; (b) a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO:2; and (c) a transcription terminator. In one embodiment, the expression vector is as disclosed above, comprising the following operably linked elements: (a) a transcription promoter; (b) a DNA segment encoding a polypeptide comprising amino acid residues 38 (Val) to 152 (Leu) of SEQ ID NO:2; and (c) a transcription terminator.

[0247] Within another aspect the present invention provides a cultured cell comprising the expression vector as disclosed above.

[0248] Within another aspect the present invention provides a method of producing a protein comprising: culturing a cell as disclosed above under conditions wherein the DNA segment is expressed; and recovering the protein encoded by the DNA segment.

[0249] Within another aspect the present invention provides a method of producing an antibody to a zcytor17lig polypeptide comprising: inoculating an animal with a polypeptide selected from the group consisting of: (a) a polypeptide consisting of 9 to 141 amino acids, wherein the polypeptide is identical to a contiguous sequence of amino acid residues in SEQ ID NO:2 from amino acid number 24 (Ser) to amino acid number 164 (Thr); a polypeptide as disclosed above; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 38-52; (d) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 83-98; (e) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 104-117; (f) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 137-152; (g) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 38-152; (h) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 24-164; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino

acid number 38-52; (d) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 85-98; (e) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 104-118; (f) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 141-157; (g) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 38-157; (h) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 24-163; (i) a polypeptide comprising an antigenic epitope according to a Hopp/Woods hydrophilicity profile of SEQ ID NO:2 or SEQ I NO 11, wherein the profile is based on a sliding six-residue window. Buried G, S, and T residues and exposed H, Y, and W residues ignored; and wherein the polypeptide elicits an immune response in the animal to produce the antibody; and isolating the antibody from the animal.

[0250] Within another aspect the present invention provides an antibody (e.g., neutralizing antibody) produced by the method as disclosed above, wherein the antibody binds to a polypeptide of SEQ ID NO:2 or SEQ ID NO:11: In one embodiment, the antibody disclosed above specifically binds to a polypeptide shown in SEQ ID NO:2 or SEQ ID NO: 11.

[0251] Within another aspect the present invention provides a method of stimulating an immune response in a mammal exposed to an antigen or pathogen comprising the steps of: (1) determining directly or indirectly the level of antigen or pathogen present in said mammal; (2) administering a composition comprising zcytor17lig polypeptide in an acceptable pharmaceutical carrier; (3) determining directly or indirectly the level of antigen or pathogen in said mammal; and (4) comparing the level of the antigen or pathogen in step 1 to the antigen or pathogen level in step 3, wherein a change in the level is indicative of stimulating an immune response. In one embodiment, the method of stimulating an immune response in a mammal disclosed above further comprises: (5) re-administering a composition comprising zcytor17lig polypeptide in an acceptable pharmaceutical carrier; (6) determining directly or indirectly the level of antigen or pathogen in said mammal; and; (7) comparing the number of comparing the antigen or pathogen level in step 1 to the antigen level in step 6, wherein a change in the level is indicative of stimulating an immune response.

[0252] Within another aspect the present invention provides a method for expansion of hematopoietic cells and hematopoietic cell progenitors comprising culturing bone marrow or peripheral blood cells with a composition comprising an amount of zcytor17lig sufficient to produce an increase in the number of lymphoid cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of zcytor17lig. In one embodiment, the method for expansion of hematopoietic cells and hematopoietic cell progenitors is as disclosed above, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells. In another embodiment, the method for expansion of hematopoietic cells and hematopoietic cell progenitors is as disclosed above, wherein the lymphoid cells are monocytic cells, macrophages or T cells.

[0253] Within another aspect the present invention provides method of stimulating an immune response in a mammal exposed to an antigen or pathogen comprising: (1) determining a level of an antigen- or pathogen-specific antibody; (2) administering a composition comprising zcytor17lig polypeptide in an acceptable pharmaceutical carrier; (3) determining a post administration level of antigen- or pathogen-specific antibody; (4) comparing the level of antibody in step (1) to the level of antibody in step (3), wherein an increase in antibody level is indicative of stimulating an immune response.

[0254] Within another aspect the present invention provides a method of detecting the presence of zcytor17lig RNA in a biological sample, comprising the steps of: (a) contacting a zcytor17lig nucleic acid probe under hybridizing conditions with either (i) test RNA molecules isolated from the biological sample, or (ii) nucleic acid molecules synthesized from the isolated RNA molecules, wherein the probe has a nucleotide sequence comprising either a portion of the nucleotide sequence of the nucleic acid molecule as disclosed above, or its complement, and (b) detecting the formation of hybrids of the nucleic acid probe and either the test RNA molecules or the synthesized nucleic acid molecules, wherein the presence of the hybrids indicates the presence of zcytor17lig RNA in the biological sample.

[0255] Within another aspect the present invention provides a method of detecting the presence of zcytor17lig in a biological sample, comprising the steps of: (a) contacting the biological sample with an antibody, or an antibody fragment as disclosed above, wherein the contacting is performed under conditions that allow the binding of the antibody or antibody fragment to the biological sample, and (b) detecting any of the bound antibody or bound antibody fragment.

[0256] Within another aspect, the present invention provides a method of killing cancer cells comprising, obtaining *ex vivo* a tissue or biological sample containing cancer cells from a patient, or identifying cancer cells *in vivo*; producing a polypeptide by the method as disclosed herein; formulating the polypeptide in a pharmaceutically acceptable vehicle; and administering to the patient or exposing the cancer cells to the polypeptide; wherein the polypeptide kills the cells. In one embodiment the method of killing cancer cells is as disclosed above, wherein the polypeptide is further conjugated to a toxin. In one embodiment the antibody is as disclosed above, wherein the antibody is selected from the group consisting of: (a) polyclonal antibody, (b) murine monoclonal antibody, (c) humanized antibody derived from (b), (d) an antibody fragment, and (e) human monoclonal antibody.

[0257] Within another aspect, the present invention provides an antibody or antibody fragment that specifically binds to a polypeptide of comprising a sequence of amino acid residues selected from the group consisting of: (a) the polypeptide shown from residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO:2; (b) the polypeptide shown from residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2; (c) the polypeptide shown from residues 24 (Thr) to 164 (Thr) as shown in SEQ

ID NO:2; and (d) the polypeptide shown from residues 1 (Met) to 164 (Thr) as shown in SEQ ID NO:2. In another embodiment the antibody is as disclosed above, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

5 **[0258]** Within another aspect, the present invention provides a method for inhibiting zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors comprising culturing bone marrow or peripheral blood cells with a composition comprising an amount of an antibody as disclosed herein sufficient to reduce proliferation or differentiation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble cytokine receptor. In one embodiment the method for inhibiting zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors is as disclosed above, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells. In another embodiment the method for inhibiting zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors is as disclosed above, wherein the lymphoid cells are macrophages or T cells.

10 **[0259]** Within another aspect, the present invention provides a method of reducing zcytor17lig-induced induced inflammation comprising administering to a mammal with inflammation an amount of a composition of an antibody as disclosed herein sufficient to reduce inflammation.

15 **[0260]** Within another aspect, the present invention provides a method of suppressing an inflammatory response in a mammal with inflammation comprising: (1) determining a level of an inflammatory molecule; (2) administering a composition comprising an antibody as disclosed herein in an acceptable pharmaceutical vehicle; (3) determining a post administration level of the inflammatory molecule; (4) comparing the level of the inflammatory molecule in step (1) to the level of the inflammatory molecule in step (3), wherein a lack of increase or a decrease the inflammatory molecule level is indicative of suppressing an inflammatory response. In one embodiment, the antibody is as disclosed above, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

20 **[0261]** Within another aspect, the present invention provides a method for inhibiting zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors comprising culturing bone marrow or peripheral blood cells with a composition comprising an amount of an antibody as disclosed herein sufficient to reduce proliferation or differentiation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble cytokine receptor. In one embodiment the method for inhibiting zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors is as disclosed above, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells. In another embodiment the method for inhibiting zcytor17lig-induced proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors is as disclosed above, wherein the lymphoid cells are macrophages or T cells.

25 **[0262]** Within another aspect, the present invention provides a method of reducing zcytor17lig-induced induced inflammation comprising administering to a mammal with inflammation an amount of a composition of an antibody as disclosed herein sufficient to reduce inflammation.

30 **[0263]** Within another aspect, the present invention provides a method of suppressing an inflammatory response in a mammal with inflammation comprising: (1) determining a level of an inflammatory molecule; (2) administering a composition comprising an antibody as disclosed herein in an acceptable pharmaceutical vehicle; (3) determining a post administration level of the inflammatory molecule; (4) comparing the level of the inflammatory molecule in step (1) to the level of the inflammatory molecule in step (3), wherein a lack of increase or a decrease in the inflammatory molecule level is indicative of suppressing an inflammatory response.

35 **[0264]** Within another aspect, the present invention provides a method of treating a mammal afflicted with an inflammatory disease in which zcytor17lig plays a role, comprising: administering an antagonist of zcytor17lig to the mammal such that the inflammation is reduced, wherein the antagonist is selected from the group consisting of an antibody or binding polypeptide that specifically binds a polypeptide or polypeptide fragment of zcytor17lig (SEQ ID NO:2). In one embodiment, the method of treating a mammal afflicted with an inflammatory disease is as disclosed above, wherein the disease is a chronic inflammatory disease. In another embodiment, the method of treating a mammal afflicted with an inflammatory disease is as disclosed above, wherein the disease is a chronic inflammatory disease selected from the group consisting of: inflammatory bowel disease; ulcerative colitis; Crohn's disease; atopic dermatitis; eczema; and psoriasis. In another embodiment, the method of treating a mammal afflicted with an inflammatory disease is as disclosed above, wherein the disease is an acute inflammatory disease. In another embodiment, the method of treating a mammal afflicted with an inflammatory disease is as disclosed above, wherein the disease is an acute inflammatory disease selected from the group consisting of: endotoxemia; septicemia; toxic shock syndrome; and infectious disease. In another embodiment, the method of treating a mammal afflicted with an inflammatory disease is as disclosed above, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

40 **[0265]** Within another aspect, the present invention provides a method for detecting inflammation in a patient, comprising: obtaining a tissue or biological sample from a patient; incubating the tissue or biological sample with an antibody

as disclosed herein under conditions wherein the antibody binds to its complementary polypeptide in the tissue or biological sample; visualizing the antibody bound in the tissue or biological sample; and comparing levels of antibody bound in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the level of antibody bound to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of inflammation in the patient.

[0266] Within another aspect, the present invention provides a method for detecting inflammation in a patient, comprising: obtaining a tissue or biological sample from a patient; labeling a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1; incubating the tissue or biological sample with under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence; visualizing the labeled polynucleotide in the tissue or biological sample; and comparing the level of labeled polynucleotide hybridization in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the labeled polynucleotide hybridization to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of inflammation in the patient.

[0267] The invention is further illustrated by the following non-limiting examples.

EXAMPLES

Example 1

Construction of MPL-zcytor17 Polypeptide Chimera: MPL Extracellular and TM Domain Fused to the zcytor17 Intracellular Singaling Domain

[0268] The 5' extracellular domain of the murine MPL receptor was isolated from a plasmid containing the murine MPL receptor (PHZ1/MPL plasmid) by digestion with EcoRI and BamHI generating a 1164 bp fragment. The digestion was run on a 1% agarose gel and the fragment was isolated using the Qiaquick gel extraction kit (Qiagen) as per manufacturer's instructions. The rest of the MPL extracellular domain and transmembrane domain were generated using PCR with primers ZC6,673 (SEQ ID NO:13) and ZC29,082 (SEQ ID NO:14). The reaction conditions were as follows: 15 cycles at 94°C for 1 min., 55°C for 1 min., 72°C for 2 min.; followed by 72°C for 7 min.; then a 4°C soak. The PCR product was run on a 1% agarose gel and the approximately 400bp MPL receptor fragment was isolated using Qiaquick™ gel extraction kit (Qiagen) as per manufacturer's instructions.

[0269] The intracellular domain of human zcytor17 was isolated from a plasmid containing zcytor17 receptor cDNA (#23/pCAP) using PCR with primers ZC29,083 (SEQ ID NO:15) and ZC29,145 (SEQ ID NO:16). The polynucleotide sequence that corresponds to the zcytor17 receptor coding sequence is shown in SEQ ID NO:5. The reaction conditions were as per above. The PCR product was run on a 1% agarose gel and the approximately 320 bp zcytor17 fragment isolated using Qiaquick gel extraction kit as per manufacturer's instructions.

[0270] Each of the isolated PCR fragments described above were mixed at a 1:1 volumetric ratio and used in a PCR reaction using ZC6673 (SEQ ID NO:13) and ZC29145 (SEQ ID NO:16) to create all but the 5' MPL portion of the MPL-zcytor17 chimera. The reaction conditions were as follows: 15 cycles at 94°C for 1 min., 55°C for 1 min., 72°C for 2 min.; followed by 72°C for 7 min.; then a 4°C soak. The entire PCR product was run on a 1% agarose gel and the approximately 700bp MPL-zcytor17 chimera fragment isolated using Qiaquick gel extraction kit (Qiagen) as per manufacturer's instructions. The MPL-zcytor17 chimera fragment was digested with BamHI (BRL) and XbaI (Boehringer Mannheim) as per manufacturer's instructions. The entire digest was run on a 1% agarose gel and the cleaved MPL-zcytor17 chimera isolated using Qiaquick™ gel extraction kit (Qiagen) as per manufacturer's instructions. The resultant cleaved MPL-zvytor17 chimera plus 5' MPL EcoRI/BamHI fragment described above were inserted into an expression vector to generate the full MPL-zcytor17 chimeric receptor as described below.

[0271] Recipient expression vector pZP-7 was digested with EcoRI (BRL) and XbaI (BRL) as per manufacturer's instructions; and gel purified as described above. This vector fragment was combined with the EcoRI and XbaI cleaved MPL-zcytor17 PCR chimera isolated above and the EcoRI and BamHI 5' MPL fragment isolated above in a ligation reaction. The ligation was run using T4 Ligase (Epicentre Technologies), at room temperature for 1 hour as per manufacturer's instructions. A sample of the ligation was electroporated into DH10B ElectroMAX™ electrocompetent E. coli cells (25µF, 200Ω, 1.8V). Transformants were plated on LB+Ampicillin plates and single colonies screened by miniprep (Qiagen) and digestion with EcoRI to check for the MPL-zcytor17 chimera. EcoRI digestion of correct clones yield about a 2kb fragment. Confirmation of the MPL-zcytor17 chimera sequence was made by sequence analyses. The insert was approximately 3.1 kb, and was full-length.

Example 2MPL-zcytor17 Chimera Based Proliferation in BAF3 Assay Using Alamar Blue5 A. Construction of BaF3 Cells Expressing MPL-zcytor17 chimera

[0272] BaF3, an interleukin-3 (IL-3) dependent pre-lymphoid cell line derived from murine bone marrow (Palacios and Steinmetz, Cell 41: 727-734, 1985; Mathey-Prevot et al., Mol. Cell. Biol. 6: 4133-4135, 1986), was maintained in complete media (RPMI medium, JRH Bioscience Inc., Lenexa, KS) supplemented with 10% heat-inactivated fetal calf serum, 1-2 ng/ml murine IL-3 (mIL-3) (R & D, Minneapolis, MN), 2mM L-glutaMax-1™ (Gibco BRL), 1 mM Sodium Pyruvate (Gibco BRL), and PSN antibiotics (GIBCO BRL). Prior to electroporation, pZP-7/MPL-zcytor17 plasmid DNA (Example 1) was prepared and purified using a Qiagen Maxi Prep kit (Qiagen) as per manufacturer's instructions. BaF3 cells for electroporation were washed twice in RPMI media and then resuspended in RPMI media at a cell density of 10⁷ cells/ml. One ml of resuspended BaF3 cells was mixed with 30 µg of the pZP-7/MPL-zcytor17 plasmid DNA and transferred to separate disposable electroporation chambers (GIBCO BRL). At room temperature cells were given 5x.1msec shocks at 800 volts followed by 5x2ms shocks at 600 volts delivered by an electroporation apparatus (Cyto-Pulse). Alternatively, cells were electroporated with two serial pulses (800 µFAD/300 V; followed by 1180 µFAD/300 V) delivered by a Cell-Porator (GibcoBRL) electroporation apparatus. The electroporated cells were transferred to 50 ml of complete media and placed in an incubator for 15-24 hours (37°C, 5% CO₂). Then Geneticin™ (Gibco) selection (1mg/ml G418) was added to the cells in a T-162 flask to isolate the G418-resistant pool. Pools of the transfected BaF3 cells, hereinafter called BaF3/MPL-zcytor17 cells, were assayed for signaling capability as described below.

B. Testing the signaling capability of the BaF3/MPL-zcytor17 cells using an Alamar Blue Proliferation Assay

25 **[0273]** BaF3/MPL-zcytor17 cells were spun down and washed in the complete media, described above, but without mIL-3 (hereinafter referred to as "mIL-3 free media"). The cells were spun and washed 3 times to ensure the removal of the mIL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 µl per well using the mIL-3 free media.

30 **[0274]** Proliferation of the BaF3/MPL-zcytor17 cells was assessed using murine thrombopoietin (mTPO) diluted with mIL-3 free media to 200 ng/ml, 100ng/ml, 50ng/ml, 25ng/ml, 12.5ng/ml, 6.25ng/ml, 3.1ng/ml, 1.5 ng/ml concentrations. One hundred microliters of the diluted mTPO was added to the BaF3/MPL-zcytor17 cells. The total assay volume was 200 µl. Negative controls were run in parallel using mIL-3 free media only, without the addition of mTPO. The assay plates were incubated at 37°C, 5% CO₂ for 3 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20µl/well. Alamar Blue gives a fluorometric readout based on the metabolic activity of cells, and is thus a direct measurement of cell proliferation in comparison to a negative control. Plates were again incubated at 37°C, 5% CO₂ for 24 hours. Plates were read on the Fmax™ plate reader (Molecular Devices Sunnyvale, CA) using the SoftMax™ Pro program, at wavelengths 544 (Excitation) and 590 (Emission), or a Wallac Victor 2 plate reader (PerkinElmer Life Sciences, Boston, MA).

35 **[0275]** Results confirmed the signaling capability of the intracellular portion of the zcytor17 receptor, as the thrombopoietin induced proliferation at approximately 9-13 fold over background at mTPO concentrations of 50ng/ml and greater.

Example 345 Construction of Expression Vector Expressing Full-length zcytor17: pZp7pX/zcytor17A. Cloning of full length zcytor17 cDNA for expression:

50 **[0276]** To obtain a full-length zcytor17 cDNA, 5' and 3' PCR products were isolated and joined using an internal PstI site. The PCR primers were designed using the nucleotide sequence SEQ ID NO:4 and include BamHI and Xho I restriction sites for cloning purposes.

55 **[0277]** A 5' PCR product was generated using a WI-38 cDNA library as a template and oligonucleotides ZC29,359 (SEQ ID NO:18) and ZC27,899 (SEQ ID NO:19) as primers. WI-38 is an in-house cDNA library generated from a human embryonic lung cell line (ATCC CRL-2221). This 5' PCR reaction was run as follows: 30 cycles at 94°C for 1 minute, 65°C for 1 minute, 72°C for 2 minutes, then 72°C for 7 minutes; 10°C soak. The PCR reaction used approximately 3 µg of plasmid prepared from the cDNA library, 20 pmoles of each oligonucleotide, and five units of PWO DNA polymerase (Roche). About 90% of the 5' PCR product was ethanol precipitated, digested with BamHI and PstI and gel purified on a 1.0% agarose gel. The approximately 600 bp band was excised and used for ligation to the cloning vector pUC18

EP 1 476 541 B1

digested with BamHI and PstI. The resulting transformants were sequenced to confirm the zcytor17 cDNA sequence. For one of these transformants, plasmid DNA was prepared and digested with BamHI and PstI. The resulting approximately 600 bp band was gel purified and used for a ligation below to form a full-length cDNA.

[0278] A 3' PCR product was generated using a human testes in-house cDNA library as a template and oligonucleotides ZC27,895 (SEQ ID NO:20) and ZC29,122 (SEQ ID NO:21) as primers. This 3' PCR reaction was run as follows: 30 cycles at 94 °C for 45 seconds, 65 °C for 45 seconds, 72 °C for 2 minutes, then 72 °C for 7 minutes; 10 °C soak. The entire 3' PCR reaction was gel purified on a 1.0% agarose gel and the major 1500 bp band excised. This band was cloned into the PCR Blunt II TOPO vector using the Zeroblunt TOPO kit (Invitrogen). The resulting transformants were sequenced to confirm the zcytor17 cDNA sequence. For one of these transformants, plasmid DNA was prepared and digested with PstI and XhoI. The resulting approximately 1500 bp band was gel purified. A three-part ligation was performed with the 5' BamHI to Pst I fragment above, the 3' PstI to XhoI fragment, and the expression vector pZp7pX digested with BamHI and XhoI. This generated a pZp7pX plasmid containing a full-length cDNA for zcytor17 (SEQ ID NO:4), designated pZp7p/zcytor17. The full length zcytor17 cDNA in pZp7p/zcytor17 has a silent mutation that changes the T to G at position 1888 of SEQ ID NO:4 (encoding a Gly residue at residue 464 of SEQ ID NO:5). As this mutation was silent, the zcytor17 cDNA in pZp7p/zcytor17 encodes the polypeptide as shown in SEQ ID NO:5. Plasmid pZp7pX is a mammalian expression vector containing an expression cassette having the CMV promoter, intron A, multiple restriction sites for insertion of coding sequences, and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a puromycin resistance gene and the SV40 terminator.

B. Construction of Expression Vector Expressing Full-Length WSX-1

[0279] The entire WSX-1 receptor (SEQ ID NO:9) was isolated from a plasmid containing the WSX-1 receptor cDNA (SEQ ID NO:8) (U.S. Patent No. 5,925,735). hWSX-1/pBluescript SK(+) plasmid DNA (Stratagene, La Jolla, CA) was digested with EcoRI and XhoI to generate a 1075 bp fragment, and also digested with XhoI and XbaI to generate a 900 bp fragment. Both digests were run on a 1% agarose gel and the cleaved WSX-1 fragments isolated.

[0280] Recipient expression vector pZp7Z was digested with EcoRI and XbaI and gel purified as described above. This vector fragment was combined with the two cleaved zcytor17 fragments isolated above in a ligation reaction using T4 Ligase (BRL). The ligation was incubated at room temperature overnight. A sample of the ligation was electroporated in to DH10B electroMAX™ electrocompetent *E. coli* cells (25 μF, 200 Ω, 2.3V). Six colonies were grown in culture and miniprep DNA was prepared and digested to confirm the correct WSX-1 full-length insert of 2.0 kb. The resulting plasmid is pZP7Z/WSX-1.

Example 4

Zcytor17 based proliferation in BAF3 assay using Alamar Blue

A. Construction of BaF3 Cells Expressing zcytor17 receptor, WSX-1 receptor and OSMR

[0281] BaF3 cells expressing the full-length zcytor17 receptor were constructed as per Example 2A above, using 30 μg of the zcytor17 expression vector, described in Example 3A. One exception is that in place of Geneticin selection, 2 μg/ml of Puromycin (ClonTech) was added to the transfected cells in a T-162 flask to isolate the puromycin-resistant pool. The BaF3 cells expressing the zcytor17 receptor mRNA were designated as BaF3/zcytor17. To obtain clones, BaF3/zcytor17 cells were counted in a hemocytometer and plated at 1 cell/well, 0.5 cell/well, 0.1 cell/well, and 0.01 cell/well in 96-well dishes. Fifteen clones were scaled up to T75 flasks, and five clones were assayed for zcytor17 expression. Total RNA was isolated from cell pellets using a S.N.A.P.™ total RNA Isolation Kit (Invitrogen). First-strand cDNA was synthesized using the proSTAR™ First Strand RT-PCR kit, and then PCR with zcytor17 specific primers ZC29,180 (SEQ ID NO:22) and ZC29,122 (SEQ ID NO:23) was performed to screen the clones for expression of zcytor17. One clone, BaF3/zcytor17#15 was chosen to expand and transfect with the WSX-1 expression vector.

[0282] BaF3 cells expressing zcytor17 and full-length WSX-1 were constructed as per Example 2A above, using 30 μg of the WSX-1 expression vector WSX-1/pZp7Z (Example 3B) to electroporate the BaF3/zcytor17#15 cells. One exception is that in place of Geneticin selection, 200 μg/ml Zeocin (Invitrogen) was added to the transfected cells in a T-162 flask to isolate the zeocin-resistant pool. The BaF3 cells expressing zcytor17 and WSX-1 were designated BaF3/zcytor17/hWSX-1. To obtain clones, pools of BaF3/zcytor17/hWSX-1 cells were plated at limiting dilution in 96-well plates. The resulting clones were expanded and total RNA was isolated using a S.N.A.P.™ total RNA Isolation Kit (Invitrogen). First-strand cDNA was synthesized using the proSTAR™ First Strand RT-PCR kit, and then PCR with WSX-1 specific primers ZC9791 (SEQ ID NO:24) and ZC9793 (SEQ ID NO:25) was used to screen the clones for expression of WSX-1. One clone, BaF3/zcytor17/hWSX-1#5 was chosen to expand further and transfect with the OS-

EP 1 476 541 B1

MRbeta expression vector.

[0283] BaF3 cells expressing zcytor17, WSX-1 and full-length OSMRbeta were constructed as per Example 2A above, using 30 ug of the OSMRbeta expression vector OSMR/pZp7NX as described in Example 29 to electroporate the BaF3/zcytor17/hWSX-1#5 cells. The BaF3 cells expressing zcytor17, WSX-1, and OSMRbeta mRNA were designated BaF3/zcytor17/WSX-1/OSMR. To obtain clones, pools of BaF3/zcytor17/WSX-1/OSMRbeta cells were plated at limiting dilution in 96-well plates. Individual clones were expanded and total RNA was isolated using a S.N.A.P.[™] total RNA Isolation Kit (In Vitrogen). First-strand cDNA was synthesized using the proSTAR[™] First Strand RT-PCR kit, and then PCR with OSMRbeta specific primers ZC40109 (SEQ ID NO:26) and ZC40112 (SEQ ID NO:27) was used to screen the clones for expression of zcytor17, WSX-1, and OSMR. One clone, BaF3/zcytor17/WSX-1/OSMR#5 was selected and these cells were used to screen for zcytor17lig as described below in Examples 5 and 6.

B. Construction of BaF3 Cells Expressing zcytor17 receptor and OSMR

[0284] BaF3 cells expressing the full-length zcytor17 receptor were constructed as per Example 2A above, using 30µg of the zcytor17 expression vector, described in Example 3A. One exception is that in place of Geneticin selection, 2ug/ml of Puromycin (ClonTech) was added to the transfected cells in a T-162 flask to isolate the puromycin-resistant pool. The BaF3 cells expressing the zcytor17 receptor mRNA were designated as BaF3/zcytor17. To obtain clones, pools of BaF3/zcytor17 cells were plated at limiting dilution in 96-well plates. These clones were expanded in culture and total RNA was isolated using a S.N.A.P.[™] total RNA Isolation Kit (InVitrogen). First-strand cDNA was synthesized using the proSTAR[™] First Strand RT-PCR kit, and then PCR was used to screen the clones for expression of zcytor17. One clone, BaF3/zcytor17 #15 was chosen to expand and transfect with the OSMRbeta expression vector.

[0285] BaF3 cells expressing zcytor17 and full-length OSMRbeta were constructed as per Example 2A above, using 30 ug of the OSMRbeta expression vector OSMR/pZp7NX (Example 29) to electroporate the BaF3/zcytor17#15 cells. The BaF3 cells expressing zcytor17 and OSMRbeta mRNA were designated BaF3/zcytor17/OSMR. These cells were used to screen for zcytor17lig as described below in Example 5.

Example 5

Screening for-zcytor17lig using BaF3/Zcytor17/WSX-1/OSMRbeta cells using an Alamar Blue Proliferation Assay

A. Activation of CCRF-CEM and CCRF-HSB2 cells to test for presence of zcytor17lig

[0286] CCRF-CEM and CCRF-HSB2 cells were obtained from ATCC and stimulated in culture to produce conditioned media to test for the presence of zcytor17lig activity as described below. The suspension cells were seeded at 2×10^5 cells/ml or 5×10^5 cells/ml in RPMI-1640 media supplemented with 10% FBS, 2 mM L-glutamine (GibcoBRL), 1X PSN (GibcoBRL), and activated with 10 ng/ml Phorbol-12-myristate-13-acetate (PMA) (Calbiochem, San Diego, CA) and 0.5ug/ml Ionomycin[™] (Calbiochem) for 24 or 48hrs. The supernatant from the stimulated cells was used to assay proliferation of the BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells as described below.

B. Screening for zcytor17lig using BaF3/Zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells using an Alamar Blue Proliferation Assay

[0287] BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells were spun down and washed in mL-3 free media. The cells were spun and washed 3 times to ensure the removal of the mL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 µl per well using the mL-3 free media.

[0288] Proliferation of the BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells was assessed using conditioned media from activated CCRFCEM and CCRF-HSB2 cells (see Example 5A). Conditioned media was diluted with mL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75%, and 0.375% concentrations. One hundred microliters of the diluted conditioned media was added to the BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells. The total assay volume was 200 µl. The assay plates were incubated at 37°C, 5% CO₂ for 3-5 days at which time Alamar Blue (Accumed, Chicago, IL) was added at 20 µl/well. Plates were again incubated at 37°C, 5% CO₂ for 24 hours. Plates were read on the Fmax[™] plate reader (Molecular devices) as described above (Example 2).

[0289] Results confirmed the proliferative response of the BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells to a factor present in the activated CCRF-CEM and CCRF-HSB2 conditioned media. The response, as measured, was approximately 10-fold over background at the 25% concentration. The untransfected BaF3 cells did not proliferate in response to this factor, nor did BaF3 cells transfected with zcytor17 and WSX-1

EP 1 476 541 B1

(BaF3/zcytor17/WSX-1 cells), showing that this factor was specific for Zcytor17/OSMRbeta or zcytor17/OSMRbeta/WSX-1 receptors. Moreover, soluble zcytor17 receptor diminished this proliferative activity of zcytor17lig in the BaF3/zcytor17/WSX-1/OSMRbeta cells (see, Example 11). Similar results are expected in BaF3/2cytor17/OSMRbeta cells.

5

C. Human Primary Source used to isolate zcytor17lig

[0290] One hundred milliliter blood draws were taken from each of six donors. The blood was drawn using 10X 10 ml vacutainer tubes containing heparin. Blood was pooled from six donors (600ml), diluted 1:1 in PBS, and separated using a Ficoll-Paque® PLUS (Pharmacia Biotech). The isolated primary human cell yield after separation on the ficoll gradient was 1.2×10^9 cells.

10

[0291] Cells were suspended in 9.6 ml MACS buffer (PBS, 0.5% EDTA, 2mM EDTA). 1.6 ml of cell suspension was removed and 0.4 ml CD3 microbeads (Miltenyi Biotec, Auburn, CA) added. The mixture was incubated for 15 min. at 4°C. These cells labeled with CD3 beads were washed with 30 ml MACS buffer, and then resuspended in 2 ml MACS buffer.

15

[0292] A VS+ column (Miltenyi) was prepared according to the manufacturer's instructions. The VS+ column was then placed in a VarioMACS™ magnetic field (Miltenyi). The column was equilibrated with 5 ml MACS buffer. The isolated primary human cells were then applied to the column. The CD3 negative cells were allowed to pass through. The column was rinsed with 9 ml (3 X 3 ml) MACS buffer. The column was then removed from the magnet and placed over a 15 ml falcon tube. CD3+ cells were eluted by adding 5 ml MACS buffer to the column and bound cells flushed out using the plunger provided by the manufacturer. The incubation of the cells with the CD3 magnetic beads, washes, and VS+ column steps (incubation through elution) above were repeated five more times. The resulting CD3+ fractions from the six column separations were pooled. The yield of CD3+ selected human cells were 3×10^8 total cells.

20

[0293] A sample of the pooled CD3+ selected human cells was removed for staining and sorting on a fluorescent antibody cell sorter (FACS) to assess their purity. The human CD3+ selected cells were 91% CD3+ cells.

25

[0294] The human CD3+ selected cells were activated by incubating in RPMI + 5% FBS + PMA 10 ng/ml and Ionomycin 0.5 µg/ml (Calbiochem) for 13 hours 37°C. The supernatant from these activated CD3+ selected human cells was tested for zcytor17lig activity as described below. Moreover, the activated CD3+ selected human cells were used to prepare a cDNA library, as described in Example 6, below.

30

D. Testing supernatant from activated CD3+ selected human cells for zcytor17lig using BaF3/Zcytor17/WSX-1/OSMRbeta cells and an Alamar Blue Proliferation Assay

[0295] BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells were spun down and washed in mL-3 free media. The cells were spun and washed 3 times to ensure the removal of the mL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 µl per well using the mL-3 free media.

35

[0296] Proliferation of the BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells were assessed using conditioned media from activated CD3+ selected human cells (see Example 5C) diluted with mL-3 free media to 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75%, 0.375% and 0.187% concentrations. One hundred microliters of the diluted conditioned media was added to the BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells. The total assay volume was 200 µl. The assay plates were incubated and assayed as described in Example 5B.

40

[0297] Results confirmed the proliferative response of the BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells to a factor present in the activated CD3+ selected human Cell conditioned media. The response, as measured, was approximately 15-fold over background at the 25% concentration. The untransfected BaF3 cells did not proliferate in response to this factor, nor did BaF3 cells transfected with zcytor17 and WSX-1 (BaF3/zcytor17/WSX-1 cells), showing that this factor was specific for Zcytor17/OSMRbeta or zcytor17/OSMRbeta/WSX-1 receptors.

45

Example 6

50

Cloning of human zcytor17lig from a human CD3+ selected cell Library

[0298] Screening of a primary human activated CD3+ selected cell cDNA library revealed an isolated cDNA that is a novel member of the four-helix bundle cytokine family. This cDNA encoded the zcytor17lig. The cDNA was identified by screening for activity of the zcytor17lig using the zcytor17/WSX-1/OSM receptors.

55

A. The vector for CD3+ selected library construction

[0299] The vector for CD3+ selected library construction was pZP7NX. The pZP7NX vector was constructed as follows: The coding region for the DHFR selective marker in vector pZP7 was removed by DNA digestion with NcoI and PstI restriction enzymes (Boehringer Mannheim). The digested DNA was run on 1% agarose gel, cut out and gel purified using the Qiagen Gel Extraction Kit (Qiagen) as per manufacturer's instructions. A DNA fragment representing the coding region of Zeocin selective marker was amplified by PCR method with primers ZC13,946 (SEQ ID NO:28) and ZC13,945 (SEQ ID NO:29), and pZeoSV2(+) as a template. There are additional PstI and BclI restriction sites in primer ZC13,946 (SEQ ID NO:28), and additional NcoI and SfuI sites in primer ZC13,945 (SEQ ID NO:29). The PCR fragment was cut with PstI and NcoI restriction enzymes and cloned into pZP7 vector prepared by cleaving with the same two enzymes and subsequent gel purification. This vector was named pZP7Z. Then the Zeocin coding region was removed by DNA digestion of vector pZP7Z with BclI and SfuI restriction enzymes. The digested DNA was run on 1% agarose gel, cut out and gel purified, and then ligated with a DNA fragment of Neomycin coding region cut from pZem228 vector (deposited at the American Type Culture Collection (ATCC), Manassas, VA; ATCC Deposit No. 69446) with the same restriction enzymes (BclI and SfuI).

[0300] This new vector was named pZP7N, in which the coding region for DHFR selective marker was replaced by the coding region for a Neomycin selective marker from vector pZem228. A stuffer fragment including an XhoI site was added to pZP7N to create a vector suitable for high efficiency directional cloning of cDNA; this new vector was called pZP7NX. To prepare the vector for cDNA, 20 µg of pZP7NX was digested with 20 units of EcoRI (Life Technologies Gaithersburg, MD) and 20 units of XhoI (Boehringer Mannheim Indianapolis, IN) for 5 hours at 37°C, then 68°C for 15 minutes. The digest was then run on a 0.8% low melt agarose 1XTAE gel to separate the stuffer from the vector. The vector band was excised and digested with "beta-Agarase" (New England Biolabs, Beverly, MA) following the manufacturer's recommendations. After ethanol precipitation the digested vector was resuspended in water to 45ng/ml in preparation for ligation of CD3+ selected cDNA library described below.

B. Preparation of primary human activated CD3+ selected cell cDNA library

[0301] Approximately 1.5×10^8 primary human CD3+ selected cells stimulated in ionomycin/PMA were isolated by centrifugation after culturing at 37°C for 13 hours (Example 5C). Total RNA was isolated from the cell pellet using the "RNeasy Midi" kit from Qiagen, Inc. (Valencia, CA). mRNA was isolated from 225 micrograms of total RNA using the "MPG mRNA purification kit" from CPG Inc. (Lincoln Park, NJ). 3.4 micrograms of mRNA was isolated and converted to double stranded cDNA using the following procedure.

[0302] First strand cDNA from stimulated human CD3+ selected cells was synthesized as follows. Nine µl Oligo d(T)-selected poly(A) CD3+ RNA at a concentration of 0.34 µg/µl and 1.0 µl of 1 µg/µl first strand primer ZC18,698 (SEQ ID NO:30) containing an XhoI restriction site were mixed and heated at 65°C for 4 minutes and cooled by chilling on ice. First strand cDNA synthesis was initiated by the addition of 9 µl of first strand buffer (5x SUPERScript® buffer; Life Technologies), 4 µl of 100 mM dithiothreitol and 2 µl of a deoxynucleotide triphosphate solution containing 10 mM each of dATP, dGTP, dTTP and 5-methyl-dCTP (Pharmacia Biotech Inc.) to the RNA-primer mixture. The reaction mixture was incubated at 45°C for 4 minutes followed by the addition of 8 µl of 200 U/µl SuperscriptII®, RNase H-reverse transcriptase (Life technologies). The reaction was incubated at 45°C for 45 minutes followed by an incubation ramp of 1°C every 2 minutes to 50°C where the reaction was held for 10 minutes. To denature any secondary structure and allow for additional extension of the cDNA the reaction was then heated to 70°C for 2 minutes then dropped to 55°C for 4 minutes after which 2 µl of SuperscriptII® RT was added and incubated an additional 15 minutes followed by a ramp up to 70°C 1minute/1°C. Unincorporated nucleotides were removed from the cDNA by twice precipitating in the presence of 2 µg of glycogen carrier, 2.0 M ammonium acetate and 2.5 volume ethanol, followed by a 100 µl wash with 70% ethanol. The cDNA was resuspended in 98 µl water for use in second strand synthesis.

[0303] Second strand synthesis was performed on the first strand cDNA under conditions that promoted first strand priming of second strand synthesis resulting in DNA hairpin formation. The second strand reaction contained 98 µl of the first strand cDNA, 30 µl of 5x polymerase I buffer (100 mM Tris: HCl, pH 7.5, 500 mM KCl, 25 mM MgCl₂, 50 mM (NH₄)₂SO₄), 2 µl of 100 mM dithiothreitol, 6 µl of a solution containing 10 mM of each deoxynucleotide triphosphate, 5 µl of 5 mM β-NAD, 1 µl of 3 U/µl *E. coli* DNA ligase (New England Biolabs Inc.) and 4 µl of 10 U/µl *E. coli* DNA polymerase I (New England Biolabs Inc.). The reaction was assembled at room temperature and was incubated at room temperature for 2 minutes followed by the addition of 4 µl of 3.8 U/µl RNase H (Life Technologies). The reaction was incubated at 15°C for two hours followed by a 15 minute incubation at room temperature. Ten microliters of 1M TRIS pH7.4 was added to the reaction and extracted twice with phenol/chloroform and once with chloroform, the organic phases were then back extracted with 50 µl of TE (10mM TRIS pH 7.4, 1mM EDTA), pooled with the other aqueous and ethanol precipitated in the presence of 0.3 M sodium acetate. The pellet was washed with 100 µl 70% ethanol air dried and resuspended in 40 µl water.

EP 1 476 541 B1

[0304] The single-stranded DNA of the hairpin structure was cleaved using mung bean nuclease. The reaction mixture contained 40 μ l of second strand cDNA, 5 μ l of 10x mung bean nuclease buffer (Life technologies), 5 μ l of mung bean nuclease (Pharmacia Biotech Corp.) diluted to 1U/ μ l in 1X mung bean nuclease buffer. The reaction was incubated at 37°C for 45 minutes. The reaction was terminated by the addition of 10 μ l of 1 M Tris: HCl, pH 7.4 followed by sequential phenol/chloroform and chloroform extractions as, described above. Following the extractions, the cDNA was ethanol precipitated in the presence of 0.3 M sodium acetate. The pellet was washed with 100 μ l 70% ethanol air dried and resuspended in 38 μ l water.

[0305] The resuspended cDNA was blunt-ended with T4 DNA polymerase. The cDNA, which was resuspended in 38 μ l of water, was mixed with 12 μ l 5x T4 DNA polymerase buffer (250 mM Tris:HCl, pH 8.0, 250 mM KCl, 25 mM MgCl₂), 2 μ l 0.1 M dithiothreitol, 6 μ l of a solution containing 10 mM of each deoxynucleotide triphosphate and 2 μ l of 1 U/ μ l T4 DNA polymerase (Boehringer Mannheim Corp.). After an incubation of 45 minutes at 15°C, the reaction was terminated by the addition of 30 μ l TE followed by sequential phenol/chloroform and chloroform extractions and back extracted with 20 μ l TE as described above. The DNA was ethanol precipitated in the presence of 2 μ l Pellet Paint™ (Novagen) carrier and 0.3 M sodium acetate and was resuspended 11 μ l of water.

[0306] Eco RI adapters were ligated onto the 5' ends of the cDNA described above to enable cloning into an expression vector. 11 μ l of cDNA and 4 μ l of 65 pmole/ μ l of Eco RI hemiphosphorylated adaptor (Pharmacia Biotech Corp) were mixed with 5 μ l 5x ligase buffer (Life Technologies), 2 μ l of 10 mM ATP and 3 μ l of 1 U/ μ l T4 DNA ligase (Life Technologies), 1 μ l 10X ligation buffer (Promega Corp), 9 μ l water. The extra dilution with 1X buffer was to prevent the pellet paint from precipitating. The reaction was incubated 9 hours in a water bath temperature ramp from 10°C to 22°C over 9 hours, followed by 45 minutes at 25°C. The reaction was terminated by incubation at 68°C for 15 minutes.

[0307] To facilitate the directional cloning of the cDNA into an expression vector, the cDNA was digested with XhoI, resulting in a cDNA having a 5' Eco RI cohesive end and a 3' XhoI cohesive end. The XhoI restriction site at the 3' end of the cDNA had been previously introduced using the ZC18698 (SEQ ID NO:30) primer. Restriction enzyme digestion was carried out in a reaction mixture containing 35 μ l of the ligation mix described above, 6 μ l of 10x H buffer (Boehringer Mannheim Corp.), 1 μ l of 2mg/ml BSA (Biolabs Corp.), 17 μ l water and 1.0 μ l of 40 U/ μ l XhoI (Boehringer Mannheim). Digestion was carried out at 37°C for 1 hour. The reaction was terminated by incubation at 68°C for 15 minutes followed by ethanol precipitation, washing drying as described above and resuspension in 30 μ l water.

[0308] The resuspended cDNA was heated to 65°C for 5 minutes and cooled on ice, 4 μ l of 5X gel loading dye (Research Genetics Corp.) was added, the cDNA was loaded onto a 0.8% low melt agarose 1X TAE gel (SEA PLAQUE GTG™ low melt agarose; FMC Corp.) and electrophoresed. The contaminating adapters and cDNA below 0.6 Kb in length were excised from the gel. The electrodes were reversed, molten agarose was added to fill in the wells, the buffer was changed and the cDNA was electrophoresed until concentrated near the lane origin. The area of the gel containing the concentrated cDNA was excised and placed in a microfuge tube, and the agarose was melted by heating to 65°C for 15 minutes. Following equilibration of the sample to 45°C, 2 μ l of 1 U/ μ l Beta-agarase I (Biolabs, Inc.) was added, and the mixture was incubated for 90 min. at 45°C to digest the agarose. After incubation, 1 tenth volume of 3 M Na acetate was added to the sample, and the mixture was incubated on ice for 15 minutes. The sample was centrifuged at 14,000 x g for 15 minutes at room temperature to remove undigested agarose, the cDNA was ethanol precipitated, washed in 70% ethanol, air-dried and resuspended in 40 μ l water.

[0309] To determine the optimum ratio of cDNA to vector several ligations were assembled and electroporated. Briefly, 2 μ l of 5X T4 ligase buffer (Life Technologies), 1 μ l of 10mM ATP, 1 μ l pZP7NX digested with EcoR1-Xho1, 1 μ l T4 DNA ligase diluted to 0.25u/ μ l (Life Technologies) water to 10 μ l and 0.5, 1, 2 or 3 μ l of cDNA were mixed in 4 separate ligations, incubated at 22°C for 4 hours, 68°C for 20 minutes, sodium acetate-ethanol precipitated, washed, dried and resuspended in 10 μ l. A single microliter of each ligation was electroporated into 40 μ l DH10b ElectroMax™ electro-competent bacteria (Life Technologies) using a 0.1cm cuvette (Biorad) and a Genepulser, pulse controller™ (Biorad) set to 2.5KV, 251F, 200ohms. These cells were immediately resuspended in 1 ml. SOC broth (Manniat et al. supra.) followed by 500 μ l of 50% glycerol-SOC as a preservative. These "glycerol stocks " were frozen in several aliquots at -70°C. An aliquot of each was thawed and plated serially on LB-agar plates supplemented with ampicillin at 100 μ g/ml. Colony numbers indicated that the optimum ratio of CD3+ cDNA to pZP7NX vector was 1 μ l to 45 ng; such a ligation yielded 4.5 million primary clones.

[0310] For the purpose of screening the library using a BaF3-based proliferation assay (Example 5) glycerol stocks from above were diluted into liquid cultures of 100 or 250 clones per pool in deep well microtiter plates, grown 24 hours at 37°C with shaking and plasmid isolated using a Qiagen kit following the manufacturer's instructions. Such DNA was subsequently transfected into BHK cells, media conditioned 72 hours, harvested and stored at -80°C, and subsequently placed on 5K BaF3/zcytor17/WSX-1/OSMRbeta cells or BaF3/zcytor17/OSMRbeta cells for 72 hours after which proliferation was assessed using an "Alamar blue" fluorescence assay (Example 5B and Example 2B).

Example 7Expression Cloning of human zcytor17lig

5 **[0311]** The glycerol stocks from the activated human CD3⁺ selected cell library (Example 6) were added to Super Broth II™ (Becton Dickinson, Cockeysville, MD) + 0.1 mg/ml ampicillin (amp) at a concentration of 250 cells per 800 microliters. The *E. coli* were allowed to equilibrate for 24 hours at room temperature. At the time of inoculation, 400 microliters was plated on LB + amp plates to determine the actual titer of the inoculation. After 24 hours the plates were counted and then the final concentration of the SuperBrothII™ + *E. coli* was adjusted so that the final concentration was
10 250 cells per 1.2 ml. Three times 2 liters were inoculated for a total of 6 liters. The media were then plated into 96-well deep well blocks (Qiagen). Plating was done on the 8-channel Q-Fill2™ dispenser (Genetix, Christchurch, Dorset, UK). The *E. coli* were grown overnight at 37°C shaking at 250 rotations/min. on a New Brunswick Scientific Innova 4900 multi-tier environment shaker. The *E. coli* were spun out of solution at 3000 rpm, using a Beckman GS-6KR centrifuge. These *E. coli* pellets were frozen at -20°C or used fresh before miniprepping the plasmid DNA. Each pellet contains approximately
15 250 cDNA clones from the human CD3⁺ selected cell library.

[0312] These pools of 250 cDNA clones were then mini-prepped using QIAprep™ 96 Turbo Miniprep kit (Qiagen). Plasmid DNA was eluted using 125 µl of TE (10 mM Tris pH 8, 1 mM EDTA). This plasmid DNA was then used to transfect BHK cells.

20 BHK transfection

[0313] BHK cells were plated in 96-well tissue culture plates at a density of 12,000 cells per well in a volume of 100 µl per well. Culture media was DMEM (GibcoBRL), 5% heat-inactivated fetal bovine serum, 2 mM L-glutamine (GibcoBRL), 1X PSN (GibcoBRL), 1 mM NaPyruvate. (GibcoBRL).

25 **[0314]** The following day, BHK cells were washed once with 100 µl SFA. SFA is serum-free media which is DMEM/F12 or DMEM (Gibco/BRL), 2 mM GlutaMax™ (Gibco/BRL), 1 mM NaPyruvate, 10 µg/ml transferrin, 5 µg/ml insulin, 10 µg/ml fetuin, 2 µg/ml selenium, 25mM HEPES (Gibco/BRL), 100 µM non-essential amino acids (Gibco/BRL).

[0315] A DNA/Lipofectamine™ mix was made as follows: 2-.2 µl Lipofectamine™ reagent (Gibco/BRL) was combined with 102.8 µl SFA at room temperature; approximately 5 µl of the plasmid DNA (200 ng/µl) was then added to the
30 Lipofectamine™/SFA to form the DNA/Lipofectamine™ mixture, which was incubated at room temperature for 30 minutes. The SFA was removed from the BHK cells and the cells were incubated with 50 µl of the DNA/lipofectamine™ mix for 5 hours at 37°C with 5% CO₂. Fifty µl of the DNA/Lipofectamine™ mixture was added to each of two wells of the BHK cells, so that transfections were done in duplicate.

[0316] After BHK cells were incubated with DNA/Lipofectamine™ mix for 5 hours, the DNA/Lipofectamine™ mix was removed and 100 µl culture media was added. Cells were incubated overnight, the media was removed and replaced
35 with 100 µl culture media. After culturing cells for 48-72 hours, conditioned media was removed, frozen at -80°C for a minimum of 20 minutes, thawed, and then 50 µl was assayed in the Baf3 proliferation assay, described in Example 5, to identify pools of 250 clones with ligand activity.

[0317] Twenty 96-well plates were screened in a single assay. This represented approximately 250 cDNAs/well or 480,000 cDNAs total. Of these, conditioned media from approximately 60 wells (representing 250 cDNAs per well) tested positive in the proliferation assay. One of these positive pools was chosen to break down and isolate a single cDNA that would encode the zcytor17lig. This was pool 62A12.

[0318] For pool 62A12, 1 µl of DNA was used to transform ElectroMax™ DH10B cells (Gibco/BRL) by electroporation. The transformants were plated on LB + amp (100 µg/ml) plates to give single colonies. From the electroporated pool,
45 672 individual colonies were selected by toothpick into seven 96-well plates containing 1.2 ml of SuperBrothII™ per well. These plates were numbered #62.1 through #62.7. These were cultured overnight and the plasmid DNA miniprepped as above. For all seven plates, plasmid DNA from the breakdown plates was transfected into BHK cells and assayed by proliferation as above, except that transfections were not done in duplicate.

[0319] Two positive clones 62.6C7 and 62.6E9 were identified by activity from a total of 672 clones. Plasmid DNA miniprepped from clone 62.6E9 was sequenced and a tentative identification was obtained, but a mixed sequence was obtained from this positive clones. To further isolate the zcytor17lig cDNA to a single clone, 1 µl of DNA from pool 62.6E9 was used to electroporate DH10B cells and the transformants plated on LB + amp (100 µg/ml) plates to give single colonies. Plasmid DNA miniprepped from several colonies was sequenced to give the exact DNA sequence. The poly-nucleotide sequence of zcytor17lig was full-length (SEQ ID NO:1) and its corresponding amino acid sequence is shown
55 (SEQ ID NO:2).

Example 8Construction of Mammalian Expression Vectors That Express zcytor17 Soluble Receptors: zcytor17CEE, zcytor17CFLG, zcytor17CHIS and zcytor17-Fc4A. Construction of zcytor17 Mammalian Expression Vector containing zcytor17CEE, zcytor17CFLG and zcytor17CHIS

[0320] An expression vector was prepared for the expression of the soluble, extracellular domain of the zcytor17 polypeptide, pZp9zcytor17CEE, where the construct was designed to express a zcytor17 polypeptide comprised of the predicted initiating methionine and truncated adjacent to the predicted transmembrane domain, and with a C-terminal Glu-Glu tag (SEQ ID NO:32).

[0321] An approximately 1500 bp PCR product was generated using ZC29,451 (SEQ ID NO:33) and ZC29,124 (SEQ ID NO:34) as PCR primers to add EcoRI and BamHI restriction sites. A human HPVS in-house cDNA library was used as a template and PCR amplification was performed as follows: 30 cycles at 94°C for 1 minute, 65°C for 1 minute, 72°C for 1.5 minutes, then 72°C for 7 minutes; 10°C soak. The PCR reaction was ethanol precipitated and digested with EcoRI and BamHI restriction enzymes. The digested PCR product was gel purified on a 1.0% agarose gel and the approximately 1500 bp band excised. This band was then re-amplified using identical primers with the following cycling: 30 cycles at 94°C for 1 minute, 65°C for 1 minute, 72°C for 3 minutes, then 72°C for 7 minutes; 10°C soak. The PCR reaction was ethanol precipitated and digested with EcoRI and BamHI restriction enzymes. The digested PCR product was gel purified on a 1.0% agarose gel and the approximately 1500 bp band excised. The excised DNA was subcloned into plasmid CEEpZp9 that had been cut with EcoRI and BamHI, to generate plasmid with a GLU-GLU C-terminally tagged soluble receptor for zcytor17, zcytor17CEEpZp9. The extracellular domain in the zcytor17CEE cDNA in zcytor17CEEpZp9 has a silent mutation that changes the T to C at position 1705 of SEQ ID NO:4 (encoding a Pro residue at residue 403 of SEQ ID NO:5). As this mutation was silent, the zcytor17 cDNA in zcytor17CEEpZp9 encodes the polypeptide as shown in SEQ ID NO:5. Moreover, because of the construct used, a Gly-Ser residue pair was inserted C-terminal to the end of the soluble, extracellular domain of zcytor17 and prior to the C-terminal Glu-Glu Tag (SEQ ID NO:32). As such, the tag at the C-terminus of the zcytor17 extracellular domain, was a Glu-Glu tag as shown in (SEQ ID NO:17). Plasmid CEEpZp9 is a mammalian expression vector containing an expression cassette having the mouse metallothionein-1 promoter, multiple restriction sites for insertion of coding sequences, and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene and the SV40 terminator. Using standard molecular biological techniques zcytor17CEEpZp9 was electroporated into DH10B competent cells (GIBCO BRL, Gaithersburg, MD) according to manufacturer's direction and plated onto LB plates containing 100 µg/ml ampicillin, and incubated overnight. Colonies were screened by restriction analysis, or PCR from DNA prepared from individual colonies. The insert sequence of positive clones was verified by sequence analysis. A large scale plasmid preparation was done using a QIAGEN® Maxi prep kit (Qiagen) according to manufacturer's instructions.

[0322] The same process was used to prepare the zcytor17 soluble receptors with a C-terminal His tag, composed of 6 His residues in a row; and a C-terminal FLAG® tag (SEQ ID NO:36), zcytor17CFLAG. To construct these constructs, the aforementioned vector has either the HIS or the FLAG® tag in place of the glu-glu tag (e.g., SEQ ID NO:17; SEQ ID NO:32 or SEQ ID NO:35).

B. Mammalian Expression Construction of Soluble human zcytor17 receptor: zcytor17-Fc4

[0323] An expression vector, pEZE-2 hzcytor17/Fc4, was prepared to express a C-terminally Fc4 tagged soluble version of hzcytor17 (human zcytor17-Fc4) in PF CHO cells. PF CHO cells are an in house CHO cell line adapted for growth in protein-free medium (ExCell 325 PF medium; JRH Biosciences). The in house CHO cell line was originally derived from CHO DG44 cells (G. Urlaub, J. Mitchell, E. Kas, L.A. Chasin, V.L. Funanage, T.T. Myoda and J.L. Hamlin, "The Effect Of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions," Somatic Cell and Molec. Genet., 12: 555-566 (1986). A fragment of zcytor17 cDNA that includes the polynucleotide sequence from extracellular domain of the zcytor17 receptor was fused in frame to the Fc4 polynucleotide sequence (SEQ ID NO:37) to generate a zcytor17-Fc4 fusion (SEQ ID NO:38 and SEQ ID NO:39). The pEZE-2 vector is a mammalian expression vector that contains the Fc4 polynucleotide sequence and a cloning site that allows rapid construction of C-terminal Fc4 fusions using standard molecular biology techniques.

[0324] A 1566 base pair fragment was generated by PCR, containing the extracellular domain of human zcytor17 and the first two amino acids of Fc4 (Glu and Pro) with FseI and BglII sites coded on the 5' and 3' ends, respectively. This PCR fragment was generated using primers ZC29,157 (SEQ ID NO:40) and ZC29,150 (SEQ ID NO:41) by amplification from a plasmid containing the extracellular domain of human zcytor17 (pZp9zcytor17CEE) (Example 8A). The PCR reaction conditions were as follows: 25 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 2 minutes; 1 cycle

EP 1 476 541 B1

at 72°C for 10 minutes; followed by a 4°C soak. The fragment was digested with FseI and BglII restriction endonucleases and subsequently purified by 1% gel electrophoresis and band purification using QiaQuick gel extraction kit (Qiagen). The resulting purified DNA was ligated for 5 hours at room temperature into a pEZE-2 vector previously digested with FseI and BglII containing Fc4 3' of the FseI and BglII sites.

5 [0325] Two μ l of the ligation mix was electroporated in 37 μ l DH10B electrocompetent *E. coli* (Gibco) according to the manufacturer's directions. The transformed cells were diluted in 400 μ l of LB media and plated onto LB plates containing 100 μ g/ml ampicillin. Clones were analyzed by restriction digests and positive clones were sent for DNA sequencing to confirm the sequence of the fusion construct. One microliter of a positive clone was transformed into 37 μ l of DH10B electrocompetent *E. coli* and streaked on a LB/amp plate. A single colony was picked from this streaked plate to start a 250 ml LB/amp culture that was then grown overnight at 37°C with shaking at 250 rpm. This culture was used to generate 750 μ g of purified DNA using a Qiagen plasmid Maxi kit (Qiagen).

Example 9

15 Transfection And Expression Of Zcytor17 Soluble Receptor Polypeptides

[0326] BHK 570 cells (ATCC No. CRL-10314), DG-44 CHO, or other mammalian cells are plated at about 1.2×10^6 cells/well (6-well plate) in 800 μ l of appropriate serum free (SF) media (e.g., DMEM, Gibco/BRL High Glucose) (Gibco BRL, Gaithersburg, MD). The cells are transfected with expression plasmids containing zcytor17CEE, zcytor17CFLG, zcytor17CHIS or zcytor17-Fc4 (Example 8), using Lipofectin™ (Gibco BRL), in serum free (SF) media according to manufacturer's instruction. Single clones expressing the soluble receptors are isolated, screened and grown up in cell culture media, and purified using standard techniques.

25 A. Mammalian expression of soluble human zcytor17CEE receptor

[0327] BHK 570 cells (ATCC NO: CRL-10314) were plated in T-75 tissue culture flasks and allowed to grow to approximately 50 to 70% confluence at 37°C, 5% CO₂ in DMEM/FBS media (DMEM, Gibco/BRL High Glucose, (Gibco BRL, Gaithersburg, MD), 5% fetal bovine serum, 1 mM L-glutamine (JRH Biosciences, Lenea, KS), 1 mM sodium pyruvate (Gibco BRL)). The cells were then transfected with the plasmid containing zcytor17CEE (Example 8A) using Lipofectamine™ (Gibco BRL), in serum free (SF) media formulation (DMEM, 10 mg/ml transferrin, 5 mg/ml insulin, 2 mg/ml fetuin, 1% L-glutamine and 1% sodium pyruvate). Ten micrograms of the plasmid DNA pZp9zcytor17CEE (Example 8A) was diluted into a 15ml tube to a total final volume of 500 μ l with SF media. Fifty microliters of Lipofectamine was mixed with 450 μ l of SF medium. The Lipofectamine mix was added to the DNA mix and allowed to incubate approximately 30 minutes at room temperature. Four ml of SF media was added to the DNA:Lipofectamine mixture. The cells were rinsed once with 5 ml of SF media, aspirated, and the DNA:Lipofectamine mixture was added. The cells were incubated at 37°C for five hours, and then 5 ml of DMEM/10%FBS media was added. The flask was incubated at 37°C overnight after which time the cells were split into the selection media (DMEM/FBS media from above with the addition of 1 μ M methotrexate or 10 μ M Methotrexate (Sigma Chemical Co., St. Louis, Mo.) in 150 mm plates at 1:2, 1:10, and 1:50. Approximately 10 days post-transfection, one 150 mm plate of 1 μ M methotrexate resistant colonies was trypsinized, the cells were pooled, and one-half of the cells were replated in 10 μ M methotrexate; to further amplify expression of the zcytor17CEE protein. A conditioned-media sample from this pool of amplified cells was tested for expression levels using SDS-PAGE and Western analysis.

45 B. Mammalian expression of soluble human zcytor17-Fc4 receptor

[0328] Five replicates of 200 μ g of pEZE-2hzcytor17Fc4 plasmid DNA (Example 8B) were linearized by restriction digestion with FspI, a restriction enzyme that cuts once within the vector and does not disturb genes necessary for expression. 200 μ g of CHO cell genomic DNA was added to each replicate as carrier DNA and then the DNA was precipitated by addition of 0.1 volumes of 3M Sodium Acetate pH 5.2 and 2.2 volumes ethanol followed by a 15 minute ice incubation and microcentrifugation at 4°C. The resulting DNA pellets were washed in 70% ethanol and air dried before being resuspended in 100 μ l protein free (PF) CHO non-selection growth media (21 g/L PF CHO Ex Cell 325 /200 mM L-glutamine (Gibco)/100 mM sodium pyruvate (Gibco)/1x HT Supplement (Gibco). Ten million PF CHO passage 61 cells were added to the DNA in 600 μ l of PF CHO non-selection growth media and then electroporated in a Gene Pulser II Electroporation system (BioRad) using 950 μ F capacitance and 300 Kv using a 0.4 cm gap Gene Pulser (BioRad) electroporation cuvette. All 5 replicates of the electroporated cells were pooled and directly selected in -HT media (21 g/L PF CHO Ex Cell 325/ 200 mM L-glutamine (Gibco)/100 mM sodium pyruvate (Gibco). Cells were selected for 15 days in -HT media before being passaged at 4×10^5 ml into 50 nm MTX selection. Eight days later cells were seeded at 3.5×10^5 cells/ml into 200 mM MTX selection. After one week, cells were seeded at 4×10^5 cells/ml into 1 μ M

EP 1 476 541 B1

MTX selection. After two weeks at 1 μ M MTX, cells were seeded at 1×10^6 cells/ml into 50 ml to generate conditioned medium. The resulting 72 hour conditioned media was analyzed by probing western blots with an antibody generated against human Ig. The cells produced zcytor17/Fc4 protein at approximately 1 mg/L.

5 C. Larger-scale mammalian expression of soluble human zcytor17-Fc4 receptor

[0329] Two hundred μ g of pEZE-2hzcytor17Fc4 plasmid DNA (Example 8B) was linearized by restriction digestion with FspI, a restriction enzyme that cuts once within the pEZE-2 vector and does not disturb genes necessary for expression. Two hundred micrograms of CHO genomic DNA (prepared in-house) was added as carrier DNA and then the DNA was precipitated by addition of 0.1 volumes of 3M Sodium Acetate pH 5.2 and 2.5 volumes ethanol followed by microcentrifugation at Room temperature. Five replicate DNA pellets were made and transformed. The resulting DNA pellet was washed in 70% ethanol and air dried before being resuspended in 100 μ l PF CHO non-selection growth media (21 g/L PF CHO Ex Cell 325 /200 mM L-glutamine (Gibco)/100 mM sodium pyruvate (Gibco)/1x HT Supplement (Gibco). Ten million PF CHO cells were added to the DNA in 600 μ l of PF CHO non-selection growth media and then electroporated in a Gene Pulser II Electroporation system (BioRad) using 950 μ F capacitance and 300 volts using a 0.4 cm gap Gene Pulser (BioRad) electroporation cuvette. The electroporated cells were pooled and put directly into selection in -HT media (21 g/L PF CHO Ex Cell 325/ 200 mM L-glutamine (Gibco)/100 mM sodium pyruvate (Gibco). Cells were selected for 14 days in -HT media before being passaged at 4×10^5 /ml into 50 nm MTX selection. Cells were amplified to 200nM MTX and then to 1 μ M MTX. The -HT, 50nM, and 1 μ M pools were seeded at 1×10^6 c/ml for 48 hours, and the resulting conditioned media was analyzed by probing western blots with an antibody generated against human Ig.

Example 10

25 Purification of zcytor17 soluble receptors from BHK 570 and CHO cells

A. Transient mammalian expression and purification of soluble human zcytor17-Fc4 receptor

[0330] pEZE-2hzcytor17Fc4 plasmid DNA (Example 8B) was introduced into 40 maxi plates of BHK cells using Lipofectamine (Gibco BRL) as described herein and in manufacturer's instructions. Cells were allowed to recover overnight, then were rinsed and refed with serum-free medium (SL7V4, made in-house). After 72 hours, the media was collected and filtered, and cells were refed with serum-free medium. After 72 hours, the media was again collected and filtered.

[0331] The serum-free conditioned media (2 x 1.5 L batches) from transiently transfected BHK cells was pumped over a 1.5 ml Protein A-agarose column in 20 mM Tris, pH 7.5, 0.5 M NaCl. The column was washed extensively with this buffer and then the bound protein was eluted with 1 ml of 0.2 M glycine, pH 2.5, 0.5 M NaCl. The eluted protein was collected into 0.1 ml of 2 M Tris, pH 8.5. Aliquots were collected for SDS-polyacrylamide gel electrophoresis and the bulk zcytor17-Fc was dialyzed overnight against PBS. The soluble receptor was sterile filtered and placed in aliquots at -80°C.

40 B. Purification of zcytor17-Fc4

[0332] Recombinant carboxyl terminal Fc4 tagged zcytor17 (Example 8 and Example 9) was produced from transfected CHO cells. The CHO transfection was performed using methods known in the art. Approximately five-liters of conditioned media were harvested and sterile filtered using Nalgene 0.2 μ m filters.

[0333] Protein was purified from the filtered media by a combination of Poros 50 protein A affinity chromatography (PerSeptive Biosystems, 1-5559-O1, Framingham, MA) and Superdex 200 gel exclusion chromatography column (Amersham Pharmacia Biotech, Piscataway, NJ). Culture medium was directly loaded onto a 10x70mm (5.5-ml bed volume) protein A affinity column at a flow of about 3-10 ml/minute. Following column washing for ten column volumes of PBS, bound protein was eluted by five column volumes of 0.1 M glycine, pH 3.0 at 10 ml/minute). Fractions of 2 ml each were collected into tubes containing 100 μ l of 2.0 M Tris, pH 8.0, in order to neutralize the eluted proteins. Samples from the affinity column were analyzed by SDS-PAGE with coomassie staining and Western blotting for the presence of zcytor17-Fc4 using human Ig-HRP. Zcytor17-Fc4-containing fractions were pooled and concentrated to 1-2 ml using Biomax-30 concentrator (Millipore), and loaded onto a 20x580 mm Superdex 200 gel filtration column. The fractions containing purified zcytor17-Fc4 were pooled, filtered through 0.2 μ m filter, aliquoted into 100 μ l each, and frozen at -80°C. The concentration of the final purified protein was determined by BCA assay (Pierce, Rockford, IL).

C. SDS-PAGE and Western blotting analysis of zcytor17/Fc4

[0334] Recombinant zcytor17-Fc4 was analyzed by SDS-PAGE (Nupage 4-12%, Invitrogen, Carlsbad, CA) with coomassie staining method and Western blotting using human Ig-HRP. Either the conditioned media or purified protein was electrophoresed using an Invitrogen Novex's Xcell II mini-cell, and transferred to nitrocellulose (0.2 mm; Invitrogen, Carlsbad, CA) at room temperature using Novex's Xcell II blot module with stirring according to directions provided in the instrument manual. The transfer was run at 500 mA for one hour in a buffer containing 25 mM Tris base, 200 mM glycine, and 20% methanol. The filters were then blocked with 10% non-fat dry milk in PBS for 10 minutes at room temperature. The nitrocellulose was quickly rinsed, then the human Ig-HRP antibody (1:2000) was added in PBS containing 2.5% non-fat dry milk. The blots were incubated for two hours at room temperature, or overnight at 4°C, with gentle shaking. Following the incubation, the blots were washed three times for 10 minutes each in PBS, then quickly rinsed in H₂O. The blots were developed using commercially available chemiluminescent substrate reagents (Super-Signal® ULTRA reagents 1 and 2 mixed 1:1; reagents obtained from Pierce, Rockford, IL), and the signal was captured using Lumi-Imager's Lumi Analyst 3.0 software (Boehringer Mannheim GmbH, Germany) for exposure times ranging from 10 second to 5 minutes or as necessary.

[0335] The purified zcytor17-Fc4 appeared as a single band with either the coomassie or silver staining at about 220 kDa under non-reducing conditions, and at about 120 kDa under reducing conditions, suggesting the dimeric form of zcytor17-Fc4 under non-reducing conditions as expected.

Example 11Assay using zcytor17 soluble receptor zcytor17-Fc4 Soluble receptor in competitive inhibition assay

[0336] BaF3/zcytor17/WSX-1/OSMRbeta cells and BaF3/zcytor17/OSMRbeta cells were spun down and washed in mL-3 free media. The cells were spun and washed 3 times to ensure the removal of the mL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at 5000 cells per well in a volume of 100 µl per well using the mL-3 free media.

[0337] Both conditioned media from the CCRF-CEM and CCRF-HSB2 cell activation and the human CD3+ selected cells, described in Example 5, were added in separate experiments at 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75%, 0.375%, and 0.187 % concentrations, with or without zcytor17 soluble receptors (Zcytor17-Fc4; See, Example 9 and Example 10) at 1-10 µg/ml. The total assay volume was 200 µl.

[0338] The assay plates were incubated at 37°C, 5% CO₂ for 3-5 days at which time Alamar Blue (Accumed) was added at 20 µl/well. Plates were again incubated at 37°C, 5% CO₂ for 16-24 hours. Plates were read on the Fmax™ plate reader (Molecular Devices) as described in Example 2. Results demonstrated partial inhibition of cell growth with zcytor17-Fc4 soluble receptor at 10 µg/ml, confirming that the factor in each sample was specific for the zcytor17 receptor.

[0339] Titration curves, diluting out the soluble receptor, or soluble receptor heterodimers comprising zcytor17/OSMR and zcytor17/WSX-1 were also ran using the above stated assay to determine whether zcytor17 receptors are able to completely inhibit growth, for example, at low or physiologic concentrations.

[0340] Similar competitive inhibition assays were carried out using purified human zcytor17lig (Example 35) and soluble receptors in luciferase assays (Example 20). The results show that both homodimeric zcytor17 and heterodimeric zcytor17/OSMR are capable of inhibiting the activity of zcytor17lig.

Example 12Secretion trap assay

[0341] A secretion trap assay was used to test the binding of the zcytor17lig to receptors comprising zcytor17 receptor, such as the zcytor17 receptor or receptor heterodimers comprising zcytor17/OSMR and zcytor417/WSX-1. Zcytor17lig plasmid DNA was transfected into COS cells, and used to assess binding of the zcytor17lig to receptors comprising zcytor17 receptor by secretion trap as described below.

A. COS Cell Transfections

[0342] The COS cell transfection was performed as follows: 800 ng of zcytor17lig cDNA and 4 µl Lipofectamine™ were mixed in 80 µl serum free DMEM media (55mg sodium pyruvate, 146mg L-glutamine, 5mg transferrin, 2.5mg insulin, 1µg selenium and 5mg fetuin in 500ml DMEM), and incubated at room temperature for 30 minutes. Then 320 µl serum free DMEM media was added. This 500 µl mixture was added onto 2×10⁵ COS cells/well plated on 12-well tissue culture plate and incubated for 5 hours at 37°C. Then 500µl 20% FBS DMEM media (100 ml FBS, 55 mg sodium

EP 1 476 541 B1

pyruvate and 146mg L-glutamine in 500ml DMEM) was added, and cells were incubated overnight.

B. Secretion Trap Assay

5 **[0343]** The secretion trap was performed as follows: Media was rinsed off cells with PBS, then cells were fixed for 15 minutes with 1.8% Formaldehyde in PBS. Cells were then washed with PBS/0.1%BSA and permeabilized with 0.1% Triton-X in PBS for 15 minutes, and again washed with PBS/0.1%BSA. Cells were blocked for 1 hour with PBS/0.1%BSA. Depending on which soluble receptor was used, the cells were incubated for 1 hour in TNB with: (A) 1-3 μ g/ml zcytor17 soluble receptor zcytor17-Fc4 fusion protein (Example 10); or (B) 1-3 μ g/ml zcytor17/OSMRbeta soluble receptor protein. 10 Cells were then washed with TNT. Depending on which soluble receptor was used (e.g., if labeled with an Fc4 tag (SEQ ID NO:37), C-terminal FLAG tag (SEQ ID NO:26), or CEE tag (SEQ ID NO:32; SEQ ID NO:35)), cells were incubated for another hour with: (A) 1:200 diluted goat-anti-human Ig-HRP (Fc specific); (B) 1:1000 diluted M2-HRP; (C) 1:1000 diluted anti-GluGlu antibody-HRP; or (D) 1:300 diluted streptavidin-HRP (NEN kit) in TNB, for example. Again cells were washed with TNT.

15 **[0344]** To detect positive binding fluorescein tyramide reagent was diluted 1:50 in dilution buffer (NEN kit) and incubated for 4-6 minutes, and washed with TNT. Cells were preserved with Vectashield Mounting Media (Vector Labs Burlingame, CA) diluted 1:5 in TNT. Cells were visualized using a FITC filter on fluorescent microscope. The results of this assay showed that human zcytor17lig does not bind to any of the soluble receptors. These data suggest that the structure of zcytor17lig was sensitive to the fixation step in this protocol, as it was clearly capable of binding to cell-surface receptors 20 (see, for example, the flow cytometry data presented below in Example 39).

Example 13

Chromosomal Assignment and Placement of the gene sequence for the zcytor17lig

25 **[0345]** The zcytor17lig gene sequence was mapped to human chromosome 12 using the commercially available version of the "Stanford G3 Radiation Hybrid Mapping Panel" (Research Genetics, Inc., Huntsville, AL). The "Stanford G3 RH Panel" contains DNA from each of 83 radiation hybrid clones of the whole human genome, plus two control DNAs (the RM donor and the A3 recipient). A publicly available WWW server located on the Internet at www.stanford.edu 30 allows chromosomal localization of markers and genes.

[0346] For the mapping of the zcytor17lig gene sequence with the "Stanford G3 RH Panel", 20 μ l reactions were set up in a 96-well microtiter plate compatible for PCR (Stratagene, La Jolla, CA) and used in a "RoboCycler Gradient 96" thermal cycler (Stratagene). Each of the 95 PCR reactions consisted of 2 μ l 10X PCR reaction buffer (Qiagen, Inc., Valencia, CA), 1.6 μ l dNTPs mix (2.5 mM each, PERKIN-ELMER, Foster City, CA), 1 μ l sense primer, ZC41,458 (SEQ ID NO:42), 1 μ l antisense primer, ZC41,457 (SEQ ID NO:43), 2 μ l "RediLoad" (Research Genetics, Inc., Huntsville, AL), 0.1 μ l Qiagen HotStarTaq DNA Polymerase (5 units/ μ l), 25 ng of DNA from an individual hybrid clone or control and distilled water for a total volume of 20 μ l. The reactions were overlaid with an equal amount of mineral oil and sealed. The PCR cycler conditions were as follows: an initial 1 cycle 15 minute denaturation at 95°C, 35 cycles of a 45 second denaturation at 95°C, 1 minute annealing at 53°C and 1 minute and 15 seconds extension at 72°C, followed by a final 40 1 cycle extension of 7 minutes at 72°C. The reactions were separated by electrophoresis on a 2% agarose gel (EM Science, Gibbstown, NJ) and visualized by staining with ethidium bromide.

[0347] The results showed linkage of the zcytor17lig gene sequence to the chromosome 12 marker SHGC-83339 with a LOD score of >11 and at a distance of 17 cR_10000 from the marker. This marker positions zcytor17lig gene in the 12q24.31 chromosomal region. 45

Example 14

Identification and cloning of murine zcytor17lig

A. Identification of full length murine zcytor17lig

50 **[0348]** Using the human zcytor17lig peptide sequence (SEQ ID NO:2) to query an in house DNA database, a murine cDNA, Genbank Accession No. AK005939, was identified as a potential partial sequence for the murine zcytor17lig. The AK005939 cDNA sequence was used to query a database containing murine genomic fragments. A genomic contig of the murine zcytor17lig was assembled (SEQ ID NO:76). Prediction of coding potential on this genomic fragment with the program Genscan revealed a likely cDNA sequence, with the same gene structure as the human zcytor17lig. A murine cDNA sequence is represented in SEQ ID NO:10, and corresponding polypeptide sequence is shown in SEQ ID NO:11. 55

B. Cloning of mouse zcytor17lig from a mouse testis cDNA library by PCR.

[0349] Based on the genomic sequence (SEQ ID NO:76), two PCR primers were designed and used to identify a cDNA source of mouse zcytor17lig by PCR. These Primers ZC41498 (SEQ ID NO:86) and ZC41496 (SEQ ID NO:87) were designed to the putative 5' and 3' untranslated regions of the mouse sequences (SEQ ID NO:76 and SEQ ID NO:10). Several cDNA sources were screened by PCR, including Marathon-ready cDNAs (Clontech) and aliquots of locally made cDNA libraries. Products were visualized on 1% agarose gels. Bands of the expected size were observed in reactions utilizing a mouse testis cDNA library template. These PCR reactions were successfully performed in approximately 50 μ l volumes with or without 10% DMSO, using pfu turbo polymerase (Stratagene) according to the manufacturer's recommendations; with an additional application of a wax hot-start employing hot start 50s (Molecular Bioproducts, Inc. San Diego, CA). PCR thermocycling was performed with a single cycle of 94°C for 4 min; followed by 40 cycles of 94°C: 30 seconds, 48°C: 30 seconds, 72°C: 50 seconds; with additional final 72°C extension for 7 minutes. The two PCR reactions were pooled and purified using low melt agarose and Gelase agarose digesting enzyme (Epicenter, Inc. Madison, WI) according to the manufacturer's recommendations.

[0350] DNA sequence determination of these PCR products revealed a murine zcytor17 cDNA sequence (SEQ ID NO:90) which comprised an ORF identical to SEQ ID NO:10, confirming that SEQ ID NO:10 encoded the mouse zcytor17lig polypeptide. PCR primers, ZC41583 (SEQ ID NO:88) and ZC41584 (SEQ ID NO:89), were then used to add FseI and AsclI restriction sites and a partial Kozak sequence to the mcytor17lig open reading frame and termination codon (SEQ ID NO:92). A Robocycler 40 thermocycler (Stratagene) was used to run a temperature gradient of annealing temperatures and cycling as follows. Pfu turbo polymerase (Stratagene) was applied as described above, but only in 10% DMSO. Cycling was performed with a single cycle of 94°C for 4 min; followed by 20 cycles of 94°C: 30 seconds, 65°C to 51°C gradient: 30 seconds, 72°C: 1 minute; and a single 72°C extension for 7 minutes. The template for this second thermocycling reaction was 1 μ l of the initial gel-purified mcytor17lig PCR product, above. Resulting PCR product from the three lowest temperature reactions were pooled and gel purified using the Gelase (Epicenter) method described above. This purified mzytor17lig was digested with FseI and AsclI and ligated into a pZP7X vector modified to have FseI and AsclI sites in its cloning site. Plasmid pZP7X is a mammalian expression vector containing an expression cassette having the mouse metallothionein-1 (MT-1) promoter, multiple restriction sites for insertion of coding sequences, and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selective marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene, and the SV40 terminator. The cloned murine cDNA sequence is represented in SEQ ID NO:90, and corresponding polypeptide sequence is shown in SEQ ID NO:91 (which is identical to SEQ ID NO:11).

Example 15Isolation of mouse zcytor17lig cDNA clone from an activated mouse spleen libraryA. Murine Primary Source used to isolate mouse zcytor17lig

[0351] Mouse spleens from Balb/C mice, are collected and mashed between frosted-end slides to create a cell suspension. The isolated primary mouse cell yield is expected to be about 6.4×10^8 cells prior to selection described below.

[0352] The spleen cells are suspended in 9.6 ml MACS buffer (PBS, 0.5% EDTA, 2mM EDTA). 1.6 ml of cell suspension is removed and 0.4 ml CD90 (Thy1.2) microbeads (Miltenyi Biotec) added. The mixture is incubated for 15 min. at 4°C. These cells labeled with CD90 beads are washed with 30 ml MACS buffer, and then resuspended in 2 ml MACS buffer.

[0353] A VS+ column (Miltenyi) is prepared according to the manufacturer's instructions. The VS+ column is then placed in a VarioMACS™ magnetic field (Miltenyi). The column is equilibrated with 5 ml MACS buffer. The isolated primary mouse cells are then applied to the column. The CD90 negative cells are allowed to pass through. The column is rinsed with 9 ml (3 X 3 ml) MACS buffer. The column is then removed from the magnet and placed over a 15 ml falcon tube. CD90+ cells are eluted by adding 5 ml MACS buffer to the column and bound cells flushed out using the plunger provided by the manufacturer. The incubation of the cells with the CD90 magnetic beads, washes, and VS+ column steps (incubation through elution) above are repeated once more. The resulting CD90+ fractions from the 2 column separations are pooled. The yield of CD90+ selected mouse spleen cells are expected to be about 1×10^8 total cells.

[0354] A sample of the pooled CD90+ selected mouse cells is removed for staining and sorting on a fluorescent antibody cell sorter (FACS) to assess their purity. A PE-conjugated hamster anti-mouse CD3 ϵ antibody (PharMingen) is used for staining and sorting the CD90+ selected cells. The mouse CD90+ selected cells should be about 93% CD3+ cells, suggesting the cells are 93% T-cells.

[0355] The murine CD90+ selected cells are activated by incubating 3×10^6 cells/ml in RPMI + 5% FBS + PMA 10 ng/ml and Ionomycin 0.5 μ g/ml (Calbiochem) for overnight at 37°C. The supernatant from these activated CD90+ selected mouse cells is tested for zcytor17lig activity as described below. Moreover, the activated CD90+ selected mouse cells

EP 1 476 541 B1

are used to prepare a cDNA library, as described in Example 16, below.

Example 16

5 Cloning of mouse zcytor17lig from a mouse CD90+ selected cell library

[0356] Screening of a primary mouse activated CD90+ selected cell cDNA library can reveal isolated cDNA that is a novel member of the four-helix bundle cytokine family that would encode the mouse ortholog of the human zcytor17lig. The cDNA is identified by hybridization screening.

10

A. The vector for CD90+ selected library construction

[0357] The vector, pZP7N is used for CD3+ selected library construction (See Example 6A).

15

B. Preparation of primary mouse activated CD90+ selected cell cDNA library

[0358] Approximately 1.5×10^8 primary mouse CD90+ selected cells stimulated in ionomycin/PMA (Example 15) are isolated by centrifugation. Total RNA is isolated from the cell pellet, and converted to double stranded cDNA as described in Example 6B. This DNA is subsequently transfected into BHK cells, as described in Example 6B, and proliferation is assessed using an "Alamar blue" fluorescence assay (Example 2B).

20

[0359] For the purpose of screening the library by secretion trap cloning, a complex, amplified form of the library is needed to transfect COS-7 cells. 4.8 million clones are plated on 110 15cm LB-agar plates supplemented with 100 μ g/ml ampicillin, 10 μ g/ml methicillin. After growing the plates overnight at 37°C the bacteria are harvested by scraping and pelleted. Plasmid DNA is extracted from the pelleted bacteria using a Nucleobond-giga™ (Clontech) following the manufacturer's instructions. This plasmid is then used to transfect COS-7 cells on slides and screened using the secretion trap technique described below (Example 17).

25

C. Screening the activated mouse cDNA library

[0360] Approximately 5×10^5 clones are plated on 10 LB/Amp Maxi plates. The colonies are lifted, denatured, neutralized, and cross-linked using the standard procedure (Sambrook, J. et al. *supra.*). Fifty nanograms of the 300 bp 5' RACE PCR fragment (Example 14) is labeled with 32 P using Prime-It[®] RmT random primer labeling kit (Stratagene). The 10 filters are hybridized with this labeled probe at 65°C overnight using ExpressHyb™ Hybridization Solution (Clontech). The filters are then washed sequentially at 60°C for 1 hour three times with 0.2xSSC (30 mM NaCl, 3 mM sodium citrate, pH 7.0), 0.1% SDS; and then at 65°C for 1 hour. The filters are exposed at - 80°C overnight, and the X-ray film are developed. Agar plugs containing the positive colonies are pulled, and the clones plated on 10-cm LB/Amp plates. The colonies are then filter-lifted and hybridized again following the same procedure described above. Single DNA clones are isolated and sequenced using standard methods, to identify the mouse cDNA.

30

35

40

Example 17

Mouse zcytor17lig does not bind to human zcytor17 soluble receptor in secretion trap assay

[0361] The DNA for mouse clone mzcyc17lig/pZP7 was transfected into COS cells, and the binding of zcytor17 comprising soluble receptors (human zcytor17 soluble receptor zcytor17-Fc4 (Example 10), or soluble receptor heterodimers (zcytor17/WSX-1 or BaF3/zcytor17/OSMRbeta), to the transfected COS cells were tested by a secretion trap assay (Example 12). The assay confirmed that the mouse zcytor17lig does not bind to human zcytor17 soluble receptor.

45

[0362] The COS cell transfection was performed as per Example 12 using about 0.7 μ g mouse zcytor17lig cDNA (Example 16) in 3 μ l.

50

[0363] The secretion trap was performed as per example 12 using, for example, 1 μ g/ml zcytor17 soluble receptor Fc4 fusion protein (Example 10) (or zcytor17 comprising soluble receptor heterodimers as described herein) in TNB, and 1:200 diluted goat-anti-human Ig-HRP (Fc specific) in TNB for the detectable antibody. Positive binding of the soluble human zcytor17 receptor to the prepared fixed cells was not detected with fluorescein tyramide reagent as per Example 12. Cells were preserved and visualized according to Example 12.

55

[0364] Results indicated that the mouse zcytor17lig does not bind to human zcytor17 soluble receptor (or zcytor17 comprising soluble receptor heterodimers as described herein).

Example 18Expression of mouse zcytor17lig in mammalian cells5 Mammalian expression of mouse zcytor17lig

[0365] BHK 570 cells (ATCC No: CRL-10314) were plated in 10 cm tissue culture dishes and allowed to grow to approximately 20% confluence overnight at 37°C, 5% CO₂, in DMEM/FBS media (DMEM, Gibco/BRL High Glucose media; Gibco BRL, Gaithersburg, MD), 5% fetal bovine serum (Hyclone, Logan, UT), 1 mM L-glutamine (JRH Biosciences, Lenexa, KS), 1 mM sodium pyruvate (Gibco BRL). The cells were then transfected with the plasmid mzcyc17lig/pZP7X (Example 14) using a mammalian stable Lipofectamine (GibcoBRL) transfection kit according to the manufacturer's instructions.

10 [0366] One day after transfection, the cells were split 1:10 and 1:20 into the selection media (DMEM/FBS media with the addition of 1 μM methotrexate (Sigma Chemical Co., St. Louis, MO)) in 150 mm plates. The media on the cells was replaced with fresh selection media at day 5 post-transfection. Approximately 10 days post-transfection, methotrexate resistant colonies were trypsinized and the cells pooled and plated into large-scale culture flasks. Once the cells were grown to approximately 90% confluence, they were rinsed with PBS three times, and cultured with serum-free ESTEP2 media (DMEM (Gibco BRL), 0.11 g/l Na Pyruvate, 3.7 g/l NaHCO₃, 2.5 mg/l insulin, 5 mg/l transferrin, pH7.0) conditioned media. The conditioned media was collected three days later, and put into a BaF3 proliferation assay using Alamar Blue, described in Example 19 below.

Example 19Mouse zcytor17lig does not activate human zcytor17 receptor in BaF3 assay using Alamar Blue

25 [0367] Proliferation of BaF3/zcytor17, BaF3/zcytor17/OSMRbeta and BaF3/zcytor17/WSX-1 cells (Example 4, and 5B) was assessed using serum-free conditioned media from BHK cells expressing mouse zcytor17lig (Example 18).

30 [0368] BaF3/Zcytor17, BaF3/zcytor17/OSMRbeta and BaF3/zcytor17WSX-1 cells were spun down, washed and plated in mL-3 free media as described in Example 5B. Conditioned media from BHK cells expressing mouse zcytor17lig (Example 18) was diluted with mL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. The proliferation assay was performed as per Example 5B. The results of this assay were negative, indicating that mouse zcytor17lig does not activate human zcytor17, zcytor17/OSMRbeta, or zcytor17/WSX-1 receptor complexes.

Example 2035 Human zcytor17lig activates human, zcytor17/OSMRbeta receptor, in luciferase assayA. Construction of BaF3/KZ134/zcytor17 cell line

40 [0369] The KZ134 plasmid was constructed with complementary oligonucleotides ZC12,749 (SEQ ID NO:44) and ZC12,748 (SEQ ID NO:45) that contain STAT transcription factor binding elements from 4 genes, which includes a modified c-fos/Sis inducible element (m67SIE, or hSIE) (Sadowski, H. et al., Science 261:1739-1744, 1993), the p21 SIE1 from the p21 WAF1 gene (Chin, Y. et al., Science 272:719-722, 1996), the mammary gland response element of the β-casein gene (Schmitt-Ney, M. et al., Mol. Cell. Biol. 11:3745-3755, 1991), and a STAT inducible element of the Fcg RI gene, (Seidel, H. et al., Proc. Natl. Acad. Sci. 92:3041-3045, 1995). These oligonucleotides contain Asp718-XhoI compatible ends and were ligated, using standard methods, into a recipient firefly luciferase reporter vector with a c-fos promoter (Poulsen, L.K. et al., J. Biol. Chem. 273:6229-6232, 1998) digested with the same enzymes and containing a neomycin selectable marker. The KZ134 plasmid was used to stably transfect BaF3 cells, using standard transfection and selection methods, to make the BaF3/KZ134 cell line.

45 [0370] A stable BaF3/KZ134 indicator cell line, expressing the full-length zcytor17 receptor or zcytor17/OSMRbeta receptor was constructed as per Example 4. Clones were diluted, plated and selected using standard techniques. Clones were screened by luciferase assay (see Example 20B, below) using the human zcytor17lig conditioned media or purified zcytor17lig protein (see Example 35, below) as an inducer. Clones with the highest luciferase response (via STAT luciferase) and the lowest background were selected. Stable transfectant cell lines were selected. The cell lines were called BaF3/KZ134/zcytor17 or BaF3/KZ134/zcytor17/OSMRbeta depending on the receptors transfected into the cell line.

55 [0371] Similarly, BHK cell lines were also constructed using the method described herein, and were used in luciferase assays described herein. The cell lines were called BHK/KZ134/zcytor17 or BHK/KZ134/zcytor17/OSMRbeta depending

on the receptors transfected into the cell line.

B. Human zcytor17lig activates human zcytor17 receptor in BaF3/KZ134/zcytor17/OSMRbeta or BHK/KZ134/zcytor17/OSMRbeta luciferase assay

[0372] BaF3/KZ134/zcytor17 and BaF3/KZ134/zcytor17/OSMRbeta cells were spun down and washed in mL-3 free media. The cells were spun and washed 3 times to ensure removal of mL-3. Cells were then counted in a hemacytometer. Cells were plated in a 96-well format at about 30,000 cells per well in a volume of 100 μ l per well using the mL-3 free media. The same procedure was used for untransfected BaF3/KZ134 cells for use as a control in the subsequent assay. BHK/KZ134/zcytor17 or BHK/KZ134/zcytor17/OSMRbeta cells were plated in a 96-well format at 15,000 cells per well in 100 μ l media. Parental BHK/KZ134 cells were used as a control.

[0373] STAT activation of the BaF3/KZ134/Zcytor17, BaF3/KZ134/zcytor17/OSMRbeta, BHK/KZ134/zcytor17, or BHK/KZ134/zcytor17/OSMRbeta cells was assessed using (1) conditioned media from BHK570 cells transfected with the human zcytor17lig (Example 7), (2) conditioned media from BHK570 cells transfected with the mouse zcytor17lig (Example 18), (3) purified human zcytor17lig (Example 35), or (4) mL-3 free media to measure media-only control response. Conditioned media was diluted with RPMI mL-3 free media to 50%, 25%, 12.5%, 6.25%, 3.125%, 1.5%, 0.75% and 0.375% concentrations. Purified human zcytor17lig was diluted to a concentration of 1200, 600, 300, 150, 75, 37.5, 18.75, or 9.4 pM. One hundred microliters of the diluted conditioned media or protein was added to the BaF3/KZ134/Zcytor17, BaF3/KZ134/zcytor17/OSMRbeta, BHK/KZ134/zcytor17, or BHK/KZ134/zcytor17/OSMRbeta cells. The assay using the conditioned media was done in parallel on untransfected BaF3/KZ134 or BHK/KZ134 cells as a control. The total assay volume was 200 μ l. The assay plates were incubated at 37°C, 5% CO₂ for 24 hours at which time the BaF3 cells were pelleted by centrifugation at 2000 rpm for 10 min., and the media was aspirated and 25 μ l of lysis buffer (Promega) was added. For the BHK cell lines, the centrifugation step was not necessary as the cells are adherent. After 10 minutes at room temperature, the plates were measured for activation of the STAT reporter construct by reading them on a luminometer (Labsystems Luminoskan, model RS) which added 40 μ l of luciferase assay substrate (Promega) at a five second integration.

[0374] The results of this assay confirmed that the STAT reporter response of the BaF3/KZ134/zcytor17/OSMRbeta and BHK/KZ134/zcytor17/OSMRbeta cells to the human zcytor17lig when compared to either the BaF3/KZ134/zcytor17 cells, the BHK/KZ134/zcytor17 cells or the untransfected BaF3/KZ134 or BHK/KZ134 control cells, showed that the response was mediated through the zcytor17/OSMRbeta receptors. The results also showed that the mouse zcytor17lig does not activate the STAT reporter assay through the human receptor complex.

Example 21

Mouse zcytor17lig is active in mouse bone marrow assay

A. Isolation of Non-adherent Low Density Marrow Cells:

[0375] Fresh mouse femur aspirate (marrow) is obtained from 6-10 week old male Balb/C or C57BL/6 mice. The marrow is then washed with RPMI+10% FBS (JRH, Lenexa KS; Hyclone, Logan UT) and suspended in RPMI+10% FBS as a whole marrow cell suspension. The whole marrow cell suspension is then subjected to a density gradient (Nycoprep, 1.077, Animal; Gibco BRL) to enrich for low density, mostly mononuclear, cells as follows: The whole marrow cell suspension (About 8 ml) is carefully pipeted on top of about 5 ml Nycoprep gradient solution in a 15 ml conical tube, and then centrifuged at 600X g for 20 minutes. The interface layer, containing the low density mononuclear cells, is then removed, washed with excess RPMI+10% FBS, and pelleted by centrifugation at 400X g for 5-10 minutes. This pellet is resuspended in RPMI +10% FBS and plated in a T-75 flask at approximately 10⁶ cells/ml, and incubated at 37°C 5% CO₂ for approximately 2 hours. The resulting cells in suspension are Non-Adherent Low Density (NA LD) Marrow Cells.

B. 96-Well Assay

[0376] NA LD Mouse Marrow Cells are plated at 25,000 to 45,000 cells/well in 96 well tissue culture plates in RPMI +10% FBS + 1ng/mL mouse Stem Cell Factor (mSCF) (R&D Systems, Minneapolis, MN), plus 5% conditioned medium from one of the following: (1) BHK 570 cells expressing mouse zcytor17lig (Example 18), (2) BHK 570 cells expressing human zcytor17lig (Example 7), or (3) control BHK 570 cells containing vector and not expressing either Ligand. These cells are then subjected to a variety of cytokine treatments to test for expansion or differentiation of hematopoietic cells from the marrow. For testing, the plated NA LD mouse marrow cells are subjected to human Interleukin-15 (hIL-15) (R&D Systems), or one of a panel of other cytokines (R&D Systems). Serial dilution of hIL-15, or the other cytokines, are tested, with 2-fold serial dilution from about 50 ng/ml down to about 0.5 ng/ml concentration. After 8 to 12 days the 96-

EP 1 476 541 B1

well assays are scored for cell proliferation by Alamar blue assay as described in Example 5B.

C. Results from the 96-well NA LD Mouse Marrow assay

5 **[0377]** Conditioned media from the BHK cells expressing both mouse and human zcytor17lig can promote the expansion of a population of hematopoietic cells either alone or in synergy with other cytokines in the NA LD mouse marrow in comparison to control BHK conditioned medium. The population hematopoietic cells expanded by the mouse zcytor17lig with or without other cytokines, and those hematopoietic cells expanded by the human zcytor17lig with or without other cytokines, are further propagated in cell culture. These hematopoietic cells are stained with a Phycoerythrin
10 labeled anti-Pan NK cell antibody (PharMingen) and subjected to flow cytometry analysis, which demonstrated that the expanded cells stained positively for this natural killer (NK) cell marker. Similarly, other specific hematopoietic cell markers can be used to determine expansion of, for example, CD4+ or CD8+ T-cells, other T-cell populations, B-cells, and other immune cell markers.

15 **[0378]** The same 96-well assay is run, using fresh human marrow cells bought from Poietic Technologies, Gaithersburg, MD. Again, a positive result shows that zcytor17lig alone or in synergy with other cytokines, the mouse and human zcytor17lig can expand a hematopoietic cell population that is stained positively for specific cell markers as disclosed above.

Example 22

20

Constructs for generating zcytor17lig Transgenic Mice

A. Construct for expressing human zcytor17lig from the MT-1 promoter

25 **[0379]** Oligonucleotides were designed to generate a PCR fragment containing a consensus Kozak sequence and the human zcytor17lig coding region. These oligonucleotides were designed with an FseI site at the 5' end and an Ascl site at the 3' end to facilitate cloning into (a) pMT12-8, standard transgenic vector, or (b) pKFO51, a lymphoid-specific transgenic vector (Example 22B).

30 **[0380]** PCR reactions are carried out with about 200 ng human zcytor17lig template (SEQ ID NO:1) and oligonucleotides designed to amplify the full-length or active portion of the zcytor17lig. PCR reaction conditions are determined using methods known in the art. PCR products are separated by agarose gel electrophoresis and purified using a QiaQuick™ (Qiagen) gel extraction kit. The isolated, correct sized DNA fragment is digested with FseI and Ascl (Boehringer-Mannheim), ethanol precipitated and ligated into pMT12-8 previously digested with FseI and Ascl. The pMT12-8 plasmid, designed for expressing a gene of interest in liver and other tissues in transgenic mice, contains an expression
35 cassette flanked by 10 kb of MT-1 5' DNA and 7 kb of MT-1 3' DNA. The expression cassette comprises the MT-1 promoter, the rat insulin II intron, a polylinker for the insertion of the desired clone, and the human growth hormone (hGH) poly A sequence.

40 **[0381]** About one microliter of each ligation reaction is electroporated into DH10B ElectroMax™ competent cells (GIBCO BRL, Gaithersburg, MD) according to manufacturer's direction and plated onto LB plates containing 100 µg/ml ampicillin, and incubated overnight. Colonies are picked and grown in LB media containing 100 µg/ml ampicillin. Miniprep DNA is prepared from the picked clones and screened for the human zcytor17lig insert by restriction digestion with EcoRI alone, or FseI and Ascl combined, and subsequent agarose gel electrophoresis. Maxipreps of the correct pMT-human zcytor17lig are performed. A Sall fragment containing with 5' and 3' flanking sequences, the MT-1 promoter, the rat insulin II intron, human zcytor17lig cDNA and the hGH poly A sequence is prepared to be used for microinjection
45 into fertilized murine oocytes. Microinjection and production of transgenic mice are produced as described in Hogan, B. et al. Manipulating the Mouse Embryo, 2nd ed., Cold Spring Harbor Laboratory Press, NY, 1994.

B. Construct for expressing human zcytor17lig from the lymphoid-specific EµLCK promoter

50 **[0382]** Oligonucleotides are designed to generate a PCR fragment containing a consensus Kozak sequence and the human zcytor17lig coding region. These oligonucleotides are designed with an FseI site at the 5' end and an Ascl site at the 3' end to facilitate cloning into pKF051, a lymphoid-specific transgenic vector.

55 **[0383]** PCR reactions are carried out with about 200 ng human zcytor17lig template (SEQ ID NO:1) and oligonucleotides designed to amplify the full-length or active portion of the zcytor17lig. A PCR reaction is performed using methods known in the art. The isolated, correct sized DNA fragment is digested with FseI and Ascl (Boehringer-Mannheim), ethanol precipitated and ligated into pKFO51 previously digested with FseI and Ascl. The pKFO51 transgenic vector is derived from p1026X (Iritani, B.M., et al., EMBO J. 16:7019-31, 1997) and contains the T cell-specific Ick proximal promoter, the B/T cell-specific immunoglobulin µ heavy chain enhancer, a polylinker for the insertion of the desired

EP 1 476 541 B1

clone, and a mutated hGH gene that encodes an inactive growth hormone protein (providing 3' introns and a polyadenylation signal).

[0384] About one microliter of each ligation reaction is electroporated, plated, clones picked and screened for the human zcytor17lig insert by restriction digestion as described above. A correct clone of pKFO51-zcytor17lig is verified by sequencing, and a maxiprep of this clone is performed. A NotI fragment, containing the Ick proximal promoter and immunoglobulin μ enhancer (E μ LCK), zcytor17lig cDNA, and the mutated hGH gene is prepared to be used for microinjection into fertilized murine oocytes.

C. Construct for expressing mouse zcytor17lig from the EF1alpha promoter

[0385] Primers ZC41,498 (SEQ ID NO:86) and ZC41,496 (SEQ ID NO:87) were used to PCR a mouse testis cDNA library template. These PCR reactions were successfully performed in approximately 50 μ l volumes with or without 10% DMSO, using pfu turbo polymerase (Stratagene) according to the manufacturer's recommendations; with an additional application of a wax hot-start employing hot start 50s (Molecular Bioproducts, Inc. San Diego, CA). PCR thermocycling was performed with a single cycle of 94°C for 4 min; followed by 40 cycles of 94°C: 30 seconds, 48°C: 30 seconds, 72°C: 50 seconds; with additional final 72°C extension for 7 minutes. The two PCR reactions were pooled and purified using low melt agarose and Gelase agarose digesting enzyme (Epicenter, Inc. Madison, WI) according to the manufacturer's recommendations.

[0386] DNA sequenced PCR products revealed a murine zcytor17 cDNA sequence (SEQ ID NO:90) which comprised an ORF identical to SEQ ID NO:10, confirming that SEQ ID NO:10 encoded the mouse zcytor17lig polypeptide. PCR primers, ZC41583 (SEQ ID NO:88) and ZC41584 (SEQ ID NO:89), were then used to add FseI and Ascl restriction sites and a partial Kozak sequence to the mcytor17lig open reading frame and termination codon (SEQ ID NO:92). A Robocycler 40 thermocycler (Stratagene) was used to run a temperature gradient of annealing temperatures and cycling as follows. Pfu turbo polymerase (Stratagene) was applied as described above, but only in 10% DMSO. Cycling was performed with a single cycle of 94°C for 4 min; followed by 20 cycles of 94°C: 30 seconds, 65°C to 51°C gradient: 30 seconds, 72°C: 1 minute; and a single 72°C extension for 7 minutes. The template for this second thermocycling reaction was 1 μ l of the initial gel-purified mcytor17lig PCR product, above. Resulting PCR product from the three lowest temperature reactions were pooled and gel purified using the Gelase (Epicenter) method described above. This purified fragment was then digested with FseI and Ascl and ligated into a pZP7X vector modified to have FseI and Ascl sites in its cloning site. This was sent to sequencing to confirm the correct sequence. The cloned murine cDNA sequence is represented in SEQ ID NO:90, and corresponding polypeptide sequence is shown in SEQ ID NO:91 (which is identical to SEQ ID NO:11).

[0387] The isolated, correct sized DNA fragment digested with FseI and Ascl (Boehringer-Mannheim) was subcloned into a plasmid containing EF1alpha promoter previously digested with FseI and Ascl. Maxipreps of the correct EF1alpha mouse zcytor17lig were performed. The expression cassette contains the EF1alpha promoter (with a deleted FseI site), the EF1alpha intron, SUR IRES like site to facilitate expression, a polylinker flanked with rat insulin II sites on the 5' end which adds FseI PmeI Ascl sites for insertion of the desired clone, and the human growth hormone (hGH) poly A sequence. A 7.5kb NotI fragment containing the EF1alpha promoter expression cassette and mouse zcytor17lig was prepared to be used for microinjection into fertilized murine oocytes. The EF1alpha plasmid was obtained from Louis-Marie of the Laboratoire de Differentiation Cellulaire, as described in Taboit-Dameron et al., 1999, Transgenic Research 8:223-235.

D. Construct for expressing mouse zcytor17lig from the lymphoid-specific E μ LCK promoter

[0388] Oligonucleotides were designed to generate a PCR fragment containing a consensus Kozak sequence and the mouse zcytor17lig coding region. These oligonucleotides were designed with an FseI site at the 5' end and an Ascl site at the 3' end to facilitate cloning into pKFO51 (see Example 22B, above).

[0389] The isolated, correct sized zcytor17lig DNA fragment used in EF1alpha constructs, digested with FseI and Ascl (Boehringer-Mannheim), was subcloned into a plasmid containing pKFO51, a lymphoid-specific transgenic vector. The pKFO51 transgenic vector is derived from p1026X (Iritani, B.M., et al., EMBO J. 16:7019-31, 1997) and contains the T cell-specific Ick proximal promoter, the B/T cell-specific immunoglobulin μ heavy chain enhancer, a polylinker for the insertion of the desired clone, and a mutated hGH gene that encodes an inactive growth hormone protein (providing 3' introns and a polyadenylation signal). A 6.5kb NotI fragment, containing the Ick proximal promoter and immunoglobulin μ enhancer (E μ LCK), mouse zcytor17lig cDNA, and the mutated hGH gene was prepared to be used for microinjection into fertilized murine oocytes (Example 41).

Example 23Construction of mammalian expression vectors that express zcytor17lip-CEE5 A. Construction of zCyt17Lig-CEE/pZMP21

[0390] An expression plasmid containing all or part of a polynucleotide encoding human zCyt17lig was constructed via homologous recombination. The plasmid was called zCyt17Lig-CEE/pZMP21.

10 **[0391]** The construction of zCyt17Lig-CEE/pZMP21 was accomplished by generating a zCyt17Lig-CEE fragment (SEQ ID NO:95) (its corresponding amino acid sequence is shown in SEQ ID NO:96) using PCR amplification. The DNA template used for the production of the zCyt17Lig-CEE fragment was zCyt17Lig/pZP7nx. The primers used for the production of the zCyt17Lig-CEE fragment were: (1) ZC41607 (SEQ ID NO:97) (sense sequence), which includes from the 5' to the 3' end: 28bp of the vector flanking sequence (5' of the insert) and 21 bp corresponding to the 5' sequence of zCyt17Lig; and (2) ZC41605 (SEQ ID NO:98) (anti-sense sequence), which includes from the 5' to the 15 3' end: 37 bp of the vector flanking sequence (3' of the insert), 3 bp of the stop codon, 21 bp encoding a C-terminal EE tag, and 21 bp corresponding to the 3' end of zCyt17Lig sequence. The fragment resulting from the above PCR amplification is a copy of the template zCyt17Lig with the addition of a C-terminal EE tag, yielding a final product zCyt17Lig-CEE.

20 **[0392]** PCR reactions were run as follows: To a 100 μ l final volume was added: 10 μ l of 10x Taq Polymerase Reaction Buffer with 15mM MgCl (Gibco), 1 μ l of Taq DNA Polymerase (5 units/ μ l, Gibco), 3 μ l of 10mM dNTPs, 78 μ l dH₂O, 3 μ l of a 20 pmol/ μ l stock of primer ZC41607 (SEQ ID NO:97) 3 μ l of a 20 pmol/ μ l stock of primer ZC41605 (SEQ ID NO: 98), and 2 μ l of a 0.13 μ g/ μ l stock of zCyt17lig template DNA. A volume equal to 50 μ l of mineral oil was added to the mixture. The reaction was heated to 94°C for 5 minutes, followed by 35 cycles at 94°C for 1 minute; 55°C for 2 minutes; 72°C for 3 minutes; followed by a 10 minute extension at 72°C and held at 4°C until the reaction was collected.

25 **[0393]** The plasmid pZMP21 was restriction digested with BglII enzyme, cleaned with a QiaQuick PCR Purification Kit (Qiagen) using a microcentrifuge protocol, and used for recombination with the PCR fragment. Plasmid pZMP21 was constructed from pZMP20 which was constructed from pZP9 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, and is designated No. 98668) with the yeast genetic elements taken from pRS316 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 30 20110-2209, and designated No. 77145), an IRES element from poliovirus, and the extracellular domain of CD8, truncated at the carboxyl terminal end of the transmembrane domain. PZMP21 is a mammalian expression vector containing an expression cassette having the MPSV promoter, immunoglobulin signal peptide intron, multiple restriction sites for insertion of coding sequences, a stop codon and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene, the SV40 terminator, as well as the URA3 and CEN-ARS sequences required for selection and replication in *S. cerevisiae*.

35 **[0394]** Fifty microliters of competent yeast cells (*S. cerevisiae*) were independently combined with 100 ng of cut plasmid, 5 μ l of previously described PCR mixture, and transferred to a 0.2. cm electroporation cuvette. The yeast/DNA mixture was electropulsed at 0.75 kV (5 kV/cm), infinite ohms, 25 μ F. Each cuvette had 600 μ l of 1.2 M sorbitol added, and the yeast was plated in one 100 μ l aliquot and one 300 μ l aliquot onto two URA-D plates and incubated at 30°C. After about 72 hours, the Ura⁺ yeast transformants from a single plate were resuspended in 1 ml H₂O and spun briefly to pellet the yeast cells. The cell pellet was resuspended in 500 μ l of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA). The 500 μ l of the lysis mixture was added to an Eppendorf tube containing 300 μ l acid washed 600 μ m glass beads and 300 μ l phenol-chloroform, vortexed for 1 minute intervals two or three 45 times, followed by a 5 minute spin in a Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase was transferred to a fresh tube, and the DNA precipitated with 600 μ l 100% ethanol (EtOH), followed by centrifugation for 10 minutes at 4°C. The DNA pellet was then washed with 500 μ l 70% EtOH, followed by centrifugation for 1 minute at 4°C. The DNA pellet was resuspended in 30 μ l H₂O.

50 **[0395]** Transformation of electrocompetent *E. coli* cells (MC1061) was done with 5 μ l of the yeast DNA prep and 50 μ l of MC1061 cells. The cells were electropulsed at 2.0 kV, 25 μ F and 400 ohms(Ω). Following electroporation, 600 μ l SOC (2% Bacto' Tryptone (Difco, Detroit, MI), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) was added. The electroporated *E.coli* cells were plated in a 200 μ l and a 50 μ l aliquot on two LB AMP plates (LB broth (Lennox), 1.8% Bacto Agar (Difco), 100 mg/L Ampicillin). The plates were incubated upside down for about 24 hours at 37°C. Three Ampicillin-resistant colonies were selected at random and submitted for sequence analysis of the insert. Large scale plasmid DNA was isolated from a sequence-confirmed clone using the Qiagen Maxi kit (Qiagen) according to manufacturer's instructions.

B. Mammalian Expression of human zcytor17lig

[0396] Full-length zCyt17Lig protein was produced in BHK cells transfected with zCyt17Lig-CEE/pZMP21 (Example 23A). BHK 570 cells (ATCC CRL-10314) were plated in T75 tissue culture flasks and allowed to grow to approximately 50 to 70% confluence at 37°C, 5% CO₂, in growth media (SL7V4, 5%FBS, 1% pen/strep). The cells were then transfected with zCyt17Lig-CEE/pZMP21 by liposome-mediated transfection (using Lipofectamine™; Life Technologies), in serum free (SF) media (SL7V4). The plasmid (16µg) was diluted into 1.5 ml tubes to a total final volume of 640 µl with SF media. Thirty-five microliters of the lipid mixture was mixed with 605 µl of SF medium, and the resulting mixture was allowed to incubate approximately 15 minutes at room temperature. Five milliliters of SF media was then added to the DNA:lipid mixture. The cells were rinsed once with 10 ml of PBS, the PBS was decanted, and the DNA:lipid mixture was added. The cells are incubated at 37°C for five hours, then 15 ml of media (SL7V4, 5% FBS, 1% pen/strep) was added to each plate. The plates were incubated at 37°C overnight, and the DNA:lipid media mixture was replaced with selection media (SL7V4, 5% FBS, 1% pen/strep, 1µM methotrexate) the next day. Approximately 10 days post-transfection, methotrexate-resistant colonies from the T75 transfection flask were trypsinized, and the cells were pooled and plated into a T-162 flask and transferred to large-scale culture.

Example 24Expression of zcytor17 Soluble Receptor in E. coliA. Construction of expression vector pCMH01 that expresses huzcytor17/MBP-6H fusion polypeptide

[0397] An expression plasmid containing a polynucleotide encoding a zcytor17 soluble receptor fused C-terminally to maltose binding protein (MBP) was constructed via homologous recombination. The fusion polypeptide contains an N-terminal approximately 388 amino acid MBP portion fused to any of the zcytor17 soluble receptors described herein. A fragment of zcytor17 cDNA (SEQ ID NO:4) was isolated using PCR as described herein. Two primers were used in the production of the zcytor17 fragment in a standard PCR reaction: (1) one containing about 40 bp of the vector flanking sequence and about 25 bp corresponding to the amino terminus of the zcytor17, and (2) another containing about 40 bp of the 3' end corresponding to the flanking vector sequence and about 25 bp corresponding to the carboxyl terminus of the zcytor17. Two µl of the 100 µl PCR reaction was run on a 1.0% agarose gel with 1 x TBE buffer for analysis, and the expected approximately fragment was seen. The remaining PCR reaction was combined with the second PCR tube and precipitated with 400 µl of absolute ethanol. The precipitated DNA used for recombining into the SmaI cut recipient vector pTAP170 to produce the construct encoding the MBP-zcytor17 fusion, as described below.

[0398] Plasmid pTAP170 was derived from the plasmids pRS316 and pMAL-c2. The plasmid pRS316 is a *Saccharomyces cerevisiae* shuttle vector (Hieter P. and Sikorski, R., Genetics 122:19-27, 1989). pMAL-C2 (NEB) is an *E. coli* expression plasmid. It carries the *tac* promoter driving *MalE* (gene encoding MBP) followed by a His tag, a thrombin cleavage site, a cloning site, and the *rnnB* terminator. The vector pTAP170 was constructed using yeast homologous recombination. 100ng of EcoR1 cut pMAL-c2 was recombined with 1µg Pvu1 cut pRS316, 1µg linker, and 1µg Sca1/EcoR1 cut pRS316. The linker consisted of oligos zc19,372 (SEQ ID NO:157) (100pmole): zc19,351 (SEQ ID NO:158) (1pmole): zc19,352 (SEQ ID NO:159) (1pmole), and zc19,371 (SEQ ID NO:160) (100pmole) combined in a PCR reaction. Conditions were as follows: 10 cycles of 94°C for 30 seconds, 50°C for 30 seconds, and 72°C for 30 seconds; followed by 4°C soak. PCR products were concentrated via 100% ethanol precipitation.

[0399] One hundred microliters of competent yeast cells (*S. cerevisiae*) were combined with 10 µl of a mixture containing approximately 1 µg of the human zcytor17 insert, and 100 ng of SmaI digested pTAP170 vector, and transferred to a 0.2 cm electroporation cuvette. The yeast/DNA mixture was electropulsed at 0.75 kV (5 kV/cm), infinite ohms, 25 µF. To each cuvette was added 600 µl of 1.2 M sorbitol. The yeast was then plated in two 300 µl aliquots onto two -URA D plates and incubated at 30°C.

[0400] After about 48 hours, the Ura⁺ yeast transformants from a single plate were picked, DNA was isolated, and transformed into electrocompetent *E. coli* cells (e.g., MC1061, Casadaban et. al. J. Mol. Biol. 138, 179-207), and plated on MM/CA +KAN 25 µg/L plates (Pryor and Leiting, Protein Expression and Purification 10:309-319, 1997) using standard procedures. Cells were grown in MM/CA with 25 µg/ml Kanomycin for two hours, shaking, at 37°C. One ml of the culture was induced with 1mM IPTG. Two to four hours later the 250 µl of each culture was mixed with 250 µl acid washed glass beads and 250 µl Thorner buffer with 5% βME and dye (8M urea, 100 mM Tris pH7.0, 10% glycerol, 2mM EDTA, 5% SDS). Samples were vortexed for one minute and heated to 65°C for 10 minutes. 20 µl were loaded per lane on a 4%-12% PAGE gel (NOVEX). Gels were run in 1X MES buffer. The positive clones were designated pCMH01 and subjected to sequence analysis.

[0401] One microliter of sequencing DNA was used to transform strain BL21. The cells were electropulsed at 2.0 kV, 25 µF and 400 ohms. Following electroporation, 0.6 ml MM/CA with 25 µg/L Kanomycin. Cells were grown in MM/CA

EP 1 476 541 B1

and induced with ITPG as described above. The positive clones were used to grow up for protein purification of the huzcytor17/MBP-6H fusion protein using standard techniques.

B. Purification of huzcytor17/MBP-6H soluble receptor from E.coli fermentation

[0402] Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for the purification of recombinant huzcytor17/MBP-6H soluble receptor polypeptide. *E. coli* cells containing the pCMH01 construct and expressing huzcytor17/MBP-6H soluble receptor polypeptide were constructed using standard molecular biology methods and cultured in SuperBroth II (12 g/L Casien, 24 g/L Yeast Extract, 11.4 g/L di-potassium phosphate, 1.7 g/L Mono-potassium phosphate; Becton Dickenson, Cockeysville, MD). The resulting cells were harvested and frozen in 0.5% glycerol. Twenty grams of the frozen cells were used for protein purification.

[0403] Thawed cells were resuspended in 500mL Amylose Equilibration buffer (20mM Tris, 100mM NaCl, pH 8.0). A French Press cell breaking system (Constant Systems Ltd., Warwick, UK) with a temperature setting of -7°C to -10°C and 30K PSI was used to lyse the cells. The resuspended cells were checked for breakage by A_{600} readings before and after cycling through the French Press. The lysed cell suspension was pelleted at 10,000G for 30 minutes. Supernatant was harvested from the debris pellet for protein purification.

[0404] Twenty-five milliliters of Amylose resin (New England Biolabs, Beverly, MA) was poured into a Bio-Rad, 2.5 cm D x 10 cm H glass column. The column was packed and equilibrated by gravity with 10 column volumes (CVs) of Amylose Equilibration buffer. The harvested cell supernatant was batch loaded to the Amylose resin, overnight with rocking. The loaded resin was returned to the glass column, washed with 10 CVs Amylose Equilibration buffer, and eluted by gravity with -2 CVs Amylose Elution buffer (Amylose Equilibration buffer, 10 mM Maltose, Fluka Biochemical, Switzerland). Ten 5 ml fractions were collected over the elution profile and assayed for absorbance at 280 and 320 nM. The Amylose resin was regenerated with 1 CV of distilled H₂O, 5 CVs of 0.1% (w/v) SDS (Sigma), 5 CVs of distilled H₂O, 5 CVs of Amylose Equilibration buffer, and finally 1 CV of Amylose Storage buffer (Amylose Equilibration buffer, 0.02% (w/v) Sodium Azide). The regenerated resin was stored at 4°C.

[0405] Elution profile fractions of interest were pooled and dialyzed in a 10K dialysis chamber (Slide-A-Lyzer, Pierce Immunochemical) against 4 changes of 4L PBS pH 7.4 (Sigma) over an 8 hour time period. Following dialysis, the material harvested represented the purified huzcytor17/MBP-6H polypeptide. The purified huzcytor17/MBP-6H polypeptide was filter sterilized and analyzed via SDS-PAGE Coomassie staining for an appropriate molecular weight product. The concentration of the huzcytor17/MBP-6H polypeptide was determined by BCA analysis to be 0.76 mg/ml.

[0406] Purified huzcytor17/MBP-6H polypeptide was appropriately formulated for the immunization of rabbits and sent to R & R Research and Development (Stanwood, WA) for polyclonal antibody production (Example 25, below).

Example 25

Human zcytor17 Soluble Receptor Polyclonal Antibody

A. Preparation and Purification

[0407] Polyclonal antibodies were prepared by immunizing 2 female New Zealand white rabbits with the purified recombinant protein huzcytor17/MBP-6H (Example 24). The rabbits were each given an initial intraperitoneal (IP) injection of 200 µg of purified protein in Complete Freund's Adjuvant followed by booster IP injections of 100 µg protein in Incomplete Freund's Adjuvant every three weeks. Seven to ten days after the administration of the second booster injection (3 total injections), the animals were bled and the serum was collected. The animals were then boosted and bled every three weeks.

[0408] The huzcytor17/MBP-6H specific rabbit serum was pre-adsorbed of anti-MBP antibodies using a CNBr-SEPHAROSE 4B protein column (Pharmacia LKB) that was prepared using 10 mg of non-specific purified recombinant MBP-fusion protein per gram of CNBr-SEPHAROSE. The huzcytor17/MBP-6H-specific polyclonal antibodies were affinity purified from the pre-adsorbed rabbit serum using a CNBr-SEPHAROSE 4B protein column (Pharmacia LKB) that was prepared using 10 mg of the specific antigen purified recombinant protein huzcytor17/MBP-6H. Following purification, the polyclonal antibodies were dialyzed with 4 changes of 20 times the antibody volume of PBS over a time period of at least 8 hours. Huzcytor17-specific antibodies were characterized by ELISA using 500 ng/ml of the purified recombinant protein huzcytor17/MBP-6H as antibody target. The lower limit of detection (LLD) of the rabbit anti-huzcytor17/MBP-6H affinity purified antibody was 500 pg/ml on its specific purified recombinant antigen huzcytor17/MBP-6H.

B. SDS-PAGE and Western blotting analysis of Rabbit Anti-human ZcytoR17 MBP-6H antibody

[0409] Rabbit anti-human ZcytoR17 MBP-6H antibody was tested by SDS-PAGE (NuPage 4-12%, Invitrogen,

EP 1 476 541 B1

Carlsbad, CA) with coomassie staining method and Western blotting using goat anti-rabbit IgG-HRP. Either purified protein (200-25 ng) or conditioned media containing zcytor17 was electrophoresed using an Invitrogen Novex's Xcell II mini-cell, and transferred to nitrocellulose (0.2 mm; Invitrogen, Carlsbad, CA) at room temperature using Novex's Xcell blot module with stirring according to directions provided in the instrument manual. The transfer was run at 300 mA for one hour in a buffer containing 25 mM Tris base, 200 mM glycine, and 20% methanol. The filter was then blocked with Western A buffer (in house, 50 mM Tris, pH 7.4, 5 mM EDTA, pH 8.0, 0.05% Igepal CA-630, 150 mM NaCl, and 0.25% gelatin) overnight with gentle rocking at 4°C. The nitrocellulose was quickly rinsed, then the rabbit anti-human zcytoR17 MBP-6H (1:1000) was added in Western A buffer. The blot was incubated for 1.5 hours at room temperature with gentle rocking. The blot was rinsed 3 times for 5 minutes each in Western A, then goat anti-rabbit IgG HRP antibody (1:1000) was added in Western A buffer. The blot was incubated for 1.25 hours at room temperature with gentle rocking. The blot was rinsed 3 times for 5 minutes each in Western A, then quickly rinsed in H₂O. The blot was developed using commercially available chemiluminescent substrate reagents (ECL Western blotting detection reagents 1 and 2 mixed 1:1; reagents obtained from Amersham Pharmacia Biotech, Buckinghamshire, England) and the blot was exposed to X-ray film for up to 15 minutes.

[0410] The rabbit anti-human zcytoR17 MBP-6H was able to detect human zcytor17 present in conditioned media as well as zcytoR17 purified protein as a band at 120 kDa under reducing conditions.

Example 26

Tissue Distribution of Mouse zcytor17 in Tissue Panels Using PCR

[0411] A panel of cDNAs from murine tissues was screened for mouse zcytor17 expression using PCR. The panel was made in-house and contained 94 marathon cDNA and cDNA samples from various normal and cancerous murine tissues and cell lines are shown in Table 6, below. The cDNAs came from in-house libraries or marathon cDNAs from in-house RNA preps, Clontech RNA, or Invitrogen RNA. The mouse marathon cDNAs were made using the marathon-Ready™ kit (Clontech, Palo Alto, CA) and QC tested with mouse transferrin receptor primers ZC10,651 (SEQ ID NO: 46) and ZC10,565 (SEQ ID NO:47) and then diluted based on the intensity of the transferrin band. To assure quality of the amplified library samples in the panel, three tests for quality control (QC) were run: (1) To assess the RNA quality used for the libraries, the in-house cDNAs were tested for average insert size by PCR with vector oligos that were specific for the vector sequences for an individual cDNA library; (2) Standardization of the concentration of the cDNA in panel samples was achieved using standard PCR methods to amplify full length alpha tubulin or G3PDH cDNA using a 5' vector oligo: ZC14,063 (SEQ ID NO:48) and 3' alpha tubulin specific oligo primer ZC17,574 (SEQ ID NO:49) or 3' G3PDH specific oligo primer ZC17,600 (SEQ ID NO:50); and (3) a sample was sent to sequencing to check for possible ribosomal or mitochondrial DNA contamination. The panel was set up in a 96-well format that included a mouse genomic DNA (Clontech, Palo Alto, CA) positive control sample. Each well contained approximately 0.2-100 pg/μl of cDNA. The PCR was set up using oligos ZC38,065 (SEQ ID NO:51) and ZC38,068 (SEQ ID NO:52), TaKaRa Ex Taq™ (TAKARA Shuzo Co LTD, Biomedicals Group, Japan), and Rediload dye (Research Genetics, Inc., Huntsville, AL). The amplification was carried out as follows: 1 cycle at 94°C for 5 minutes; 5 cycles of 94 for 30 seconds, 68°C for 30 seconds; 35 cycles of 94°C for 30 seconds, 56°C for 30 seconds and 72°C for 30 seconds, followed by 1 cycle at 72°C for 5 minutes. About 10 μl of the PCR reaction product was subjected to standard Agarose gel electrophoresis using a 4% agarose gel. The correct predicted DNA fragment size was observed in brain, CD90+ cells, dendritic, embryo, MEWt#2, Tuvak-prostate cell line, salivary gland, skin and testis.

[0412] The DNA fragment for skin and testis were excised and purified using a Gel Extraction Kit (Qiagen, Chatsworth, CA) according to manufacturer's instructions. Fragments were confirmed by sequencing to show that they were indeed mouse zcytor17.

Table 6

Tissue/Cellline	#samples		Tissue/Cell line	#samples
229	1			
7F2	1			
Adipocytes-Amplified	1			
aTC1.9	1			
Brain	4			
CCC4	1			

EP 1 476 541 B1

CD90+ Amplified	1			
OC10B	1			
Dentritic	1			
Embryo	1			
Heart	2			
Kidney	3			
Liver	2			
Lung	2			
MEWt#2	1			
P388D1	1			
Pancreas	1			
Placenta	2			
Jakotay-Prostate Cell Line	1			
Nelix-Prostate Cell Line	1			
Paris-Prostate Cell Line	1			
Torres-Prostate Cell Line	1			
Tuvak-Prostate Cell Line	1			
Salivary Gland	2			
Skeletal Muscle	1			
Skin	2			
Small Intestine	1			
Smooth Muscle	2			
Spleen	2			
Stomach	1			
Testis	3			
Thymus	1			

Example 27

Human Zcytor17 Expression in Various Tissues Using Real-Time Quantitative RT/PCR

A. Primers and Probes for Human Zcytor17, OSMRbeta and Zcytor17lig for Conventional and Quantitative RT-PCR

[0413] Real-time quantitative RT-PCR using the ABI PRISM 7900 Sequence Detection System (PE Applied Biosystems, Inc., Foster City, CA) has been previously described (See, Heid, C.A. et al., Genome Research 6:986-994, 1996; Gibson, U.E.M. et al., Genome Research 6:995-1001, 1996; Sundaresan, S. et al., Endocrinology 139:4756-4764, 1998). This method incorporates use of a gene specific probe containing both reporter and quencher fluorescent dyes. When the probe is intact the reporter dye emission is negated due to the close proximity of the quencher dye. During PCR extension using additional gene-specific forward and reverse primers, the probe is cleaved by 5' nuclease activity of Taq polymerase which releases the reporter dye from the probe resulting in an increase in fluorescent emission.

[0414] The primers and probes used for real-time quantitative RT-PCR analyses of human Zcytor17, OSMRbeta and Zcytor17lig expression were designed using the primer design software Primer Express™ (PE Applied Biosystems, Foster City, CA). Primers for human Zcytor17 were designed spanning an intron-exon junction to eliminate possible amplification of genomic DNA. The forward primer, ZC37,877 (SEQ ID NO:53) and the reverse primer, ZC37,876 (SEQ ID NO:54) were used in a PCR reaction at a 200 nM concentration to synthesize a 73 bp product. The corresponding Zcytor17 TaqMan® probe, designated ZC37,776 (SEQ ID NO:55) was synthesized and labeled by PE Applied Biosystems

EP 1 476 541 B1

and used in each PCR reaction at a concentration of 200nM. The ZC37,776 (SEQ ID NO:55) probe was labeled at the 5' end with a reporter fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied Biosystems) and at the 3' end with a fluorescent quencher dye (6-carboxy-tetramethylrhodamine) (TAMRA) (Epoch Biosciences, Bothell, WA).

[0415] Primers for human OSMRbeta were designed spanning an intron-exon junction to eliminate possible amplification of genomic DNA. The forward primer, ZC43,891 (SEQ ID NO:122) and the reverse primer, ZC43,900 (SEQ ID NO:123) were used in a PCR reaction (below) at a 200 nM concentration. The corresponding OSMRbeta TaqMan® probe, designated ZC43,896 (SEQ ID NO:124) was synthesized and labeled by PE Applied Biosystems and used in each PCR reaction at a concentration of 200nM. The ZC43,896 (SEQ ID NO:124) probe was labeled at the 5' end with a reporter fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied Biosystems) and at the 3' end with a non-fluorescent quencher dye (ECLIPSE) (Epoch Biosciences).

[0416] Primers for human Zcytor17lig were designed spanning an intron-exon junction to eliminate possible amplification of genomic DNA. The forward primer, ZC43,280 (SEQ ID NO: 125) and the reverse primer, ZC43,281 (SEQ ID NO:126) were used in a PCR reaction (below) at about 200 nM concentration. The corresponding Zcytor17lig TaqMan® probe, designated ZC43,275 (SEQ ID NO:127) was synthesized and labeled by PE Applied Biosystems and used in each PCR reaction at a concentration of 200nM. The ZC43,275 (SEQ ID NO:127) probe was labeled at the 5' end with a reporter fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied Biosystems) and at the 3' end with a non-fluorescent quencher dye (ECLIPSE) (Epoch Biosciences).

[0417] As a control to test the integrity and quality of RNA samples tested, all RNA samples were screened for either rRNA or GUS using primer and probe sets either ordered from PE Applied Biosystems (rRNA kit) or designed in-house (GUS). The rRNA kit contained the forward primer (SEQ ID NO:56), the rRNA reverse primer (SEQ ID NO:57), and the rRNA TaqMan® probe (SEQ ID NO:58). The rRNA probe was labeled at the 5' end with a reporter fluorescent dye VIC (PE Applied Biosystems) and at the 3' end with the quencher fluorescent dye TAMRA (PE Applied Biosystems). The GUS primers and probe were generated in-house and used in each PCR reaction at 200nM and 100nM, respectively. The forward primer was ZC40,574 (SEQ ID NO:128) and the reverse primer was ZC40,575 (SEQ ID NO:129). The GUS probe ZC43,017 (SEQ ID NO:130) was labeled at the 5' end with a reporter fluorescent dye (Yakima-Yellow) (Epoch Biosciences) and at the 3' end with a non-fluorescent quencher dye (ECLIPSE) (Epoch Biosciences). The rRNA and GUS results also serve as an endogenous control and allow for the normalization of the Zcytor17 mRNA expression results seen in the test samples.

[0418] For conventional non-quantitative RT-PCR, primers were designed using the primer design software Primer Express™ (PE Applied Biosystems, Foster City, CA). The human zcytor17 primers generate an approximately 1000 base pair product and are as follows: forward primer ZC28,917 (SEQ ID NO:83), and reverse primer ZC28,480 (SEQ ID NO:131). The human OSMRbeta primers generate a 202 base pair product and are as follows: forward primer ZC41,653 (SEQ ID NO:132) and reverse primer ZC41,655 (SEQ ID NO:133). The human Zcytor17lig primers generate a 305 base pair product and are as follows: forward primer ZC41,703 (SEQ ID NO:134) and reverse primer ZC41,704 (SEQ ID NO:135).

B. Primers and Probes for Murine Zcytor17, OSMRbeta and Zcytor17lig for Conventional and Quantitative RT-PCR

[0419] The primers and probes used for real-time quantitative RT-PCR analyses of murine Zcytor17, OSMRbeta and Zcytor17lig expression were designed using the primer design software Primer Express™ (PE Applied Biosystems, Foster City, CA). Primers for murine Zcytor17 were designed spanning an intron-exon junction to eliminate possible amplification of genomic DNA. The forward primer, ZC43,272 (SEQ ID NO:136) and the reverse primer, ZC43,273 (SEQ ID NO:137) were used in the PCR reactions (below) at 300 nM concentration. The corresponding Zcytor17 TaqMan® probe, designated ZC43,478 (SEQ ID NO: 138) was synthesized and labeled by PE Applied Biosystems. The ZC43,478 (SEQ ID NO: 138) probe was labeled at the 5' end with a reporter fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied Biosystems) and at the 3' end with a quencher fluorescent dye (6-carboxy-tetramethylrhodamine) (TAMRA) (PE Applied Biosystems). The ZC43,478 (SEQ ID NO:138) probe was used in the PCR reactions at a concentration of 100nM.

[0420] Primers for murine Zcytor17lig were designed spanning an intron-exon junction to eliminate possible amplification of genomic DNA. The forward primer, ZC43,278 (SEQ ID NO:139) and the reverse primer, ZC43,279 (SEQ ID NO:140) were used in the PCR reactions at 500 nM concentration. The corresponding Zcytor17lig TaqMan® probe, designated ZC43,276 (SEQ ID NO:141) was synthesized and labeled by PE Applied Biosystems. The ZC43,478 (SEQ ID NO:138) probe was labeled at the 5' end with a reporter fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied Biosystems) and at the 3' end with a non-fluorescent quencher dye (ECLIPSE) (Epoch Biosciences). The ZC43,276 (SEQ ID NO:141) probe was used in the PCR reactions (below) at a concentration of 200nM.

[0421] Primers for murine OSMRbeta were designed spanning an intron-exon junction to eliminate possible amplification of genomic DNA. The forward primer, ZC43,045 (SEQ ID NO:142) and the reverse primer, ZC43,046 (SEQ ID NO:143) were used in the PCR reactions at a 300 nM concentration. The corresponding OSMRbeta TaqMan® probe, designated ZC43,141 (SEQ ID NO:144) was synthesized and labeled by Epoch Biosciences: The ZC43,141 (SEQ ID

EP 1 476 541 B1

NO:144) probe was labeled at the 5' end with a reporter fluorescent dye (6-carboxy-fluorescein) (FAM) (PE Applied Biosystems) and at the 3' end with a non-fluorescent quencher dye (ECLIPSE) (Epoch Biosciences). The ZC43,141 (SEQ ID NO:144) probe was used in the PCR reactions (below) at a concentration of 100nM.

[0422] As a control to test the integrity and quality of RNA samples tested, all RNA samples were screened for either murine GUS or transferrin receptor using primers and probes designed using the primer design program Primer Express™ (PE Applied Biosystems Inc., Foster City, CA). The murine GUS-primers are as follows: forward primer, ZC43,004 (SEQ ID NO:145), reverse primer, ZC43,005 (SEQ ID NO:146), and TaqMan® probe ZC43,018 (SEQ ID NO:147). The murine GUS probe ZC43,018 (SEQ ID NO:147) was labeled at the 5' end with a reporter fluorescent dye Yakima-Yellow (Epoch Biosciences) and at the 3' end with the non-fluorescent quencher dye ECLIPSE (Epoch Biosciences). The murine GUS primers were used in the PCR reactions at 300 nM and the probe, ZC43,018 (SEQ ID NO:147), was used at 100nM. In some cases murine Transferrin Receptor was used instead of GUS as the endogenous control. The transferrin receptor forward primer, ZC40,269 (SEQ ID NO:148) and the reverse primer, ZC40,268 (SEQ ID NO:149) were used at 300nM. The transferrin receptor probe, ZC40,298 (SEQ ID NO:150) was used in PCR at 100nM and was labeled at the 5' end with a reporter fluorescent dye VIC (PE Applied Biosystems) and at the 3' end with a fluorescent quencher dye (TAMRA) (PE Applied Biosystems). The murine GUS and transferrin receptor results also serve as an endogenous control and allow for the normalization of the Zcytor17, OSMRbeta and Zcytor17lig mRNA expression results seen in the test samples.

[0423] For conventional semi-quantitative RT-PCR, primers were designed using the primer design software Primer Express™ (PE Applied Biosystems). The murine Zcytor17 primers generate a 276 base pair product and are as follows: forward primer ZC43,140 (SEQ ID NO:151), and reverse primer ZC43,139 (SEQ ID NO:152). The murine OSMRbeta primers generate a 575 base pair product and are as follows: forward primer ZC41,608 (SEQ ID NO:153) and reverse primer ZC41,609 (SEQ ID NO:154). The murine Zcytor17lig primers generate a 657bp product and are as follows: forward primer ZC41,502 (SEQ ID NO:155) and reverse primer ZC41,500 (SEQ ID NO:156).

C. Protocols for Realtime Quantitative RT-PCR and Conventional Semi-quantitative RT-PCR

[0424] Relative levels of Zcytor17, OSMRbeta and Zcytor17lig mRNA were determined by analyzing total RNA samples using the one-step RT-PCR method (PE Applied Biosystems). Total RNA from Zcytor17- and OSMRbeta-transfected BAF cells (human) or BHK cells (murine) was isolated by standard methods and used to generate a standard curve used for quantitation of Zcytor17 and OSMRbeta. The curve consisted of 10-fold serial dilutions ranging from 100-0.01ng/ μ l with each standard curve point analyzed in triplicate. Similarly, for Zcytor17lig, activated CD4+ T cell RNA (previously shown to make Zcytor17lig) was used to generate a standard curve in the same 100-0.01ng/ μ l range. Total RNA from human or murine cells was analyzed in triplicate for either human or murine Zcytor17, OSMRbeta and Zcytor17lig transcript levels and for one of the following endogenous control genes: rRNA, GUS or transferrin receptor. In a total volume of 10 μ l, each RNA sample was subjected to a One-Step RT-PCR reaction containing: approximately 50-100ng of total RNA in a preformulated 2X master mix containing an internal control dye (ROX)(carboxy-x-rhodamine) and Thermo-Start® DNA Polymerase (Abgene, Surrey, UK); appropriate primers for the gene of interest (see parts A and B of current example); the appropriate probe (see parts A and B for concentration); Superscript® reverse transcriptase (50 U/ μ l) (PE Applied Biosystems), and an appropriate volume of RNase-free water. PCR thermal cycling conditions were as follows: an initial reverse transcription (RT) step of one cycle at 48°C for 30 minutes; followed by a Thermo-Start® enzyme activation step of one cycle at 95°C for 10 minutes; followed by 40 cycles of amplification at 95°C for 15 seconds and 60°C for 1 minute. Relative Zcytor17, OSMRbeta and Zcytor17lig RNA levels were determined by using the Standard Curve Method as described by the manufacturer, PE Biosystems (User Bulletin #2: ABI Prism 7700 Sequence Detection System, Relative Quantitation of Gene Expression, December 11, 1997). The rRNA, GUS or Transferrin Receptor measurements were used to normalize the levels of the gene of interest.

[0425] The semi-quantitative RT-PCR reactions used the 'Superscript One-Step RT-PCR System with Platinum Taq' (Invitrogen, Carlsbad, CA). Each 25 μ l reaction consisted of the following: 12.5 μ l of 2X Reaction Buffer, 0.5 μ l (20pmol/ μ l) of forward primer, 0.5 μ l (20pmol/ μ l) of reverse primer, 0.4 μ l RT/Taq polymerase mix, 5.0 μ l of Rediload Gel Loading Buffer (Invitrogen), 5.1 μ l RNase-free water, and 1.0 μ l total RNA (100ng/ μ l). The amplification was carried out as follows: one cycle at 45°C for 30 minutes followed by 35-38 cycles of 94°C, 20 seconds; Variable annealing temp (See Table 7 below), 20 seconds; 72°C, 45 seconds; then ended with a final extension at 72°C for 5 minutes. Eight to ten microliters of the PCR reaction product was subjected to standard agarose gel electrophoresis using a 2% agarose gel.

Table 7

Murine Zcytor17	58°C anneal temp
Murine OSMRbeta	60°C anneal temp
Murine Zcytor17lig	52°C anneal temp

EP 1 476 541 B1

(continued)

Human Zcytor17	55°C anneal temp
Human OSMRbeta	59°C anneal temp
Human Zcytor17lig	59°C anneal temp

D. Isolation of RNA from Human and Murine PBMC Subsets and Cell Lines

[0426] Blood was drawn from several anonymous donors and peripheral blood mononuclear cells (PBMC) isolated using standard Ficoll gradient methodology. Monocytes were then isolated using the Monocyte Isolation Kit and the Magnetic Cell Separation System (Miltenyi Biotec, Auburn, CA). The monocytes were then plated onto ultra-low adherence 24-well plates in endotoxin-free media. They were either unstimulated or treated with recombinant human IFN γ (R&D Systems Inc.) at 10ng/ml. Cells were collected at 24 and 48 hours. In similar manner, CD4 $^{+}$ and CD8 $^{+}$ T cells were isolated from PBMC's using the anti-CD4 or anti-CD8 magnetic beads from Miltenyi Biotec. Cells were then activated for 4 or 16 hours in tissue culture plates coated with 0.5 μ g/ml anti-CD3 antibodies in media containing 5 μ g/ml anti-CD28 antibodies. NK cells were also isolated from PBMC's using Miltenyi's anti-CD56 coated magnetic beads. Some of the NK cells were collected at time zero for RNA and the others were plated in media containing Phorbol Myristate Acetate (PMA) (5ng/ml) and ionomycin (0.5 μ g/ml) for 24 hours. Additionally, several human monocyte-like cell lines, U937, THP-1 and HL-60, were collected in either their resting or activated states. U937 cells were activated overnight with PMA (10ng/ml). HL-60's were activated overnight with PMA (10ng/ml) or for 72 and 96 hours with IFN γ (10ng/ml) to drive them down a monocytic pathway. THP-1 cells were activated overnight with a combination of LPS (10ng/ml) and IFN γ (10ng/ml). RNA was prepared from all primary cells using the RNeasy MidiprepTM Kit (Qiagen, Valencia, CA) as per manufacturer's instructions. Carryover DNA was removed using the DNA-FreeTM kit (Ambion, Inc., Austin, TX). RNA concentration was determined using standard spectrophotometry and RNA quality determined using the Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA).

[0427] Murine T Cell RNA was collected using a variety of methods well-known in the art. Primary splenic CD4 $^{+}$ and CD8 $^{+}$ T cells were isolated from the spleens of C57B1/6 mice using antibody-coated magnetic beads and the Magnetic Cell Separation System from Miltenyi Biotec. The CD4 $^{+}$ and CD8 $^{+}$ T cells were then activated by culturing the cells in 24-well plates coated with anti-CD3 antibodies (500ng/ml) in media containing anti-CD28 antibodies at 5 μ g/ml. Cells were harvested for RNA at 0, 4 and 16 hours. Similarly, CD4 $^{+}$ T cells were isolated and then skewed towards a Th1 or Th2 phenotype using the following protocol. Since C57B1/6 T cells are already skewed in the Th1 direction, all that was required was to activate for 6 hours with 0.5 μ g/ml PMA and 10ng/ml ionomycin. 'Th2' skewing was obtained by plating naive CD4 $^{+}$ T cells with 2.5 μ g/ml anti-CD28, 10ng/ml mL-2 (R&D Systems Inc.) and 25ng/ml mL-4 (R&D Systems) into plates coated with 0.5 μ g/ml anti-CD3. After 2 days in culture, cells were resuspended in media containing 10ng/ml mL-2 (R&D Systems) and 25ng/ml mL-4. Cells were cultured for an additional three days then activated with PMA and ionomycin for 6 hours.

[0428] One additional set of Th1 and Th2 skewed T cells was derived using the T Cell Receptor Transgenic DO11.10 T cell line. All cells were plated into anti-CD3 and anti-CD28 coated plates. The 'Th1' cells were plated in media containing mL-12 (1ng/ml) and anti-IL-4 (10 μ g/ml). The 'Th2' cells were plated in media containing mL-4 (10ng/ml) and anti-IFN γ (10 μ g/ml). After 24 hours, all cultures were given mL-2 (10ng/ml). After two more days, the media on the cells was changed and new media containing the aforementioned cytokines was added and cells were cultured an additional 4 days before being harvested.

[0429] All of the murine T cell RNA was prepared using the RNeasy MidiprepTM Kit (Qiagen) and contaminating DNA was removed using the DNA-freeTM kit from Ambion.

E. Isolation of RNA from the Murine Models of Pancreatitis and Irritable Bowel Disease

[0430] To induce a condition similar to human Irritable Bowel Disease (IBD), the hybrid mouse strain C57B16/129S6F1 was used. Mice were divided into 4 groups with an average size of six mice per group. Group 1 was given no Dextran Sulfate Sodium (DSS) and was sacrificed on day 14. Group 2 received 2% DSS for two days prior to being sacrificed. Group 3 received 2% DSS for seven days prior to sacrifice. Group 4 received 2% DSS for seven days then allowed to recover for seven days and was sacrificed on day 14. On the day of sacrifice, the distal colon sections were removed and placed in RNAlaterTM (Ambion). The colon sections were homogenized using standard techniques and RNA was isolated using the RNeasy MidiprepTM Kit (Qiagen). Contaminating DNA was removed by DNA-freeTM (Ambion) treatment as per manufacturer's instructions.

[0431] In a different study, acute pancreatitis was induced in male CD-1 mice by caerulein injection. Mice were divided into three groups (n= 8 mice/group). Group 1 animals were given seven i.p. injections (1 injection per hour) with Vehicle

(saline), and then sacrificed at 12 and 24 hours following the first injection. Groups 2 and 3 were given seven i.p. injections of caerulein (Sigma) (Catalog#C-9026) at a dose of 50/ μ g/kg/hr for six hours (1 injection per hour). Group 2 was sacrificed at 12 hrs after the first injection and Group 3 was sacrificed at 24 hrs following the first injection. Pancreases were removed at the time of sacrifice and snap frozen for RNA isolation. Tissues were homogenized and RNA was isolated

5 using the Qiagen RNeasy Midiprep™ Kit.
[0432] In yet another study, murine Zcytor17lig transgenic mice were generated and observed for phenotypic changes (see Example 41). Piloerection and hair loss was observed in many of the transgenic mice. Four transgenic mice were sacrificed and skin samples from both normal and hairless areas were removed and snap frozen for later RNA isolation. Skin sections from two non-transgenic control mice were collected as well. Skin samples were homogenized and then
 10 digested with Proteinase K (Qiagen) (Catalog# 19133) for 20 minutes at 60°C. RNA was then isolated using the Qiagen RNeasy Midiprep™ Kit following manufacturer's instructions. Carryover DNA was removed using DNA-free™ kit from Ambion.

F. Results of Quantitative and Semi-Quantitative RT-PCR for Human Zcytor17, OSMRbeta and Zcytor17lig

15 **[0433]** Zcytor17 and OSMRbeta expression was examined by quantitative RT-PCR in four sets of primary human monocytes that were either in their resting state or activated with IFNg for 24 or 48 hours. Zcytor17 expression was below detection in the unstimulated cells but increased dramatically after the 24-hour activation with IFNg, and was the highest after 48 hours of activation. In all cases OSMRbeta was below detection. Zcytor17lig was not tested in these
 20 samples.

[0434] In the primary T cells, Zcytor17 was below detection in both the resting CD4+ and CD8+ subsets. After a four-hour activation, however, expression of Zcytor17 went up in both subsets and then decreased to a slightly lower level at the 16 hour time point. OSMRbeta was below detection in these samples. Zcytor17lig expression was examined using semi-quantitative RT-PCR. No expression was detected in the unstimulated CD4+ and CD8+ T cells. However, after
 25 the four hour activation, high levels of Zcytor17lig were detected. This level dropped somewhat at the 16 hour time point.

[0435] Expression of Zcytor17 was not examined in NK cells. OSMRb was below detection in these samples. Zcytor17lig expression was below detection in the resting NK cells, however there was a faint signal generated by the activated NK cells suggesting that these cells may make Zcytor17lig under certain conditions.

[0436] In the human monocyte-like cell lines, U937, THP-1 and HL-60, OSMRbeta expression was below detection in all of the resting and activated samples except for activated THP-1 samples where a faint signal was detected. Zcytor17 expression was high in both the U937 and THP-1 resting cell lines and showed a strong upregulation following activation. Expression in U937's was the highest of any cell type. In the HL-60's, Zcytor17 was expressed at moderate levels in the unstimulated cells and decreased upon stimulation with PMA. However, the expression of Zcytor17 was dramatically
 30 upregulated in the HL-60's when stimulated with IFNg for 72 and 96 hours. All of the human expression data is summarized in Table 8 below.
 35

Table 8

Primary Human Monocytes	Activation Status	Zcytor17	OSMRbeta	Zcytor17lig
Human Monocytes	Unstim	-	-	
Human Monocytes	Act. 24hr IFNg	+	-	
Human Monocytes	Act. 48hr IFNg	++	-	
Human CD4+	Unstim	-	-	-
Human CD4+	Act 4hr	++	-	++
Human CD4+	Act. 16hr	+	-	+
Human CD8+	Unstim	-	-	-
Human CD8+	Act 4hr	++	-	++
Human CD8+	Act. 16hr	+	-	+
Human NK Cells	Unstim		-	-
Human NK Cells	Act 24hr		-	+

EP 1 476 541 B1

(continued)

Primary Human Monocytes	Activation Status	Zcytor17	OSMRbeta	Zcytor17lig
U937	Unstim	++	-	-
U937	Act. 16hr	+++	-	-
THP-1	Unstim	++	-	-
THP-1	Act. 16hr	+++	+	-
HL-60	Unstim	++	-	-
HL-60	Act. 16hr PMA	+	-	-
HL-60	Act. 72hr IFNg	+++	-	-
HL-60	Act. 96hr IFNg	+++	-	-

G. Results of Quantitative and Semi-Quantitative RT-PCR for Murine Zcytor17, OSMRbeta and Zcytor17lig

[0437] Murine Zcytor17, OSMRbeta and Zcytor17lig expression levels were examined in several murine T cells populations and the results are summarized in Table 9. below. Murine Zcytor17 expression was tested by semi-quantitative RT-PCR and shown to be at low levels on both resting and activated primary CD4+ T cells. Expression of Zcytor17 was detected on resting CD8+ T cells and then seemed to drop upon activation with anti-CD3 and anti-CD28 antibodies at both the 4- and 16-hour time points. OSMRbeta expression was measured by quantitative RT-PCR and shown to be expressed in resting and activated CD4+ and CD8+ T cells. The expression of OSMRbeta went up after a 4-hour activation and then returned to the unstimulated levels by 16 hours in both the CD4+ and CD8+ T cells. Zcytor17lig was detected by quantitative RT-PCR and shown to be expressed at very low levels in unstimulated CD4+ T cells. However, following a 4-hour activation, Zcytor17lig expression was dramatically upregulated and then dropped slightly by the 16-hour time point. In CD8+ T cells, no Zcytor17lig was detected in the unstimulated cells. There was some Zcytor17lig expression at the 4-hour time point, but by 16 hours expression levels had dropped back below detection.

[0438] In the DO11.10 T cells, Zcytor17 expression was detected in the naïve and Th2 skewed cells, but not in the Th1 skewed cells. OSMRbeta expression was at low levels in the naïve DO11.10 cells. There was a dramatic increase in OSMRbeta expression levels in the Th1 skewed cells and a moderate increase of expression in the Th2-skewed cells. The Zcytor17lig expression in these cells was shown to be predominantly by the Th2 skewed subset. Low levels were detected in the Th1 subset and no expression was detected in the naïve cells. These results are summarized in the Table 9 below.

[0439] In the primary CD4+ T cells that were skewed in either the Th1 or Th2 direction, Zcyto17 wasn't examined. OSMRbeta expression was detected in all three samples with the highest levels found in the Th2 sample. Similar to the DO11.10 results, Zcytor17lig expression was detected at high levels in the Th2 skewed subset, with a small amount detected in the Th 1 subset and levels were below detection in the unstimulated cells. These results are summarized in the Table 9 below.

Table 9

Murine T Cells	Zcytor17	OSMRbeta	Zcytor17lig
CD4+ T Cells Unstimulated	+	+	+/-
CD4+ T Cells 4hr Activation	+	++	++
CD4+ T Cells 16hr Activation	+	+	+
CD8+ T Cells Unstimulated	+	+	-
CD8+T Cells 4hr Activation	+/-	++	+
CD8+ T Cells 16hr Activation	-	+	-

EP 1 476 541 B1

(continued)

Murine T Cells	Zcytor17	OSMRbeta	Zcytor17lig
DO11.10 Naïve	+	+	-
DO11.10 Th1	-	+++	+
DO11.10 Th2	+	++	++
CD4+ T Cells Unstimulated		++	-
CD4+ T Cells - Th1 Skewed		+++	+
CD4+ T Cells - Th2 Skewed		++	+++

[0440] In the Zcytor17lig transgenic skin samples, Zcytor17, OSMRbeta and Zcytor17lig expression levels were determined using quantitative RT-PCR. Zcytor17 was shown to be present in all samples at roughly equivalent levels. There were dramatically higher levels of OSMRbeta expression in the non-transgenic control animals than the transgenic samples. Zcytor17lig expression was below detection in the non-transgenic control animals with moderate to high levels of expression in the transgenic animals. The results are summarized in Table 10 below.

Table 10

Murine Zcytor17lig	Skin	Zcytor17	OSMRbeta	Zcytor17lig
Transgenic Skin	Phenotype	Zcytor17	OSMRbeta	Zcytor17lig
Wild Type Mouse	Normal	+	+++	-
Wild Type Mouse	Normal	+	+++	-
Transgenic #1	Normal	+	+	+
Transgenic #1	Hair Loss	+	+	+
Transgenic #2	Normal	+	+	+
Transgenic #2	Hair Loss	+	+	+
Transgenic #3	Normal	+	+	+
Transgenic #3	Hair Loss	+	+	+
Transgenic #4	Normal	+	+	+++
Transgenic #4	Hair Loss	+	+	+++

[0441] In a different experiment, Zcytor17, OSMRbeta and Zcytor17lig expression levels were measured by quantitative RT-PCR in the pancreases of mice subjected to acute pancreatitis. Zcytor17 expression was below detection in all of the samples. OSMRbeta expression was seen at low levels in the normal control samples (Group 1), but showed a strong upregulation at the 12-hour time point (Group 2) and slightly lower levels at the 24-hour time point (Group 3). Zcytor17lig expression was below detection in the control animals, but showed high levels in both of the caerulein injected groups. The data is summarized in Table 11 below.

Table 11

Pancreatitis Model	Description	Zcytor17	OSMRbeta	Zcytor17lig
Group 1	Normal Control	-	+	-
Group 2	12hr Post Injection	-	+++	++
Group 3	24hr Post Injection	-	++	++

[0442] In another experiment, Zcytor17 and OSMRbeta expression levels were examined in the distal colons of mice

EP 1 476 541 B1

subjected to DSS treatment. In this murine model of Inflammatory Bowel Disease, expression levels of both genes were determined by quantitative RT-PCR and are summarized in Table 12 below. Zcytor17 expression levels increased with the severity of the disease, with low levels of expression in the Group1 normal animals and increasing amounts seen Groups 2 and 3. In the Group 4 animals, the Zcytor17 levels had returned to more normal levels. Unlike Zcytor17 expression, OSMRbeta levels were the highest in the control animals and levels actually decreased in all three DSS treated groups.

Table 12

<i>IBD Model</i>	Description	SAC Day		Zcytor17	OSMRbeta
Group 1	Normal Control	14		+	++
Group 2	DSS-Treated 2 days	2		++	+
Group 3	DSS-Treated 7 days	7		+++	+
Group 4	DSS-Treated 7 days	14		+	+

Example 28

Human Zcytor17lig Tissue Distribution Expression based on RT-PCR Analysis of Multiple Tissue First-Strand cDNAs

[0443] Gene expression of the zcytor17lig was examined using commercially available normalized multiple tissue first-strand cDNA panels (OriGene Technologies, Inc. Rockville, MD; BD Biosciences Clontech, Palo Alto, CA). These included the OriGene "Human Tissue Rapid-Scan™ Panel" (Cat. #CHSCA-101, containing 22 different tissues, bone marrow, and plasma blood leucocytes) and the BD Biosciences Clontech "Human Blood Fractions MTC™ Panel" (Cat. #K1428-1, containing 9 different blood fractions).

[0444] PCR reactions were set up using the zcytor17lig specific oligo primers ZC41,458 (SEQ ID NO:60), and ZC41,457 (SEQ ID NO:61), which yield a 139 bp product, and ZC41,459 (SEQ ID NO:62), and ZC41,460 (SEQ ID NO:63), which yield a 92 bp product, Qiagen HotStarTaq DNA polymerase and buffer (Qiagen, Inc., Valencia, CA), dH₂O, and RediLoad™ dye (Research Genetics, Inc., Huntsville, AL). The PCR cyclor conditions were as follows: an initial 1 cycle 15 minute denaturation at 95°C, 35 cycles of a 45 second denaturation at 95°C, 1 minute annealing at 53°C or 56°C and 1 minute and 15 seconds extension at 72°C, followed by a final 1 cycle extension of 7 minutes at 72°C. The reactions were separated by electrophoresis on a 2% agarose gel (EM Science, Gibbstown, NJ) and visualized by staining with ethidium bromide.

[0445] A DNA fragment of the correct size was observed in the following human adult tissues using the OriGene "Human Tissue Rapid-Scan™ Panel": testis, plasma blood leucocytes (PBL), and bone marrow.

[0446] A DNA fragment of the correct size was observed in the following human blood fractions using the BD Biosciences Clontech "Human Blood Fractions MTC™ Panel": activated mononuclear cells (B- & T-cells and monocytes), activated CD8+ cells (T-suppressor/cytotoxic), activated CD4+ cells (T-helper/inducer) and faintly in resting CD8+ cells.

Example 29

Cloning the human Oncostatin M receptor

[0447] The OncostatinM beta receptor (OSMRbeta) is a type I cytokine receptor with structural similarity to IL12R-B2. ZcytoR17 has structural similarity to IL12R - B1. The OSMRbeta and zcytor17 were tested to see whether they could interact as subunits in a cytokine signaling complex, and whether together they could act as a signaling receptor, or soluble receptor antagonist, for zcytor17lig.

[0448] To isolate OSMRbeta, oligonucleotide PCR primers ZC39982 (SEQ ID NO:64) and ZC39983 (SEQ ID NO:65) were designed to amplify the full length coding region of the human OncostatinM beta cDNA sequence (SEQ ID NO:6) (Genbank Accession No. U60805; Mosley B, JBC Volume 271, Number 50, Issue of December 20, 1996 pp. 32635-32643).

[0449] PCR reactions were run on an array of cDNA library templates using a robust polymerase, Advantage II (Clontech, PaloAlto, CA), in order to identify a source of the cDNA. The template DNA used was from amplified cDNA plasmid libraries each containing 5 million independent cDNA clones. Reactions were assembled as per manufacturer's instructions using 400 fmol/μl of each oligonucleotide and 2-20 ng/μl purified plasmid library DNA as template. The cDNA libraries were derived from the following human tissues and cell lines: fetal brain, prostate smooth muscle, bone marrow, RPMI1588, thyroid, WI-38, testis, stimulated peripheral blood mononuclear cells, stimulated CD3+ cells, THP-1, activated tonsil, HACAT and fetal liver. Reactions were performed on a thermocycler machine using the following

EP 1 476 541 B1

conditions: 30 cycles of 95°C for 20 seconds, 68°C for 3 minutes. At the conclusion of 30 cycles an additional single extension cycle of 8 minutes at 68°C was run. PCR products were visualized by TAE agarose, gel electrophoresis in the presence of ethidium bromide followed by UV illumination. The most abundant product was found to be from a prostate smooth muscle cDNA library. The PCR reaction using prostate smooth muscle template and oligonucleotides ZC39982 (SEQ ID NO:64) and ZC39983 (SEQ ID NO:65) was repeated using a less robust but higher fidelity thermostable DNA polymerase "turboPfu", (Stratagene, La Jolla, CA). Thirty amplification cycles were run with the following conditions: denaturing at 94°C, 30 seconds, annealing at 63°C 45 seconds, extension at 72°C 3.5 minutes. A single band product was gel purified on a 0.8% TAE, agarose gel.

[0450] This DNA was then amplified again using primers ZC39980 (SEQ ID NO:66) and ZC39981 (SEQ ID NO:67) designed to include restriction enzyme recognition sequences to allow the cloning of this cDNA into a mammalian expression vector.

[0451] The PCR reaction was performed using "TurboPfu" and the purified PCR product for 15 cycles of: 95°C 1 minute, 64°C 1 minute 20 seconds, 72°C 4.5 minutes. The PCR reaction was then digested with EcoR1 and Xho1, (Invitrogen, Carlsbad, CA) and gel purified as described above. A mammalian expression vector, pZ7NX, was prepared by digesting with EcoR1 and Xho1 and the PCR product was ligated to this vector and electroporated into *E. coli* DH10b cells. Several bacterial colonies were isolated and sequenced. One clone was correct with the exception of a single non-conservative mutation. In order to change this base to match the expected sequence, an oligonucleotide spanning mutation and a neighboring Pst1 restriction site was used in a PCR reaction with "TurboPfu" using the pZP7Nx-h. OncostatinM R plasmid previously sequenced as a template. The PCR amplified DNA was digested with Pst1 and Xho1 and cloned back into the pZP7Nx-h OncostatinM R plasmid in place of the Pst1/Xho1 fragment containing the offending mutation. This new plasmid was sequenced over the recently amplified Pst1 to Xho1 region to confirm the correction and make sure no other errors were created in the amplification process. This analysis confirmed sequence that matched the expected sequence over the coding region. The sequence is shown in SEQ ID NO:6, and corresponding amino acid sequence shown in SEQ ID NO:7.

Example 30

Constructs for Generating a Human Zcytor17 / OncostatinM receptor (OSMRbeta) Heterodimer

[0452] A system for construction, expression and purification of such soluble heterodimeric receptors is known in the art, and has been adapted to the receptor pair, human oncostatin M receptor (OSMRbeta) and human zcytor17. For this construct, the polynucleotide for the soluble receptor for OSMRbeta is shown in SEQ ID NO:68 and corresponding polypeptide is shown in SEQ ID NO:69; and the polynucleotide for the soluble receptor for human zcytor17 is shown in SEQ ID NO:70 and corresponding polypeptide is shown in SEQ ID NO:71.

[0453] To construct a cell line expressing a secreted soluble hzcytor17/human OSMRbeta heterodimer, a construct was made so that the resulting heterodimeric soluble receptor comprises the extracellular domain of human OSMRbeta fused to the heavy chain of IgG gamma1 (Fc4) (SEQ ID NO:37) with a Glu-Glu tag (SEQ ID NO:35) at the C-terminus; while the extracellular domain of zcytoR17 was fused to Fc4 (SEQ ID NO:37) with a His tag (SEQ ID NO:72) at the C-terminus. For both of the hzcytor17 and human OSMRbeta arms of the heterodimer a Gly-Ser spacer of 12 amino acids (SEQ ID NO:73) was engineered between the extracellular portion of the receptor and the N-terminus of Fc4.

A. Construction of human soluble OSMRbeta/Fc4-CEE

[0454] For construction of the human soluble OSMRbeta/Fc4-CEE portion of the heterodimer the extracellular portion of human OSMRbeta was isolated using PCR with oligos ZC14063 (SEQ ID NO:48) and ZC41557 (SEQ ID NO:74) under PCR reaction conditions as follows: 30 cycles of 95°C for 60 sec., 57°C for 30 sec., and 72°C for 100 sec.; and 72°C for 7 min. PCR products were purified, using QIAquick PCR Purification Kit (Qiagen), digested with EcoR1 and BglII (Boehringer-Mannheim), separated by gel electrophoresis and purified using a QIAquick gel extraction kit (Qiagen).

[0455] The expression cassette, plasmid backbone and Fc4-GluGlu tag portion of the chimera were contained within a previously made in house plasmid vector. The plasmid vector was digested with EcoR1 and BamH1 (Boehringer-Mannheim), separated by gel electrophoresis and purified using a QIAquick gel extraction kit (Qiagen). The digested and purified fragments of human OSMRbeta and Fc4-CEE containing plasmid were ligated together using T4 DNA Ligase (Life Technologies, Bethesda, MD) using standard ligation methods. Minipreps of the resulting ligation were screened for an EcoRI/Sma1 insert of the correct size (772bp) for the soluble OSMRbeta and positive minipreps were sequenced to confirm accuracy of the PCR reaction. This new plasmid construction is termed pZP9-ONCOMR-Fc4CEE.

B. Construction of human soluble Zcytor17 / Fc4-CHIS .

[0456] For construction of the hzcytor17/Fc4-CHIS portion of the heterodimer, the extracellular portion of human zcytor17 was isolated by digestion of a plasmid previously containing Zcytor17-Fc4 soluble receptor. The plasmid was first digested with Sal1 (New England Biolabs, Beverly, MA) after which the reaction was serially phenol chloroform extracted and ethanol precipitated. The digested DNA was then treated with T4 DNA Polymerase (Boehringer-Mannheim), to fill in the 5' overhangs created by the Sall digestion, leaving the DNA ends blunt, after which the reaction was serially phenol chloroform extracted and ethanol precipitated. The blunted DNA was then further digested with BglII to cut at the 3' end.), separated by gel electrophoresis and purified using a QIAquick gel extraction kit (Qiagen) as per manufacturer's instruction. The resulting DNA fragment containing the sequence coding for the extracellular domain of zcytor17 was ligated into an Fc4-CHIS tag containing mammalian expression vector prepared as follows.

[0457] The expression cassette, plasmid backbone and Fc4-CHIS tag portion of the chimera were contained within a previously made in house plasmid vector: This plasmid vector was digested with EcoR1(Boehringer-Mannheim) after which the reaction was serially phenol chloroform extracted and ethanol precipitated. The digested DNA was then treated with T4 DNA Polymerase (Boehringer-Mannheim), to fill in the 5' overhangs created by the EcoR1 digestion, leaving the DNA ends blunt, after which the reaction was serially phenol chloroform extracted and ethanol precipitated. The blunted DNA was then further digested with BamH1 (Boehringer-Mannheim) to cut at the 3' end, separated by gel electrophoresis and purified using a QIAquick gel extraction kit (Qiagen). The digested and purified fragments of human zcytor17 and Fc4-CHIS containing plasmid were ligated together using T4 DNA Ligase (Life Technologies, Bethesda, MD) using standard ligation methods.

[0458] Minipreps of the resulting ligation were screened by PCR using the zcytor17 specific sense primer ZC29180 (SEQ ID NO:22) and the Fc4 specific antisense primer ZC29232 (SEQ ID NO:75) with the following PCR reaction conditions: 30 cycles of 94°C for 60 sec., 68°C for 150 sec; and 72°C for 7 min. An expected product size of 848 bp confirmed the correct assembly of the plasmid termed pZEM228 hzcytor17/Fc4HIS.

[0459] A second zcytor17-Fc4 construction was created for use in generating homodimer protein from COS cells. Briefly the coding region for the full fusion protein was isolated by digestion of a plasmid previously containing Zcytor17-Fc4 soluble receptor with Sall (Boehringer-Mannheim). The reaction was serially phenol chloroform extracted and ethanol precipitated. The digested DNA was then treated with T4 DNA Polymerase (Boehringer-Mannheim), to fill in the 5' overhangs created by the EcoR1 digestion, leaving the DNA ends blunt, after which the reaction was serially phenol chloroform extracted and ethanol precipitated. The blunted DNA was then further digested with Not1 (Boehringer-Mannheim) to cut at the 3' end, separated by gel electrophoresis and purified using a QIAquick gel extraction kit (Qiagen). A mammalian expression vector containing a CMV driven expression cassette was digested to generate compatible ends and the 2 fragments were ligated together. Minipreps of the resulting ligation were screened by PCR using the vector specific sense primer ZC14063 (SEQ ID NO:48) and the zcytor17 specific antisense primer ZC27899 (SEQ ID NO:19) with the following PCR reaction conditions: 30 cycles of 94°C for 30 sec., 64°C for 30 sec; 70°C for 90 sec; and 72°C for 7 min. An expected product size of approximately 1000 bp confirmed the correct assembly of the plasmid termed pZP7NX-hzcytor17-Fc4. This plasmid was subsequently transfected into COS cells using Lipofectamine (Gibco/BRL), as per manufacturer's instructions. The cells were conditioned for 60 hours in DMEM + 5%FBS (Gibco/BRL) after which the protein was purified over a protein G-sepharose 4B chromatography column and made available for *in vitro* bioassays, for example, such as those described herein.

C. Generating a Human Zcytor17 / OncostatinM receptor (OSMRbeta)

[0460] About 16 µg each of the pZP9-ONCOMR-Fc4CEE and pZEM228 hzcytor17/Fc4HIS were co-transfected into BHK-570 (ATCC No. CRL-10314) cells using lipofectamine (Gibco/BRL), as per manufacturer's instructions. The transfected cells were selected for 10 days in DMEM + 5%FBS (Gibco/BRL) containing 0.5 mg/ml G418 (Gibco/BRL) and 250 nM methyltrexate (MTX)(Sigma, St. Louis, MO) for 10 days.

[0461] The resulting pool of doubly-selected cells was used to generate the heterodimeric protein. Three cell Factories (Nunc, Denmark) of this pool were used to generate 10 L of serum free conditioned medium. This conditioned media was passed over a 1 ml protein-A column and eluted in (10) 750 microliter fractions. Four of these fractions found to have the highest concentration were pooled and dialyzed (10 kD MW cutoff) against PBS. The desired heterodimeric soluble zcytor17/OSMRbeta protein complex was isolated from other media components by passing the pool over a Nickel column and washing the column with various concentrations of Imidazole. The soluble zcytor17/OSMRbeta protein eluted at intermediate concentrations of Imidazole, while hzcytor17/Fc4HIS homodimer eluted at higher concentrations of Imidazole.

Example 31Tissue Distribution of Human zcytor17 in Tissue Panels Using Northern Blot and PCR5 A. Human zcytor17 Tissue Distribution using Northern Blot

[0462] Human Multiple Tissue Northern Blots (Human 12-lane MTN Blot I and II, and Human Immune System MTN Blot II; Human Endocrine MTN, Human Fetal MTN Blot II, Human Multiple Tissue Array) (Clontech) as well as in house blots containing various tissues were probed to determine the tissue distribution of human zcytor17 expression. The in-

10 house prepared blots included the following tissue and cell line mRNA: SK-Hep-I cells, THP1 cells, Adrenal gland (Clontech); Kidney (Clontech), Liver (Clontech and Invitrogen); Spinal cord (Clontech), Testis (Clontech), Human CD4+ T-cells, Human CD8+ T-cells, Human CD19+ T-cells, human mixed lymphocyte reaction (MLR), THP1 cell line (ATCC No. TIB-202), U937 cell line, p388D1 mouse lymphoblast cell line (ATCC No. CCL-46) with or without stimulation by ionomycin; and WI-38 human embryonic lung cell line (ATCC No. CRL-2221) with or without stimulation by ionomycin.

15 **[0463]** An approximately 500 bp PCR derived probe for zcytor17 (SE ID NO:4) was amplified using oligonucleotides ZC28,575 (SEQ ID NO:77) and ZC27,899 (SEQ ID NO:19) as primers. The PCR amplification was carried out as follows: 30 cycles of 94°C for 1 minute, 65°C for 1 minute, and 72°C for 1 minute; followed by 1 cycle at 72°C for 7 minutes. The PCR product was visualized by agarose gel electrophoresis and the approximately 500 bp PCR product was gel purified as described herein. The probe was radioactively labeled using the PRIME IT II™ Random Primer Labeling Kit (Strat-

20 agene) according to the manufacturer's instructions. The probe was purified using a NUCTRAP™ push column (Strat-agene). EXPRESSHYB™ (Clontech) solution was used for the prehybridization and as a hybridizing solution for the Northern blots. Prehybridization was carried out at 68°C for 2 hours. Hybridization took place overnight at 68°C with about 1.5X10⁶cpm/ml of labeled probe. The blots were washed three times at room temperature in 2X SSC, 0.05% SDS, followed by 1 wash for 10 minutes in 2X SSC, 0.1% SDS at 50°C. Several faint bands were seen after several

25 days exposure. An approximately 9 kb transcript was seen in trachea, skeletal muscle and thymus; an approximately 2 kb transcript was seen in PBL, HPV, U937 and THP-1 cells; and about a 1.2 kb transcript was seen in placenta, bone marrow and thyroid, and HPV and U937 cells. In all the tissues listed above, the signal intensity was faint. There appeared to be little expression in most normal tissues, suggesting that zcytor17 expression may be dependent on activation of the cell or tissues in which it is expressed.

30

B. Tissue Distribution in tissue panels using PCR

[0464] A panel of cDNAs from human tissues was screened for zcytor17 expression using PCR. The panel was made in-house and contained 94 marathon cDNA and cDNA samples from various normal and cancerous human tissues and

35 cell lines is shown in Table 13, below. The cDNAs came from in-house libraries or marathon cDNAs from in-house RNA preps, Clontech RNA, or Invitrogen RNA. The marathon cDNAs were made using the marathon-Ready™ kit (Clontech, Palo Alto, CA) and QC tested with clathrin primers ZC21195 (SEQ ID NO:78) and ZC21196 (SEQ ID NO:79) and then diluted based on the intensity of the clathrin band. To assure quality of the panel samples, three tests for quality control (QC) were run: (1) To assess the RNA quality used for the libraries, the in-house cDNAs were tested for average insert

40 size by PCR with vector oligos that were specific for the vector sequences for an individual cDNA library; (2) Standardization of the concentration of the cDNA in panel samples was achieved using standard PCR methods to amplify full length alpha tubulin or G3PDH cDNA using a 5' vector oligo ZC14,063 (SEQ ID NO:48) and 3' alpha tubulin specific oligo primer ZC17,574 (SEQ ID NO:49) or 3' G3PDH specific oligo primer ZC17,600 (SEQ ID NO:50); and (3) a sample was sent to sequencing to check for possible ribosomal or mitochondrial DNA contamination. The panel was set up in

45 a 96-well format that included a human genomic DNA (Clontech, Palo Alto, CA) positive control sample. Each well contained approximately 0.2-100 pg/μl of cDNA. The PCR reactions were set up using oligos ZC26,358 (SEQ ID NO: 80) and ZC26,359 (SEQ ID NO:81), TaKaRa Ex Taq™ (TAKARA Shuzo Co LTD, Biomedicals Group, Japan), and Rediload dye (Research Genetics, Inc., Huntsville, AL). The amplification was carried out as follows: 1 cycle at 94°C for 2 minutes, 35 cycles of 94°C for 30 seconds, 66.3°C for 30 seconds and 72°C for 30 seconds, followed by 1 cycle at

50 72°C for 5 minutes. About 10 μl of the PCR reaction product was subjected to standard agarose gel electrophoresis using a 4% agarose gel. The correct predicted DNA fragment size was observed in lymph node, prostate, thyroid, HPV (prostate epithelia), HPVS (prostate epithelia, selected), lung tumor, uterus tumor reactions, along with the genomic DNA reaction.

[0465] The DNA fragment for prostate tissue (2 samples), HPV (prostate epithelia), HPVS (prostate epithelia, selected), and genomic were excised and purified using a Gel Extraction Kit (Qiagen, Chatsworth, CA) according to manufacturer's

55 instructions. Fragments were confirmed by sequencing to show that they were indeed zcytor17.

EP 1 476 541 B1

Table 13

	Tissue/Cell line	#samples		Tissue/Cell line	#samples
5	Adrenal gland	1		Bone marrow	3
	Bladder	1		Fetal brain	3
	Bone Marrow	1		Islet	2
10	Brain	1		Prostate	3
	Cervix	1		RPML #1788 (ATCC # CCL-156)	2
	Colon	1		Testis	4
	Fetal brain	1		Thyroid	2
15	Fetal heart	1		WI38 (ATCC # CCL-75	2
	Fetal kidney	1		ARIP (ATCC # CRL-1674 - rat)	1
	Fetal liver	1		HaCat - human keratinocytes	1
20	Fetal lung	1		HPV (ATCC # CRL-2221)	1
	Fetal muscle	1		Adrenal gland	1
	Fetal skin	1		Prostate SM	2
	Heart	2		CD3+ selected PBMC's Ionomycin + PMA stimulated	1
25	K562 (ATCC # CCL-243)	1		HPVS (ATCC # CRL-2221)-selected	1
	Kidney	1		Heart	1
	Liver	1		Pituitary	1
30	Lung	1		Placenta	2
	Lymph node	1		Salivary gland	1
	Melanoma	1		HL60 (ATCC #CCL-240)	3
	Pancreas	1		Platelet	1
35	Pituitary	1		HBL-100	1
	Placenta	1		Renal mesangial	1
	Prostate	1		T-cell	1
40	Rectum	1		Neutrophil	1
	Salivary Gland	1		MPC	1
	Skeletal muscle	1		Hut-102 (ATCC # TIB-162)	1
	Small intestine	1		Endothelial	1
45	Spinal cord	1		HepG2 (ATCC #HB-8065)	1
	Spleen	1		Fibroblast	1
	Stomach	1		E. Histo	1
50	Testis	2			
	Thymus	1			
	Thyroid	1			
	Trachea	1			
55	Uterus	1			
	Esophagus tumor	1			

EP 1 476 541 B1

(continued)

Tissue/Cell line	#samples		Tissue/Cell line	#samples
Gastric tumor	1			
Kidney tumor	1			
Liver tumor	1			
Lung tumor	1			
Ovarian tumor	1			
Rectal tumor	1			
Uterus tumor	1			

15 C. Expression analysis of zcytorR 17 by PCR and Northern

[0466] Annotation of the cell types and growth conditions that affect expression of the receptor is a useful means of elucidating its function and predicting a source of ligand. To that end a wide variety of tissue and cell types were surveyed by PCR. The thermostable polymerase Advantage II™ (Clontech, La Jolla, CA) was used with the oligonucleotide primers ZC29,180 (SEQ ID NO:22) and ZC29,179 (SEQ ID NO:82) and 1-10ng of the various cDNA templates listed below for 30 amplification cycles of (94°C, 30 sec.; 66°C, 20 sec.; 68°C, 1 min. 30 sec.). Following this, 20% of each reaction was run out on 0.8% agarose, TAE /ethidium bromide gels and visualized with UV light. Samples were then scored on the basis of band intensity. See Table 14 below.

25 Table 14

Cells and Conditions	Score 0-5
Hel stimulated with PMA	0
U937	3
MCF-7	0
HuH7	1
Human follicle	0
HT-29	0
HEPG2	0
HepG2 stimulated with IL6	0
Human dermal endothelial	0
Human venous endothelial	0
Human CD4+	0
BEWO	0
Human CD19+	1
Human PBMC stimulated with PHA, PMA, Ionomycin, IL2, IL4, TNF α 24 hours	0
Human PBMC stimulated with LPS, PWM, IFN γ , TNF α , 24 hours	0
Human PBMC all of the above conditions for 48 hours	4
HUVEC p.2	4
RPMI1788	0
TF1	0
Monkey spleen T cells stimulated with PMA, Ionomycin	0
Human prostate epithelia HPV transformed	5

EP 1 476 541 B1

(continued)

Cells and Conditions	Score 0-5
Human tonsils, inflamed	0
HACAT	0
Human chondrocyte	1
Human synovialocyte	1
THP1	5
REH	0

[0467] Of the strong positive PCR signals, two were from the human monocyte cell lines U937 and THP1.

[0468] These two cell lines along with a prostate epithelia line were selected for further analysis by Northern blot. Previous attempts at visualizing a transcript by northern analysis using mRNA from various tissues yielded weak and diffuse signals in the surprisingly large size range of 7-10kb making this data difficult to interpret. A denaturing formaldehyde/MOPS/0.8% agarose gel was prepared (RNA Methodologies, Farrell, RE Academic Press) and 2 µg of polyA+ mRNA was run for each sample along side an RNA ladder (Life Technologies, Bethesda, MD). The gel was then transferred to Hybond nylon (Amersham, Buckinghamshire, UK), UV crosslinked, and hybridized in ExpressHyb solution (Clontech, LaJolla, CA) at 68°C overnight using a probe to human zcytoR17 generated by PCR with the oligos ZC28,575 (SEQ ID NO:77), and ZC27,899 (SEQ ID NO: 19) and labeled with a Megaprime ³²P kit (Amersham). The northern blot was subsequently washed with 0.2xSSC+0.1%SDS at 65C for 15 minutes and exposed to film for 7 days with intensifying screens. A prominent 8kb band was seen in both the prostate epithelia and U937 lanes while a fainter band was present in the THP1 lane.

[0469] To optimize the cDNA used as a hybridization probe, four different regions of the full-length human zcytoR17 sequence were amplified by PCR, labeled and hybridized as described above to southern blots containing genomic and amplified cDNA library DNA. The four probes, herein designated probes A-D, were amplified using the following primer pairs: (A) ZC28,575 (SEQ ID NO:77), ZC27,899 (SEQ ID NO:19); (B) ZC27,895 (SEQ ID NO:20), ZC28,917 (SEQ ID NO:83); (C) ZC28,916 (SEQ ID NO:84), ZC28,918 (SEQ ID NO:85); and (D) ZC28,916 (SEQ ID NO:84), ZC29,122 (SEQ ID NO:21). Human genomic DNA along with amplified cDNA libraries demonstrated to contain zcytoR17 by PCR were digested with EcoR1 and Xho1 to liberate inserts and run out on duplicate TAE/0.8% agarose gels, denatured with 0.5M NaOH, 1.5 M NaCl, blotted to Hybond, UV crosslinked and each hybridized with a distinct probe. Probe B was found to have the least nonspecific binding and strongest signal. Thus, Probe B was used for all subsequent hybridizations.

[0470] Given that the THP1 cells are an excellent model of circulating monocytes and expressed zcytoR17 at low levels we treated them with a variety of compounds in an effort to increase expression of zcytoR17. The cells were grown to a density of 2e5/ml, washed and resuspended in various stimulating media, grown for four or thirty hours, and harvested for RNA preparations. Each media was supplemented with one of the following drugs or pairs of cytokines: LPS 2ug/ml (Sigma Chemicals, St. Louis, MO), hTNFα 2 ng/ml (R&D Systems, Minneapolis, MN), hGM-CSF 2ng/ml (R&D Systems, Minneapolis, MN), hIFNγ 50 ng/ml (R&D Systems, Minneapolis, MN), hMCSF 1ng/ml (R&D Systems, Minneapolis, MN), hIL6 1ng/ml (R&D Systems, Minneapolis, MN), hIL1β 2ng/ml (R&D Systems, Minneapolis, MN), hIFNγ 50ng/ml+hIL4 0.5ng/ml (R&D Systems, Minneapolis, MN), hIFNγ 50ng/ml+hIL10 1ng/ml (R&D Systems, Minneapolis, MN), PMA 10ng/ml (Calbiochem, San Diego, CA) and an untreated control. At the end of the culture period Total RNA was prepared using an RNAeasy Midi-kit (Qiagen, Valencia, CA). Poly A+ RNA was selected from the total RNA using an MPG kit (CPG, Lincoln Park, NJ). 2 ug of polyA+ RNA from each condition was run on formaldehyde/MOPS/agarose gels, transferred to nylon and UV crosslinked as described above. These northern blots were then hybridized, as above, to probe B at 68°C overnight, washed at high stringency with 0.2XSSC, 0.1%SDS at 65C, exposed to film overnight then exposed to phosphor screens for signal quantitation. A dominant 8 kb mRNA as well a relatively weaker 2.8 kb band were seen in all lanes. A 20-fold increase in zcytoR17 mRNA was seen in RNA from cells treated with hIFNγ for 30 hours, this effect was slightly muted with simultaneous treatment with IL4. Minor 3 fold increases in mRNA were seen in RNA from cells treated with LPS, TNFα and GM-CSF while MCSF, IL6, and IL1β had no effect on zcytoR17 mRNA levels. This data suggests a role for the zcytoR17 receptor and its ligand in monocyte macrophage biology and by extension any number of disease processes in which these cells participate.

Example 32Tissue Distribution of human zcytor17lig in Tissue Panels Using Northern Blot and PCR

5 **[0471]** A human zcytor17lig cDNA fragment was obtained using PCR with gene specific primers: Sense primer ZC41438 (SEQ ID NO:93) and antisense primer ZC41437 (SEQ ID NO:94) and template human zcytor17lig cDNA (SEQ ID NO:90) This fragment was purified using standard methods and about 25ng labeled with ³²P alpha dCTP using the Prime-It RmT random primer labeling kit (Stratagene) and hybridized in Ultrahyb, (Ambion) and used to expose Biomax film/intensifying screens per the manufacturer's recommendations in each case. New, previously unused blots including the Clontech Human 12 lane MTN, the human brain MTN II, and the human brain MTN blot IV, the human immune system MTN II, and the human MTE array II, from Clontech were hybridized overnight at 42°C per the Ambion ultrahyb method. Non-specific radioactive counts were washed off using .1SSC/.5% SDS at 55°C. The positive blots included the human 12 lane MTN (Clontech). Of the 12 tissues examined, only placenta was positive for an approximately 1.2 KB transcript.

Example 33Construction of mammalian expression vectors that express human zcytor17lig-CEE,20 A. Construction of zCyt17Lig-CEE/pZMP21

[0472] An expression plasmid containing all or part of a polynucleotide encoding zCyt17Lig-CEE (SEQ ID NO:95) was constructed via homologous recombination. The plasmid was called zCyt17Lig-CEE/pZMP21.

25 **[0473]** The construction of zCyt17Lig-CEE/pZMP21 was accomplished by generating a zCyt17Lig-CEE fragment using PCR amplification. The DNA template used for the production of the zCyt17Lig-CEE fragment was zCyt17Lig/pZP7nx. The primers used for the production of the zCyt17Lig-CEE fragment were: (1) ZC41,607 (SEQ ID NO:97) (sense sequence), which includes from the 5' to the 3' end: 28bp of the vector flanking sequence (5' of the insert) and 21 bp corresponding to the 5' sequence of zCyt17Lig; and (2) ZC41,605 (SEQ ID NO:98) (anti-sense sequence), which includes from the 5' to the 3' end: 37 bp of the vector flanking sequence (3' of the insert), 3 bp of the stop codon, 21 bp encoding a C-terminal EE tag, and 21 bp corresponding to the 3' end of zCyt17Lig sequence. The fragment resulting from the above PCR amplification was a copy of the template zCyt17Lig with the addition of a C-terminal EE tag, yielding a final product zCyt17Lig-CEE.

35 **[0474]** PCR reactions were run as follows: To a 100µl final volume was added: 10µl of 10x Taq Polymerase Reaction Buffer with 15mM MgCl (Gibco), 1µl of Taq DNA Polymerase (5 units/µl, Gibco), 3µl of 10mM dNTPs, 78µl dH₂O, 3µl of a 20 pmol/µl stock of primer ZC41,607 (SEQ ID NO:97) 3µl of a 20 pmol/µl stock of primer ZC41,605 (SEQ ID NO:98), and 2µl of a 0.13µg/µl stock of zCyt17lig template DNA. A volume equal to 50µl of mineral oil was added to the mixture. The reaction was heated to 94°C for 5 minutes, followed by 35 cycles at 94°C for 1 minute; 55°C for 2 minutes; 72°C for 3 minutes; followed by a 10 minute extension at 72°C and held at 4°C until the reaction was collected.

40 **[0475]** The plasmid pZMP21 was restriction digested with BglII enzyme, cleaned with a QiaQuick PCR Purification Kit (Qiagen) using a microcentrifuge protocol, and used for recombination with the PCR fragment. Plasmid pZMP21 was constructed from pZMP20 which was constructed from pZP9 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, and is designated No. 98668) with the yeast genetic elements from pRS316 (deposited at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209, and designated No. 77145), an IRES element from poliovirus, and the extracellular domain of CD8, truncated at the carboxyl terminal end of the transmembrane domain. PZMP21 is a mammalian expression vector containing an expression cassette having the MPSV promoter, immunoglobulin signal peptide intron, multiple restriction sites for insertion of coding sequences, a stop codon and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene, the SV40 terminator, as well as the URA3 and CEN-ARS sequences required for selection and replication in *S. cerevisiae*.

50 **[0476]** Fifty microliters of competent yeast cells (*S. cerevisiae*) were independently combined with 100 ng of cut plasmid, 5 µl of previously described PCR mixture, and transferred to a 0.2 cm electroporation cuvette. The yeast/DNA mixture was electropulsed at 0.75 kV (5 kV/cm), ∞ ohms, 25 µF. Each cuvette had 600 µl of 1.2 M sorbitol added, and the yeast was plated in one 100 µl aliquot and one 300 µl aliquot onto two URA-D plates and incubated at 30°C. After about 72 hours, the Ura⁺ yeast transformants from a single plate were resuspended in 1 ml H₂O and spun briefly to pellet the yeast cells. The cell pellet was resuspended in 500 µl of lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA). The 500 µl of the lysis mixture was added to an Eppendorf tube containing 300 µl acid washed 600µm glass beads and 300 µl phenol-chloroform, vortexed for 1 minute intervals two or three times,

EP 1 476 541 B1

followed by a 5 minute spin in a Eppendorf centrifuge at maximum speed. Three hundred microliters of the aqueous phase was transferred to a fresh tube, and the DNA precipitated with 600 μ l 100% ethanol (EtOH), followed by centrifugation for 10 minutes at 4°C. The DNA pellet was then washed with 500 μ l 70% EtOH, followed by centrifugation for 1 minute at 4°C. The DNA pellet was resuspended in 30 μ l H₂O.

5 **[0477]** Transformation of electrocompetent *E. coli* cells (MC1061) was done with 5 μ l of the yeast DNA prep and 50 μ l of MC1061 cells. The cells were electropulsed at 2.0 kV, 25 μ F and 400 ohms(Ω). Following electroporation, 600 μ l SOC (2% Bacto' Tryptone (Difco, Detroit, MI), 0.5% yeast extract (Difco), 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, 10 mM MgSO₄, 20 mM glucose) was added. The electroporated *E. coli* cells were plated in a 200 μ l and a 50 μ l aliquot on two LB AMP plates (LB broth (Lennox), 1.8% Bacto Agar (Difco), 100 mg/L Ampicillin). The plates were incubated upside
10 down for about 24 hours at 37°C. Three Ampicillin-resistant colonies were selected at random and submitted for sequence analysis of the insert. Large-scale plasmid DNA was isolated from a sequence-confirmed clone using the Qiagen Maxi kit (Qiagen) according to manufacturer's instructions.

B. Construction of mouse zCyt17Lig(m)-CEE/pZMP21

15 **[0478]** An expression plasmid containing the entire polynucleotide encoding murine zCyt17Lig-CEE (SEQ ID NO: 104 and SEQ ID NO:105) was also constructed via homologous recombination using the method described in Example 33A above. The primers used were: (1) ZC41643 (SEQ ID NO:106) (forward, 5' to 3' sense) having a 28bp vector overlap
20 5' of the insertion point; 21 bp of the 5' end of zcytor17lig(m) and (2) ZC41641 (SEQ ID NO:107) (reverse, 5' to 3' anti-sense) having a 37bp vector overlap 3' of the insertion point; 3 bp stop codon; 21 bp C-terminal EE tag; 24 bp of the 3' end of zCyt17Lig(m)-CEE. The plasmid was called zcytor17lig(m)-CEE/pZMP21. The polynucleotide sequence of zcytor17lig(m)-CEE is shown in SEQ ID NO: 104, and corresponding polypeptide sequence is shown in SEQ ID NO:105.

Example 34

Transfection And Expression Of zcytor17lig-CEE Polypeptides

A. Expression of human zcytor17lig-CEE/pZMP21 in 293T cells

30 **[0479]** ZCyt17Lig-CEE was expressed transiently in 293T cells (Stanford University School of Medicine, Stanford, CA, ATCC (SD-3515)) to generate initial purified protein. The day before the transfection, 293T cells were seeded at 6.5x 10⁴ cells/cm² in 30 T162 culture flasks with a total volume of 30ml of culture media (SL7V4 +5%FBS +1% Pen/Strep) per flask. The cells were allowed to incubate for 24 hours at 37°C.

35 **[0480]** A DNA/Liposome mixture was prepared as follows: Two 50 ml conical tubes were filled with 25 mLs of transfection media (SL7V4 +1%Pen/Strep) and 1.13 mg of zCyt17Lig-CEE/pZMP21 (Example 33) was added to each. A separate set of two 50 ml conical tubes were filled with 22 ml of transfection media (above) and 3 ml of liposomes (Lipofectamine, Gibco) was added to each. For each set of tubes, one tube of DNA was added to one tube of liposomes and the DNA/liposome mix was incubated for 30 minutes. The two 50 ml conical tubes containing the DNA/liposome mixtures were pooled (about 100 ml) and 300 ml of transfection media was added.

40 **[0481]** The 30 flasks of the 293T cells were decanted, washed 1x with about 15 ml of PBS, and 12.5 ml of the diluted DNA/liposome mixture was added to each flask. The flasks were incubated for 3 hours at 37°C. After the incubation period, 25 ml of culture media (above) were added to each T162 flask. The transfection media was harvested after approximately 96 hours and was used for protein purification (Example 35).

B. Expression of human zcytor17lig-CEE/pZMP21 in BHK cells

45 **[0482]** Full-length zCyt17Lig protein was produced in BHK cells transfected with zCyt17Lig-CEE/pZMP21 (see Example 33 above). BHK 570 cells (ATCC CRL-10314) were plated in T75 tissue culture flasks and allowed to grow to approximately 50 to 70% confluence at 37°C, 5% CO₂, in growth media (SL7V4, 5%FBS, 1% pen/strep). The cells were
50 then transfected with zCyt17Lig-CEE/pZMP21 by liposome-mediated transfection (using Lipofectamine™; Life Technologies), in serum free (SF) media (SL7V4). The plasmid (16 μ g) was diluted into 1.5 ml tubes to a total final volume of 640 μ l with SF media. Thirty-five microliters the lipid mixture was mixed with 605 μ l of SF medium, and the resulting mixture was allowed to incubate approximately 15 minutes at room temperature. Five milliliters of SF media was then added to the DNA:lipid mixture. The cells were rinsed once with 10 ml of PBS, the PBS was decanted, and the DNA:
55 lipid mixture was added. The cells are incubated at 37°C for five hours, then 15 ml of media (SL7V4, 5% FBS, 1% pen/strep) was added to each plate. The plates were incubated at 37°C overnight, and the DNA:lipid media mixture was replaced with selection media (SL7V4, 5% FBS, 1% pen/strep, 1 μ M methotrexate) the next day. Approximately 10 days post-transfection, methotrexate-resistant colonies from the T75 transfection flask were trypsinized, and the cells were

EP 1 476 541 B1

pooled and plated into a T-162 flask and transferred to large-scale culture.

C. Expression of mouse zcytor17lig-CEE(m)/pZMP21 in 293T cells

5 **[0483]** Mouse zcytor17lig(m)-CEE was expressed transiently in 293T cells as described in Example 34A and cultured media was used for protein purification (Example 35).

Example 35

10 Purification of Zcytor17lig-CEE from 293T cells

[0484] Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used for purifying both mouse and human Zcytor17lig containing C-terminal Glu-Glu (EE) tags (SEQ ID NO:103). Conditioned media from 293T cells expressing Zcytor17lig-CEE (Example 34) was purified. Total target protein concentrations of the conditioned media were determined via SDS-PAGE and Western blot analysis with the anti-EE antibody.

15 **[0485]** A 5.5 ml column of anti-EE Poros 50 A (PE BioSystems, Framingham, MA) (prepared as described below) was poured in a Waters AP-1, 1 cm x 7cm glass column (Waters, Milford, MA). The column was flow packed and equilibrated on a BioCad Sprint (PE BioSystems, Framingham, MA) with phosphate buffered saline (PBS) pH 7.4. The conditioned media was adjusted with NaCl to 0.3 M and the pH adjusted to 7.2. The conditioned media was then loaded on the column overnight with about 3 ml/minute flow rate. The column was washed with 10 column volumes (CVs) of PBS pH 7.4, and again washed with 3CVs 5X Sigma PBS pH 7.4. It was step eluted with 0.5 M Acetate, 0.5 M NaCl, pH 2.5 at 3 ml/minute. The fraction tubes contained 1ml Tris base (no pH adjustment) to neutralize the elution immediately. The column was again washed for 2CVs with 5X Sigma PBS, pH 7.4 to neutralize the column and then equilibrated in PBS (pH 7.4). Two ml fractions were collected over the entire elution chromatography and absorbance at 280 and 215 nM were monitored; the pass through and wash pools were also saved and analyzed. The 5X PBS and the acid elution peak fractions were analyzed for the target protein via SDS-PAGE Silver staining and Western Blotting with the primary antibody anti-EE and secondary antibody, anti mouse-HRP conjugated. The acid elution fractions of interest were pooled and concentrated from 38 ml to 0.8ml using a 5000 Dalton molecular weight cutoff membrane spin concentrator (Millipore, Bedford, MA) according to the manufacturer's instructions.

25 **[0486]** To separate Zcytor17lig-CEE from aggregated material and any other contaminating co-purifying proteins, the pooled concentrated fractions were subjected to size exclusion chromatography on a 1.6 x 60 cm (120 ml) Superdex 75 (Pharmacia, Piscataway, NJ) column equilibrated and loaded in PBS at a flow rate of 1.0 ml/min using a BioCad Sprint. Three ml fractions were collected across the entire chromatography and the absorbance at 280 and 215 nM were monitored. The peak fractions were characterized via SDS-PAGE Silver staining, and only the most pure fractions were pooled. This material represented purified Zcytor17lig -CEE protein.

30 **[0487]** On Western blotted, Coomassie Blue and Silver stained SDS-PAGE gels, the Zcytor17lig-CEE was one major band. The protein concentration of the purified material was performed by BCA analysis (Pierce, Rockford, IL) and the protein was aliquoted, and stored at -80°C according to standard procedures.

35 **[0488]** To prepare PorosA50 anti-EE, a 65 ml bed volume of Poros A50 (PE Biosystems) was washed with 100 ml of water and then 0.1 M triethanolamine, pH 8.2 (TEA, ICN, Aurora, Ohio), 1 M Na₂SO₄, pH 8.8 containing 0.02% sodium azide using a vacuum flask filter unit. The EE monoclonal antibody solution, at a concentration of 2 mg/ml in a volume of 300 ml, was mixed with the washed resin in a volume of 250 ml. After an overnight incubation at room temperature, the unbound antibody was removed by washing the resin with 5 volumes of 200 mM TEA, 1 M Na₂SO₄, pH 8.8 containing 0.02% sodium azide as described above. The resin was resuspended in 2 volumes of TEA, 1 M Na₂SO₄, pH 8.8 containing 0.02% sodium azide and transferred to a suitable container. Three ml of 25 mg/ml (68mM) Disuccinimidyl suberate (in DMSO supplied by Pierce, Rockford, IL) was added and the solution was incubated for three hours at room temperature. Nonspecific sites on the resin were then blocked by incubating for 10 min at room temperature with 5 volumes of 20 mM ethanolamine (Sigma, St. Louis, MO) in 200 mM TEA, pH 8.8 using the vacuum flask filter unit. The resin was washed with PBS, pH 7.4, followed by 0.1 M Glycine, pH 3 and then neutralized with 10X PBS. After washing with distilled water, the final coupled anti-EE Poros-A 50 resin was stored at 4°C in 20% Ethanol.

Example 36

N-terminal sequencing of human and mouse Zcytor17lig

55

A. N-terminal sequencing of human Zcytor17lig

[0489] Standard automated N-terminal polypeptide sequencing (Edman degradation) was performed using reagents

from Applied Biosystems. N-terminal sequence analysis was performed on a Model 494 Protein Sequencer System (Applied Biosystems, Inc., Foster City, CA). Data analysis was performed with Model 610A Data Analysis System for Protein Sequencing, version 2.1a (Applied Biosystems).

[0490] A purified human zcytor17lig-CEE sample (Example 35) was supplied. The sample was loaded onto a prepared glass fiber filter for n-terminal sequencing. The glass fiber filter was prepared by precycling it with Biobrene™.

[0491] N-terminal sequence analysis of the secreted human zcytor17lig polypeptide did not verify the predicted cleavage site of the signal sequence but resulted in a mature start at residue 27(Leu) in SEQ ID NO:2 of the human zcytor17lig precursor sequence.

B. N-terminal sequencing of mouse Zcytor17lig

[0492] Standard automated N-terminal polypeptide sequencing (Edman degradation) was performed using reagents from Applied Biosystems. N-terminal sequence analysis was performed on a Model 494 Protein Sequencer System (Applied Biosystems, Inc., Foster City, CA). Data analysis was performed with Model 610A Data Analysis System for Protein Sequencing, version 2.1a (Applied Biosystems).

[0493] A purified mouse zcytor17lig-CEE sample was supplied as captured on Protein G Sepharose/anti-EE beads (Example 35). The beads were placed in reducing SDS PAGE sample buffer and on a boiling water bath before running on SDS PAGE, using a Novex SDS PAGE system (4-12% Bis-Tris MES NuPAGE; Invitrogen) as per manufacturer's instructions. The gel was electrotransferred to a Novex PVDF membrane (Invitrogen), and Coomassie blue stained (Sigma, St. Louis, MO) using standard methods. Corresponding anti-EE Western blots were performed to identify the zcytor17lig band for N-terminal protein sequencing. The mouse anti-EE IgG HRP conjugated antibody used was produced in house.

[0494] N-terminal sequence analysis of the secreted mouse zcytor17lig polypeptide verified the predicted cleavage site of the signal sequence resulting in a mature start at 31 (Ala) in reference to SEQ ID NO:11 and SEQ ID NO:91 of the mouse zcytor17lig precursor sequence.

Example 37

Cos cell binding assay

[0495] A binding assay was used to test the binding of the zcytor17lig to receptors comprising zcytor17 receptor, such as the zcytor17 receptor or receptor heterodimers and trimers comprising zcytor17 receptor (e.g., zcytor17/OSMR, zcytor17/WSX-1, or zcytor17/OSMR/WSX-1, or other Class I cytokine receptor subunits). Zcytor17 receptor plasmid DNA was transfected into COS cells and transfected COS cells were used to assess binding of the zcytor17lig to receptors comprising zcytor17 receptor as described below.

A. COS Cell Transfections

[0496] The COS cell transfection was performed as follows: Mix 800 ng receptor plasmid DNA in the following combinations: pZp7pX/zcytor17 alone; pZp7Z/WSX-1 alone; pZp7NX/OSMR alone; pZp7pX/zcytor17 + pZp7NX/OSMR; pZp7pX/zcytor17 + pZp7Z/WSX-1; pZp7NX/OSMR + pZp7Z/WSX-1; pZp7pX/zcytor17 + pZp7NX/OSMR + pZp7Z/WSX-1) and 4ul Lipofectamine™ in 80 ul serum free DMEM media (55mg sodium pyruvate, 146mg L-glutamine, 5 mg transferrin, 2.5 mg insulin, 1 µg selenium and 5 mg fetuin in 500 ml DMEM), incubate at room temperature for 30 minutes and then add 320 µl serum free DMEM media. Add this 400 µl mixture onto 2 x10⁵ COS cells/well plated on 12-well tissue culture plate (fibronectin-coated) and incubate for 5 hours at 37°C. Add 500ul 20% FBS DMEM media (100 ml FBS, 55 mg sodium pyruvate and 146mg L-glutamine in 500 ml DMEM) and incubate overnight.

B. Binding Assay

[0497] The binding assay was performed as follows: media was rinsed off cells with PBS + 0.1% BSA, and then cells were blocked for 60 minutes with the same solution. The cells were then incubated for 1 hour in PBS + 0.1% BSA with 1.0 µg/ml zcytor17ligCEE purified protein. Cells were then washed with PBS + 0.1% BSA and incubated for another hour with 1:1000 diluted mouse anti-GluGlu antibody. Again cells were washed with PBS + 0.1% BSA, then incubated for 1 hour with 1:200 diluted goat anti-mouse-HRP conjugated antibody.

[0498] Positive binding was detected with fluorescein tyramide reagent diluted 1:50 in dilution buffer (NEN kit) and incubated for 4-6 minutes, and washed with PBS + 0.1% BSA. Cells were fixed for 15 minutes with 1.8% Formaldehyde in PBS, then washed with PBS + 0.1%BSA. Cells were preserved with Vectashield Mounting Media (Vector Labs Burlingame, CA) diluted 1:5 in PBS. Cells were visualized using a FITC filter on fluorescent microscope.

[0499] Positive binding was detected for cells transfected with zcytor17 only, zcytor17+OSMRbeta, zcytor17+WSX-1, and zcytor17+OSMRbeta+WSX-1. No binding was detected for cells transfected with WSX-1 + OSMRbeta, with OSMRbeta only, or with WSX-1 only.

5 Example 38

Mouse zcytor17lig activates mouse zcytor17/OSMRbeta receptor-in luciferase assay

10 A. Cloning of full-length mouse zcytor17 and mouse OSMRbeta for expression

[0500] A mouse testes cDNA library was screened for a full-length clone of mouse zcytoR17. The library was plated at 65,500 cfu/plate on 24 LB + Amp plates. Filter lifts were prepared using Hybond N (Amersham-Pharmacia Biotech, Inc., Piscataway, NJ) on a total of approximately 1.6 million colonies. The filters were marked with a hot needle for orientation and then denatured for 6 minutes in 0.5 M NaOH and 1.5 M Tris-HCl, pH 7.2. The filters were then neutralized in 1.5 M NaCl and 0.5 M Tris-HCl, pH 7.2 for 6 minutes. The DNA was affixed to the filters using a UV crosslinker (Stratalinker®, Stratagene, La Jolla, CA) at 1200 joules. The filters were then left to dry overnight at room temperature.

[0501] The next day, the filters were pre-washed at 65°C in pre-wash buffer consisting of 0.25X SSC, 0.25% SDS and 1mM EDTA. Cell debris was manually removed using Kimwipes® (Kimberly-Clark) and the solution was changed 3 times over a period of 1 hour. Filters were air dried and stored at room temperature until needed. The filters were then prehybridized for approximately 3 hours at 63°C in 20 ml of ExpressHyb™ Hybridization Solution (Clontech, Palo Alto, CA).

[0502] Probe B (Example 31) was generated by PCR from human zcytoR17 template using oligonucleotide primers ZC27,895 (SEQ ID NO:20) and ZC28,917 (SEQ ID NO:83) and was radioactively labeled with ³²P using a commercially available kit (Megaprime DNA Labeling System; Amersham Pharmacia Biotech, Piscataway, NJ) according to the manufacturer's instructions. The probe was purified using a Stratagene™ push column (NucTrap® column; Stratagene, La Jolla, CA). The probe was denatured at 100°C for 15 min and added to ExpressHyb™. Filters were hybridized in 15 ml hybridizing solution containing 1.6 x 10⁶ cpm/ml of probe at 63°C overnight. Filters were washed at 55°C in 2X SSC, 0.1 % SDS and 1 mM EDTA and exposed to X-ray film at -80°C for 4 1/2 days. Thirteen positives were picked from the plates as plugs and placed in 1 ml LB +amp in 1.7 ml tubes. Tubes were placed at 4°C overnight. These 13 positives were subjected to two further rounds of purification. The tertiary plates were outgrown at 37°C after filter lifts were taken and single colonies were picked and sent to sequencing. Three of these were determined to contain sequence of the mouse ortholog of zcytoR17.

[0503] In addition, a PCR product was generated using CTLL-2 cDNA as a template and oligonucleotides ZC38,239 (SEQ ID NO:108) and ZC38,245 (SEQ ID NO:109) as primers. CTLL-2 is a mouse cytotoxic T lymphocyte cell line (ATCC No. TIB-214). This PCR reaction was run as follows: 1 cycle at 95°C for 1 minute, 30 cycles at 95°C for 15 seconds, 68°C for 3 minutes, then 68°C for 10 minutes; 4°C soak. The PCR reaction used approximately 0.5 ng of cDNA, 20 pmoles of each oligonucleotide, and 1 µl of Advantage II polymerase mix (ClonTech). About 6% of the PCR product was used as a template in a new PCR reaction, as above, except with oligonucleotides ZC38,239 (SEQ ID NO:108) and ZC38,238 (SEQ ID NO:110). This PCR reaction was run as follows: 30 cycles at 94°C for 45 seconds, 65°C for 45 seconds, 72°C for 1 minute, then 72°C for 7 minutes; 10°C soak. Most of the PCR reaction was loaded on a 1.0% agarose gel and the predominant band at approximately 360 bp was excised, the DNA fragment was eluted, and DNA sequencing was performed.

[0504] The sequence of the mouse zcytor17 polynucleotide is shown in SEQ ID NO:111 and the corresponding amino acid sequence shown in SEQ ID NO:112. In addition, a truncated soluble form of the mouse zcytor17 polynucleotide is shown in SEQ ID NO:113 and the corresponding amino acid sequence shown in SEQ ID NO: 114.

[0505] To obtain a full-length mouse OSMRbeta cDNA, 5' and 3' PCR products were isolated and joined using an internal BamHI site. The PCR primers were designed using the nucleotide sequence SEQ ID NO:119 and include EcoRI and XbaI restriction sites for cloning purposes. The genomic mouse OSMRbeta nucleic acid sequence is shown in SEQ ID NO:119, wherein the coding sequence encompasses residues 780 to 3692 encoding a mouse OSMRbeta 970 amino acid polypeptide, which is shown in SEQ ID NO:120. A degenerate nucleic acid sequence which encodes the polypeptide of SEQ ID NO:120 is shown in SEQ ID NO:121.

[0506] A 5' PCR product was generated using an in-house 3T3-L1 (differentiated mouse adipocyte) cDNA library as a template and oligonucleotides ZC41,764 (SEQ ID NO:115) and ZC41,598 (SEQ ID NO:116) as primers. This 5' PCR reaction was run as follows: 30 cycles at 95°C for 45 seconds, 55°C. for 45 seconds, 72°C for 1 minute 30 seconds, then 72°C for 7 minutes; 4°C soak. The PCR reaction used approximately 3 µg of plasmid prepared from the cDNA library, 20 pmoles of each oligonucleotide, and five units of *Pwo* DNA polymerase (Roche). About 90% of the 5' PCR product was digested with EcoRI and BamHI and gel purified on a 1.0% agarose gel. The approximately 1446 bp band was excised and used for ligation (see below).

[0507] A 3' PCR product was generated using a mouse placenta in-house cDNA library as a template and oligonu-

EP 1 476 541 B1

cleotides ZC41,948 (SEQ ID NO:117) and ZC41,766 (SEQ ID NO:118) as primers. This 3' PCR reaction was run as follows: 30 cycles at 95°C for 45 seconds, 55°C for 45 seconds, 72°C for 1 minute 30 seconds, then 72°C for 7 minutes; 4°C soak. The PCR reaction used approximately 3 µg of plasmid prepared from the cDNA library; 20 pmoles of each oligonucleotide, and five units of *Pwo* DNA polymerase (Roche). About 90% of the 3' PCR product was digested with BamHI and XbaI and gel purified on a 1.0% agarose gel. The approximately 2200 bp band was excised and used for ligation along with the 5' PCR product (described above) to the expression vector pZP-5Z digested with EcoRI and XbaI. The three-part ligation was performed with the 5' EcoRI to BamHI fragment above, the 3' BamHI to XbaI fragment, and the expression vector pZP-5Z digested with EcoRI and XbaI. This generated a pZP-5Z plasmid containing a full-length cDNA for mouse OSMRbeta (nucleotides 780 to 3692 of SEQ ID NO:119), designated pZP-5Z/OSMRbeta. The full length mouse OSMRbeta cDNA in pZPSZ/OSMRbeta has two amino acid insertions from SEQ ID NO:120. There is a duplication of amino acid Glycine at position 370 and a duplication of amino acid Glutamic Acid at position 526. Plasmid pZP-5Z is a mammalian expression vector containing an expression cassette having the CMV promoter, multiple restriction sites for insertion of coding sequences, and a human growth hormone terminator. The plasmid also has an *E. coli* origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a zeocin resistance gene and the SV40 terminator.

[0508] The resulting transformants were sequenced to confirm the mouse OSMRbeta cDNA sequence.

B. Construction of BaF3/KZ134/zcytor17m, BaF3/KZ134/zcytor17m/OSMRbetam BHK/KZ134/zcytor17m, and BHK/KZ134/zcytor17m/OSMRbetam cell lines

[0509] Stable BaF3/KZ134 and BHK/KZ134 cell lines (Example 20) were transfected with an expression plasmid encoding full-length mouse zcytor17, pZP-7P/zcytor17m (Example 38A), to create BaF3/KZ134/zcytor17m and BHK/KZ134/zcytor17m cells, respectively. The mouse OSMRbeta expression plasmid, pZP-5Z/OSMRbetam (Example 38A), was then transfected into these cells to create BaF3/KZ134/zcytor17m/OSMRbetam and BHK/KZ134/zcytor17m/OSMRbetam cell lines, respectively. Methods were as described in Example 4 with the exception that BaF3/KZ134/zcytor17m and BHK/KZ134/zcytor17m were selected with, in addition to Geneticin, 2ug/ml puromycin while BaF3/KZ134/zcytor17m/OSMRbetam and BHK/KZ134/zcytor17m/OSMRbetam were selected with, in addition to Geneticin, 2ug/ml puromycin and 200 ug/ml zeocin.

[0510] Clones were diluted, plated and selected using standard techniques. Clones were screened by luciferase assay (see Example 20, above) using the mouse zcytor17lig conditioned media or purified mouse zcytor17lig protein (Example 35) as an inducer. Clones with the highest luciferase response (via STAT luciferase) and the lowest background were selected. Stable transfectant cell lines were selected.

C. Mouse Zcytor17lig activates mouse zcytor17 receptor in BaF3/KZ134/zcytor17m/OSMRbetam or BHK/KZ134/zcytor17m/OSMRbetam luciferase assay

[0511] Cell lines were plated for luciferase assays as described in Example 20 above. STAT activation of the BaF3/KZ134/Zcytor17m, BaF3/KZ134/zcytor17m/OSMRbetam, BHK/KZ134/zcytor17m, or BHK/KZ134/zcytor17m/OSMRbetam cells was assessed using (1) conditioned media from BHK570 cells transfected with the human zcytor17lig (Example 7), (2) conditioned media from BHK570 cells transfected with the mouse zcytor17lig (Example 18), (3) purified mouse and human zcytor17lig (Example 35), and (4) mL-3 free media to measure media-only control response. Luciferase assays were performed as described in Example 20.

[0512] The results of this assay confirm the STAT reporter response of the BaF3/KZ134/zcytor17m/OSMRbetam and BHK/KZ134/zcytor17m/OSMRbetam cells to the mouse zcytor17lig when compared to either the BaF3/KZ134/zcytor17m cells, the BHK/KZ134/zcytor17m cells or the untransfected BaF3/KZ134 or BHK/KZ134 control cells, and show that the response is mediated through the mouse zcytor17/OSMRbeta receptors. The results also show that the human zcytor17lig does not activate the STAT reporter assay through the mouse receptor complex.

Example 39

Human zcytor17lig binding to zcytor17 and zcytor17/OSMRbeta by Flow Cytometry

[0513] The biotinylation of human zcytor17L was done as follows: 100µL of zcytor17 at 5.26mg/mL was combined with 30µL of 10mg/mL EZ-link Sulfo-NHS-LC-biotin (Pierce, Rockford, IL) dissolved in ddH₂O. This solution was incubated on a rocker for 30 minutes at room temperature. After biotinylation the solution was dialyzed in PBS using a Slide-A-Lyzer dialysis cassette.

[0514] To test the binding properties of human zcytor17lig to different receptor combinations both BHK and BAF3 cells were transfected with expression plasmids using standard techniques well-known in the art. These plasmids were

EP 1 476 541 B1

transfected into both cell lines in the following combinations: zcytor17 alone, OSMRbeta alone, and both zcytor17 and OSMRbeta. Transfection was performed as detailed above. Untransfected BHK and BAF3 cells were used as controls. Cells were stained by FACS as follows: 2E5 cells were stained with either: 2.0µg/mL, 100ng/mL, 10ng/mL, 1.0ng/mL, 100pg/mL, 10pg/mL, 1.0pg/mL of biotinylated zcytor17L or left unstained for 30 minutes on ice in FACS buffer (PBS + 2%BSA + 2%NHS (Gemini) + 2%NGS). Cells were washed 1.5 times and then stained with SA-PE (Jackson Immuno Laboratories) at 1:250 for 30 minutes on ice. Cells were then washed 1.5 times with FACS buffer and resuspended in FACS buffer and analyzed by FACS on a BD FACSCaliber using CellQuest software (Becton Dickinson, Mountain View, CA).

[0515] Both BHK and BAF3 cells showed that zcytor17lig bound to both zcytor17 alone and in combination with OSMRbeta with the binding to the zcytor17/OSMRbeta heterodimer being slightly stronger. No binding was seen in either cell lines expressing OSMRbeta alone. The zcytor17lig bound in a concentration dependent manner. The mean fluorescent intensity (N4FI) values for the BHK binding are shown below in Table 15.

Table 15

zcytor17 µg/mL	2.0	0.100	0.010	0.001	0.0001	0.00001	0.000001	0.0
BHK	3780	2126	328	53	17	15	14	13
C17+OSMRbeta								
BHK-C17	3032	1600	244	39	16	15	14	15
BHK-OSMRbeta	13	X	X	X	X	X	X	0
BHK-WT	15	14	13	X	X	X	X	13

zcytor17 µg/mL	10.0	3.33	1.11	0.37	0.12	0.04	0.00
BAF3-C17+OSMRbeta	531	508	489	441	364	247	7
BAF3-OSMRbeta	6	5	5	5	5	5	11
BAF3-WT	13	13	12	12	12	12	13

zcytor17 ng/mL	100.0	10.0	1.0	0.0
BAF3-C17	347	72	17	7

Example 40

Gene Expression Array Analysis of Human Zcytor17lig Treated Cells

[0516] RNA was isolated from human zcytor17lig treated A549 cells, zcytor17lig treated SK-LU-1 cells, and untreated control cells using a RNeasy Midi Kit (Qiagen, Valencia, CA) according to the manufactures instructions.

[0517] Gene expression profiling of the cells treated with zcytor17lig and the respective control cells was carried out using GEArray Q series cDNA expression arrays (SuperArray Inc., Bethesda, MD). The Q Series cDNA expression arrays contain up to 96 cDNA fragments associated with a specific biological pathway, or genes with similar functions or structural features. Comparison of arrays from treated and control cells allows for a determination of the up and down regulation of specific genes. Probe labeling, hybridization and detection were carried out according to the manufactures instructions. Chemiluminescent signal detection and data acquisition was carried out on a Lumi-Imager workstation (Roche, Indianapolis, IN). The resulting image data was analyzed using ImageQuant 5.2 (Amersham Biosciences, Inc., Piscataway, NJ) and GEArray Analyzer 1.2 (SuperArray Inc., Bethesda, MD) software.

[0518] Analysis of the results from the Human Interleukin and Receptor Q series HS-014N arrays, showed, after normalization, an approximate 4.7 fold increase of IL13RA2 signal in the zcytor17lig treated human SK-LU-1 cells and an approximate 2.2 fold increase of the IL13RA2 signal in the zcytor17lig treated human A549 cells.

[0519] These results indicate that zcytor17lig significantly up regulated IL13RA2 in the SK-LU-1 and A549 cells. Both of these are established cell lines derived from human lung carcinomas (Blobel et al., Virchows Arch B Cell Pathol Incl Mol Pathol., 1984;45(4):407-29). More specifically, A549 is characterized as a human pulmonary epithelial cell line (Lin, et al., J Pharm Pharmacol., 2002 Sep;54(9):1271-8; Martinez et al., Toxicol Sci., 2002 Oct;69(2):409-23).

[0520] Interleukin-13 (IL13), a cytokine secreted by activated T lymphocytes, has been demonstrated to be both necessary and sufficient for the expression of allergic asthma and for use in experimental models of asthma, which

include airway hyperresponsiveness, eosinophil recruitment, and mucus overproduction (Wills-Karp et al., Science, 1998;282:2258-2261). It has been shown, that selective neutralization of IL13 will ameliorate the asthma phenotype (Grunig et al., Science, 1998; 282:2261-2263). It has also been reported that IL13 is involved in the up regulation of mucin gene MUC8 expression in human nasal polyp epithelium and cultured nasal epithelium (Kimm et al., Acta Otolaryngol., 2002; Sep;122(6):638-643; Seong et al., Acta Otolaryngol., 2002; Jun;122(4)-401-407). MUC8, a major airway mucin glycoprotein, is implicated as playing a role in the pathogenesis of mucus hypersecretion in chronic sinusitis with polyps (Seong et al., Acta Otolaryngol., 2002; Jun;122(4):401-407).

[0521] Functionally, IL13 signals through a receptor complex consisting of the interleukin-13 receptor alpha-1 chain (IL13RA1) and IL-4 receptor alpha (IL4RA) (Daines and Hershey, J Biol Chem., 2002; 22(12):10387-10393). It has also been shown, that the interleukin-13 receptor alpha-2 (IL13RA2) binds IL13 with high affinity, but by itself (Daines and Hershey, J Biol Chem., 2002; 22(12):10387-10393). This receptor lacks, however, the cytoplasmic domain necessary for signaling and, therefore, is considered to be a decoy receptor. It has been shown that IL13RA2 is predominately an intracellular molecule that can be quickly mobilized from intracellular stores and surface expressed following cellular treatment with interferon (IFN)-gamma. The surface expression of IL13RA2 after IFN-gamma treatment does not involve protein synthesis and results in diminished IL13 signaling (Daines and Hershey, J Biol Chem., 2002; 22(12):10387-10393).

[0522] The results of the gene expression array analysis for zcytor17lig indicate the action of zcytor17lig to be novel to that of IFN-gamma in that the zcytor17lig treatment of lung epithelial derived cell lines resulted in a significant increase of IL13RA2 gene expression. Thus, zcytor17lig treatment can be beneficial in cases where long-term up regulation of IL13RA2 expression and down regulation of IL13 is desired such as in asthma, airway hyperactivity (AHR), and mucin regulation, including chronic sinusitis with polyps.

Example 41

Murine zcytor17lig Transgenic Mice

[0523] To evaluate the *in vivo* effects of zcytor17lig overexpression, multiple founders of transgenic mice expressing the murine form of the gene were generated, driven by two different promoters: the lymphocyte-specific promoter E μ /Ick, and the ubiquitous promoter, EF1 α (Example 22). Serum protein levels range from approximately 20-300 ng/ml. The E μ /Ick promoter generated mice with higher levels of serum protein than those in the EF1 α -zcytor17lig transgenic mice.

[0524] The zcytor17lig transgenic mice developed a skin phenotype around 4-8 weeks of age. The fur of the transgenic mice became "ruffled," with obvious piloerection and mild to severe hair loss, usually on their backs, sides of the torso, and around their eyes. This phenotype was consistently found in mice with detectable levels of zcytor17Lig protein in their serum. Among the founders, 100% incidence rate among the mice expressing the E μ /Ick -driven gene, and a 50% incidence in the EF1 α -zcytor17lig transgenic mice was noted, correlating well with the relative levels of zcytor17lig that was detected in their serum. The transgenic skin appeared to be pruritic, as evidenced by the scratching behavior of the mice, sometimes excessive enough to induce excoriation and lesions of the skin, which usually became infected (with at least *Staphylococcus aureus*). The mice were originally identified with metal ear tags, but in most cases, the ear tags were forcibly removed by the mice themselves. This often resulted in severe damage to the external ear. These wounded ears often did not heal properly, as reflected in the presence of long-lasting pustules and crusting, and a seeping, expanding wound would that developed in many of the animals, behind and between their ears. Some of the transgenic mice also developed scabby wounds on their shoulders and neck. Skin lesions were observed in a subset of the animals, generally evolving on areas of skin where hair loss had already been apparent, and were often exacerbated by the scratching behavior of the mice.

[0525] RealTime quantitative RT-PCR was used to detect zcytor17lig RNA transcripts in transgenic (but not non-transgenic) skin samples, with the E μ /Ick transgenic skin expressing more zcytor17lig RNA than skin from EF1 α -zcytor17lig transgenic mice. The genes encoding the zcytor17 receptor subunits, zcytor17 and OSM-Rbeta were expressed in the skin of both non-transgenic and zcytor17lig-transgenic mice.

[0526] An examination of the lymphoid tissues from a subset of the E μ /Ick-transgenic founders by flow cytometry revealed a significant increase in the proportion of activated T cells in the spleen and lymph nodes of these mice. Two of the four mice analyzed had severely enlarged cervical lymph nodes, possibly due to the presence of lesions on their necks. A subtle increase in spleen weight and a slight increase in monocytes and neutrophils circulating in the blood of the transgenic mice was observed. There was no increase in a variety of cytokines tested, nor were there changes in the circulating serum amyloid A levels in these mice. The effects on the immune cells in the transgenic mice may be a direct or an indirect result of zcytor17lig, or are secondary effects of the skin lesions.

[0527] Histopathology was performed on many tissues other than skin, including liver, thymus, spleen, kidney, and testes, and no significant abnormalities in these organs were noted. Analysis of the transgenic skin, however, did reveal a number of alterations, which varied greatly depending upon the source and location of skin (e.g., normal, hairless, or

lesional). In many cases, the ears of the transgenic mice had a thickened epidermis as compared to the non-transgenic controls (e.g., approximately 4 layers versus 2 layers), and the underlying tissues contained low to moderate numbers of inflammatory cells, which were primarily mononuclear with occasional neutrophils. The epidermis over the abdomen appeared multifocally slightly thicker in the transgenic, but there was no apparent increase in inflammatory cells in the underlying dermis or subcutis. In the hairless portions of skin from these mice, there were dilated hair follicles that contained some debris but no hair shafts (e.g., the hairs fell out by the roots). In the lesioned areas, there was severe thickening of the epidermis (acanthosis), increased keratin on the surface of the skin (hyperkeratosis), scattered ulcers of varying size and significant numbers of inflammatory cells in the dermis (mainly neutrophils, with varying numbers of macrophages and lymphocytes). The dermis also contained numerous mast cells bordering the lesions. Some of the hair shafts in the lesioned areas of the transgenic skin were in the active stage (anagen), in contrast to many of the hair shafts in "normal" areas which were in the involuting (catagen) to inactive (telogen) stage.

[0528] The phenotype of the zcytor17lig transgenic mice strongly resembles that of atopic dermatitis (AD) patients, and mouse models of AD. AD is a common chronic inflammatory disease that is characterized by hyperactivated cytokines of the helper T cell subset 2 (Th2). Zcytor17lig is preferentially expressed by Th2 vs. Th1 cells, which lends further credence to this comparison. Although the exact etiology of AD is unknown, multiple factors have been implicated, including hyperactive Th2 immune responses, autoimmunity, infection, allergens, and genetic predisposition. Key features of the disease include xerosis (dryness of the skin), pruritus (itchiness of the skin), conjunctivitis, inflammatory skin lesions, *Staphylococcus aureus* infection, elevated blood eosinophilia, elevation of serum IgE and IgG1, and chronic dermatitis with T cell, mast cell, macrophage and eosinophil infiltration. Colonization or infection with *S. aureus* has been recognized to exacerbate AD and perpetuate chronicity of this skin disease.

[0529] AD is often found in patients with asthma and allergic rhinitis, and is frequently the initial manifestation of allergic disease. About 20% of the population in Western countries suffer from these allergic diseases, and the incidence of AD in developed countries is rising for unknown reasons. AD typically begins in childhood and can often persist through adolescence into adulthood. Current treatments for AD include topical corticosteroids, oral cyclosporin A, non-corticosteroid immunosuppressants such as tacrolimus (FK506 in ointment form), and interferon-gamma. Despite the variety of treatments for AD, many patients' symptoms do not improve, or they have adverse reactions to medications, requiring the search for other, more effective therapeutic agents.

[0530] Epithelial cells, which express the heterodimeric receptor for zcytor17lig (zcytoR17 and OSM-Rbeta), are located at the sites (e.g., skin, gut, lung, etc.) of allergen entry into the body and interact closely with dendritic cells (professional antigen presenting cells) *in situ*. Dendritic cells play an important role in the pathogenesis of allergic diseases, and zcytor17lig may interact with its receptor on epithelial cells in the skin and lung and influence immune responses in these organs. Zcytor17lig and its receptor(s) may therefore contribute to the pathogenesis of allergic diseases such as AD and asthma. Furthermore, the phenotype of the zcytor17lig transgenic mice suggests that this ligand may play a role in wound healing, since the mice seem unable to repair damage to their ears, and often bear long-lasting lesions on their backs and sides. An antagonist of zcytor17lig might therefore represent a viable therapeutic for these and other indications.

Example 42

Luciferase Assay on Human Transformed Epithelial Cell Lines via Transient Infection with an Adenoviral STAT/SRE Reporter Gene

[0531] A wide variety of human transformed epithelial cell lines (see Table 16 below) were seeded in 96-well flat-bottom plates at 10,000 cell/well in regular growth media as specified for each cell type. The following day, the cells were infected with an adenovirus reporter construct, KZ136, at a multiplicity of infection of 5000. The KZ136 reporter contains the STAT elements in addition to a serum response element. The total volume was 100 μ l/well using DMEM supplemented with 2 mM L-glutamine (GibcoBRL), 1 mM Sodium Pyruvate (GibcoBRL) and 1x Insulin-Transferrin-Selenium supplement (GibcoBRL) (hereinafter referred to as serum-free media). Cells were cultured overnight.

[0532] The following day, the media was removed and replaced with 100 μ l of induction media. The induction media was human zcytor17lig diluted in serum-free media at 100ng/ml, 50 ng/ml, 25 ng/ml, 12.5 ng/ml, 6.25 ng/ml, 3.125 ng/ml and 1.56 ng/ml. A positive control of 20% FBS was used to validate the assay and to ensure the infection by adenovirus was successful. The cells were induced for 5 hours at which time the media was aspirated. The cells were then washed in 50 μ l/well of PBS, and subsequently lysed in 30 μ l/well of 1X cell lysis buffer (Promega). After a 10-minute incubation at room temperature, 25 μ l/well of lysate was transferred to opaque white 96-well plates. The plates were then read on the Luminometer using 5-second integration with 40 μ l/well injection of luciferase substrate (Promega).

[0533] The results revealed the ability of multiple epithelial cell lines to respond to zcytor17lig as shown in Table 16 below.

Table 16

	Cell Line	Species	Tissue	Morphology	Disease	Fold Induction
5	A549	Human	Lung	Epithelial	Carcinoma	2x
	Sk-Lu-1	Human	Lung	Epithelial	Adenocarcinoma	6x
	WI-38	Human	Embryonic Lung	Fibroblast		Negative
	MRC-5	Human	Lung	Fibroblast		Negative
	DU 145	Human	Prostate	Epithelial	Carcinoma	10x
10	PZ-HPV-7	Human	Prostate	Epithelial	Transformed with HPV	5x
	PC-3	Human	Prostate	Epithelial	Adenocarcinoma	Negative
	U20S	Human	Bone	Epithelial	Osteosarcoma	15.5x
	SaOS2	Human	Bone	Epithelial	Osteosarcoma	22x
15	MG-63	Human	Bone	Fibroblast	Osteosarcoma	Negative
	143B	Human	Bone	Fibroblast	Osteosarcoma	3.5x
	HOS	Human	Bone	Fibroblast and Epithelial		8x
	TRBMeC	Human	Vascular Bone Marrow	Epithelial		2x
20	HT144	Human	Skin	Fibroblast	Melanoma	5x
	C32	Human	Skin		Melanoma	Negative
	Sk-Mel-2	Human	Skin	Polygonal	Melanoma	2.7x
	WM-115	Human	Skin	Epithelial	Melanoma	2x
25	HCT-116	Human	Colon	Epithelial	Carcinoma	Negative
	HT-29	Human	Colon	Epithelial	Carcinoma	Negative
	CaCo2	Human	Colon	Epithelial	Adenocarcinoma	3x
	HBL-100	Human	Breast	Epithelial		1.5x
	ME-180	Human	Cervix	Epithelial	Carcinoma	Negative
30	HeLa 299	Human	Cervix	Epithelial	Adenocarcinoma	Negative
	SK-N-SH	Human	Brain	Epithelial	Neuroblastoma	Negative
	U138 MG	Human	Brain	Polygonal	Glioblastoma	Negative
	HepG2	Human	Liver	Epithelial	Carcinoma	Negative
	Chang liver	Human	Liver	Epithelial		Negative
35	Sk-Hep-1	Human	Liver	Epithelial	Adenocarcinoma	4x
	Int 407	Human	Intestine	Epithelial		Negative
	3a-Sub E	Human	Placenta			Negative

40 Example 43Cytokine production by human epithelial cell lines cultured with human zcytor17lig

45 **[0534]** Human disease-state epithelial cell lines (A549, human lung epithelial carcinoma; SkLu1, human lung epithelial adenocarcinoma; DU145, human prostate epithelial carcinoma; PZ-HPV-7, human prostate epithelial HPV transformed; U20S, human bone epithelial osteosarcoma) were screened for cytokine production in response to zcytor17lig *in vitro*. These cell lines have both zcytor17 and OSMR-beta, identified by RT-PCR, and respond to human zcytor17lig when assayed with the adenoviral luciferase reporter construct, KZ136 (Example 42). Cytokine production by these cell lines was determined in response to human zcytor17lig in a series of three experiments.

50

A. Cytokine production by human disease-state epithelial cell lines cultured with human zcytor17lig

55 **[0535]** Cells were plated at a density of 4.5×10^5 cells per well in a 6 well plate (Costar) and cultured in respective growth media. The cells were cultured with test reagents; 100ng/mL zcytor17lig, 10ng/mL Interferon gamma (IFN gamma) (R&D Systems, Minneapolis, MN), 10ng/mL Tumor Necrosis Factor alpha (TNF alpha) (R&D Systems, Minneapolis, MN), 10ng/mL IL-1beta (R&D Systems, Minneapolis, MN) or 100ug/mL Lipopolysaccharide (LPS) (Sigma). Supernatants were harvested at 24 and 48 hours and assayed for cytokines; GM-CSF (Granulocyte-Macrophage Colony-Stimulating

EP 1 476 541 B1

Factor), IL-1b, IL-6, IL-8, MCP-1 (Macrophage Chemoattractant Protein-1) and TNFa. Multiplex Antibody Bead kits from BioSource International (Camarillo, CA) were used to measure cytokines in samples. Assays were read on a Luminex-100 instrument (Luminex, Austin, TX) and data was analyzed using MasterPlex software (MiraiBio, Alameda, CA). Cytokine production (pg/mL) for each cell line in the 24-hour samples is shown below in Table 17.

5

Table 17

10

15

20

25

30

35

40

45

50

GM-CSF pg/mL					
	A549	SkLu 1	DU145	U2OS	PZ-HPV-7
zcytor17L	18.80	10.26	16.19	13.26	14.10
IFN-g	16.19	13.36	11.56	16.26	11.81
IL-1b	104.60	126.44	76.77	338.25	27.32
TNFa	106.67	33.20	58.50	107.09	33.79
LPS	17.64	10.62	11.81	25.47	18.34
control	14.81	8.56	13.26	21.67	13.96
IL-1b pg/mL					
	A549	SkLu1	DU145	U2OS	PZ-HPV-7
zcytor17L	26.90	30.17	28.77	29.07	28.00
IFN-g	29.07	35.33	21.96	26.90	26.73
IL-1b	1332.88	1256.17	979.02	1107.35	998.60
TNFa	31.11	33.28	35.33	31.24	25.66
LPS	33.28	28.77	29.07	31.11	31.24
control	28.77	28.77	26.73	31.24	29.07
IL-6 pg/mL					
	A549	SkLu1	DU145	U2OS	PZ-HPV-7
zcytor17L	20.09	26.89	193.05	19.37	17.30
IFN-g	17.52	33.64	217.58	27.02	17.63
IL-1b	175.44	5920.19	2375.29	304.08	18.44
TNFa	354.16	1002.51	1612.17	103.58	18.33
LPS	18.06	35.65	162.18	22.42	17.30
control	17.63	27.80	71.23	19.32	17.19
IL-8 pg/mL					
	A549	SkLu1	DU145	U2OS	PZ-HPV-7
zcytor17L	86.33	150.81	150.61	45.92	6.81
IFN-g	24.07	72.82	163.31	81.78	1.35
IL-1b	1726.24	4083.12	4407.79	5308.83	124.17
TNFa	3068.68	3811.75	2539.39	3324.02	69.65
LPS	20.28	167.13	230.39	115.08	7.95
control	14.92	109.78	107.27	93.44	9.49

55

EP 1 476 541 B1

(continued)

MCP-1 pg/mL		A549	SkLu1	DU145	U2OS	PZ-HPV-7
zcytor17L		8.97	187.29	26.84	105.15	7.20
IFN-g		7.30	267.99	17.05	88.68	7.71
IL-1b		8.11	8039.84	88.78	3723.81	4.70
TNFa		8.50	7100.37	153.26	3826.80	2.80
LPS		9.40	185.83	22.65	61.62	5.61
control		8.16	167.93	13.68	47.78	5.61
TNFa pg/mL		A549	SkLu1	DU145	U2OS	PZ-HPV-7
zcytor17L		16.23	17.52	16.67	15.80	17.09
IFN-g		15.80	17.09	15.80	16.65	15.80
IL-1b		16.66	17.09	15.80	17.95	16.23
TNFa		1639.92	1648.83	2975.07	1348.33	3554.82
LPS		16.87	15.80	15.37	17.09	17.52
control		16.23	15.80	15.80	17.09	16.66

[0536] All cell lines tested produced GM-CSF and IL-8 in response to stimulation with control cytokines IL-1b and TNFa. Most cell lines produced EL-6 and MCP-1 in response to IL-1b and TNFa stimulation. Zcytor17lig stimulated IL-6 production in the DU145 cell line compared to control (193pg/mL vs. 71pg/mL). Zcytor17lig stimulated 3 of 5 cell lines to produce IL-8 with the greatest effect seen in A549 cells (5 fold), and reduced IL-8 production in U2OS cells by 2 fold. There was a slight effect on MCP-1 production by DU145 and U2OS cells when cultured with zcytor17lig.

B. Cytokine production by normal human epithelial cell lines cultured with human zcytor17lig

[0537] In addition to the human epithelial cell lines, normal human bronchial epithelial cells (NHBE, Clonetics) were also tested. Cells were plated at a density of 1×10^5 cells per well in a 24 well plate and cultured with test reagents; 1000ng/mL, 100ng/mL and 10ng/mL zcytor17lig (A760F), 10ng/mL TNFa, 10ng/mL OSM, 10ng/mL IFNa, 10ng/mL TGFb or 10ng/mL Lymphotoxin. Supernatants were harvested at 24 and 48 hours and assayed for cytokines; IL-6, IL-8, MCP-1, MIP-1a, RANTES and Eotaxin. Cytokines were assayed as previously described. Cytokine production (pg/mL) for each cell line in the 48-hour samples is shown below in Table 18.

Table 18

IL-6 pg/ml		A549	DU145	SkLu1	U2OS	NHBE
r17L 1000ng/ml		24.5	56.3	32.1	25.2	64.5
r171L 100ng/ml		25.0	65.0	31.0	25.4	50.2
r17L 10ng/ml		24.8	51.8	30.2	25.3	54.3
TNFa		272.9	355.4	437.5	36.1	299.3
OSM		26.4	73.5	112.4	25.6	80.4
IFNa		24.6	109.3	33.7	26.4	52.4
TGFb		24.4	102.6	42.7	27.8	268.9
control		24.5	36.3	29.9	25.2	47.9
IL-8 pg/ml		A549	DU145	SkLu1	U2OS	NHBE
r17L 1000ng/ml		35.0	243.3	45.6	18.6	402.0
r171L 100ng/ml		31.0	290.7	40.1	21.3	296.0

EP 1 476 541 B1

(continued)

IL-8 pg/ml					
	A549	DU145	SkLu1	U2OS	NHBE
r17L 10ng/ml	30.4	240.4	33.4	18.9	361.8
TNF α	2809.3	2520.9	1385.2	784.9	1486.3
OSM	37.8	60.6	68.0	22.5	494.6
IFN α	18.9	315.3	39.5	33.1	231.6
TGF β	9.9	77.5	19.6	88.9	246.9
control	10.9	238.0	38.0	39.7	315.8
MCP-1 pg/ml					
	A549	DU145	SkLu1	U2OS	NHBE
r17L 1000ng/ml	nd	nd	149.1	81.0	nd
r17L 100ng/ml	nd	nd	130.6	81.9	nd
r17L 10ng/ml	nd	nd	111.7	49.1	nd
TNF α	nd	22.1	2862.6	1104.7	nd
OSM	nd	17.2	448.2	85.8	nd
IFN α	nd	nd	131.7	10.5	nd
TGF β	nd	1.7	54.5	27.6	nd
control	nd	nd	113.0	1.7	nd
nd = not detected					

[0538] DU145 cells produced IL-6 in response to zcytor17lig, repeating the previous results in Example 43A. However, only A549 and U2OS had similar IL-8 responses as seen Example 43A. SkLu1 and U2OS cells both produced MCP-1 in response to zcytor17lig. Cytokine production by NHBE cells was marginal compared to controls.

C. Cytokine production by human disease-state epithelial cell lines co-cultured with human zcytor17lig and IFN gamma

[0539] Cells were plated at a density of 2×10^5 cells per well in 24 well plate and co-cultured with 10ng/mL IFN gamma +/- zcytor17lig at 100ng/mL, 10ng/mL or 1ng/mL. Supernatants were collected at 24 and 48 hours and assayed for IL-8 and MCP-1 as described above. Cytokine production (pg/mL) for each cell line in the 24-hour samples is shown below in Table 19.

Table 19

		IL-8 pg/ml	MCP-1 pg/ml
A549	10ng/mL IFNg+100ng/mL r17L	86.7	nd
	10ng/mL IFNg+10ng/mL r17L	75.1	nd
	10ng/mL IFNg+1ng/mL r17L	63.6	nd
	10ng/ml IFNg	35.4	nd
	control	36.6	nd
	DU145	10ng/mL IFNg+100ng/mL r17L	102.3
10ng/mL IFNg+10ng/mL r17L		92.9	nd
10ng/mL IFNg+1ng/mL r17L		79.9	nd
10ng/ml IFNg		70.7	nd
control		79.4	nd
SkLu1		10ng/mL IFNg+100ng/mL r17L	152.2
	10ng/mL IFNg+10ng/mL r17L	194.4	870.7
	10ng/mL IFNg+1ng/mL r17L	138.7	585.4

EP 1 476 541 B1

(continued)

	IL-8 pg/ml	MCP-1 pg/ml
10ng/ml IFNg	170.8	652.6
control	203.0	292.3
U2OS 10ng/mL IFNg+100ng/mL r17L	106.8	357.0
10ng/mL IFNg+10ng/mL r17L	108.2	347.7
10ng/mL IFNg+1ng/mL r17L	109.9	293.3
10ng/ml IFNg	118.8	159.8
control	146.8	7.0

[0540] A549 cells produced IL-8 in response to zcytor17lig, however there was no effect of co-culturing cells with the addition of IFN gamma. U2OS cells made 20 fold more MCP-1 when cultured with IFNg and 50 fold more MCP-1 when cultured with IFN gamma + zcytor17lig.

Example 44

Zcytor17lig Effects on ³H-TdR Incorporation in DU145 Prostate Epithelial Carcinoma Cells

[0541] Cells were seeded in 96-well tissue clusters (Falcon) at a density of 25,000/well in MEM (Life Technologies) growth medium supplemented with glutamine, pyruvate, non-essential amino acids (Life Technologies) and 10% fetal bovine serum (Hyclone). At confluence (24 hours later), cells were switched to growth arrest media by substituting 0.1% BSA (Life Technologies) for serum. After 48 hours to achieve cell synchronization, the growth-arrest medium was replaced with fresh medium. Then, human recombinant zcytor17lig (test reagent) was added at various concentrations (from 0.24 to 60 ng/mL) (see Table 16 below), to test for the effect of the protein on basal DNA replication. Some wells received 2.5% FBS (Hyclone) in addition to zcytor17lig, in order to test effect of the protein on elevated levels of TdR incorporation. FBS 10% and 20ng/ml Platelet Derived Growth Factor-BB (PDGF-BB) (R&D) were used as positive control.

[0542] Eighteen hours following addition of zcytor17lig and the rest of the test reagents, cells were pulsed with 250 nCi/mL [³H]-thymidine (NEN) for 4 hours. Following the 4-hour pulse, media were discarded and 100 μL trypsin solution (Life Technologies) was added in each well to dislodge the cells. The radioactivity incorporated by DU145 was determined by harvesting the cells with a Packard Filtermate 196 cell harvester and by counting the incorporated label using a Packard TopCount NXT microplate scintillation counter.

[0543] As can be seen in Table 20 below, zcytor17lig induced thymidine incorporation in quiescent cells (in 0.1% BSA) in a concentration-dependent manner. This effect reached 2.5-fold of the BSA control at the highest concentration used, 60 ng/mL. In addition, this effect of zcytor17lig was also detectable when the baseline incorporation was elevated by the addition of 2.5% FBS (in this series as potent a mitogen as 10% FBS). These results therefore indicate that under both basal and stimulated conditions zcytor17lig can act as a mitogenic factor for the DU145 carcinoma cells.

[0544] Table 16 shows the effects of zcytor17lig on thymidine incorporation by DU145 cells. Results are expressed in cpm/well and numbers are the mean ± st.dev of triplicate wells.

Table 20

	<u>0.1 %BSA</u>	<u>2.5%FBS</u>
BSA Control	1139±336	4228±600
Zcytor17lig (0.24ng/mL)	1430±136	4894±1037
Zcytor17lig (0.74ng/mL)	1657±32	5038±810
Zcytor17lig (2.22ng/mL)	1646±57	5162±808
Zcytor17lig (6.67ng/mL)	2226±189	6385±1613
Zcytor17lig (20ng/mL)	2168±108	5880±1085
Zcytor17lig (60ng/mL)	2512±111	6165±417

EP 1 476 541 B1

(continued)

	0.1 %BSA	2.5%FBS
PDGF-BB (20ng/mL)	4094±202	5927±360

Example 45

Expression of huzcytor17lig in *E. coli*

A. Construction of expression vector pRPS01 that expresses huzcytor17Lig/MBP-6H fusion polypeptide

[0545] An expression plasmid containing a polynucleotide encoding a huzcytor17lig fused C-terminally to Maltose Binding Protein (MBP) was constructed via homologous recombination. The fusion polypeptide contains an N-terminal approximately 388 amino acid MBP portion fused to the huzcytor17Lig described herein. A fragment of huzcytor17lig cDNA was isolated using the PCR method as described herein. Two primers were used in the production of the zcytor17lig fragment in a standard PCR reaction: (1) one containing 40 bp of the vector flanking sequence and 20 bp corresponding to the amino terminus of the huzcytor17lig, and (2) another containing 40 bp of the 3' end corresponding to the flanking vector sequence and 20 bp corresponding to the carboxyl terminus of the huzcytor17lig. Two microliters of the 100 μ l PCR reaction was run on a 1.0% agarose gel with 1 x TBE buffer for analysis, and the expected molecular weight fragment was observed. The remaining PCR reaction was combined with the second PCR tube and precipitated with 400 μ l of absolute ethanol. The precipitated DNA was used for recombination into the Sma1 cut recipient vector pTAP98 to produce the construct encoding the MBP-huzcytor17lig fusion, as described below.

[0546] The vector pTAP98 was constructed using yeast homologous recombination. One hundred nanograms of EcoR1 cut pMAL-c2 was recombined with 1 μ g Pvu1 cut pRS316, 1 μ g linker, and 1 μ g Sca1/EcoR1 cut pRS316 were combined in a PCR reaction. PCR products were concentrated via 100% ethanol precipitation. The competent yeast cell (*S. cerevisiae*) strain, SF838-9D α , was combined with 10 μ l of a mixture containing approximately 1 μ g of the huzcytor17lig PCR product (above) and 100 ng of Sma1 digested pTAP98 vector, and electroporated at 0.75 kV, 25 μ F and ∞ ohms. The resulting reaction mixture was plated onto URA-D plates and incubated at 30°C.

[0547] After 48 hours, the Ura+ yeast transformants from a single plate were selected. DNA was isolated and transformed into electrocompetent *E. coli* cells (e.g., MC1061, Casadaban et. al. J. Mol. Biol. 138, 179-207). The resulting *E. coli* cells were plated on MM/CA +AMP 100 mg/L plates (Pryor and Leiting, Protein Expression and Purification 10: 309-319, 1997) using standard procedures. Four individual clones were harvested from the plates and inoculated into MM/CA with 100 μ g/ml Ampicillin for two hours at 37°C. One milliliter of each of the culture was induced with 1mM IPTG. Approximately 2-4 hours later, 250 μ l of each induced culture was mixed with 250 μ l acid washed glass beads and 250 μ l Thorner buffer with 5% β ME and dye (8M urea, 100 mM Tris pH7.0, 10% glycerol, 2mM EDTA, 5% SDS). Samples were vortexed for one minute and heated to 65°C for 10 minutes. Twenty microliters of each sample was loaded per lane on a 4%-12% PAGE gel (NOVEX). Gels were run in 1XMES buffer. The positive clones were designated pRPS01 and subjected to sequence analysis.

[0548] One microliter of sequencing DNA was used to transform electrocompetent *E. coli* cell strain MC1061. The cells were electropulsed at 2.0 kV, 25 μ F and 400 ohms. Following electroporation, cells were rescued 0.6 ml SOC and grown on LB+Amp plates at 37°C overnight, with 100 mg/L Ampicillin. Four cultures were induced with ITPG and screened for positives as described above. The positive clones were expanded for protein purification of the huzcytor17lig/MBP-6H fusion protein using standard techniques.

B. Purification of huzcytor17Lig/MBP-6H from *E. coli* fermentation

[0549] Unless otherwise noted, all operations were carried out at 4°C. The following procedure was used to purify recombinant huzcytor17Lig/MBP-6H polypeptide. *E. coli* cells containing the pRPS01 construct and expressing huzcytor17Lig/MBP-6H, were constructed using standard molecular biology methods and cultured in 50.0 g/L SuperBroth II (12 g/L Casien, 24 g/L Yeast Extract, 11.4 g/L di-potassium phosphate, 1.7 g/L Mono-potassium phosphate; Becton Dickenson, Cockeysville, MD), 5 g/L glycerol and 5 mL/L 1M Magnesium Sulfate. Twenty grams of cells were harvested and frozen for protein purification.

[0550] The thawed cells were resuspended in 500 mL Amylose Equilibration buffer (20mM Tris, 100mM NaCl, pH 8.0). A French Press cell breaking system (Constant Systems Ltd., Warwick, UK) with a temperature setting of -7°C to -10°C and 30K PSI was used to lyse the cells. The resuspended cells were assayed for breakage by A_{600} readings before and after cycling through the French Press. The processed cell suspension was pelleted at 10,000G for 30 minutes to remove the cellular debris and the supernatant was harvested for protein purification.

EP 1 476 541 B1

[0551] A 25 ml column of Amylose resin (New England Biolabs, Beverly, MA) (prepared as described below) was poured into a Bio-Rad, 2.5 cm D x 10 cm H glass column. The column was packed and equilibrated by gravity with 10 column volumes (CVs) of Amylose Equilibration buffer. The processed cell supernatant was batch loaded to the Amylose resin overnight, with rocking. The resin was returned to the Bio-Rad column and washed with 10 CV's of Amylose Equilibration buffer by gravity. The column was eluted with -2 CV of Amylose Elution buffer (Amylose Equilibration buffer + 10 mM Maltose, Fluka Biochemical, Switzerland) by gravity. Ten 5 mL fractions were collected over the elution profile and assayed for Absorbance at 280 and 320 nM. The Amylose resin was regenerated with 1 CV of distilled H₂O, 5 CVs of 0.1% (w/v) SDS (Sigma), 5 CVs of distilled H₂O, 5 CVs of Amylose Equilibration buffer and finally 1 CV of Amylose Storage buffer (Amylose Equilibration buffer + 0.02% Sodium Azide). The regenerated column was stored at 4°C.

[0552] Elution profile fractions of interest were pooled and dialyzed in a 10K dialysis chamber (Slide-A-Lyzer, Pierce Immunochemicals) against 4 x 4L PBS pH 7.4 (Sigma) over an 8 hour time period to remove low molecular weight contaminants, buffer exchange and desalt. Following dialysis, the material harvested represented the purified huzcytor17Lig/MBP-6H polypeptide. The purified huzcytor17Lig/MBP-6H polypeptide was filter sterilized and analyzed via SDS-PAGE Coomassie staining for an appropriate molecular weight product. The concentration of the huzcytor17Lig/MBP-6H polypeptide was determined by BCA analysis to be 1.28 mg/mL.

Example 46

Human zcytor17lig Polyclonal Antibody

A. Preparation and Purification

[0553] Polyclonal antibodies were prepared by immunizing 2 female New Zealand white rabbits with the purified recombinant protein hzcytor17L/MBP-6H (Example 45). The rabbits were each given an initial intraperitoneal (IP) injection of 200 µg of purified protein in Complete Freund's Adjuvant followed by booster IP injections of 100 µg protein in Incomplete Freund's Adjuvant every three weeks. Seven to ten days after the administration of the second booster injection (3 total injections), the animals were bled and the serum was collected. The animals were then boosted and bled every three weeks.

[0554] The hzcytor17L/MBP-6H specific rabbit serum was pre-adsorbed of anti-MBP antibodies using a CNBr-SEPHAROSE 4B protein column (Pharmacia LKB) that was prepared using 10 mg of non-specific purified recombinant MBP-fusion protein per gram of CNBr-SEPHAROSE. The hzcytor17L/MBP-6H-specific polyclonal antibodies were affinity purified from the pre-adsorbed rabbit serum using a CNBr-SEPHAROSE 4B protein column (Pharmacia LKB) that was prepared using 10 mg of the specific antigen purified recombinant protein hzcytor17L/MBP-6H. Following purification, the polyclonal antibodies were dialyzed with 4 changes of 20 times the antibody volume of PBS over a time period of at least 8 hours. Hzcytor17-Ligand-specific antibodies were characterized by ELISA using 500 ng/ml of the purified recombinant proteins hzcytor17L/MBP-6H or hzcytor17L-CEE produced in a baculovirus expression system as antibody targets. The lower limit of detection (LLD) of the rabbit anti-hzcytor17L/MBP-6H affinity purified antibody was 100 pg/ml on its specific purified recombinant antigen hzcytor17L/MBP-6H and 500 pg/ml on purified recombinant hzcytor17L-CEE produced in a baculovirus expression system.

B. SDS-PAGE and Western blotting analysis of Rabbit Anti-human ZcytoR17lig MBP-6H antibody

[0555] Rabbit Anti-human ZcytoR17lig MBP-6H antibody was tested by SDS-PAGE (NuPage 4-12%, Invitrogen, Carlsbad, CA) with coomassie staining method and Western blotting using goat anti-rabbit IgG-HRP. Human and mouse zcytor17lig purified protein (200-25 ng) was electrophoresed using an Invitrogen Novex's Xcell II mini-cell, and transferred to nitrocellulose (0.2 mm; Invitrogen, Carlsbad, CA) at room temperature using Novex's Xcell blot module with stirring according to directions provided in the instrument manual. The transfer was run at 300 mA for one hour in a buffer containing 25 mM Tris base, 200 mM glycine, and 20% methanol. The filter was then blocked with Western A buffer (in house, 50 mM Tris, pH 7.4, 5 mM EDTA, pH 8.0, 0.05% Igepal CA-630, 150 mM NaCl, and 0.25% gelatin) overnight with gentle rocking at 4°C. The nitrocellulose was quickly rinsed, then the rabbit anti-human zcytoR17lig MBP-6H (1:1000) was added in Western A buffer. The blot was incubated for 1.5 hours at room temperature with gentle rocking. The blot was rinsed 3 times for 5 minutes each in Western A, then goat anti-rabbit IgG HRP antibody (1:5000) was added in Western A buffer. The blot was incubated for 1 hour at room temperature with gentle rocking. The blot was rinsed 3 times for 5 minutes each in Western A, then quickly rinsed in H₂O. The blot was developed using commercially available chemiluminescent substrate reagents (ECLWestern blotting detection reagents 1 and 2 mixed 1:1; reagents obtained from Amersham Pharmacia Biotech, Buckinghamshire, England) and the blot was exposed to x-ray film for up to 5 minutes.

[0556] The purified human zcytor17lig appeared as a large band at about 30 kDa and a smaller band at about 20 kDa

EP 1 476 541 B1

under reduced conditions. The mouse zcytor17lig was not detected by the rabbit anti-human zcytor17lig antibody.

Example 47

5 Zcytor17lig Effects on U937 Monocyte Adhesion to Transformed Bone Marrow Endothelial Cell (TRBMEC) Monolayer

10 **[0557]** Transformed Bone Marrow Endothelial Cells (TRBMEC) were seeded in 96-well tissue clusters (Falcon) at a density of 25,000/well in medium M131 (Cascade Biologics) supplemented with Microvascular Growth Supplement (MVGS) (Cascade Biologics). At confluence (24 hours later), cells were switched to M199 (Gibco-Life Technologies) supplemented with 1% Fetal Bovine Serum (Hyclone). Human recombinant zcytor17lig (test reagent) was added at various concentrations (from 0.4 to 10 ng/mL) (see Table 21 below), to test for the effect of the protein on immune cell-endothelial cell interactions resulting in adhesion. Some wells received 0.3ng/ml Tumor Necrosis Factor (TNFalpha R&D Systems), a known pro-inflammatory cytokine, in addition to zcytor17lig, to test an effect of the protein on endothelial cells under inflammatory conditions. TNFalpha at 0.3ng/ml alone was used as positive control and the concentration used represents approximately 70% of the maximal TNFalpha effect in this system, i.e., it does not induce maximal adherence of U937 cells (a human monocyte-like cell line) to the endothelium. For this reason, this setup can detect both upregulation and downregulation of the TNFalpha effects. Basal levels of adhesion both with and without TNFalpha were used as baseline to assess effect of test reagents.

20 **[0558]** After overnight incubation of the endothelial cells with the test reagents (zcytor17ligand \pm TNFalpha), U937 cells, stained with 5 μ M Calcein-AM fluorescent marker (Molecular Probes), the cells were suspended in RPMI 1640 (no phenol-red) supplemented with 1% FBS and plated at 100,000 cells/well on the rinsed TRBMEC monolayer. Fluorescence levels at excitation/emission wavelengths of 485/538nm (Molecular Devices micro-plate reader, CytoFluor application) were measured 30 minutes later, before and after rinsing the well three times with warm RPMI 1640 (no phenol-red), to remove non-adherent U937. Pre-rinse (total) and post-rinse (adherence-specific) fluorescence levels were used to determine percent adherence (net adherent/net total x 100 = % adherence).

25 **[0559]** As can be seen in Table 21 below, zcytor17lig when added alone affected the basal adherence of U937 cells to the endothelial monolayers at the concentration range used (less than 2-fold increases, $p < 0.01$ by ANOVA test). By itself, the positive control, 0.3ng/mL TNFalpha, increased the adherence of U937 cells from a basal 5.8% to 35% (6-fold). In the presence of TNFalpha, zcytor17lig synergized with TNFalpha and further enhanced U937 adhesion in a concentration-dependent manner between 0.4 and 10ng/mL ($p < 0.01$ by ANOVA test). At 10ng/mL, zcytor17lig enhanced the effect of TNFalpha by 62%. These results indicate that zcytor17lig may by itself be a pro-inflammatory agent. Zcytor17lig was able to synergize with sub-maximal concentrations of TNFalpha to increase monocyte adherence to endothelial cells. These results also show that endothelial cells, especially when exposed to pro-inflammatory cytokines such as TNFalpha, are a likely target tissue of zcytor17lig action. The consequence of zcytor17ligand on endothelial cells may be to heighten monocyte or macrophage adhesion to a site of proinflammatory activity. Activated monocytes and macrophages are important in many inflammatory diseases. Therefore inhibition of monocyte/macrophage adhesions may provide a therapeutic rationale for zcytor17ligand antagonists. This data would support the use of zcytor17 ligand antagonists for treatment lung diseases, vascular diseases, autoimmunity, tumor metastasis, disease involving allergic reactions, wound healing and diseases of the skin including contact, allergic or non-allergic dermatistic or psoriasis and inflammatory bowel disease. Table 21 shows the effects of zcytor17lig on U937 monocyte adhesion to TRBMEC endothelial monolayers. Results are expressed in percent adhesion and numbers are the mean \pm st.dev of triplicate wells.

Table 21

	<i>Basal</i>	<i>0.3ng/mL TNFalpha</i>
Basal	5.8 \pm 1.2	35 \pm 5.5
zcytor17lig 0.4 ng/mL	9 \pm 0.7	44.7 \pm 2.5
zcytor17lig 1.1 ng/mL	10.4 \pm 0.8	45.2 \pm 0.6
zcytor17lig 3.3 ng/mL	7.9 \pm 1.7	51.1 \pm 4
zcytor17lig 10 ng/mL	9.5 \pm 0.5	56.6 \pm 3.9

SEQUENCE LISTING

55 **[0560]**

EP 1 476 541 B1

<110> ZymoGenetics Inc.

<120> NOVEL CYTOKINE ZCYTOR17 LIGAND

5 <130> 02-01PC

<150> US 60/350, 325

<151> 2002-01-18

10 <150> US 60/375.323

<151> 2002-04-25

<150> US 60/435.315

<151> 2002-12-19

15 <160> 168

<170> FastSEQ for Windows Version 3.0

20 <210> 1

<211> 904

<212> DNA

<213> Homo sapiens

25 <220>

<221> CDS

<222> (28)...(519)

<400> 1

30 ctgaagctgg ccttgctctc tctcgcc atg gcc tct cac tca ggc ccc tcg acg 54
Met Ala Ser His Ser Gly Pro Ser Thr

35

40

45

50

55

EP 1 476 541 B1

1

5

5 tct gtg ctc ttt ctg ttc tgc tgc ctg gga ggc tgg ctg gcc tcc cac 102
 Ser Val Leu Phe Leu Phe Cys Cys Leu Gly Gly Trp Leu Ala Ser His
 10 15 20 25

10 acg ttg ccc gtc cgt tta cta cga cca agt gat gat gta cag aaa ata 150
 Thr Leu Pro Val Arg Leu Leu Arg Pro Ser Asp Asp Val Gln Lys Ile
 30 35 40

15 gtc gag gaa tta cag tcc ctc tcg aag atg ctt ttg aaa gat gtg gag 198
 Val Glu Glu Leu Gln Ser Leu Ser Lys Met Leu Leu Lys Asp Val Glu
 45 50 55

20 gaa gag aag ggc gtg ctc gtg tcc cag aat tac acg ctg ccg tgt ctc 246
 Glu Glu Lys Gly Val Leu Val Ser Gln Asn Tyr Thr Leu Pro Cys Leu
 60 65 70

25 agc cct gac gcc cag ccg cca aac aac atc cac agc cca gcc atc cgg 294
 Ser Pro Asp Ala Gln Pro Pro Asn Asn Ile His Ser Pro Ala Ile Arg
 75 80 85

30 gca tat ctc aag aca atc aga cag cta gac aac aaa tct gtt att gat 342
 Ala Tyr Leu Lys Thr Ile Arg Gln Leu Asp Asn Lys Ser Val Ile Asp
 90 95 100 105

35 gag atc ata gag cac ctc gac aaa ctc ata ttt caa gat gca cca gaa 390
 Glu Ile Ile Glu His Leu Asp Lys Leu Ile Phe Gln Asp Ala Pro Glu
 110 115 120

40 aca aac att tct gtg cca aca gac acc cat gaa tgt aaa cgc ttc atc 438
 Thr Asn Ile Ser Val Pro Thr Asp Thr His Glu Cys Lys Arg Phe Ile
 125 130 135

45 ctg act att tct caa cag ttt tca gag tgc atg gac ctc gca cta aaa 486
 Leu Thr Ile Ser Gln Gln Phe Ser Glu Cys Met Asp Leu Ala Leu Lys
 140 145 150

50 tca ttg acc tct gga gcc caa cag gcc acc act taaggccatc tcttccttc 539
 Ser Leu Thr Ser Gly Ala Gln Gln Ala Thr Thr
 155 160

55 ggattggcag gaacttaagg agccttaaaa agatgaccga cagctaagtg tgggaactct 599

gccgtgattc ctaagtaca tttttccaat gaataatctc agggaccctt catatgggct 659
 agtccccgga gggctgagat gtgaatttgt gaattacctt gaaaaacatt aggttattgt 719
 5 tattagtctt ggtatttatg gaatgctttt ctctgcagg ctaagtctt acttattata 779
 ccctcgtgag ggtgggaggt ggcagctatg ttaatttatt gatatttatt gtactaagag 839
 ttgtcaatgc tccctggggg agccctcgga atctatttaa taaattatat tgaatttttc 899
 tcata 904

10

<210> 2
 <211> 164
 <212> PRT
 15 <213> Homo sapiens

<400> 2

20 Met Ala Ser His Ser Gly Pro Ser Thr Ser Val Leu Phe Leu Phe Cys
 1 5 10 15
 Cys Leu Gly Gly Trp Leu Ala Ser His Thr Leu Pro Val Arg Leu Leu
 20 25 30
 25 Arg Pro Ser Asp Asp Val Gln Lys Ile Val Glu Glu Leu Gln Ser Leu
 35 40 45
 Ser Lys Met Leu Leu Lys Asp Val Glu Glu Glu Lys Gly Val Leu Val
 50 55 60
 30 Ser Gln Asn Tyr Thr Leu Pro Cys Leu Ser Pro Asp Ala Gln Pro Pro
 65 70 75 80
 Asn Asn Ile His Ser Pro Ala Ile Arg Ala Tyr Leu Lys Thr Ile Arg
 85 90 95
 35 Gln Leu Asp Asn Lys Ser Val Ile Asp Glu Ile Ile Glu His Leu Asp
 100 105 110
 Lys Leu Ile Phe Gln Asp Ala Pro Glu Thr Asn Ile Ser Val Pro Thr
 115 120 125
 40 Asp Thr His Glu Cys Lys Arg Phe Ile Leu Thr Ile Ser Gln Gln Phe
 130 135 140
 Ser Glu Cys Met Asp Leu Ala Leu Lys Ser Leu Thr Ser Gly Ala Gln
 145 150 155 160
 45 Gln Ala Thr Thr

<210> 3
 <211> 492
 50 <212> DNA
 <213> Artificial Sequence

<220>

55 <223> human zcytor17lig degenerate polynucleotide of SEQ ID NO:2

<221> misc_feature
 <222> (1)...(492)

EP 1 476 541 B1

<223> n = A,T,C or G

<400> 3

5 atggcnwsnc aywsnggncc nwsnacnwsn gtnytnttyy tnttytgytg yytngngngn 60
 tgytngcnw sncaayacny t nccngtnmgn ytnytmgnc cnwsngayga ygtncaraar 120
 athgtngarg arytnarws nytnwsnaar atgytnytna argaygtnga rgargaraar 180
 10 ggngtnytng twnsncaraa ytayacnytn ccntgyytrw snccngaygc ncarccnccn 240
 aayaayathc aywsnccngc nathmgngcn tayytnaara cnathmgnc rytngayaay 300
 aarwsngtna thgaygarat hathgaray ytngayaary tnathttyca rgaygcncn 360
 garacnaaya thwsngtncc nacngayacn caygartgya armgnttyat hytnacnath 420
 15 wsnarcart tywsngartg yatggayytn gcnytnaarw snytnacnws ngngncncar 480
 cargcnacna cn 492

<210> 4

<211> 2903

20 <212> DNA

<213> Homo sapiens

<220>

<221> CDS

25 <222> (497)...(2482)

<400> 4

30 tgaaaagaca tgtgtgtgca gtatgaaaat tgagacagga aggcagagtg tcagcttgtt 60
 ccacctcagc tgggaatgtg catcaggcaa ctcaagtttt tcaccacggc atgtgtctgt 120
 gaatgtccgc aaaacattag tttcactctt gtcgccaggt tggagtacaa tggcacgac 180
 ttggctcact gcaacctctg cctcccgggt tcaagcgatt ctctgcctc agcctcccga 240
 35 gtagctggga ttacagtaa caataatgca atccatttcc cagcataagt gggtaagtgc 300
 cactttgact tgggctgggc ttaaaagcac aagaaaagct cgcagacaat cagagtggaa 360
 aactcccac atcttagtgt ggataaatta aagtccagat tgttcttctt gtctgactt 420
 gtgctgtggg aggtggagtt gcctttgatg caaatccttt gagccagcag aacatctgtg 480
 40 gaacatcccc tgatac atg aag ctc tct ccc cag cct tca tgt gtt aac ctg 532
 Met Lys Leu Ser Pro Gln Pro Ser Cys Val Asn Leu
 1 5 10

45 ggg atg atg tgg acc tgg gca ctg tgg atg ctc cct tca ctc tgc aaa 580
 Gly Met Met Trp Thr Trp Ala Leu Trp Met Leu Pro Ser Leu Cys Lys
 15 20 25

50

55

EP 1 476 541 B1

5 ttc agc ctg gca gct ctg cca gct aag cct gag aac att tcc tgt gtc 628
 Phe Ser Leu Ala Ala Leu Pro Ala Lys Pro Glu Asn Ile Ser Cys Val
 30 35 40

10 tac tac tat agg aaa aat tta acc tgc act tgg agt cca gga aag gaa 676
 Tyr Tyr Tyr Arg Lys Asn Leu Thr Cys Thr Trp Ser Pro Gly Lys Glu
 45 50 55 60

15 acc agt tat acc cag tac aca gtt aag aga act tac gct ttt gga gaa 724
 Thr Ser Tyr Thr Gln Tyr Thr Val Lys Arg Thr Tyr Ala Phe Gly Glu
 65 70 75

20 aaa cat gat aat tgt aca acc aat agt tct aca agt gaa aat cgt gct 772
 Lys His Asp Asn Cys Thr Thr Asn Ser Ser Thr Ser Glu Asn Arg Ala
 80 85 90

25 tcg tgc tct ttt ttc ctt cca aga ata acg atc cca gat aat tat acc 820
 Ser Cys Ser Phe Phe Leu Pro Arg Ile Thr Ile Pro Asp Asn Tyr Thr
 95 100 105

30 att gag gtg gaa gct gaa aat gga gat ggt gta att aaa tct cat atg 868
 Ile Glu Val Glu Ala Glu Asn Gly Asp Gly Val Ile Lys Ser His Met
 110 115 120

35 aca tac tgg aga tta gag aac ata gcg aaa act gaa cca cct aag att 916
 Thr Tyr Trp Arg Leu Glu Asn Ile Ala Lys Thr Glu Pro Pro Lys Ile
 125 130 135 140

40 ttc cgt gtg aaa cca gtt ttg ggc atc aaa cga atg att caa att gaa 964
 Phe Arg Val Lys Pro Val Leu Gly Ile Lys Arg Met Ile Gln Ile Glu
 145 150 155

45 tgg ata aag cct gag ttg gcg cct gtt tca tct gat tta aaa tac aca 1012
 Trp Ile Lys Pro Glu Leu Ala Pro Val Ser Ser Asp Leu Lys Tyr Thr
 160 165 170

50 ctt cga ttc agg aca gtc aac agt acc agc tgg atg gaa gtc aac ttc 1060
 Leu Arg Phe Arg Thr Val Asn Ser Thr Ser Trp Met Glu Val Asn Phe
 175 180 185

55 gct aag aac cgt aag gat aaa aac caa acg tac aac ctc acg ggg ctg 1108
 Ala Lys Asn Arg Lys Asp Lys Asn Gln Thr Tyr Asn Leu Thr Gly Leu

EP 1 476 541 B1

	190		195		200		
5	cag cct ttt aca gaa tat gtc ata gct ctg cga tgt gcg gtc aag gag						1156
	Gln Pro Phe Thr Glu Tyr Val Ile Ala Leu Arg Cys Ala Val Lys Glu						
	205		210		215		220
10	tca aag ttc tgg agt gac tgg agc caa gaa aaa atg gga atg act gag						1204
	Ser Lys Phe Trp Ser Asp Trp Ser Gln Glu Lys Met Gly Met Thr Glu						
			225		230		235
15	gaa gaa gct cca tgt ggc ctg gaa ctg tgg aga gtc ctg aaa cca gct						1252
	Glu Glu Ala Pro Cys Gly Leu Glu Leu Trp Arg Val Leu Lys Pro Ala						
			240		245		250
20	gag gcg gat gga aga agg cca gtg cgg ttg tta tgg aag aag gca aga						1300
	Glu Ala Asp Gly Arg Arg Pro Val Arg Leu Leu Trp Lys Lys Ala Arg						
			255		260		265
25	gga gcc cca gtc cta gag aaa aca ctt ggc tac aac ata tgg tac tat						1348
	Gly Ala Pro Val Leu Glu Lys Thr Leu Gly Tyr Asn Ile Trp Tyr Tyr						
			270		275		280
30	cca gaa agc aac act aac ctc aca gaa aca atg aac act act aac cag						1396
	Pro Glu Ser Asn Thr Asn Leu Thr Glu Thr Met Asn Thr Thr Asn Gln						
			285		290		295
35	cag ctt gaa ctg cat ctg gga ggc gag agc ttt tgg gtg tct atg att						1444
	Gln Leu Glu Leu His Leu Gly Gly Glu Ser Phe Trp Val Ser Met Ile						
			305		310		315
40	tct tat aat tct ctt ggg aag tct cca gtg gcc acc ctg agg att cca						1492
	Ser Tyr Asn Ser Leu Gly Lys Ser Pro Val Ala Thr Leu Arg Ile Pro						
			320		325		330
45	gct att caa gaa aaa tca ttt cag tgc att gag gtc atg cag gcc tgc						1540
	Ala Ile Gln Glu Lys Ser Phe Gln Cys Ile Glu Val Met Gln Ala Cys						
			335		340		345
50	gtt gct gag gac cag cta gtg gtg aag tgg caa agc tct gct cta gac						1588
	Val Ala Glu Asp Gln Leu Val Val Lys Trp Gln Ser Ser Ala Leu Asp						
			350		355		360
55	gtg aac act tgg atg att gaa tgg ttt ccg gat gtg gac tca gag ccc						1636

EP 1 476 541 B1

Val Asn Thr Trp Met Ile Glu Trp Phe Pro Asp Val Asp Ser Glu Pro
 365 370 375 380

5
 acc acc ctt tcc tgg gaa tct gtg tct cag gcc acg aac tgg acg atc 1684
 Thr Thr Leu Ser Trp Glu Ser Val Ser Gln Ala Thr Asn Trp Thr Ile
 385 390 395

10
 cag caa gat aaa tta aaa cct ttc tgg tgc tat aac atc tct gtg tat 1732
 Gln Gln Asp Lys Leu Lys Pro Phe Trp Cys Tyr Asn Ile Ser Val Tyr
 400 405 410

15
 cca atg ttg cat gac aaa gtt ggc gag cca tat tcc atc cag gct tat 1780
 Pro Met Leu His Asp Lys Val Gly Glu Pro Tyr Ser Ile Gln Ala Tyr
 415 420 425

20
 gcc aaa gaa ggc gtt cca tca gaa ggt cct gag acc aag gtg gag aac 1828
 Ala Lys Glu Gly Val Pro Ser Glu Gly Pro Glu Thr Lys Val Glu Asn
 430 435 440

25
 att ggc gtg aag acg gtc acg atc aca tgg aaa gag att ccc aag agt 1876
 Ile Gly Val Lys Thr Val Thr Ile Thr Trp Lys Glu Ile Pro Lys Ser
 445 450 455 460

30
 gag aga aag ggt atc atc tgc aac tac acc atc ttt tac caa gct gaa 1924
 Glu Arg Lys Gly Ile Ile Cys Asn Tyr Thr Ile Phe Tyr Gln Ala Glu
 465 470 475

35
 ggt gga aaa gga ttc tcc aag aca gtc aat tcc agc atc ttg cag tac 1972
 Gly Gly Lys Gly Phe Ser Lys Thr Val Asn Ser Ser Ile Leu Gln Tyr
 480 485 490

40
 ggc ctg gag tcc ctg aaa cga aag acc tct tac att gtt cag gtc atg 2020
 Gly Leu Glu Ser Leu Lys Arg Lys Thr Ser Tyr Ile Val Gln Val Met
 495 500 505

45
 gcc agc acc agt gct ggg gga acc aac ggg acc agc ata aat ttc aag 2068
 Ala Ser Thr Ser Ala Gly Gly Thr Asn Gly Thr Ser Ile Asn Phe Lys
 510 515 520

50
 aca ttg tca ttc agt gtc ttt gag att atc ctc ata act tct ctg att 2116
 Thr Leu Ser Phe Ser Val Phe Glu Ile Ile Leu Ile Thr Ser Leu Ile
 525 530 535 540

55

EP 1 476 541 B1

5 ggt gga ggc ctt ctt att ctc att atc ctg aca gtg gca tat ggt ctc 2164
 Gly Gly Gly Leu Leu Ile Leu Ile Ile Leu Thr Val Ala Tyr Gly Leu
 545 550 555

10 aaa aaa ccc aac aaa ttg act cat ctg tgt tgg ccc acc gtt ccc aac 2212
 Lys Lys Pro Asn Lys Leu Thr His Leu Cys Trp Pro Thr Val Pro Asn
 560 565 570

15 cct gct gaa agt agt ata gcc aca tgg cat gga gat gat ttc aag gat 2260
 Pro Ala Glu Ser Ser Ile Ala Thr Trp His Gly Asp Asp Phe Lys Asp
 575 580 585

20 aag cta aac ctg aag gag tct gat gac tct gtg aac aca gaa gac agg 2308
 Lys Leu Asn Leu Lys Glu Ser Asp Asp Ser Val Asn Thr Glu Asp Arg
 590 595 600

25 atc tta aaa cca tgt tcc acc ccc agt gac aag ttg gtg att gac aag 2356
 Ile Leu Lys Pro Cys Ser Thr Pro Ser Asp Lys Leu Val Ile Asp Lys
 605 610 615 620

30 ttg gtg gtg aac ttt ggg aat gtt ctg caa gaa att ttc aca gat gaa 2404
 Leu Val Val Asn Phe Gly Asn Val Leu Gln Glu Ile Phe Thr Asp Glu
 625 630 635

35 gcc aga acg ggt cag gaa aac aat tta gga ggg gaa aag aat ggg act 2452
 Ala Arg Thr Gly Gln Glu Asn Asn Leu Gly Gly Glu Lys Asn Gly Thr
 640 645 650

40 aga att ctg tct tcc tgc cca act tca ata taagtgtgga ctaaaatgcg 2502
 Arg Ile Leu Ser Ser Cys Pro Thr Ser Ile
 655 660

45 agaaaggtgt cctgtggtct atgcaaatta gaaaggacat gcagagtttt ccaactagga 2562
 agactgaatc tgtggcccca agagaaccat ctctgaagac tgggtatgtg gtcttttcca 2622
 cacatggacc acctacggat gcaatctgta atgcatgtgc atgagaagtc tgttattaag 2682
 tagagtgtga aaacatggtt atggtaatag gaacagcttt taaaatgctt ttgtatttgg 2742
 gcctttcata caaaaaagcc ataataccat tttcatgtaa tgctatactt ctatactatt 2802
 50 ttcattgtaat actatacttc tatactattt tcatgtaata ctatacttct atactatatt 2862
 catgtaatac tatacttcta tattaagtt ttaccactc a 2903

55 <210> 5
 <211> 662
 <212> PRT
 <213> Homo sapiens

<400> 5

5 Met Lys Leu Ser Pro Gln Pro Ser Cys Val Asn Leu Gly Met Met Trp
 1 5 10 15
 Thr Trp Ala Leu Trp Met Leu Pro Ser Leu Cys Lys Phe Ser Leu Ala
 20 25 30
 10 Ala Leu Pro Ala Lys Pro Glu Asn Ile Ser Cys Val Tyr Tyr Tyr Arg
 35 40 45
 Lys Asn Leu Thr Cys Thr Trp Ser Pro Gly Lys Glu Thr Ser Tyr Thr
 50 55 60
 15 Gln Tyr Thr Val Lys Arg Thr Tyr Ala Phe Gly Glu Lys His Asp Asn
 65 70 75 80
 Cys Thr Thr Asn Ser Ser Thr Ser Glu Asn Arg Ala Ser Cys Ser Phe
 85 90 95
 20 Phe Leu Pro Arg Ile Thr Ile Pro Asp Asn Tyr Thr Ile Glu Val Glu
 100 105 110
 Ala Glu Asn Gly Asp Gly Val Ile Lys Ser His Met Thr Tyr Trp Arg
 115 120 125
 25 Leu Glu Asn Ile Ala Lys Thr Glu Pro Pro Lys Ile Phe Arg Val Lys
 130 135 140
 Pro Val Leu Gly Ile Lys Arg Met Ile Gln Ile Glu Trp Ile Lys Pro
 145 150 155 160
 30 Glu Leu Ala Pro Val Ser Ser Asp Leu Lys Tyr Thr Leu Arg Phe Arg
 165 170 175
 Thr Val Asn Ser Thr Ser Trp Met Glu Val Asn Phe Ala Lys Asn Arg
 180 185 190
 35 Lys Asp Lys Asn Gln Thr Tyr Asn Leu Thr Gly Leu Gln Pro Phe Thr
 195 200 205
 Glu Tyr Val Ile Ala Leu Arg Cys Ala Val Lys Glu Ser Lys Phe Trp
 210 215 220
 40 Ser Asp Trp Ser Gln Glu Lys Met Gly Met Thr Glu Glu Glu Ala Pro
 225 230 235 240
 Cys Gly Leu Glu Leu Trp Arg Val Leu Lys Pro Ala Glu Ala Asp Gly
 245 250 255
 45 Arg Arg Pro Val Arg Leu Leu Trp Lys Lys Ala Arg Gly Ala Pro Val
 260 265 270
 Leu Glu Lys Thr Leu Gly Tyr Asn Ile Trp Tyr Tyr Pro Glu Ser Asn
 275 280 285
 50 Thr Asn Leu Thr Glu Thr Met Asn Thr Thr Asn Gln Gln Leu Glu Leu
 290 295 300
 His Leu Gly Gly Glu Ser Phe Trp Val Ser Met Ile Ser Tyr Asn Ser
 305 310 315 320
 55

EP 1 476 541 B1

Leu Gly Lys Ser Pro Val Ala Thr Leu Arg Ile Pro Ala Ile Gln Glu
 325 330 335
 5 Lys Ser Phe Gln Cys Ile Glu Val Met Gln Ala Cys Val Ala Glu Asp
 340 345 350
 Gln Leu Val Val Lys Trp Gln Ser Ser Ala Leu Asp Val Asn Thr Trp
 355 360 365
 10 Met Ile Glu Trp Phe Pro Asp Val Asp Ser Glu Pro Thr Thr Leu Ser
 370 375 380
 Trp Glu Ser Val Ser Gln Ala Thr Asn Trp Thr Ile Gln Gln Asp Lys
 385 390 395 400
 15 Leu Lys Pro Phe Trp Cys Tyr Asn Ile Ser Val Tyr Pro Met Leu His
 405 410 415
 Asp Lys Val Gly Glu Pro Tyr Ser Ile Gln Ala Tyr Ala Lys Glu Gly
 420 425 430
 20 Val Pro Ser Glu Gly Pro Glu Thr Lys Val Glu Asn Ile Gly Val Lys
 435 440 445
 Thr Val Thr Ile Thr Trp Lys Glu Ile Pro Lys Ser Glu Arg Lys Gly
 450 455 460
 25 Ile Ile Cys Asn Tyr Thr Ile Phe Tyr Gln Ala Glu Gly Gly Lys Gly
 465 470 475 480
 Phe Ser Lys Thr Val Asn Ser Ser Ile Leu Gln Tyr Gly Leu Glu Ser
 485 490 495
 30 Leu Lys Arg Lys Thr Ser Tyr Ile Val Gln Val Met Ala Ser Thr Ser
 500 505 510
 Ala Gly Gly Thr Asn Gly Thr Ser Ile Asn Phe Lys Thr Leu Ser Phe
 515 520 525
 35 Ser Val Phe Glu Ile Ile Leu Ile Thr Ser Leu Ile Gly Gly Gly Leu
 530 535 540
 Leu Ile Leu Ile Ile Leu Thr Val Ala Tyr Gly Leu Lys Lys Pro Asn
 545 550 555 560
 40 Lys Leu Thr His Leu Cys Trp Pro Thr Val Pro Asn Pro Ala Glu Ser
 565 570 575
 Ser Ile Ala Thr Trp His Gly Asp Asp Phe Lys Asp Lys Leu Asn Leu
 580 585 590
 45 Lys Glu Ser Asp Asp Ser Val Asn Thr Glu Asp Arg Ile Leu Lys Pro
 595 600 605
 Cys Ser Thr Pro Ser Asp Lys Leu Val Ile Asp Lys Leu Val Val Asn
 610 615 620
 50 Phe Gly Asn Val Leu Gln Glu Ile Phe Thr Asp Glu Ala Arg Thr Gly
 625 630 635 640
 Gln Glu Asn Asn Leu Gly Gly Glu Lys Asn Gly Thr Arg Ile Leu Ser
 645 650 655
 55 Ser Cys Pro Thr Ser Ile

660

5 <210> 6
 <211> 2964
 <212> DNA
 <213> Homo sapiens

10 <220>
 <221> CDS
 <222> (13)...(2949)

15 <400> 6

gaattcgcca cc atg gct cta ttt gca gtc ttt cag aca aca ttc ttc tta 51
 Met Ala Leu Phe Ala Val Phe Gln Thr Thr Phe Phe Leu
 1 5 10

20 aca ttg ctg tcc ttg agg act tac cag agt gaa gtc ttg gct gaa cgt 99
 Thr Leu Leu Ser Leu Arg Thr Tyr Gln Ser Glu Val Leu Ala Glu Arg
 15 20 25

25 tta cca ttg act cct gta tca ctt aaa gtt tcc acc aat tct acg cgt 147
 Leu Pro Leu Thr Pro Val Ser Leu Lys Val Ser Thr Asn Ser Thr Arg
 30 35 40 45

35 cag agt ttg cac tta caa tgg act gtc cac aac ctt cct tat cat cag 195
 Gln Ser Leu His Leu Gln Trp Thr Val His Asn Leu Pro Tyr His Gln
 50 55 60

40 gaa ttg aaa atg gta ttt cag atc cag atc agt agg att gaa aca tcc 243
 Glu Leu Lys Met Val Phe Gln Ile Gln Ile Ser Arg Ile Glu Thr Ser
 65 70 75

45 aat gtc atc tgg gtg ggg aat tac agc acc act gtg aag tgg aac cag 291
 Asn Val Ile Trp Val Gly Asn Tyr Ser Thr Thr Val Lys Trp Asn Gln
 80 85 90

50 gtt ctg cat tgg agc tgg gaa tct gag ctc cct ttg gaa tgt gcc aca 339
 Val Leu His Trp Ser Trp Glu Ser Glu Leu Pro Leu Glu Cys Ala Thr
 95 100 105

55 cac ttt gta aga ata aag agt ttg gtg gac gat gcc aag ttc cct gag 387
 His Phe Val Arg Ile Lys Ser Leu Val Asp Asp Ala Lys Phe Pro Glu

EP 1 476 541 B1

	110		115			120		125	
5	cca aat ttc tgg agc aac tgg agt tcc tgg gag gaa gtc agt gta caa								435
	Pro Asn Phe Trp Ser Asn Trp Ser Ser Trp Glu Glu Val Ser Val Gln								
			130			135		140	
10	gat tct act gga cag gat ata ttg ttc gtt ttc cct aaa gat aag ctg								483
	Asp Ser Thr Gly Gln Asp Ile Leu Phe Val Phe Pro Lys Asp Lys Leu								
		145		150		155			
15	gtg gaa gaa ggc acc aat gtt acc att tgt tac gtt tct agg aac att								531
	Val Glu Glu Gly Thr Asn Val Thr Ile Cys Tyr Val Ser Arg Asn Ile								
		160		165		170			
20	caa aat aat gta tcc tgt tat ttg gaa ggg aaa cag att cat gga gaa								579
	Gln Asn Asn Val Ser Cys Tyr Leu Glu Gly Lys Gln Ile His Gly Glu								
		175		180		185			
25	caa ctt gat cca cat gta act gca ttc aac ttg aat agt gtg cct ttc								627
	Gln Leu Asp Pro His Val Thr Ala Phe Asn Leu Asn Ser Val Pro Phe								
		190		195		200		205	
30	att agg aat aaa ggg aca aat atc tat tgt gag gca agt caa gga aat								675
	Ile Arg Asn Lys Gly Thr Asn Ile Tyr Cys Glu Ala Ser Gln Gly Asn								
			210		215		220		
35	gtc agt gaa ggc atg aaa ggc atc gtt ctt ttt gtc tca aaa gta ctt								723
	Val Ser Glu Gly Met Lys Gly Ile Val Leu Phe Val Ser Lys Val Leu								
		225		230		235			
40	gag gag ccc aag gac ttt tct tgt gaa acc gag gac ttc aag act ttg								771
	Glu Glu Pro Lys Asp Phe Ser Cys Glu Thr Glu Asp Phe Lys Thr Leu								
		240		245		250			
45	cac tgt act tgg gat cct ggg acg gac act gcc ttg ggg tgg tct aaa								819
	His Cys Thr Trp Asp Pro Gly Thr Asp Thr Ala Leu Gly Trp Ser Lys								
		255		260		265			
50	caa cct tcc caa agc tac act tta ttt gaa tca ttt tct ggg gaa aag								867
	Gln Pro Ser Gln Ser Tyr Thr Leu Phe Glu Ser Phe Ser Gly Glu Lys								
		270		275		280		285	
55	aaa ctt tgt aca cac aaa aac tgg tgt aat tgg caa ata act caa gac								915

EP 1 476 541 B1

Lys Leu Cys Thr His Lys Asn Trp Cys Asn Trp Gln Ile Thr Gln Asp
 290 295 300

5
 tca caa gaa acc tat aac ttc aca ctc ata gct gaa aat tac tta agg 963
 Ser Gln Glu Thr Tyr Asn Phe Thr Leu Ile Ala Glu Asn Tyr Leu Arg
 305 310 315

10
 aag aga agt gtc aat atc ctt ttt aac ctg act cat cga gtt tat tta 1011
 Lys Arg Ser Val Asn Ile Leu Phe Asn Leu Thr His Arg Val Tyr Leu
 320 325 330

15
 atg aat cct ttt agt gtc aac ttt gaa aat gta aat gcc aca aat gcc 1059
 Met Asn Pro Phe Ser Val Asn Phe Glu Asn Val Asn Ala Thr Asn Ala
 335 340 345

20
 atc atg acc tgg aag gtg cac tcc ata agg aat aat ttc aca tat ttg 1107
 Ile Met Thr Trp Lys Val His Ser Ile Arg Asn Asn Phe Thr Tyr Leu
 350 355 360 365

25
 tgt cag att gaa ctc cat ggt gaa gga aaa atg atg caa tac aat gtt 1155
 Cys Gln Ile Glu Leu His Gly Glu Gly Lys Met Met Gln Tyr Asn Val
 370 375 380

30
 tcc atc aag gtg aac ggt gag tac ttc tta agt gaa ctg gaa cct gcc 1203
 Ser Ile Lys Val Asn Gly Glu Tyr Phe Leu Ser Glu Leu Glu Pro Ala
 385 390 395

35
 aca gag tac atg gcg cga gta cgg tgt gct gat gcc agc cac ttc tgg 1251
 Thr Glu Tyr Met Ala Arg Val Arg Cys Ala Asp Ala Ser His Phe Trp
 400 405 410

40
 aaa tgg agt gaa tgg agt ggt cag aac ttc acc aca ctt gaa gct gct 1299
 Lys Trp Ser Glu Trp Ser Gly Gln Asn Phe Thr Thr Leu Glu Ala Ala
 415 420 425

45
 ccc tca gag gcc cct gat gtc tgg aga att gtg agc ttg gag cca gga 1347
 Pro Ser Glu Ala Pro Asp Val Trp Arg Ile Val Ser Leu Glu Pro Gly
 430 435 440 445

50
 aat cat act gtg acc tta ttc tgg aag cca tta tca aaa ctg cat gcc 1395
 Asn His Thr Val Thr Leu Phe Trp Lys Pro Leu Ser Lys Leu His Ala
 450 455 460

55

EP 1 476 541 B1

5	aat gga aag atc ctg ttc tat aat gta gtt gta gaa aac cta gac aaa Asn Gly Lys Ile Leu Phe Tyr Asn Val Val Val Glu Asn Leu Asp Lys	1443
	465 470 475	
10	cca tcc agt tca gag ctc cat tcc att cca gca cca gcc aac agc aca Pro Ser Ser Ser Glu Leu His Ser Ile Pro Ala Pro Ala Asn Ser Thr	1491
	480 485 490	
15	aaa cta atc ctt gac agg tgt tcc tac caa atc tgc gtc ata gcc aac Lys Leu Ile Leu Asp Arg Cys Ser Tyr Gln Ile Cys Val Ile Ala Asn	1539
	495 500 505	
20	aac agt gtg ggt gct tct cct gct tct gta ata gtc atc tct gca gac Asn Ser Val Gly Ala Ser Pro Ala Ser Val Ile Val Ile Ser Ala Asp	1587
	510 515 520 525	
25	ccc gaa aac aaa gag gtt gag gaa gaa aga att gca ggc aca gag ggt Pro Glu Asn Lys Glu Val Glu Glu Glu Arg Ile Ala Gly Thr Glu Gly	1635
	530 535 540	
30	gga ttc tct ctg tct tgg aaa ccc caa cct gga gat gtt ata ggc tat Gly Phe Ser Leu Ser Trp Lys Pro Gln Pro Gly Asp Val Ile Gly Tyr	1683
	545 550 555	
35	gtt gtg gac tgg tgt gac cat acc cag gat gtg ctc ggt gat ttc cag Val Val Asp Trp Cys Asp His Thr Gln Asp Val Leu Gly Asp Phe Gln	1731
	560 565 570	
40	tgg aag aat gta ggt ccc aat acc aca agc aca gtc att agc aca gat Trp Lys Asn Val Gly Pro Asn Thr Thr Ser Thr Val Ile Ser Thr Asp	1779
	575 580 585	
45	gct ttt agg cca gga gtt cga tat gac ttc aga att tat ggg tta tct Ala Phe Arg Pro Gly Val Arg Tyr Asp Phe Arg Ile Tyr Gly Leu Ser	1827
	590 595 600 605	
50	aca aaa agg att gct tgt tta tta gag aaa aaa aca gga tac tct cag Thr Lys Arg Ile Ala Cys Leu Leu Glu Lys Lys Thr Gly Tyr Ser Gln	1875
	610 615 620	
55	gaa ctt gct cct tca gac aac cct cac gtg ctg gtg gat aca ttg aca Glu Leu Ala Pro Ser Asp Asn Pro His Val Leu Val Asp Thr Leu Thr	1923
	625 630 635	

EP 1 476 541 B1

5 tcc cac tcc ttc act ctg agt tgg aaa gat tac tct act gaa tct caa 1971
 Ser His Ser Phe Thr Leu Ser Trp Lys Asp Tyr Ser Thr Glu Ser Gln
 640 645 650

10 cct ggt ttt ata caa ggg tac cat gtc tat ctg aaa tcc aag gcg agg 2019
 Pro Gly Phe Ile Gln Gly Tyr His Val Tyr Leu Lys Ser Lys Ala Arg
 655 660 665

15 cag tgc cac cca cga ttt gaa aag gca gtt ctt tca gat ggt tca gaa 2067
 Gln Cys His Pro Arg Phe Glu Lys Ala Val Leu Ser Asp Gly Ser Glu
 670 675 680 685

20 tgt tgc aaa tac aaa att gac aac ccg gaa gaa aag gca ttg att gtg 2115
 Cys Cys Lys Tyr Lys Ile Asp Asn Pro Glu Glu Lys Ala Leu Ile Val
 690 695 700

25 gac aac cta aag cca gaa tcc ttc tat gag ttt ttc atc act cca ttc 2163
 Asp Asn Leu Lys Pro Glu Ser Phe Tyr Glu Phe Phe Ile Thr Pro Phe
 705 710 715

30 act agt gct ggt gaa ggc ccc agt gct acg ttc acg aag gtc acg act 2211
 Thr Ser Ala Gly Glu Gly Pro Ser Ala Thr Phe Thr Lys Val Thr Thr
 720 725 730

35 ccg gat gaa cac tcc tcg atg ctg att cat atc cta ctg ccc atg gtt 2259
 Pro Asp Glu His Ser Ser Met Leu Ile His Ile Leu Leu Pro Met Val
 735 740 745

40 ttc tgc gtc ttg ctc atc atg gtc atg tgc tac ttg aaa agt cag tgg 2307
 Phe Cys Val Leu Leu Ile Met Val Met Cys Tyr Leu Lys Ser Gln Trp
 750 755 760 765

45 atc aag gag acc tgt tat cct gac atc cct gac cct tac aag agc agc 2355
 Ile Lys Glu Thr Cys Tyr Pro Asp Ile Pro Asp Pro Tyr Lys Ser Ser
 770 775 780

50 atc ctg tca tta ata aaa ttc aag gag aac cct cac cta ata ata atg 2403
 Ile Leu Ser Leu Ile Lys Phe Lys Glu Asn Pro His Leu Ile Ile Met
 785 790 795

55 aat gtc agt gac tgt atc cca gat gct att gaa gtt gta agc aag cca 2451
 Asn Val Ser Asp Cys Ile Pro Asp Ala Ile Glu Val Val Ser Lys Pro

EP 1 476 541 B1

	800	805	810	
5	gaa ggg aca aag ata cag ttc cta ggc act agg aag tca ctc aca gaa Glu Gly Thr Lys Ile Gln Phe Leu Gly Thr Arg Lys Ser Leu Thr Glu 815	820	825	2499
10	acc gag ttg act aag cct aac tac ctt tat ctc ctt cca aca gaa aag Thr Glu Leu Thr Lys Pro Asn Tyr Leu Tyr Leu Leu Pro Thr Glu Lys 830	835	840	2547
15	aat cac tct ggc cct ggc ccc tgc atc tgt ttt gag aac ttg acc tat Asn His Ser Gly Pro Gly Pro Cys Ile Cys Phe Glu Asn Leu Thr Tyr 850	855	860	2595
20	aac cag gca gct tct gac tct ggc tct tgt ggc cat gtt cca gta tcc Asn Gln Ala Ala Ser Asp Ser Gly Ser Cys Gly His Val Pro Val Ser 865	870	875	2643
25	cca aaa gcc cca agt atg ctg gga cta atg acc tca cct gaa aat gta Pro Lys Ala Pro Ser Met Leu Gly Leu Met Thr Ser Pro Glu Asn Val 880	885	890	2691
30	cta aag gca cta gaa aaa aac tac atg aac tcc ctg gga gaa atc cca Leu Lys Ala Leu Glu Lys Asn Tyr Met Asn Ser Leu Gly Glu Ile Pro 895	900	905	2739
35	gct gga gaa aca agt ttg aat tat gtg tcc cag ttg gct tca ccc atg Ala Gly Glu Thr Ser Leu Asn Tyr Val Ser Gln Leu Ala Ser Pro Met 910	915	920	2787
40	ttt gga gac aag gac agt ctc cca aca aac cca gta gag gca cca cac Phe Gly Asp Lys Asp Ser Leu Pro Thr Asn Pro Val Glu Ala Pro His 930	935	940	2835
45	tgt tca gag tat aaa atg caa atg gca gtc tcc ctg cgt ctt gcc ttg Cys Ser Glu Tyr Lys Met Gln Met Ala Val Ser Leu Arg Leu Ala Leu 945	950	955	2883
50	cct ccc ccg acc gag aat agc agc ctc tcc tca att acc ctt tta gat Pro Pro Pro Thr Glu Asn Ser Ser Leu Ser Ser Ile Thr Leu Leu Asp 960	965	970	2931
55	cca ggt gaa cac tac tgc taaccagcac tcgag			2964

Pro Gly Glu His Tyr Cys
975

5

<210> 7

<211> 979

<212> PRT

10

<213> Homo sapiens

<400> 7

15

Met Ala Leu Phe Ala Val Phe Gln Thr Thr Phe Phe Leu Thr Leu Leu
1 5 10 15

Ser Leu Arg Thr Tyr Gln Ser Glu Val Leu Ala Glu Arg Leu Pro Leu
20 25 30

20

Thr Pro Val Ser Leu Lys Val Ser Thr Asn Ser Thr Arg Gln Ser Leu
35 40 45

His Leu Gln Trp Thr Val His Asn Leu Pro Tyr His Gln Glu Leu Lys
50 55 60

25

Met Val Phe Gln Ile Gln Ile Ser Arg Ile Glu Thr Ser Asn Val Ile
65 70 75 80

Trp Val Gly Asn Tyr Ser Thr Thr Val Lys Trp Asn Gln Val Leu His
85 90 95

30

Trp Ser Trp Glu Ser Glu Leu Pro Leu Glu Cys Ala Thr His Phe Val
100 105 110

Arg Ile Lys Ser Leu Val Asp Asp Ala Lys Phe Pro Glu Pro Asn Phe
115 120 125

35

Trp Ser Asn Trp Ser Ser Trp Glu Glu Val Ser Val Gln Asp Ser Thr
130 135 140

Gly Gln Asp Ile Leu Phe Val Phe Pro Lys Asp Lys Leu Val Glu Glu
145 150 155 160

40

Gly Thr Asn Val Thr Ile Cys Tyr Val Ser Arg Asn Ile Gln Asn Asn
165 170 175

Val Ser Cys Tyr Leu Glu Gly Lys Gln Ile His Gly Glu Gln Leu Asp
180 185 190

45

Pro His Val Thr Ala Phe Asn Leu Asn Ser Val Pro Phe Ile Arg Asn
195 200 205

Lys Gly Thr Asn Ile Tyr Cys Glu Ala Ser Gln Gly Asn Val Ser Glu
210 215 220

50

Gly Met Lys Gly Ile Val Leu Phe Val Ser Lys Val Leu Glu Glu Pro
225 230 235 240

Lys Asp Phe Ser Cys Glu Thr Glu Asp Phe Lys Thr Leu His Cys Thr
245 250 255

55

Trp Asp Pro Gly Thr Asp Thr Ala Leu Gly Trp Ser Lys Gln Pro Ser

EP 1 476 541 B1

				260					265				270				
	Gln	Ser	Tyr	Thr	Leu	Phe	Glu	Ser	Phe	Ser	Gly	Glu	Lys	Lys	Leu	Cys	
5				275					280				285				
	Thr	His	Lys	Asn	Trp	Cys	Asn	Trp	Gln	Ile	Thr	Gln	Asp	Ser	Gln	Glu	
				290					295				300				
10	Thr	Tyr	Asn	Phe	Thr	Leu	Ile	Ala	Glu	Asn	Tyr	Leu	Arg	Lys	Arg	Ser	
	305					310						315				320	
	Val	Asn	Ile	Leu	Phe	Asn	Leu	Thr	His	Arg	Val	Tyr	Leu	Met	Asn	Pro	
					325					330					335		
15	Phe	Ser	Val	Asn	Phe	Glu	Asn	Val	Asn	Ala	Thr	Asn	Ala	Ile	Met	Thr	
				340						345				350			
	Trp	Lys	Val	His	Ser	Ile	Arg	Asn	Asn	Phe	Thr	Tyr	Leu	Cys	Gln	Ile	
				355					360					365			
20	Glu	Leu	His	Gly	Glu	Gly	Lys	Met	Met	Gln	Tyr	Asn	Val	Ser	Ile	Lys	
				370				375					380				
	Val	Asn	Gly	Glu	Tyr	Phe	Leu	Ser	Glu	Leu	Glu	Pro	Ala	Thr	Glu	Tyr	
	385					390						395				400	
25	Met	Ala	Arg	Val	Arg	Cys	Ala	Asp	Ala	Ser	His	Phe	Trp	Lys	Trp	Ser	
					405					410					415		
	Glu	Trp	Ser	Gly	Gln	Asn	Phe	Thr	Thr	Leu	Glu	Ala	Ala	Pro	Ser	Glu	
				420					425					430			
30	Ala	Pro	Asp	Val	Trp	Arg	Ile	Val	Ser	Leu	Glu	Pro	Gly	Asn	His	Thr	
				435				440					445				
	Val	Thr	Leu	Phe	Trp	Lys	Pro	Leu	Ser	Lys	Leu	His	Ala	Asn	Gly	Lys	
							455					460					
35	Ile	Leu	Phe	Tyr	Asn	Val	Val	Val	Glu	Asn	Leu	Asp	Lys	Pro	Ser	Ser	
	465					470						475				480	
	Ser	Glu	Leu	His	Ser	Ile	Pro	Ala	Pro	Ala	Asn	Ser	Thr	Lys	Leu	Ile	
					485					490					495		
40	Leu	Asp	Arg	Cys	Ser	Tyr	Gln	Ile	Cys	Val	Ile	Ala	Asn	Asn	Ser	Val	
				500					505					510			
	Gly	Ala	Ser	Pro	Ala	Ser	Val	Ile	Val	Ile	Ser	Ala	Asp	Pro	Glu	Asn	
				515				520					525				
45	Lys	Glu	Val	Glu	Glu	Glu	Arg	Ile	Ala	Gly	Thr	Glu	Gly	Gly	Phe	Ser	
				530				535					540				
	Leu	Ser	Trp	Lys	Pro	Gln	Pro	Gly	Asp	Val	Ile	Gly	Tyr	Val	Val	Asp	
	545					550						555				560	
50	Trp	Cys	Asp	His	Thr	Gln	Asp	Val	Leu	Gly	Asp	Phe	Gln	Trp	Lys	Asn	
					565					570					575		
	Val	Gly	Pro	Asn	Thr	Thr	Ser	Thr	Val	Ile	Ser	Thr	Asp	Ala	Phe	Arg	
				580					585				590				
55	Pro	Gly	Val	Arg	Tyr	Asp	Phe	Arg	Ile	Tyr	Gly	Leu	Ser	Thr	Lys	Arg	
				595				600						605			

EP 1 476 541 B1

Ile Ala Cys Leu Leu Glu Lys Lys Thr Gly Tyr Ser Gln Glu Leu Ala
 610 615 620
 5 Pro Ser Asp Asn Pro His Val Leu Val Asp Thr Leu Thr Ser His Ser
 625 630 635 640
 Phe Thr Leu Ser Trp Lys Asp Tyr Ser Thr Glu Ser Gln Pro Gly Phe
 645 650 655
 10 Ile Gln Gly Tyr His Val Tyr Leu Lys Ser Lys Ala Arg Gln Cys His
 660 665 670
 Pro Arg Phe Glu Lys Ala Val Leu Ser Asp Gly Ser Glu Cys Cys Lys
 675 680 685
 15 Tyr Lys Ile Asp Asn Pro Glu Glu Lys Ala Leu Ile Val Asp Asn Leu
 690 695 700
 Lys Pro Glu Ser Phe Tyr Glu Phe Phe Ile Thr Pro Phe Thr Ser Ala
 705 710 715 720
 20 Gly Glu Gly Pro Ser Ala Thr Phe Thr Lys Val Thr Thr Pro Asp Glu
 725 730 735
 His Ser Ser Met Leu Ile His Ile Leu Leu Pro Met Val Phe Cys Val
 740 745 750
 25 Leu Leu Ile Met Val Met Cys Tyr Leu Lys Ser Gln Trp Ile Lys Glu
 755 760 765
 Thr Cys Tyr Pro Asp Ile Pro Asp Pro Tyr Lys Ser Ser Ile Leu Ser
 770 775 780
 30 Leu Ile Lys Phe Lys Glu Asn Pro His Leu Ile Ile Met Asn Val Ser
 785 790 795 800
 Asp Cys Ile Pro Asp Ala Ile Glu Val Val Ser Lys Pro Glu Gly Thr
 805 810 815
 35 Lys Ile Gln Phe Leu Gly Thr Arg Lys Ser Leu Thr Glu Thr Glu Leu
 820 825 830
 Thr Lys Pro Asn Tyr Leu Tyr Leu Leu Pro Thr Glu Lys Asn His Ser
 835 840 845
 40 Gly Pro Gly Pro Cys Ile Cys Phe Glu Asn Leu Thr Tyr Asn Gln Ala
 850 855 860
 Ala Ser Asp Ser Gly Ser Cys Gly His Val Pro Val Ser Pro Lys Ala
 865 870 875 880
 45 Pro Ser Met Leu Gly Leu Met Thr Ser Pro Glu Asn Val Leu Lys Ala
 885 890 895
 Leu Glu Lys Asn Tyr Met Asn Ser Leu Gly Glu Ile Pro Ala Gly Glu
 900 905 910
 50 Thr Ser Leu Asn Tyr Val Ser Gln Leu Ala Ser Pro Met Phe Gly Asp
 915 920 925
 Lys Asp Ser Leu Pro Thr Asn Pro Val Glu Ala Pro His Cys Ser Glu
 930 935 940
 55 Tyr Lys Met Gln Met Ala Val Ser Leu Arg Leu Ala Leu Pro Pro Pro

EP 1 476 541 B1

	cgg gaa cag ctc acc atg tct gac aaa ctc ctt gtc tgg ggc act aag	459
	Arg Glu Gln Leu Thr Met Ser Asp Lys Leu Leu Val Trp Gly Thr Lys	
5	95 100 105	
	gca ggc cag cct ctc tgg ccc ccc gtc ttc gtg aac cta gaa acc caa	507
	Ala Gly Gln Pro Leu Trp Pro Pro Val Phe Val Asn Leu Glu Thr Gln	
10	110 115 120 125	
	atg aag cca aac gcc ccc cgg ctg ggc cct gac gtg gac ttt tcc gag	555
	Met Lys Pro Asn Ala Pro Arg Leu Gly Pro Asp Val Asp Phe Ser Glu	
15	130 135 140	
	gat gac ccc ctg gag gcc act gtc cat tgg gcc cca cct aca tgg cca	603
	Asp Asp Pro Leu Glu Ala Thr Val His Trp Ala Pro Pro Thr Trp Pro	
20	145 150 155	
	tct cat aaa gtt ctg atc tgc cag ttc cac tac cga aga tgt cag gag	651
	Ser His Lys Val Leu Ile Cys Gln Phe His Tyr Arg Arg Cys Gln Glu	
25	160 165 170	
	gcg gcc tgg acc ctg ctg gaa ccg gag ctg aag acc ata ccc ctg acc	699
	Ala Ala Trp Thr Leu Leu Glu Pro Glu Leu Lys Thr Ile Pro Leu Thr	
30	175 180 185	
	cct gtt gag atc caa gat ttg gag cta gcc act ggc tac aaa gtg tat	747
	Pro Val Glu Ile Gln Asp Leu Glu Leu Ala Thr Gly Tyr Lys Val Tyr	
35	190 195 200 205	
	ggc cgc tgc cgg atg gag aaa gaa gag gat ttg tgg ggc gag tgg agc	795
	Gly Arg Cys Arg Met Glu Lys Glu Glu Asp Leu Trp Gly Glu Trp Ser	
40	210 215 220	
	ccc att ttg tcc ttc cag aca ccg cct tct gct cca aaa gat gtg tgg	843
	Pro Ile Leu Ser Phe Gln Thr Pro Pro Ser Ala Pro Lys Asp Val Trp	
45	225 230 235	
	gta tca ggg aac ctc tgt ggg acg cct gga gga gag gaa cct ttg ctt	891
	Val Ser Gly Asn Leu Cys Gly Thr Pro Gly Gly Glu Glu Pro Leu Leu	
50	240 245 250	
	cta tgg aag gcc cca ggg ccc tgt gtg cag gtg agc tac aaa gtc tgg	939
	Leu Trp Lys Ala Pro Gly Pro Cys Val Gln Val Ser Tyr Lys Val Trp	
55	255 260 265	

EP 1 476 541 B1

5 ttc tgg gtt gga ggt cgt gag ctg agt cca gaa gga att acc tgc tgc 987
Phe Trp Val Gly Gly Arg Glu Leu Ser Pro Glu Gly Ile Thr Cys Cys
270 275 280 285

10 tgc tcc cta att ccc agt ggg gcg gag tgg gcc agg gtg tcc gct gtc 1035
Cys Ser Leu Ile Pro Ser Gly Ala Glu Trp Ala Arg Val Ser Ala Val
290 295 300

15 aac gcc aca agc tgg gag cct ctc acc aac ctc tct ttg gtc tgc ttg 1083
Asn Ala Thr Ser Trp Glu Pro Leu Thr Asn Leu Ser Leu Val Cys Leu
305 310 315

20 gat tca gcc tct gcc ccc cgt agc gtg gca gtc agc agc atc gct ggg 1131
Asp Ser Ala Ser Ala Pro Arg Ser Val Ala Val Ser Ser Ile Ala Gly
320 325 330

25 agc acg gag cta ctg gtg acc tgg caa ccg ggg cct ggg gaa cca ctg 1179
Ser Thr Glu Leu Leu Val Thr Trp Gln Pro Gly Pro Gly Glu Pro Leu
335 340 345

30 gag cat gta gtg gac tgg gct cga gat ggg gac ccc ctg gag aaa ctc 1227
Glu His Val Val Asp Trp Ala Arg Asp Gly Asp Pro Leu Glu Lys Leu
350 355 360 365

35 aac tgg gtc cgg ctt ccc cct ggg aac ctc agt gct ctg tta cca ggg 1275
Asn Trp Val Arg Leu Pro Pro Gly Asn Leu Ser Ala Leu Leu Pro Gly
370 375 380

40 aat ttc act gtc ggg gtc ccc tat cga atc act gtg acc gca gtc tct 1323
Asn Phe Thr Val Gly Val Pro Tyr Arg Ile Thr Val Thr Ala Val Ser
385 390 395

45 gct tca ggc ttg gcc tct gca tcc tcc gtc tgg ggg ttc agg gag gaa 1371
Ala Ser Gly Leu Ala Ser Ala Ser Ser Val Trp Gly Phe Arg Glu Glu
400 405 410

50 tta gca ccc cta gtg ggg cca acg ctt tgg cga ctc caa gat gcc cct 1419
Leu Ala Pro Leu Val Gly Pro Thr Leu Trp Arg Leu Gln Asp Ala Pro
415 420 425

55 cca ggg acc ccc gcc ata gcg tgg gga gag gtc cca agg cac cag ctt 1467
Pro Gly Thr Pro Ala Ile Ala Trp Gly Glu Val Pro Arg His Gln Leu

EP 1 476 541 B1

	430		435			440		445	
5	cga ggc cac ctc acc cac tac acc ttg tgt gca cag agt gga acc agc								1515
	Arg Gly His Leu Thr His Tyr Thr Leu Cys Ala Gln Ser Gly Thr Ser								
			450			455		460	
10	ccc tcc gtc tgc atg aat gtg agt ggc aac aca cag agt gtc acc ctg								1563
	Pro Ser Val Cys Met Asn Val Ser Gly Asn Thr Gln Ser Val Thr Leu								
			465			470		475	
15	cct gac ctt cct tgg ggt ccc tgt gag ctg tgg gtg aca gca tct acc								1611
	Pro Asp Leu Pro Trp Gly Pro Cys Glu Leu Trp Val Thr Ala Ser Thr								
			480			485		490	
20	atc gct gga cag ggc cct cct ggt ccc atc ctc cgg ctt cat cta cca								1659
	Ile Ala Gly Gln Gly Pro Pro Gly Pro Ile Leu Arg Leu His Leu Pro								
			495			500		505	
25	gat aac acc ctg agg tgg aaa gtt ctg cca ggc atc cta ttc ttg tgg								1707
	Asp Asn Thr Leu Arg Trp Lys Val Leu Pro Gly Ile Leu Phe Leu Trp								
			510			515		520	
30	ggc ttg ttc ctg ttg ggg tgt ggc ctg agc ctg gcc acc tct gga agg								1755
	Gly Leu Phe Leu Leu Gly Cys Gly Leu Ser Leu Ala Thr Ser Gly Arg								
			530			535		540	
35	tgc tac cac cta agg cac aaa gtg ctg ccc cgc tgg gtc tgg gag aaa								1803
	Cys Tyr His Leu Arg His Lys Val Leu Pro Arg Trp Val Trp Glu Lys								
			545			550		555	
40	gtt cct gat cct gcc aac agc agt tca ggc cag ccc cac atg gag caa								1851
	Val Pro Asp Pro Ala Asn Ser Ser Ser Gly Gln Pro His Met Glu Gln								
			560			565		570	
45	gta cct gag gcc cag ccc ctt ggg gac ttg ccc atc ctg gaa gtg gag								1899
	Val Pro Glu Ala Gln Pro Leu Gly Asp Leu Pro Ile Leu Glu Val Glu								
			575			580		585	
50	gag atg gag ccc ccg ccg gtt atg gag tcc tcc cag ccc gcc cag gcc								1947
	Glu Met Glu Pro Pro Pro Val Met Glu Ser Ser Gln Pro Ala Gln Ala								
			590			595		600	
55	acc gcc ccg ctt gac tct ggg tat gag aag cac ttc ctg ccc aca cct								1995

EP 1 476 541 B1

Thr Ala Pro Leu Asp Ser Gly Tyr Glu Lys His Phe Leu Pro Thr Pro
 610 615 620
 5 gag gag ctg ggc ctt ctg ggg ccc ccc agg cca cag gtt ctg gcc 2040
 Glu Glu Leu Gly Leu Leu Gly Pro Pro Arg Pro Gln Val Leu Ala
 625 630 635
 10 tgaaccacac gtctggctgg gggctgccag ccaggctaga gggatgctca tgcaggttgc 2100
 accccagtcc tggattagcc ctcttgatgg atgaagacac tgaggactca gagaggctga 2160
 15 gtcacttacc tgaggacacc cagccaggca gagctgggat tgaaggaccc ctatagagaa 2220
 gggcttgccc cccatgggga agacacggat ggaaggtgga gcaaaggaaa atacatgaaa 2280
 ttgagagtgg cagctgcctg ccaaaatctg ttccgctgta acagaactga atttggacct 2340
 cagcacagtg gctcacgcct gtaatccag cactttggca ggccaagggtg gaaggatcac 2400
 20 ttagagctag gagtttgaga ccagcctggg caatatagca agaccctca ctacaaaaat 2460
 aaaacatcaa aaacaaaaac aattagctgg gcatgatggc acacacctgt agtccgagcc 2520
 acttgggagg ctgaggtggg aggatcggtt gagcccagga gttcgaagct gcagggacct 2580
 ctgattgcac cactgcactc caggctgggt aacagaatga gaccttatct caaaaataaa 2640
 25 caaactaata aaaagca 2657

 <210> 9
 <211> 636
 <212> PRT
 30 <213> Homo sapiens

 <400> 9

 35 Met Arg Gly Gly Arg Gly Ala Pro Phe Trp Leu Trp Pro Leu Pro Lys
 1 5 10 15
 Leu Ala Leu Leu Pro Leu Leu Trp Val Leu Phe Gln Arg Thr Arg Pro
 20 25 30
 40 Gln Gly Ser Ala Gly Pro Leu Gln Cys Tyr Gly Val Gly Pro Leu Gly
 35 40 45
 Asp Leu Asn Cys Ser Trp Glu Pro Leu Gly Asp Leu Gly Ala Pro Ser
 50 55 60
 45 Glu Leu His Leu Gln Ser Gln Lys Tyr Arg Ser Asn Lys Thr Gln Thr
 65 70 75 80
 Val Ala Val Ala Ala Gly Arg Ser Trp Val Ala Ile Pro Arg Glu Gln
 85 90 95
 50 Leu Thr Met Ser Asp Lys Leu Leu Val Trp Gly Thr Lys Ala Gly Gln
 100 105 110
 Pro Leu Trp Pro Pro Val Phe Val Asn Leu Glu Thr Gln Met Lys Pro
 115 120 125
 55 Asn Ala Pro Arg Leu Gly Pro Asp Val Asp Phe Ser Glu Asp Asp Pro
 130 135 140

EP 1 476 541 B1

Leu Glu Ala Thr Val His Trp Ala Pro Pro Thr Trp Pro Ser His Lys
 145 150 155 160
 5 Val Leu Ile Cys Gln Phe His Tyr Arg Arg Cys Gln Glu Ala Ala Trp
 165 170 175
 Thr Leu Leu Glu Pro Glu Leu Lys Thr Ile Pro Leu Thr Pro Val Glu
 180 185 190
 10 Ile Gln Asp Leu Glu Leu Ala Thr Gly Tyr Lys Val Tyr Gly Arg Cys
 195 200 205
 Arg Met Glu Lys Glu Glu Asp Leu Trp Gly Glu Trp Ser Pro Ile Leu
 210 215 220
 15 Ser Phe Gln Thr Pro Pro Ser Ala Pro Lys Asp Val Trp Val Ser Gly
 225 230 235 240
 Asn Leu Cys Gly Thr Pro Gly Gly Glu Glu Pro Leu Leu Leu Trp Lys
 245 250 255
 20 Ala Pro Gly Pro Cys Val Gln Val Ser Tyr Lys Val Trp Phe Trp Val
 260 265 270
 Gly Gly Arg Glu Leu Ser Pro Glu Gly Ile Thr Cys Cys Cys Ser Leu
 275 280 285
 25 Ile Pro Ser Gly Ala Glu Trp Ala Arg Val Ser Ala Val Asn Ala Thr
 290 295 300
 Ser Trp Glu Pro Leu Thr Asn Leu Ser Leu Val Cys Leu Asp Ser Ala
 305 310 315 320
 30 Ser Ala Pro Arg Ser Val Ala Val Ser Ser Ile Ala Gly Ser Thr Glu
 325 330 335
 Leu Leu Val Thr Trp Gln Pro Gly Pro Gly Glu Pro Leu Glu His Val
 340 345 350
 35 Val Asp Trp Ala Arg Asp Gly Asp Pro Leu Glu Lys Leu Asn Trp Val
 355 360 365
 Arg Leu Pro Pro Gly Asn Leu Ser Ala Leu Leu Pro Gly Asn Phe Thr
 370 375 380
 40 Val Gly Val Pro Tyr Arg Ile Thr Val Thr Ala Val Ser Ala Ser Gly
 385 390 395 400
 Leu Ala Ser Ala Ser Ser Val Trp Gly Phe Arg Glu Glu Leu Ala Pro
 405 410 415
 45 Leu Val Gly Pro Thr Leu Trp Arg Leu Gln Asp Ala Pro Pro Gly Thr
 420 425 430
 Pro Ala Ile Ala Trp Gly Glu Val Pro Arg His Gln Leu Arg Gly His
 435 440 445
 50 Leu Thr His Tyr Thr Leu Cys Ala Gln Ser Gly Thr Ser Pro Ser Val
 450 455 460
 Cys Met Asn Val Ser Gly Asn Thr Gln Ser Val Thr Leu Pro Asp Leu
 465 470 475 480
 55 Pro Trp Gly Pro Cys Glu Leu Trp Val Thr Ala Ser Thr Ile Ala Gly

5 Gln Gly Pro Pro Gly Pro Ile Leu Arg Leu His Leu Pro Asp Asn Thr
 500 505 510
 Leu Arg Trp Lys Val Leu Pro Gly Ile Leu Phe Leu Trp Gly Leu Phe
 515 520 525
 10 Leu Leu Gly Cys Gly Leu Ser Leu Ala Thr Ser Gly Arg Cys Tyr His
 530 535 540
 Leu Arg His Lys Val Leu Pro Arg Trp Val Trp Glu Lys Val Pro Asp
 545 550 555 560
 15 Pro Ala Asn Ser Ser Ser Gly Gln Pro His Met Glu Gln Val Pro Glu
 565 570 575
 Ala Gln Pro Leu Gly Asp Leu Pro Ile Leu Glu Val Glu Glu Met Glu
 580 585 590
 20 Pro Pro Pro Val Met Glu Ser Ser Gln Pro Ala Gln Ala Thr Ala Pro
 595 600 605
 Leu Asp Ser Gly Tyr Glu Lys His Phe Leu Pro Thr Pro Glu Glu Leu
 610 615 620
 25 Gly Leu Leu Gly Pro Pro Arg Pro Gln Val Leu Ala
 625 630 635

30 <210> 10
 <211> 755
 <212> DNA
 <213> Mus musculus

35 <220>
 <221> CDS
 <222> (1)...(489)

<400> 10

40 atg atc ttc cac aca gga aca acg aag cct acc ctg gtg ctg ctt tgc 48
 Met Ile Phe His Thr Gly Thr Thr Lys Pro Thr Leu Val Leu Leu Cys
 1 5 10 15

45 tgt ata gga acc tgg ctg gcc acc tgc agc ttg tcc ttc ggt gcc cca 96
 Cys Ile Gly Thr Trp Leu Ala Thr Cys Ser Leu Ser Phe Gly Ala Pro
 20 25 30

50 ata tcg aag gaa gac tta aga act aca att gac ctc ttg aaa caa gag 144
 Ile Ser Lys Glu Asp Leu Arg Thr Thr Ile Asp Leu Leu Lys Gln Glu
 35 40 45

55

EP 1 476 541 B1

5 tct cag gat ctt tat aac aac tat agc ata aag cag gca tct ggg atg 192
 Ser Gln Asp Leu Tyr Asn Asn Tyr Ser Ile Lys Gln Ala Ser Gly Met
 50 55 60

10 tca gca gac gaa tca ata cag ctg ccg tgt ttc agc ctg gac cgg gaa 240
 Ser Ala Asp Glu Ser Ile Gln Leu Pro Cys Phe Ser Leu Asp Arg Glu
 65 70 75 80

15 gca tta acc aac atc tcg gtc atc ata gca cat ctg gag aaa gtc aaa 288
 Ala Leu Thr Asn Ile Ser Val Ile Ile Ala His Leu Glu Lys Val Lys
 85 90 95

20 gtg ttg agc gag aac aca gta gat act tct tgg gtg ata aga tgg cta 336
 Val Leu Ser Glu Asn Thr Val Asp Thr Ser Trp Val Ile Arg Trp Leu
 100 105 110

25 aca aac atc agc tgt ttc aac cca ctg aat tta aac att tct gtg cct 384
 Thr Asn Ile Ser Cys Phe Asn Pro Leu Asn Leu Asn Ile Ser Val Pro
 115 120 125

30 gga aat act gat gaa tcc tat gat tgt aaa gtg ttc gtg ctt acg gtt 432
 Gly Asn Thr Asp Glu Ser Tyr Asp Cys Lys Val Phe Val Leu Thr Val
 130 135 140

35 tta aag cag ttc tca aac tgc atg gca gaa ctg cag gct aag gac aat 480
 Leu Lys Gln Phe Ser Asn Cys Met Ala Glu Leu Gln Ala Lys Asp Asn
 145 150 155 160

40 act aca tgc tgagtgatgg gggggggggg ggtgcagtgt cctcagcagt 529
 Thr Thr Cys

45 gcctgtcctt cgagggctga gcttgcaacc caggacttaa ctccaaaggg actgtgcggt 589
 cactactagt catgttattt atgtttttat tttgtccact gaaatcttgt tctgctaccc 649
 ttagaggact ggaagtggca gctatattta tttatttatg tactgagttt gttaacgctc 709
 catggaggag ccttcagagt ctatttaata aattatattg acatga 755

<210> 11
 <211> 163
 <212> PRT
 <213> Mus musculus

<400> 11

Met Ile Phe His Thr Gly Thr Thr Lys Pro Thr Leu Val Leu Leu Cys
 1 5 10 15
 5 Cys Ile Gly Thr Trp Leu Ala Thr Cys Ser Leu Ser Phe Gly Ala Pro
 20 25 30
 Ile Ser Lys Glu Asp Leu Arg Thr Thr Ile Asp Leu Leu Lys Gln Glu
 35 40 45
 10 Ser Gln Asp Leu Tyr Asn Asn Tyr Ser Ile Lys Gln Ala Ser Gly Met
 50 55 60
 Ser Ala Asp Glu Ser Ile Gln Leu Pro Cys Phe Ser Leu Asp Arg Glu
 65 70 75 80
 15 Ala Leu Thr Asn Ile Ser Val Ile Ile Ala His Leu Glu Lys Val Lys
 85 90 95
 Val Leu Ser Glu Asn Thr Val Asp Thr Ser Trp Val Ile Arg Trp Leu
 100 105 110
 20 Thr Asn Ile Ser Cys Phe Asn Pro Leu Asn Leu Asn Ile Ser Val Pro
 115 120 125
 Gly Asn Thr Asp Glu Ser Tyr Asp Cys Lys Val Phe Val Leu Thr Val
 130 135 140
 25 Leu Lys Gln Phe Ser Asn Cys Met Ala Glu Leu Gln Ala Lys Asp Asn
 145 150 155 160
 Thr Thr Cys

30 <210> 12
 <211> 489
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> mouse zcytor17lig degenerate polynucleotide of SEQ ID NO:11

<221> misc_feature
 <222> (1)...(489)
 40 <223> n = A,T,C or G

<400> 12

45 atgathttyc ayacnggnac nacnaarccn acnytngtny tnytntgytg yathggnacn 60
 tggytngcna cntgywsnyt nwsnttyggn gcncnathw snaargarga yytnmgnacn 120
 acnathgayy tnytnaarca rgarwsncar gayytnaya ayaaytayws nathaarcar 180
 gcnwsnggna tgwsngcnga ygarwsnath carytncnt gyttywsnyt ngaymgngar 240
 50 gcnytnacna ayathwsngt nathathgcn cayyngara argtnaargt nytnwsngar 300

55

EP 1 476 541 B1

5 aayacngtng ayacnwsntg ggtnathmgn tggynacna ayathwsntg yttyaayccn 360
ytnaayyna ayathwsngt nccnggnaay acngaygarw sntaygaytg yaargtntty 420
gtnytnacng tnytnaarca rttywsnaay tgyatggcng arytncargc naargayaay 480
acnacntgy 489

10 <210> 13
<211> 21
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Oligonucleotide primer ZC6673

<400> 13
gcgcaaggtg ccgttcacag c 21

20 <210> 14
<211> 36
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Oligonucleotide primer ZC29082

30 <400> 14
caattgttg ggttttita gcagcagtag gccacg 36

<210> 15
<211> 36
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Oligonucleotide primer ZC29083

40 <400> 15
ctgggcctac tgctgctaaa aaaacccaac aaattg 36

45 <210> 16
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC29145

50 <400> 16
gcgtctagag gggtatattg aagttgggca ggaaga 36

55 <210> 17
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

EP 1 476 541 B1

<223> Gly-Ser Modified Glu-Glu (CEE) peptide tag

<400> 17

5

Gly Ser Glu Tyr Met Pro Met Glu
1 5

10

<210> 18

<211> 33

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Oligonucleotide primer ZC29359

<400> 18

gcgggatcca tgaagctctc tcccagcct tca 33

20

<210> 19

<211> 23

<212> DNA

<213> Artificial Sequence

25

<220>

<223> Oligonucleotide primer ZC27899

<400> 19

ccagaacttt gactccttga ccg 23

30

<210> 20

<211> 23

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Oligonucleotide primer ZC27895

<400> 20

gaagtcaact tcgctaagaa ccg 23

40

<210> 21

<211> 34

45

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC29122

50

<400> 21

ccgctcgagt tatattgaag ttggcagga agac 34

55

<210> 22

<211> 22

<212> DNA

<213> Artificial Sequence

EP 1 476 541 B1

<220>
<223> Oligonucleotide primer ZC29180

5 <400> 22
cctggagtcc ctgaaacgaa ag 22

<210> 23
<211> 34
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC29122

15 <400> 23
ccgctcgagt tatattgaag ttggcagga agac 34

<210> 24
<211> 20
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC9791

25 <400> 24
cgtccaaca aaaccagac 20

<210> 25
30 <211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC9793

35 <400> 25
tggcgtgac agcggacac 19

40 <210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC40109

45 <400> 26
ccattccagc accagccaac 20

50 <210> 27
<211> 22
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Oligonucleotide primer ZC40112

EP 1 476 541 B1

<400> 27
tacaactca atagcatctg gg 22

5 <210> 28
<211> 40
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Oligonucleotide primer ZC13496

<400> 28
ccctgcagtg atcaacatgg ccaagttgac cagtgccgtt 40

15 <210> 29
<211> 45
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Oligonucleotide primer ZC13945

<400> 29
gcccatggac tagtttcgaa aggtcgagtg tcagtcctgc tctc 45

25 <210> 30
<211> 34
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Oligonucleotide primer ZC18698

<400> 30
35 ttttttctc gagactttt tttttttt tttt 34

<210> 31

<220>
40 <223> Skipped Sequence

<400> 31
000

45 <210> 32
<211> 10
<212> PRT
<213> Artificial Sequence

50 <220>
<223> Glu-Glu (CEE) peptide tag with Gly-Ser residue pair

<400> 32

55 Gly Ser Gly Gly Glu Tyr Met Pro Met Glu
1 5 10

EP 1 476 541 B1

<210> 33
<211> 33
<212> DNA
<213> Artificial Sequence
5
<220>
<223> Oligonucleotide primer ZC29451
<400> 33
10 ccggaattcc cctgatacat gaagctctct ccc 33
<210> 34
<211> 33
<212> DNA
15 <213> Artificial Sequence
<220>
<223> Oligonucleotide primer ZC29124
20 <400> 34
cgcggatccc tcaaagacac tgaatgacaa tgt 33
<210> 35
<211> 6
25 <212> PRT
<213> Artificial Sequence
<220>
<223> Glu-Glu (CEE) peptide tag without Gly-Ser residue pair
30 <400> 35

35 Glu Tyr Met Pro Met Glu
1 5

<210> 36
<211> 8
40 <212> PRT
<213> Artificial Sequence
<220>
<223> C-terminal FLAG peptide sequence
45 <400> 36

50 Asp Tyr Lys Asp Asp Asp Asp Lys
1 5

55 <210> 37
<211> 684
<212> DNA
<213> Homo sapiens
<400> 37

EP 1 476 541 B1

```

tcagacaaaa ctcacacatg cccaccgtgc ccagcacctg aagccgaggg ggcaccgtca 60
gtcttcctct tcccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc 120
5  acatgcgtgg tggtagcagt gagccacgaa gaccctgagg tcaagttcaa ctggtacgtg 180
gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg 240
taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtac 300
aagtgaagg tctccaacaa agccctcca tcctccatcg agaaaacat ctccaagcc 360
10 aaagggcagc cccgagaacc acaggtgtac accctgcccc catcccggga tgagctgacc 420
aagaaccagg tcagcctgac ctgcctggtc aaaggcttct atcccagcga catcgccgtg 480
gagtgggaga gcaatgggca gccggagaac aactacaaga ccacgcctcc cgtgctggac 540
tccgacggct ctttcttct ctacagcaag ctaccctgg acaagagcag gtggcagcag 600
15 ggaacgtct tctcatgctc cgtgatgcat gaggctctgc acaaccacta cagcagaag 660
agcctctccc tgtctccggg taaa 684

```

```

<210> 38
<211> 2295
20 <212> DNA
    <213> Artificial Sequence

<220>
<223> human zcytor17-Fc4 fusion polynucleotide
25
<221> CDS
<222> (1)...(2295)

<400> 38
30

```

35

40

45

50

55

EP 1 476 541 B1

atg aag ctc tct ccc cag cct tca tgt gtt aac ctg ggg atg atg tgg 48
 Met Lys Leu Ser Pro Gln Pro Ser Cys Val Asn Leu Gly Met Met Trp
 1 5 10 15
 5
 acc tgg gca ctg tgg atg ctc cct tca ctc tgc aaa ttc agc ctg gca 96
 Thr Trp Ala Leu Trp Met Leu Pro Ser Leu Cys Lys Phe Ser Leu Ala
 20 25 30
 10
 gct ctg cca gct aag cct gag aac att tcc tgt gtc tac tac tat agg 144
 Ala Leu Pro Ala Lys Pro Glu Asn Ile Ser Cys Val Tyr Tyr Tyr Arg
 35 40 45
 15
 aaa aat tta acc tgc act tgg agt cca gga aag gaa acc agt tat acc 192
 Lys Asn Leu Thr Cys Thr Trp Ser Pro Gly Lys Glu Thr Ser Tyr Thr
 50 55 60
 20
 cag tac aca gtt aag aga act tac gct ttt gga gaa aaa cat gat aat 240
 Gln Tyr Thr Val Lys Arg Thr Tyr Ala Phe Gly Glu Lys His Asp Asn
 65 70 75 80
 25
 tgt aca acc aat agt tct aca agt gaa aat cgt gct tct tgc tct ttt 288
 Cys Thr Thr Asn Ser Ser Thr Ser Glu Asn Arg Ala Ser Cys Ser Phe
 85 90 95
 30
 ttc ctt cca aga ata acg atc cca gat aat tat acc att gag gtg gaa 336
 Phe Leu Pro Arg Ile Thr Ile Pro Asp Asn Tyr Thr Ile Glu Val Glu
 100 105 110
 35
 gct gaa aat gga gat ggt gta att aaa tct cat atg aca tac tgg aga 384
 Ala Glu Asn Gly Asp Gly Val Ile Lys Ser His Met Thr Tyr Trp Arg
 115 120 125
 40
 tta gag aac ata gcg aaa act gaa cca cct aag att ttc cgt gtg aaa 432
 Leu Glu Asn Ile Ala Lys Thr Glu Pro Pro Lys Ile Phe Arg Val Lys
 130 135 140
 45
 cca gtt ttg ggc atc aaa cga atg att caa att gaa tgg ata aag cct 480

EP 1 476 541 B1

Pro Val Leu Gly Ile Lys Arg Met Ile Gln Ile Glu Trp Ile Lys Pro
 145 150 155 160

5 gag ttg gcg cct gtt tca tct gat tta aaa tac aca ctt cga ttc agg 528
 Glu Leu Ala Pro Val Ser Ser Asp Leu Lys Tyr Thr Leu Arg Phe Arg
 165 170 175

10 aca gtc aac agt acc agc tgg atg gaa gtc aac ttc gct aag aac cgt 576
 Thr Val Asn Ser Thr Ser Trp Met Glu Val Asn Phe Ala Lys Asn Arg
 180 185 190

15 aag gat aaa aac caa acg tac aac ctc acg ggg ctg cag cct ttt aca 624
 Lys Asp Lys Asn Gln Thr Tyr Asn Leu Thr Gly Leu Gln Pro Phe Thr
 195 200 205

20 gaa tat gtc ata gct ctg cga tgt gcg gtc aag gag tca aag ttc tgg 672
 Glu Tyr Val Ile Ala Leu Arg Cys Ala Val Lys Glu Ser Lys Phe Trp
 210 215 220

25 agt gac tgg agc caa gaa aaa atg gga atg act gag gaa gaa gct cca 720
 Ser Asp Trp Ser Gln Glu Lys Met Gly Met Thr Glu Glu Glu Ala Pro
 225 230 235 240

30 tgt ggc ctg gaa ctg tgg aga gtc ctg aaa cca gct gag gcg gat gga 768
 Cys Gly Leu Glu Leu Trp Arg Val Leu Lys Pro Ala Glu Ala Asp Gly
 245 250 255

35 aga agg cca gtg cgg ttg tta tgg aag aag gca aga gga gcc cca gtc 816
 Arg Arg Pro Val Arg Leu Leu Trp Lys Lys Ala Arg Gly Ala Pro Val
 260 265 270

40 cta gag aaa aca ctt ggc tac aac ata tgg tac tat cca gaa agc aac 864
 Leu Glu Lys Thr Leu Gly Tyr Asn Ile Trp Tyr Tyr Pro Glu Ser Asn
 275 280 285

45 act aac ctc aca gaa aca atg aac act act aac cag cag ctt gaa ctg 912
 Thr Asn Leu Thr Glu Thr Met Asn Thr Thr Asn Gln Gln Leu Glu Leu
 290 295 300

50 cat ctg gga ggc gag agc ttt tgg gtg tct atg att tct tat aat tct 960
 His Leu Gly Gly Glu Ser Phe Trp Val Ser Met Ile Ser Tyr Asn Ser
 305 310 315 320

55

EP 1 476 541 B1

5 ctg aaa cga aag acc tct tac att gtt cag gtc atg gcc agc acc agt 1536
 Leu Lys Arg Lys Thr Ser Tyr Ile Val Gln Val Met Ala Ser Thr Ser
 500 505 510

10 gct ggg gga acc aac ggg acc agc ata aat ttc aag aca ttg tca ttc 1584
 Ala Gly Gly Thr Asn Gly Thr Ser Ile Asn Phe Lys Thr Leu Ser Phe
 515 520 525

15 agt gtc ttt gag gag ccc aga tct tca gac aaa act cac aca tgc cca 1632
 Ser Val Phe Glu Glu Pro Arg Ser Ser Asp Lys Thr His Thr Cys Pro
 530 535 540

20 ccg tgc cca gca cct gaa gcc gag ggg gca ccg tca gtc ttc ctc ttc 1680
 Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe
 545 550 555 560

25 ccc cca aaa ccc aag gac acc ctc atg atc tcc cgg acc cct gag gtc 1728
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 565 570 575

30 aca tgc gtg gtg gtg gac gtg agc cac gaa gac cct gag gtc aag ttc 1776
 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 580 585 590

35 aac tgg tac gtg gac ggc gtg gag gtg cat aat gcc aag aca aag ccg 1824
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 595 600 605

40 cgg gag gag cag tac aac agc acg tac cgt gtg gtc agc gtc ctc acc 1872
 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 610 615 620

45 gtc ctg cac cag gac tgg ctg aat ggc aag gag tac aag tgc aag gtc 1920
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 625 630 635 640

50 tcc aac aaa gcc ctc cca tcc tcc atc gag aaa acc atc tcc aaa gcc 1968
 Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
 645 650 655

55 aaa ggg cag ccc cga gaa cca cag gtg tac acc ctg ccc cca tcc cgg 2016
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg

EP 1 476 541 B1

	660		665		670	
5	gat gag ctg acc aag aac cag gtc agc ctg acc tgc ctg gtc aaa ggc					2064
	Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly					
	675		680		685	
10	ttc tat ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg					2112
	Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro					
	690		695		700	
15	gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc					2160
	Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser					
	705		710		715	720
20	ttc ttc ctc tac agc aag ctc acc gtg gac aag agc agg tgg cag cag					2208
	Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln					
	725		730		735	
25	ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac					2256
	Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His					
	740		745		750	
30	tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa taa					2295
	Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys *					
	755		760			
35	<210> 39					
	<211> 764					
	<212> PRT					
	<213> Artificial Sequence					
40	<220>					
	<223> human zcytor17-Fc4 fusion polypeptide					
	<400> 39					
45	Met Lys Leu Ser Pro Gln Pro Ser Cys Val Asn Leu Gly Met Met Trp					
	1 5 10 15					
	Thr Trp Ala Leu Trp Met Leu Pro Ser Leu Cys Lys Phe Ser Leu Ala					
	20 25 30					
50	Ala Leu Pro Ala Lys Pro Glu Asn Ile Ser Cys Val Tyr Tyr Tyr Arg					
	35 40 45					
	Lys Asn Leu Thr Cys Thr Trp Ser Pro Gly Lys Glu Thr Ser Tyr Thr					

55

EP 1 476 541 B1

	50					55					60					
	Gln	Tyr	Thr	Val	Lys	Arg	Thr	Tyr	Ala	Phe	Gly	Glu	Lys	His	Asp	Asn
	65					70					75					80
5	Cys	Thr	Thr	Asn	Ser	Ser	Thr	Ser	Glu	Asn	Arg	Ala	Ser	Cys	Ser	Phe
				85						90					95	
	Phe	Leu	Pro	Arg	Ile	Thr	Ile	Pro	Asp	Asn	Tyr	Thr	Ile	Glu	Val	Glu
				100					105					110		
10	Ala	Glu	Asn	Gly	Asp	Gly	Val	Ile	Lys	Ser	His	Met	Thr	Tyr	Trp	Arg
			115					120					125			
	Leu	Glu	Asn	Ile	Ala	Lys	Thr	Glu	Pro	Pro	Lys	Ile	Phe	Arg	Val	Lys
15			130				135					140				
	Pro	Val	Leu	Gly	Ile	Lys	Arg	Met	Ile	Gln	Ile	Glu	Trp	Ile	Lys	Pro
	145					150					155					160
	Glu	Leu	Ala	Pro	Val	Ser	Ser	Asp	Leu	Lys	Tyr	Thr	Leu	Arg	Phe	Arg
20					165					170					175	
	Thr	Val	Asn	Ser	Thr	Ser	Trp	Met	Glu	Val	Asn	Phe	Ala	Lys	Asn	Arg
			180					185						190		
	Lys	Asp	Lys	Asn	Gln	Thr	Tyr	Asn	Leu	Thr	Gly	Leu	Gln	Pro	Phe	Thr
25			195				200					205				
	Glu	Tyr	Val	Ile	Ala	Leu	Arg	Cys	Ala	Val	Lys	Glu	Ser	Lys	Phe	Trp
	210					215						220				
	Ser	Asp	Trp	Ser	Gln	Glu	Lys	Met	Gly	Met	Thr	Glu	Glu	Glu	Ala	Pro
30	225				230						235					240
	Cys	Gly	Leu	Glu	Leu	Trp	Arg	Val	Leu	Lys	Pro	Ala	Glu	Ala	Asp	Gly
				245						250					255	
	Arg	Arg	Pro	Val	Arg	Leu	Leu	Trp	Lys	Lys	Ala	Arg	Gly	Ala	Pro	Val
35			260					265						270		
	Leu	Glu	Lys	Thr	Leu	Gly	Tyr	Asn	Ile	Trp	Tyr	Tyr	Pro	Glu	Ser	Asn
			275				280							285		
	Thr	Asn	Leu	Thr	Glu	Thr	Met	Asn	Thr	Thr	Asn	Gln	Gln	Leu	Glu	Leu
40			290				295					300				
	His	Leu	Gly	Gly	Glu	Ser	Phe	Trp	Val	Ser	Met	Ile	Ser	Tyr	Asn	Ser
	305					310					315					320
	Leu	Gly	Lys	Ser	Pro	Val	Ala	Thr	Leu	Arg	Ile	Pro	Ala	Ile	Gln	Glu
45				325						330					335	
	Lys	Ser	Phe	Gln	Cys	Ile	Glu	Val	Met	Gln	Ala	Cys	Val	Ala	Glu	Asp
			340						345					350		
	Gln	Leu	Val	Val	Lys	Trp	Gln	Ser	Ser	Ala	Leu	Asp	Val	Asn	Thr	Trp
50			355				360							365		
	Met	Ile	Glu	Trp	Phe	Pro	Asp	Val	Asp	Ser	Glu	Pro	Thr	Thr	Leu	Ser
			370			375						380				
	Trp	Glu	Ser	Val	Ser	Gln	Ala	Thr	Asn	Trp	Thr	Ile	Gln	Gln	Asp	Lys
55	385				390						395					400

EP 1 476 541 B1

Leu Lys Pro Phe Trp Cys Tyr Asn Ile Ser Val Tyr Pro Met Leu His
 405 410 415
 5 Asp Lys Val Gly Glu Pro Tyr Ser Ile Gln Ala Tyr Ala Lys Glu Gly
 420 425 430
 Val Pro Ser Glu Gly Pro Glu Thr Lys Val Glu Asn Ile Gly Val Lys
 435 440 445
 10 Thr Val Thr Ile Thr Trp Lys Glu Ile Pro Lys Ser Glu Arg Lys Gly
 450 455 460
 Ile Ile Cys Asn Tyr Thr Ile Phe Tyr Gln Ala Glu Gly Gly Lys Gly
 465 470 475 480
 15 Phe Ser Lys Thr Val Asn Ser Ser Ile Leu Gln Tyr Gly Leu Glu Ser
 485 490 495
 Leu Lys Arg Lys Thr Ser Tyr Ile Val Gln Val Met Ala Ser Thr Ser
 500 505 510
 20 Ala Gly Gly Thr Asn Gly Thr Ser Ile Asn Phe Lys Thr Leu Ser Phe
 515 520 525
 Ser Val Phe Glu Glu Pro Arg Ser Ser Asp Lys Thr His Thr Cys Pro
 530 535 540
 25 Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe
 545 550 555 560
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 565 570 575
 30 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe
 580 585 590
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 595 600 605
 35 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 610 615 620
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 625 630 635 640
 40 Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
 645 650 655
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
 660 665 670
 45 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 675 680 685
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 690 695 700
 50 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 705 710 715 720
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
 725 730 735
 55 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His

EP 1 476 541 B1

740 745 750
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
755 760

5

<210> 40

<211> 34

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC29157

15

<400> 40

ctagtatggc cggccatgaa gctctctccc cagc 34

<210> 41

<211> 41

20 <212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC29150

25

<400> 41

gtctgaagat ctgggctcct caaagacact gaatgacaat g 41

<210> 42

30 <211> 21

<212> DNA

<213> Artificial Sequence

<220>

35 <223> Oligonucleotide primer ZC41458

<400> 42

tggacctcgc actaaaatca t 21

40

<210> 43

<211> 22

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Oligonucleotide primer ZC41457

<400> 43

50 aatcacggca gagtcccac ac 22

<210> 44

<211> 100

<212> DNA

<213> Artificial Sequence

55

<220>

<223> Oligonucleotide primer ZC12749

EP 1 476 541 B1

<400> 44

5 gtaccttccc gtaaaccct ccccttcccg gaattacacc cgcgtatttc ccagaaaagg 60
 aactgtagat ttctaggaat tcaatccttg gccacgcgtc 100

<210> 45

<211> 100

10 <212> DNA

<213> Artificial Sequence

<220>

15 <223> Oligonucleotide primer ZC12748

<400> 45

20 tcgagacgcg tggccaagga ttgaattcct agaaatctac agttcctttt ctgggaaata 60
 cgcgggtgta attccgggaa ggggagggat ttacgggaag 100

<210> 46

<211> 20

25 <212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC10651

30 <400> 46

agcttttctg cagcagctct 20

<210> 47

<211> 23

35 <212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC10565

40

<400> 47

ttgcagaaa aggtgcaaa tgc 23

<210> 48

45 <211> 25

<212> DNA

<213> Artificial Sequence

<220>

50 <223> Oligonucleotide primer ZC14063

<400> 48

caccagacat aatagctgac agact 25

55 <210> 49

<211> 21

<212> DNA

<213> Artificial Sequence

EP 1 476 541 B1

<220>
<223> Oligonucleotide primer ZC17574

5 <400> 49
ggtrttgctc agcatgcaca c 21

<210> 50
<211> 24
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC17600

15 <400> 50
catgtaggcc atgaggtcca ccac 24

<210> 51
<211> 21
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC38065

25 <400> 51
ctttcctggg aatctgtgc t 21

<210> 52
30 <211> 18
<212> DNA
<213> Artificial Sequence

<220>
35 <223> Oligonucleotide primer ZC38068

<400> 52
cctccagctc tggtgctg 18

40 <210> 53
<211> 24
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Oligonucleotide primer ZC37877

<400> 53
50 caaaaaaacc aacaaattga ctca 24

<210> 54
<211> 25
<212> DNA
55 <213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC37876

EP 1 476 541 B1

<400> 54
catgtggcta tactacttcc agcag 25

5 <210> 55
<211> 22
<212> DNA
<213> Artificial Sequence

10 <220>
<223> zcytor17 receptor TaqMan® probe

<400> 55
ctgtgttggc ccaccgttcc ca 22

15 <210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

20 <220>
<223> rRNA forward primer

<400> 56
cggctaccac atccaaggaa 20

25 <210> 57
<211> 18
<212> DNA
<213> Artificial Sequence

30 <220>
<223> the rRNA reverse primer

<400> 57
gctggaatta cgcggct 18

35 <210> 58
<211> 22
<212> DNA
<213> Artificial Sequence

40 <220>
<223> rRNA TaqMan® probe

45 <400> 58
tgctggcacc agactgccc tc 22

<210> 59

50 <220>
<223> Skipped Sequence

<400> 59
000

55 <210> 60
<211> 21
<212> DNA

EP 1 476 541 B1

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC41458

5

<400> 60

tggacctcgc actaaaatca t 21

<210> 61

10

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

15

<223> Oligonucleotide primer ZC41457

<400> 61

aatcacggca gaggccccac ac 22

<210> 62

20

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

25

<223> Oligonucleotide primer ZC41459

<400> 62

agaagggcgt gctcgtgtc 19

30

<210> 63

<211> 18

<212> DNA

<213> Artificial Sequence

35

<220>

<223> Oligonucleotide primer ZC41460

<400> 63

40

ccggatggct gggctgtg 18

<210> 64

<211> 25

<212> DNA

45

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC39982

<400> 64

50

aatgtctgtg tagcataagg tatga 25

<210> 65

55

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

EP 1 476 541 B1

<223> Oligonucleotide primer ZC39983

<400> 65

cctgcctacc tgaaaaccag aa 22

5

<210> 66

<211> 36

<212> DNA

<213> Artificial Sequence

10

<220>

<223> Oligonucleotide primer ZC39980

<400> 66

tttgaattcg ccaccatggc tctattgca gtcttt 36

15

<210> 67

<211> 28

<212> DNA

<213> Artificial Sequence

20

<220>

<223> Oligonucleotide primer ZC39981

<400> 67

ctgtctcgag tgctggtag cagtggtc 28

25

<210> 68

<211> 2217

<212> DNA

<213> Homo sapiens

30

<220>

<221> CDS

<222> (1)...(2217)

35

<400> 68

40

45

50

55

EP 1 476 541 B1

	85	90	95	
5	tgg agc tgg gaa tct gag ctc cct ttg gaa tgt gcc aca cac ttt gta			336
	Trp Ser Trp Glu Ser Glu Leu Pro Leu Glu Cys Ala Thr His Phe Val			
	100	105	110	
10	aga ata aag agt ttg gtg gac gat gcc aag ttc cct gag cca aat ttc			384
	Arg Ile Lys Ser Leu Val Asp Asp Ala Lys Phe Pro Glu Pro Asn Phe			
	115	120	125	
15	tgg agc aac tgg agt tcc tgg gag gaa gtc agt gta caa gat tct act			432
	Trp Ser Asn Trp Ser Ser Trp Glu Glu Val Ser Val Gln Asp Ser Thr			
	130	135	140	
20	gga cag gat ata ttg ttc gtt ttc cct aaa gat aag ctg gtg gaa gaa			480
	Gly Gln Asp Ile Leu Phe Val Phe Pro Lys Asp Lys Leu Val Glu Glu			
	145	150	155	160
25	ggc acc aat gtt acc att tgt tac gtt tct agg aac att caa aat aat			528
	Gly Thr Asn Val Thr Ile Cys Tyr Val Ser Arg Asn Ile Gln Asn Asn			
	165	170	175	
30	gta tcc tgt tat ttg gaa ggg aaa cag att cat gga gaa caa ctt gat			576
	Val Ser Cys Tyr Leu Glu Gly Lys Gln Ile His Gly Glu Gln Leu Asp			
	180	185	190	
35	cca cat gta act gca ttc aac ttg aat agt gtg cct ttc att agg aat			624
	Pro His Val Thr Ala Phe Asn Leu Asn Ser Val Pro Phe Ile Arg Asn			
	195	200	205	
40	aaa ggg aca aat atc tat tgt gag gca agt caa gga aat gtc agt gaa			672
	Lys Gly Thr Asn Ile Tyr Cys Glu Ala Ser Gln Gly Asn Val Ser Glu			
	210	215	220	
45	ggc atg aaa ggc atc gtt ctt ttt gtc tca aaa gta ctt gag gag ccc			720
	Gly Met Lys Gly Ile Val Leu Phe Val Ser Lys Val Leu Glu Glu Pro			
	225	230	235	240
50	aag gac ttt tct tgt gaa acc gag gac ttc aag act ttg cac tgt act			768
	Lys Asp Phe Ser Cys Glu Thr Glu Asp Phe Lys Thr Leu His Cys Thr			
	245	250	255	
55	tgg gat cct ggg acg gac act gcc ttg ggg tgg tct aaa caa cct tcc			816

EP 1 476 541 B1

Trp Asp Pro Gly Thr Asp Thr Ala Leu Gly Trp Ser Lys Gln Pro Ser
 260 265 270
 5
 caa agc tac act tta ttt gaa tca ttt tct ggg gaa aag aaa ctt tgt 864
 Gln Ser Tyr Thr Leu Phe Glu Ser Phe Ser Gly Glu Lys Lys Leu Cys
 275 280 285
 10
 aca cac aaa aac tgg tgt aat tgg caa ata act caa gac tca caa gaa 912
 Thr His Lys Asn Trp Cys Asn Trp Gln Ile Thr Gln Asp Ser Gln Glu
 290 295 300
 15
 acc tat aac ttc aca ctc ata gct gaa aat tac tta agg aag aga agt 960
 Thr Tyr Asn Phe Thr Leu Ile Ala Glu Asn Tyr Leu Arg Lys Arg Ser
 305 310 315 320
 20
 gtc aat atc ctt ttt aac ctg act cat cga gtt tat tta atg aat cct 1008
 Val Asn Ile Leu Phe Asn Leu Thr His Arg Val Tyr Leu Met Asn Pro
 325 330 335
 25
 ttt agt gtc aac ttt gaa aat gta aat gcc aca aat gcc atc atg acc 1056
 Phe Ser Val Asn Phe Glu Asn Val Asn Ala Thr Asn Ala Ile Met Thr
 340 345 350
 30
 tgg aag gtg cac tcc ata agg aat aat ttc aca tat ttg tgt cag att 1104
 Trp Lys Val His Ser Ile Arg Asn Asn Phe Thr Tyr Leu Cys Gln Ile
 355 360 365
 35
 gaa ctc cat ggt gaa gga aaa atg atg caa tac aat gtt tcc atc aag 1152
 Glu Leu His Gly Glu Gly Lys Met Met Gln Tyr Asn Val Ser Ile Lys
 370 375 380
 40
 gtg aac ggt gag tac ttc tta agt gaa ctg gaa cct gcc aca gag tac 1200
 Val Asn Gly Glu Tyr Phe Leu Ser Glu Leu Glu Pro Ala Thr Glu Tyr
 385 390 395 400
 45
 atg gcg cga gta cgg tgt gct gat gcc agc cac ttc tgg aaa tgg agt 1248
 Met Ala Arg Val Arg Cys Ala Asp Ala Ser His Phe Trp Lys Trp Ser
 405 410 415
 50
 gaa tgg agt ggt cag aac ttc acc aca ctt gaa gct gct ccc tca gag 1296
 Glu Trp Ser Gly Gln Asn Phe Thr Thr Leu Glu Ala Ala Pro Ser Glu
 420 425 430
 55

EP 1 476 541 B1

5 gcc cct gat gtc tgg aga att gtg agc ttg gag cca gga aat cat act 1344
 Ala Pro Asp Val Trp Arg Ile Val Ser Leu Glu Pro Gly Asn His Thr
 435 440 445

10 gtg acc tta ttc tgg aag cca tta tca aaa ctg cat gcc aat gga aag 1392
 Val Thr Leu Phe Trp Lys Pro Leu Ser Lys Leu His Ala Asn Gly Lys
 450 455 460

15 atc ctg ttc tat aat gta gtt gta gaa aac cta gac aaa cca tcc agt 1440
 Ile Leu Phe Tyr Asn Val Val Val Glu Asn Leu Asp Lys Pro Ser Ser
 465 470 475 480

20 tca gag ctc cat tcc att cca gca cca gcc aac agc aca aaa cta atc 1488
 Ser Glu Leu His Ser Ile Pro Ala Pro Ala Asn Ser Thr Lys Leu Ile
 485 490 495

25 ctt gac agg tgt tcc tac caa atc tgc gtc ata gcc aac aac agt gtg 1536
 Leu Asp Arg Cys Ser Tyr Gln Ile Cys Val Ile Ala Asn Asn Ser Val
 500 505 510

30 ggt gct tct cct gct tct gta ata gtc atc tct gca gac ccc gaa aac 1584
 Gly Ala Ser Pro Ala Ser Val Ile Val Ile Ser Ala Asp Pro Glu Asn
 515 520 525

35 aaa gag gtt gag gaa gaa aga att gca ggc aca gag ggt gga ttc tct 1632
 Lys Glu Val Glu Glu Glu Arg Ile Ala Gly Thr Glu Gly Gly Phe Ser
 530 535 540

40 ctg tct tgg aaa ccc caa cct gga gat gtt ata ggc tat gtt gtg gac 1680
 Leu Ser Trp Lys Pro Gln Pro Gly Asp Val Ile Gly Tyr Val Val Asp
 545 550 555 560

45 tgg tgt gac cat acc cag gat gtg ctc ggt gat ttc cag tgg aag aat 1728
 Trp Cys Asp His Thr Gln Asp Val Leu Gly Asp Phe Gln Trp Lys Asn
 565 570 575

50 gta ggt ccc aat acc aca agc aca gtc att agc aca gat gct ttt agg 1776
 Val Gly Pro Asn Thr Thr Ser Thr Val Ile Ser Thr Asp Ala Phe Arg
 580 585 590

55 cca gga gtt cga tat gac ttc aga att tat ggg tta tct aca aaa agg 1824
 Pro Gly Val Arg Tyr Asp Phe Arg Ile Tyr Gly Leu Ser Thr Lys Arg
 595 600 605

EP 1 476 541 B1

5 att gct tgt tta tta gag aaa aaa aca gga tac tct cag gaa ctt gct 1872
 Ile Ala Cys Leu Leu Glu Lys Lys Thr Gly Tyr Ser Gln Glu Leu Ala
 610 615 620

10 cct tca gac aac cct cac gtg ctg gtg gat aca ttg aca tcc cac tcc 1920
 Pro Ser Asp Asn Pro His Val Leu Val Asp Thr Leu Thr Ser His Ser
 625 630 635 640

15 ttc act ctg agt tgg aaa gat tac tct act gaa tct caa cct ggt ttt 1968
 Phe Thr Leu Ser Trp Lys Asp Tyr Ser Thr Glu Ser Gln Pro Gly Phe
 645 650 655

20 ata caa ggg tac cat gtc tat ctg aaa tcc aag gcg agg cag tgc cac 2016
 Ile Gln Gly Tyr His Val Tyr Leu Lys Ser Lys Ala Arg Gln Cys His
 660 665 670

25 cca cga ttt gaa aag gca gtt ctt tca gat ggt tca gaa tgt tgc aaa 2064
 Pro Arg Phe Glu Lys Ala Val Leu Ser Asp Gly Ser Glu Cys Cys Lys
 675 680 685

30 tac aaa att gac aac ccg gaa gaa aag gca ttg att gtg gac aac cta 2112
 Tyr Lys Ile Asp Asn Pro Glu Glu Lys Ala Leu Ile Val Asp Asn Leu
 690 695 700

35 aag cca gaa tcc ttc tat gag ttt ttc atc act cca ttc act agt gct 2160
 Lys Pro Glu Ser Phe Tyr Glu Phe Phe Ile Thr Pro Phe Thr Ser Ala
 705 710 715 720

40 ggt gaa ggc ccc agt gct acg ttc acg aag gtc acg act ccg gat gaa 2208
 Gly Glu Gly Pro Ser Ala Thr Phe Thr Lys Val Thr Thr Pro Asp Glu
 725 730 735

45 cac tcc tcg 2217
 His Ser Ser

<210> 69
 <211> 739
 <212> PRT
 <213> Homo sapiens
 <400> 69

EP 1 476 541 B1

Met Ala Leu Phe Ala Val Phe Gln Thr Thr Phe Phe Leu Thr Leu Leu
 1 5 10 15
 Ser Leu Arg Thr Tyr Gln Ser Glu Val Leu Ala Glu Arg Leu Pro Leu
 5 20 25 30
 Thr Pro Val Ser Leu Lys Val Ser Thr Asn Ser Thr Arg Gln Ser Leu
 35 40 45
 His Leu Gln Trp Thr Val His Asn Leu Pro Tyr His Gln Glu Leu Lys
 10 50 55 60
 Met Val Phe Gln Ile Gln Ile Ser Arg Ile Glu Thr Ser Asn Val Ile
 65 70 75 80
 Trp Val Gly Asn Tyr Ser Thr Thr Val Lys Trp Asn Gln Val Leu His
 15 85 90 95
 Trp Ser Trp Glu Ser Glu Leu Pro Leu Glu Cys Ala Thr His Phe Val
 100 105 110
 Arg Ile Lys Ser Leu Val Asp Asp Ala Lys Phe Pro Glu Pro Asn Phe
 20 115 120 125
 Trp Ser Asn Trp Ser Ser Trp Glu Glu Val Ser Val Gln Asp Ser Thr
 130 135 140
 Gly Gln Asp Ile Leu Phe Val Phe Pro Lys Asp Lys Leu Val Glu Glu
 25 145 150 155 160
 Gly Thr Asn Val Thr Ile Cys Tyr Val Ser Arg Asn Ile Gln Asn Asn
 165 170 175
 Val Ser Cys Tyr Leu Glu Gly Lys Gln Ile His Gly Glu Gln Leu Asp
 30 180 185 190
 Pro His Val Thr Ala Phe Asn Leu Asn Ser Val Pro Phe Ile Arg Asn
 195 200 205
 Lys Gly Thr Asn Ile Tyr Cys Glu Ala Ser Gln Gly Asn Val Ser Glu
 35 210 215 220
 Gly Met Lys Gly Ile Val Leu Phe Val Ser Lys Val Leu Glu Glu Pro
 225 230 235 240
 Lys Asp Phe Ser Cys Glu Thr Glu Asp Phe Lys Thr Leu His Cys Thr
 40 245 250 255
 Trp Asp Pro Gly Thr Asp Thr Ala Leu Gly Trp Ser Lys Gln Pro Ser
 260 265 270
 Gln Ser Tyr Thr Leu Phe Glu Ser Phe Ser Gly Glu Lys Lys Leu Cys
 45 275 280 285
 Thr His Lys Asn Trp Cys Asn Trp Gln Ile Thr Gln Asp Ser Gln Glu
 290 295 300
 Thr Tyr Asn Phe Thr Leu Ile Ala Glu Asn Tyr Leu Arg Lys Arg Ser
 50 305 310 315 320
 Val Asn Ile Leu Phe Asn Leu Thr His Arg Val Tyr Leu Met Asn Pro
 325 330 335

55

EP 1 476 541 B1

Phe Ser Val Asn Phe Glu Asn Val Asn Ala Thr Asn Ala Ile Met Thr
 340 345 350
 5 Trp Lys Val His Ser Ile Arg Asn Asn Phe Thr Tyr Leu Cys Gln Ile
 355 360 365
 Glu Leu His Gly Glu Gly Lys Met Met Gln Tyr Asn Val Ser Ile Lys
 370 375 380
 10 Val Asn Gly Glu Tyr Phe Leu Ser Glu Leu Glu Pro Ala Thr Glu Tyr
 385 390 395 400
 Met Ala Arg Val Arg Cys Ala Asp Ala Ser His Phe Trp Lys Trp Ser
 405 410 415
 15 Glu Trp Ser Gly Gln Asn Phe Thr Thr Leu Glu Ala Ala Pro Ser Glu
 420 425 430
 Ala Pro Asp Val Trp Arg Ile Val Ser Leu Glu Pro Gly Asn His Thr
 435 440 445
 20 Val Thr Leu Phe Trp Lys Pro Leu Ser Lys Leu His Ala Asn Gly Lys
 450 455 460
 Ile Leu Phe Tyr Asn Val Val Glu Asn Leu Asp Lys Pro Ser Ser
 465 470 475 480
 25 Ser Glu Leu His Ser Ile Pro Ala Pro Ala Asn Ser Thr Lys Leu Ile
 485 490 495
 Leu Asp Arg Cys Ser Tyr Gln Ile Cys Val Ile Ala Asn Asn Ser Val
 500 505 510
 30 Gly Ala Ser Pro Ala Ser Val Ile Val Ile Ser Ala Asp Pro Glu Asn
 515 520 525
 Lys Glu Val Glu Glu Glu Arg Ile Ala Gly Thr Glu Gly Gly Phe Ser
 530 535 540
 35 Leu Ser Trp Lys Pro Gln Pro Gly Asp Val Ile Gly Tyr Val Val Asp
 545 550 555 560
 Trp Cys Asp His Thr Gln Asp Val Leu Gly Asp Phe Gln Trp Lys Asn
 565 570 575
 40 Val Gly Pro Asn Thr Thr Ser Thr Val Ile Ser Thr Asp Ala Phe Arg
 580 585 590
 Pro Gly Val Arg Tyr Asp Phe Arg Ile Tyr Gly Leu Ser Thr Lys Arg
 595 600 605
 45 Ile Ala Cys Leu Leu Glu Lys Lys Thr Gly Tyr Ser Gln Glu Leu Ala
 610 615 620
 Pro Ser Asp Asn Pro His Val Leu Val Asp Thr Leu Thr Ser His Ser
 625 630 635 640
 50 Phe Thr Leu Ser Trp Lys Asp Tyr Ser Thr Glu Ser Gln Pro Gly Phe
 645 650 655
 Ile Gln Gly Tyr His Val Tyr Leu Lys Ser Lys Ala Arg Gln Cys His
 660 665 670
 55 Pro Arg Phe Glu Lys Ala Val Leu Ser Asp Gly Ser Glu Cys Cys Lys

EP 1 476 541 B1

		675				680						685					
	Tyr	Lys	Ile	Asp	Asn	Pro	Glu	Glu	Lys	Ala	Leu	Ile	Val	Asp	Asn	Leu	
5		690				695						700					
	Lys	Pro	Glu	Ser	Phe	Tyr	Glu	Phe	Phe	Ile	Thr	Pro	Phe	Thr	Ser	Ala	
	705					710					715					720	
10	Gly	Glu	Gly	Pro	Ser	Ala	Thr	Phe	Thr	Lys	Val	Thr	Thr	Pro	Asp	Glu	
					725						730					735	
	His	Ser	Ser														
	<210> 70																
15	<211> 1557																
	<212> DNA																
	<213> Homo sapiens																
	<220>																
20	<221> CDS																
	<222> (1)...(1557)																
	<400> 70																
25	atg	atg	tgg	acc	tgg	gca	ctg	tgg	atg	ctc	ccc	tca	ctc	tgc	aaa	ttc	48
	Met	Met	Trp	Thr	Trp	Ala	Leu	Trp	Met	Leu	Pro	Ser	Leu	Cys	Lys	Phe	
	1				5					10					15		
30	agc	ctg	gca	gct	ctg	cca	gct	aag	cct	gag	aac	att	tcc	tgt	gtc	tac	96
	Ser	Leu	Ala	Ala	Leu	Pro	Ala	Lys	Pro	Glu	Asn	Ile	Ser	Cys	Val	Tyr	
				20					25					30			
35	tac	tat	agg	aaa	aat	tta	acc	tgc	act	tgg	agt	cca	gga	aag	gaa	acc	144
	Tyr	Tyr	Arg	Lys	Asn	Leu	Thr	Cys	Thr	Trp	Ser	Pro	Gly	Lys	Glu	Thr	
			35					40					45				
40	agt	tat	acc	cag	tac	aca	ggt	aag	aga	act	tac	gct	ttt	gga	gaa	aaa	192
	Ser	Tyr	Thr	Gln	Tyr	Thr	Val	Lys	Arg	Thr	Tyr	Ala	Phe	Gly	Glu	Lys	
		50					55					60					
45	cat	gat	aat	tgt	aca	acc	aat	agt	tct	aca	agt	gaa	aat	cgt	gct	tcg	240
	His	Asp	Asn	Cys	Thr	Thr	Asn	Ser	Ser	Thr	Ser	Glu	Asn	Arg	Ala	Ser	
	65					70					75				80		
50	tgc	tct	ttt	ttc	ctt	cca	aga	ata	acg	atc	cca	gat	aat	tat	acc	att	288
	Cys	Ser	Phe	Phe	Leu	Pro	Arg	Ile	Thr	Ile	Pro	Asp	Asn	Tyr	Thr	Ile	
55																	

EP 1 476 541 B1

	85	90	95			
5	gag gtg gaa gct gaa aat gga gat ggt gta att aaa tct cat atg aca Glu Val Glu Ala Glu Asn Gly Asp Gly Val Ile Lys Ser His Met Thr	100	105	110	336	
10	tac tgg aga tta gag aac ata gcg aaa act gaa cca cct aag att ttc Tyr Trp Arg Leu Glu Asn Ile Ala Lys Thr Glu Pro Pro Lys Ile Phe	115	120	125	384	
15	cgt gtg aaa cca gtt ttg ggc atc aaa cga atg att caa att gaa tgg Arg Val Lys Pro Val Leu Gly Ile Lys Arg Met Ile Gln Ile Glu Trp	130	135	140	432	
20	ata aag cct gag ttg gcg cct gtt tca tct gat tta aaa tac aca ctt Ile Lys Pro Glu Leu Ala Pro Val Ser Ser Asp Leu Lys Tyr Thr Leu	145	150	155	160	480
25	cga ttc agg aca gtc aac agt acc agc tgg atg gaa gtc aac ttc gct Arg Phe Arg Thr Val Asn Ser Thr Ser Trp Met Glu Val Asn Phe Ala	165	170	175	528	
30	aag aac cgt aag gat aaa aac caa acg tac aac ctc acg ggg ctg cag Lys Asn Arg Lys Asp Lys Asn Gln Thr Tyr Asn Leu Thr Gly Leu Gln	180	185	190	576	
35	cct ttt aca gaa tat gtc ata gct ctg cga tgt gcg gtc aag gag tca Pro Phe Thr Glu Tyr Val Ile Ala Leu Arg Cys Ala Val Lys Glu Ser	195	200	205	624	
40	aag ttc tgg agt gac tgg agc caa gaa aaa atg gga atg act gag gaa Lys Phe Trp Ser Asp Trp Ser Gln Glu Lys Met Gly Met Thr Glu Glu	210	215	220	672	
45	gaa gct cca tgt ggc ctg gaa ctg tgg aga gtc ctg aaa cca gct gag Glu Ala Pro Cys Gly Leu Glu Leu Trp Arg Val Leu Lys Pro Ala Glu	225	230	235	240	720
50	gcg gat gga aga agg cca gtg cgg ttg tta tgg aag aag gca aga gga Ala Asp Gly Arg Arg Pro Val Arg Leu Leu Trp Lys Lys Ala Arg Gly	245	250	255	768	
55	gcc cca gtc cta gag aaa aca ctt ggc tac aac ata tgg tac tat cca				816	

EP 1 476 541 B1

Ala Pro Val Leu Glu Lys Thr Leu Gly Tyr Asn Ile Trp Tyr Tyr Pro
 260 265 270

5
 gaa agc aac act aac ctc aca gaa aca atg aac act act aac cag cag 864
 Glu Ser Asn Thr Asn Leu Thr Glu Thr Met Asn Thr Thr Asn Gln Gln
 275 280 285

10
 ctt gaa ctg cat ctg gga ggc gag agc ttt tgg gtg tct atg att tct 912
 Leu Glu Leu His Leu Gly Gly Glu Ser Phe Trp Val Ser Met Ile Ser
 290 295 300

15
 tat aat tct ctt ggg aag tct cca gtg gcc acc ctg agg att cca gct 960
 Tyr Asn Ser Leu Gly Lys Ser Pro Val Ala Thr Leu Arg Ile Pro Ala
 305 310 315 320

20
 att caa gaa aaa tca ttt cag tgc att gag gtc atg cag gcc tgc gtt 1008
 Ile Gln Glu Lys Ser Phe Gln Cys Ile Glu Val Met Gln Ala Cys Val
 325 330 335

25
 gct gag gac cag cta gtg gtg aag tgg caa agc tct gct cta gac gtg 1056
 Ala Glu Asp Gln Leu Val Val Lys Trp Gln Ser Ser Ala Leu Asp Val
 340 345 350

30
 aac act tgg atg att gaa tgg ttt ccg gat gtg gac tca gag ccc acc 1104
 Asn Thr Trp Met Ile Glu Trp Phe Pro Asp Val Asp Ser Glu Pro Thr
 355 360 365

35
 acc ctt tcc tgg gaa tct gtg tct cag gcc acg aac tgg acg atc cag 1152
 Thr Leu Ser Trp Glu Ser Val Ser Gln Ala Thr Asn Trp Thr Ile Gln
 370 375 380

40
 caa gat aaa tta aaa cct ttc tgg tgc tat aac atc tct gtg tat cca 1200
 Gln Asp Lys Leu Lys Pro Phe Trp Cys Tyr Asn Ile Ser Val Tyr Pro
 385 390 395 400

45
 atg ttg cat gac aaa gtt ggc gag cca tat tcc atc cag gct tat gcc 1248
 Met Leu His Asp Lys Val Gly Glu Pro Tyr Ser Ile Gln Ala Tyr Ala
 405 410 415

50
 aaa gaa ggc gtt cca tca gaa ggt cct gag acc aag gtg gag aac att 1296
 Lys Glu Gly Val Pro Ser Glu Gly Pro Glu Thr Lys Val Glu Asn Ile
 420 425 430

55

EP 1 476 541 B1

5 ggc gtg aag acg gtc acg atc aca tgg aaa gag att ccc aag agt gag 1344
 Gly Val Lys Thr Val Thr Ile Thr Trp Lys Glu Ile Pro Lys Ser Glu
 435 440 445

10 aga aag ggt atc atc tgc aac tac acc atc ttt tac caa gct gaa ggt 1392
 Arg Lys Gly Ile Ile Cys Asn Tyr Thr Ile Phe Tyr Gln Ala Glu Gly
 450 455 460

15 gga aaa gga ttc tcc aag aca gtc aat tcc agc atc ttg cag tac ggc 1440
 Gly Lys Gly Phe Ser Lys Thr Val Asn Ser Ser Ile Leu Gln Tyr Gly
 465 470 475 480

20 ctg gag tcc ctg aaa cga aag acc tct tac att gtt cag gtc atg gcc 1488
 Leu Glu Ser Leu Lys Arg Lys Thr Ser Tyr Ile Val Gln Val Met Ala
 485 490 495

25 agc acc agt gct ggg gga acc aac ggg acc agc ata aat ttc aag aca 1536
 Ser Thr Ser Ala Gly Gly Thr Asn Gly Thr Ser Ile Asn Phe Lys Thr
 500 505 510

30 ttg tca ttc agt gtc ttt gag 1557
 Leu Ser Phe Ser Val Phe Glu
 515

35 <210> 71
 <211> 519
 <212> PRT
 <213> Homo sapiens

40 <400> 71

45 Met Met Trp Thr Trp Ala Leu Trp Met Leu Pro Ser Leu Cys Lys Phe
 1 5 10 15
 Ser Leu Ala Ala Leu Pro Ala Lys Pro Glu Asn Ile Ser Cys Val Tyr
 20 25 30
 Tyr Tyr Arg Lys Asn Leu Thr Cys Thr Trp Ser Pro Gly Lys Glu Thr
 35 40 45
 50 Ser Tyr Thr Gln Tyr Thr Val Lys Arg Thr Tyr Ala Phe Gly Glu Lys
 50 55 60
 His Asp Asn Cys Thr Thr Asn Ser Ser Thr Ser Glu Asn Arg Ala Ser
 65 70 75 80
 55 Cys Ser Phe Phe Leu Pro Arg Ile Thr Ile Pro Asp Asn Tyr Thr Ile
 85 90 95

Glu Val Glu Ala Glu Asn Gly Asp Gly Val Ile Lys Ser His Met Thr
 100 105 110
 5 Tyr Trp Arg Leu Glu Asn Ile Ala Lys Thr Glu Pro Pro Lys Ile Phe
 115 120 125
 Arg Val Lys Pro Val Leu Gly Ile Lys Arg Met Ile Gln Ile Glu Trp
 130 135 140
 10 Ile Lys Pro Glu Leu Ala Pro Val Ser Ser Asp Leu Lys Tyr Thr Leu
 145 150 155 160
 Arg Phe Arg Thr Val Asn Ser Thr Ser Trp Met Glu Val Asn Phe Ala
 165 170 175
 15 Lys Asn Arg Lys Asp Lys Asn Gln Thr Tyr Asn Leu Thr Gly Leu Gln
 180 185 190
 Pro Phe Thr Glu Tyr Val Ile Ala Leu Arg Cys Ala Val Lys Glu Ser
 195 200 205
 20 Lys Phe Trp Ser Asp Trp Ser Gln Glu Lys Met Gly Met Thr Glu Glu
 210 215 220
 Glu Ala Pro Cys Gly Leu Glu Leu Trp Arg Val Leu Lys Pro Ala Glu
 225 230 235 240
 25 Ala Asp Gly Arg Arg Pro Val Arg Leu Leu Trp Lys Lys Ala Arg Gly
 245 250 255
 Ala Pro Val Leu Glu Lys Thr Leu Gly Tyr Asn Ile Trp Tyr Tyr Pro
 260 265 270
 30 Glu Ser Asn Thr Asn Leu Thr Glu Thr Met Asn Thr Thr Asn Gln Gln
 275 280 285
 Leu Glu Leu His Leu Gly Gly Glu Ser Phe Trp Val Ser Met Ile Ser
 290 295 300
 35 Tyr Asn Ser Leu Gly Lys Ser Pro Val Ala Thr Leu Arg Ile Pro Ala
 305 310 315 320
 Ile Gln Glu Lys Ser Phe Gln Cys Ile Glu Val Met Gln Ala Cys Val
 325 330 335
 40 Ala Glu Asp Gln Leu Val Val Lys Trp Gln Ser Ser Ala Leu Asp Val
 340 345 350
 Asn Thr Trp Met Ile Glu Trp Phe Pro Asp Val Asp Ser Glu Pro Thr
 355 360 365
 45 Thr Leu Ser Trp Glu Ser Val Ser Gln Ala Thr Asn Trp Thr Ile Gln
 370 375 380
 Gln Asp Lys Leu Lys Pro Phe Trp Cys Tyr Asn Ile Ser Val Tyr Pro
 385 390 395 400
 50 Met Leu His Asp Lys Val Gly Glu Pro Tyr Ser Ile Gln Ala Tyr Ala
 405 410 415
 Lys Glu Gly Val Pro Ser Glu Gly Pro Glu Thr Lys Val Glu Asn Ile
 420 425 430
 55 Gly Val Lys Thr Val Thr Ile Thr Trp Lys Glu Ile Pro Lys Ser Glu

EP 1 476 541 B1

<210> 75
 <211> 65
 <212> DNA
 <213> Artificial Sequence

5

<220>
 <223> Oligonucleotide primer ZC29232

<400> 75

10

cgactgactc gagtcagtga tggatgatggt gatggccacc tgatccttta cccggagaca 60
 gggag 65

15

<210> 76
 <211> 3196
 <212> DNA
 <213> Mus musculus

20

<400> 76

25

tgtatgtctg cacagtttgt gtatgcctgg tgcccacaga ggctcgagag tgtcagattc 60
 ccccaaaaac tggagttaca gttttgagcc gccccatgct tgatagcaat caaacctggg 120
 tcctctgaaa gagcatccag tgcattgtaac cactgaacca tctctccaaa ccatgaacat 180
 cactttaatt ttttttaata gttaaaggat attttgattc taaagatgta aaagaacgtc 240
 tcacattatt tgaattttgg taataaatgt ttcttcaaag cttaaaaaaa ttagttcagg 300
 tttttttttt ttttcagtcg gtgatttgct aagctgcca aactggctta gaatttgatg 360
 cctcttgtc tcagcatact gagtgtaag attacaagtg cacccttac ccagttcca 420
 taattaactg atccacccc accccatcc caccctcact ccattgcctg ggcaagtaac 480
 tcttgagccc cattctggtt cttagtctg aagtcacaaa ggtgcagggtg agaacgcaag 540
 gacaagggca ggccctggag cacagatgcc ttctccttat gccttccctg tgttactag 600
 agccatcccc ctgcctccgg aattcccaca gatggatcgc tctgtggctt cttaaaactt 660
 ccctgcaggg cactgaccct cagcccctct aagtcacttc ttcccagtg attgtacttt 720
 tcaatcgggc ttcaaacttt cctctcatta aatcagcaag cactttcaa gaaaagagag 780
 atgctcaaga tgccttctg tgtggtatgt gtatgcgttt gtgtgtgtgc acgcatgtgt 840
 gtgcatgtga ctcaatctc tgccttgccct tgagggtaac ctacgattt ccttccagcc 900
 ctgctttccc caggccgagc cgaggctggc aaccttttga aatgttttc tggagaaaag 960
 ctgagcaatg gttttgccat gggcgggcct ttgatctgct tcctcatgac aaccctttat 1020
 atattgcctg gtggccatgg cgaacacacc aggctccaga gaccacaggc aaagcgggcc 1080

45

50

55

ttctcactc tcttaccgtc gccatgatct tccacacagg taccgctggc tccacacgca 1140
 gctcagcatg gcttcagctc catggctctt atcatgttag ggaaggagc cgggaatggc 1200
 5 tgctcaggt ggttgctgga cagaggctgt tgtaactgaa gctgggatgg gcaggggcat 1260
 ctgacctatc agctccatgg tatccttctt tttctccagg aacaacgaag cctaccctgg 1320
 tgctgctttg ctgtatagga acctggctgg ccacctgcag cttgtccttc ggtgccccaa 1380
 tatcgaagga agacttaaga actacaattg acctcttgaa acaagagtct caggatcttt 1440
 10 ataacaacta tgtaagtgcc cttgagattg tttttctta accatttctt taaaatgtct 1500
 tattttgcta tctaagcaca gctatccttt ctcgatataa agccagctat ggaagccaga 1560
 gaggcattgg gaaacattgg aattcggttg gggtgaaatg tttccaaggg ggtaaattgca 1620
 ctgacagaag aggcagaggc agactggctc agggactgaa acctggcag cttacgaaac 1680
 15 actacaggat gtatgctccc tgaattcttt atctcaaate caccggctc acagtcctca 1740
 ctaaacgagc attcttgctg aaagggcctc cttagagaag ggccagcttg attcaggaat 1800
 cccccaagag caatgagagc cagtttcagc agccaaagat gtcctagtgg aagcaggggtg 1860
 tgaggatctt cctttgggtc tccggtgact aactaggcaa ctgtctgtgt gttcttgag 1920
 20 catcctggag ggccctctgc ctggccagag cctggcacag gtacagcaca ggaccagaa 1980
 agtgtgaata cttcatttcc ttgggaccgc ttagataact tcagttgaag caagtaacag 2040
 ggaaactgat ggagacacag ataacctccc tgcccctctc acttcagtca ctgagcctcc 2100
 gagaacaggt tgcagatggc taggggcagc ctgagccaga taggcggagg cagactgggt 2160
 25 agaagcatcc ttaggaacca cggccaacct gggtggtat gccatgtctt ctgactcata 2220
 agccaactag acctcgatt cctgtagaca cagagttagt gatggcccaa gcttcagaag 2280
 gttgtgttac caattagata aggtctgagg caggctagac acagaggaag ccctggaaat 2340
 gagctgttct gagctgtagg gttgttacia atgtcttctt tacaatattt caaacctctt 2400
 30 cttctacag agcataaagc aggcattctg gatgtcagca gacgaatcaa tacagctgcc 2460
 gtgtttcagc ctggaccggg aagcattaac caacatctcg gtcacatag cacatctgga 2520
 gaaagtcaaa gtgttgagcg agaacacagt agatacttct tgggtgataa gatggctaac 2580
 aaacatcagc tgtttcaacc cactgaattt aaacatttct gtgcctggaa atactgatga 2640
 35 atcctatgat tgtaaagtgt tcgtgcttac ggttttaag cagttctcaa actgcatggc 2700
 agaactgcag gctaaggaca atactacatg ctgagtgatg gggggggggg ggtgcagtgt 2760
 cctcagcagt gcctgtcctt cgagggctga gcttgcaacc caggacttaa ctcaaaggg 2820
 actgtgaggc cactactagt catgttattt atgtttttat tttgtccact gaaatcttgt 2880
 40 tctgtaccc tgtagggact ggaagtggca gctatattta tttatttatg tactgagttt 2940
 gtaacgctc catggaggag ccttcagagt ctatttaata aattatattg acatgatcac 3000
 ataacagtt ttggaatttg tgatggggtt gaaatcaaag attaggaatg ttctggaaat 3060
 45 agtttatgct accctctccc tccattagac agactcatga gcaaataatc ccagcagcat 3120
 cacgtgatg ataaacatct ttgttccagg tcataagtac aatcactgtc cttttggtat 3180
 gtaggctgga aactaa 3196

50 <210> 77
 <211> 24
 <212> DNA
 <213> Artificial Sequence

55 <220>
 <223> Oligonucleotide primer ZC28575

<400> 77

EP 1 476 541 B1

ccaggaaagg aaaccagtta tacc 24

<210> 78
<211> 23
5 <212> DNA
<213> Artificial Sequence

<220>
10 <223> Oligonucleotide primer ZC21195

<400> 78
gaggagacca taacccccga cag 23

<210> 79
15 <211> 23
<212> DNA
<213> Artificial Sequence

<220>
20 <223> Oligonucleotide primer ZC21196

<400> 79
catagctccc accacacgat ttt 23

<210> 80
25 <211> 25
<212> DNA
<213> Artificial Sequence

<220>
30 <223> Oligonucleotide primer ZC26358

<400> 80
35 aaaaccaaac gtacaacctc acggg 25

<210> 81
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
40 <223> Oligonucleotide primer ZC26359

<400> 81
45 gagcagccat acaccagagc agaca 25

<210> 82
<211> 19
<212> DNA
50 <213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC29179

<400> 82
55 gcagggttgg gaacggtgg 19

<210> 83

<211> 20
<212> DNA
<213> Artificial Sequence

5 <220>
<223> Oligonucleotide primer ZC28917

<400> 83
tgcaagatgc tggaattgac 20

10 <210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Oligonucleotide primer ZC28916

<400> 84
agtcaatcc agcatctgc 20

20 <210> 85
<211> 20
<212> DNA
25 <213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC28918

30 <400> 85
tcacagagtc atcagactcc 20

<210> 86
<211> 18
35 <212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer ZC41498

40 <400> 86
ggctccagag accacagg 18

<210> 87
45 <211> 22
<212> DNA
<213> Artificial Sequence

<220>
50 <223> Oligonucleotide primer ZC41496

<400> 87
atgactagta atgaccgcac ag 22

55 <210> 88
<211> 39
<212> DNA
<213> Artificial Sequence

EP 1 476 541 B1

<220>

<223> Oligonucleotide primer ZC41583

<400> 88

5 cgtacgggcc ggccaccatg atcttcaca caggaaca 39

<210> 89

<211> 36 .

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC41584

<400> 89

15 tgacgaggcg cgctcagca ttagtattg tcctta 36

<210> 90

<211> 650

20 <212> DNA

<213> Mus musculus

<220>

<221> CDS

25 <222> (53)...(542)

<400> 90

30

35

40

45

50

55

EP 1 476 541 B1

ggctccagag accacaggca aagcgggctt tcctcactct cttaccgtcg cc atg atc 58
 Met Ile
 1

5
 ttc cac aca gga aca acg aag cct acc ctg gtg ctg ctt tgc tgt ata 106
 Phe His Thr Gly Thr Thr Lys Pro Thr Leu Val Leu Leu Cys Cys Ile
 5 10 15

10
 gga acc tgg ctg gcc acc tgc agc ttg tcc ttc ggt gcc cca ata tcg 154
 Gly Thr Trp Leu Ala Thr Cys Ser Leu Ser Phe Gly Ala Pro Ile Ser
 20 25 30

15
 aag gaa gac tta aga act aca att gac ctc ttg aaa caa gag tct cag 202
 Lys Glu Asp Leu Arg Thr Thr Ile Asp Leu Leu Lys Gln Glu Ser Gln
 35 40 45 50

20
 gat ctt tat aac aac tat agc ata aag cag gca tct ggg atg tca gca 250
 Asp Leu Tyr Asn Asn Tyr Ser Ile Lys Gln Ala Ser Gly Met Ser Ala
 55 60 65

25
 gac gaa tca ata cag ctg ccg tgt ttc agc ctg gac cgg gaa gca tta 298
 Asp Glu Ser Ile Gln Leu Pro Cys Phe Ser Leu Asp Arg Glu Ala Leu
 70 75 80

30
 acc aac atc tcg gtc atc ata gca cat ctg gag aaa gtc aaa gtg ttg 346

35

40

45

50

55

EP 1 476 541 B1

Thr Asn Ile Ser Val Ile Ile Ala His Leu Glu Lys Val Lys Val Leu
 85 90 95
 5
 agc gag aac aca gta gat act tct tgg gtg ata aga tgg cta aca aac 394
 Ser Glu Asn Thr Val Asp Thr Ser Trp Val Ile Arg Trp Leu Thr Asn
 100 105 110
 10
 atc agc tgt ttc aac cca ctg aat tta aac att tct gtg cct gga aat 442
 Ile Ser Cys Phe Asn Pro Leu Asn Leu Asn Ile Ser Val Pro Gly Asn
 115 120 125 130
 15
 act gat gaa tcc tat gat tgt aaa gtg ttc gtg ctt acg gtt tta aag 490
 Thr Asp Glu Ser Tyr Asp Cys Lys Val Phe Val Leu Thr Val Leu Lys
 135 140 145
 20
 cag ttc tca aac tgc atg gca gaa ctg cag gct aag gac aat act aca 538
 Gln Phe Ser Asn Cys Met Ala Glu Leu Gln Ala Lys Asp Asn Thr Thr
 150 155 160
 25
 tgc t gagt gatggg ggggggtgc agtgcctca gcagtgcctg tccttcgagg 592
 Cys
 30
 gctgagcttg caaccagga ctaactcca aaggactgt gcggtcatta ctagtcat 650
 35
 <210> 91
 <211> 163
 <212> PRT
 <213> Mus musculus
 40
 <400> 91
 Met Ile Phe His Thr Gly Thr Thr Lys Pro Thr Leu Val Leu Leu Cys
 1 5 10 15
 Cys Ile Gly Thr Trp Leu Ala Thr Cys Ser Leu Ser Phe Gly Ala Pro
 45 20 25 30
 Ile Ser Lys Glu Asp Leu Arg Thr Thr Ile Asp Leu Leu Lys Gln Glu
 35 40 45
 Ser Gln Asp Leu Tyr Asn Asn Tyr Ser Ile Lys Gln Ala Ser Gly Met
 50 50 55 60
 Ser Ala Asp Glu Ser Ile Gln Leu Pro Cys Phe Ser Leu Asp Arg Glu
 65 70 75 80
 Ala Leu Thr Asn Ile Ser Val Ile Ile Ala His Leu Glu Lys Val Lys
 55 85 90 95

EP 1 476 541 B1

Val Leu Ser Glu Asn Thr Val Asp Thr Ser Trp Val Ile Arg Trp Leu
 100 105 110
 5 Thr Asn Ile Ser Cys Phe Asn Pro Leu Asn Leu Asn Ile Ser Val Pro
 115 120 125
 Gly Asn Thr Asp Glu Ser Tyr Asp Cys Lys Val Phe Val Leu Thr Val
 130 135 140
 10 Leu Lys Gln Phe Ser Asn Cys Met Ala Glu Leu Gln Ala Lys Asp Asn
 145 150 155 160
 Thr Thr Cys

15 <210> 92

<211> 511

<212> DNA

<213> Artificial Sequence

20 <220>

<223> Cloned murine cDNA sequence (SEQ ID NO:90) w/ FseI and AsclI restriction sites and a partial Kozak sequence to the mcytor17lig open reading frame and termination codon

25 <400> 92

30 ggccggccac catgatcttc cacacaggaa caacgaagcc taccctggtg ctgctttgct 60
 gtataggaac ctggctggcc acctgcagct tgtccttcgg tgccccaata tcgaaggaag 120
 acttaagaac tacaattgac ctcttgaaac aagagtctca ggatctttat aacaactata 180
 gcataaagca ggcattctggg atgtcagcag acgaatcaat acagctgccg tgtttcagcc 240
 tggaccggga agcattaacc aacatctcgg tcatcatagc acatctggag aaagtcaaag 300
 tgttgagcga gaacacagta gatacttctt gggtgataag atggctaaca aacatcagct 360
 35 gtttcaacc actgaattta aacatttctg tgcctggaaa tactgatgaa tcctatgatt 420
 gtaaagtgtt cgtgcttacg gttttaaagc agttctcaaa ctgcatggca gaactgcagg 480
 ctaaggacaa tactacatgc tgaggcgcgc c 511

40 <210> 93

<211> 21

<212> DNA

<213> Artificial Sequence

45 <220>

<223> Oligonucleotide primer ZC41438

<400> 93

50 gccatggcct ctcaactcagg c 21

<210> 94

<211> 24

<212> DNA

55 <213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC41437

EP 1 476 541 B1

<400> 94
ccagggagca ttgacaactc ttag 24

5 <210> 95
<211> 516
<212> DNA
<213> Artificial Sequence

10 <220>
<223> human zCyt17Lig-CEE polynucleotide

<221> CDS
<222> (1)...(516)

15 <400> 95

atg gcc tct cac tca ggc ccc tcg acg tct gtg ctc ttt ctg ttc tgc 48
Met Ala Ser His Ser Gly Pro Ser Thr Ser Val Leu Phe Leu Phe Cys
20 1 5 10 15

tgc ctg gga ggc tgg ctg gcc tcc cac acg ttg ccc gtc cgt tta cta 96
Cys Leu Gly Gly Trp Leu Ala Ser His Thr Leu Pro Val Arg Leu Leu
25 20 25 30

cga cca agt gat gat gta cag aaa ata gtc gag gaa tta cag tcc ctc 144
Arg Pro Ser Asp Asp Val Gln Lys Ile Val Glu Glu Leu Gln Ser Leu
30 35 40 45

tcg aag atg ctt ttg aaa gat gtg gag gaa gag aag ggc gtg ctc gtg 192
Ser Lys Met Leu Leu Lys Asp Val Glu Glu Glu Lys Gly Val Leu Val
35 50 55 60

tcc cag aat tac acg ctg ccg tgt ctc agc cct gac gcc cag ccg cca 240
Ser Gln Asn Tyr Thr Leu Pro Cys Leu Ser Pro Asp Ala Gln Pro Pro
40

45

50

55

EP 1 476 541 B1

	65		70		75		80	
5	aac aac atc cac agc cca gcc atc cgg gca tat ctc aag aca atc aga							288
	Asn Asn Ile His Ser Pro Ala Ile Arg Ala Tyr Leu Lys Thr Ile Arg							
		85		90			95	
10	cag cta gac aac aaa tct gtt att gat gag atc ata gag cac ctc gac							336
	Gln Leu Asp Asn Lys Ser Val Ile Asp Glu Ile Ile Glu His Leu Asp							
		100		105			110	
15	aaa ctc ata ttt caa gat gca cca gaa aca aac att tct gtg cca aca							384
	Lys Leu Ile Phe Gln Asp Ala Pro Glu Thr Asn Ile Ser Val Pro Thr							
		115		120			125	
20	gac acc cat gaa tgt aaa cgc ttc atc ctg act att tct caa cag ttt							432
	Asp Thr His Glu Cys Lys Arg Phe Ile Leu Thr Ile Ser Gln Gln Phe							
		130		135			140	
25	tca gag tgc atg gac ctc gca cta aaa tca ttg acc tct gga gcc caa							480
	Ser Glu Cys Met Asp Leu Ala Leu Lys Ser Leu Thr Ser Gly Ala Gln							
		145		150			155	160
30	cag gcc acc act gaa gaa tac atg ccg atg gaa taa							516
	Gln Ala Thr Thr Glu Glu Tyr Met Pro Met Glu *							
		165		170				
35	<210> 96							
	<211> 171							
	<212> PRT							
	<213> Artificial Sequence							
40	<220>							
	<223> human zCyt17Lig-CEE polypeptide							
45	<400> 96							
	Met Ala Ser His Ser Gly Pro Ser Thr Ser Val Leu Phe Leu Phe Cys							
	1 5 10 15							
50	Cys Leu Gly Gly Trp Leu Ala Ser His Thr Leu Pro Val Arg Leu Leu							
	20 25 30							
	Arg Pro Ser Asp Asp Val Gln Lys Ile Val Glu Glu Leu Gln Ser Leu							
	35 40 45							
55	Ser Lys Met Leu Leu Lys Asp Val Glu Glu Glu Lys Gly Val Leu Val							

EP 1 476 541 B1

50 55 60
 Ser Gln Asn Tyr Thr Leu Pro Cys Leu Ser Pro Asp Ala Gln Pro Pro
 5 65 70 75 80
 Asn Asn Ile His Ser Pro Ala Ile Arg Ala Tyr Leu Lys Thr Ile Arg
 85 90 95
 Gln Leu Asp Asn Lys Ser Val Ile Asp Glu Ile Ile Glu His Leu Asp
 10 100 105 110
 Lys Leu Ile Phe Gln Asp Ala Pro Glu Thr Asn Ile Ser Val Pro Thr
 115 120 125
 Asp Thr His Glu Cys Lys Arg Phe Ile Leu Thr Ile Ser Gln Gln Phe
 15 130 135 140
 Ser Glu Cys Met Asp Leu Ala Leu Lys Ser Leu Thr Ser Gly Ala Gln
 145 150 155 160
 Gln Ala Thr Thr Glu Glu Tyr Met Pro Met Glu
 20 165 170

25 <210> 97
 <211> 49
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Oligonucleotide primer ZCZC41607

<400> 97
 tccaggaat tcatataggc cggccacat ggctctcac tcaggcccc 49

35 <210> 98
 <211> 82
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Oligonucleotide primer ZCZC41605

<400> 98

45 caaccccaga gctgttttaa ggcgcgcctc tagattatta ttccatcggc atgtattctt 60
 cagtgtggc ctgtgggct cc 82

50 <210> 99
 <211> 629
 <212> DNA
 <213> Mus musculus

55 <220>
 <221> CDS
 <222> (28)...(528)

<400> 99

EP 1 476 541 B1

aacccttgg aggaccagaa cgagaca atg gtt ctt gcc agc tct acc acc agc 54
Met Val Leu Ala Ser Ser Thr Thr Ser
1 5

5

atc cac acc atg ctg ctc ctg ctc ctg atg ctc ttc cac ctg gga ctc 102
Ile His Thr Met Leu Leu Leu Leu Met Leu Phe His Leu Gly Leu
10 10 15 20 25

caa gct tca atc agt ggc cgg gat acc cac cgt tta acc aga acg ttg 150
Gln Ala Ser Ile Ser Gly Arg Asp Thr His Arg Leu Thr Arg Thr Leu
15 30 35 40

aat tgc agc tct att gtc aag gag att ata ggg aag ctc cca gaa cct 198
Asn Cys Ser Ser Ile Val Lys Glu Ile Ile Gly Lys Leu Pro Glu Pro
20 45 50 55

gaa ctc aaa act gat gat gaa gga ccc tct ctg agg aat aag agc ttt 246
Glu Leu Lys Thr Asp Asp Glu Gly Pro Ser Leu Arg Asn Lys Ser Phe
25 60 65 70

cgg aga gta aac ctg tcc aaa ttc gtg gaa agc caa gga gaa gtg gat 294
Arg Arg Val Asn Leu Ser Lys Phe Val Glu Ser Gln Gly Glu Val Asp
30 75 80 85

cct gag gac aga tac gtt atc aag tcc aat ctt cag aaa ctt aac tgt 342
Pro Glu Asp Arg Tyr Val Ile Lys Ser Asn Leu Gln Lys Leu Asn Cys
35 90 95 100 105

tgc ctg cct aca tct gcg aat gac tct gcg ctg cca ggg gtc ttc att 390
Cys Leu Pro Thr Ser Ala Asn Asp Ser Ala Leu Pro Gly Val Phe Ile
40 110 115 120

cga gat ctg gat gac ttt cgg aag aaa ctg aga ttc tac atg gtc cac 438
Arg Asp Leu Asp Asp Phe Arg Lys Lys Leu Arg Phe Tyr Met Val His
45 125 130 135

50

55

EP 1 476 541 B1

ctt aac gat ctg gag aca gtg cta acc tct aga cca cct cag ccc gca 486
 Leu Asn Asp Leu Glu Thr Val Leu Thr Ser Arg Pro Pro Gln Pro Ala
 5 140 145 150

tct ggc tcc gtc tct cct aac cgt gga acc gtg gaa tgt taa 528
 Ser Gly Ser Val Ser Pro Asn Arg Gly Thr Val Glu Cys *
 10 155 160 165

aacagcaggc agagcaccta aagtctgaat gttcctcatg gcccatggtc aaaaggattt 588
 tacattcctt tatgccatca aatgtcttat caatttatct a 629

15
 <210> 100
 <211> 166
 <212> PRT
 <213> Mus musculus

20
 <400> 100

25 Met Val Leu Ala Ser Ser Thr Thr Ser Ile His Thr Met Leu Leu Leu
 1 5 10 15
 Leu Leu Met Leu Phe His Leu Gly Leu Gln Ala Ser Ile Ser Gly Arg
 20 25 30
 Asp Thr His Arg Leu Thr Arg Thr Leu Asn Cys Ser Ser Ile Val Lys
 35 40 45
 30 Glu Ile Ile Gly Lys Leu Pro Glu Pro Glu Leu Lys Thr Asp Asp Glu
 50 55 60
 Gly Pro Ser Leu Arg Asn Lys Ser Phe Arg Arg Val Asn Leu Ser Lys
 65 70 75 80
 35 Phe Val Glu Ser Gln Gly Glu Val Asp Pro Glu Asp Arg Tyr Val Ile
 85 90 95
 Lys Ser Asn Leu Gln Lys Leu Asn Cys Cys Leu Pro Thr Ser Ala Asn
 100 105 110
 40 Asp Ser Ala Leu Pro Gly Val Phe Ile Arg Asp Leu Asp Asp Phe Arg
 115 120 125
 Lys Lys Leu Arg Phe Tyr Met Val His Leu Asn Asp Leu Glu Thr Val
 130 135 140
 45 Leu Thr Ser Arg Pro Pro Gln Pro Ala Ser Gly Ser Val Ser Pro Asn
 145 150 155 160
 Arg Gly Thr Val Glu Cys
 165

50
 <210> 101
 <211> 674
 <212> DNA
 <213> Homo sapiens

55
 <220>
 <221> CDS
 <222> (10)...(464)

EP 1 476 541 B1

<400> 101

5 gatccaaac atg agc cgc ctg ccc gtc ctg ctc ctg ctc caa ctc ctg gtc 51
Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val
1 5 10

10 cgc ccc gga ctc caa gct ccc atg acc cag aca acg tcc ttg aag aca 99
Arg Pro Gly Leu Gln Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr
15 20 25 30

15 agc tgg gtt aac tgc tct aac atg atc gat gaa att ata aca cac tta 147
Ser Trp Val Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu
35 40 45

20 aag cag cca cct ttg cct ttg ctg gac ttc aac aac ctc aat ggg gaa 195
Lys Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu
50 55 60

25 gac caa gac att ctg atg gaa aat aac ctt cga agg cca aac ctg gag 243
Asp Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu
65 70 75

30 gca ttc aac agg gct gtc aag agt tta cag aac gca tca gca att gag 291
Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu
80 85 90

35 agc att ctt aaa aat ctc ctg cca tgt ctg ccc ctg gcc acg gcc gca 339
Ser Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala
95 100 105 110

40 ccc acg cga cat cca atc cat atc aag gac ggt gac tgg aat gaa ttc 387
Pro Thr Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe
115 120 125

45 cgg agg aaa ctg acg ttc tat ctg aaa acc ctt gag aat gcg cag gct 435
Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala
130 135 140

50

55

EP 1 476 541 B1

caa cag acg act ttg agc ctc gcg atc tt ttagtccaac gtccagctcg 484
 Gln Gln Thr Thr Leu Ser Leu Ala Ile
 5 145 150

ttctctgggc cttctcacca cagcgctctg ggacatcaaa aacagcagaa cttctgaaac 544
 ctctgggtca tctctcacac attccaggac cagaagcatt tcaccttttc ctgcggcatc 604
 10 agatgaattg ttaattatct aatttctgaa atgtgcagct cccatttggc cttgtgcggt 664
 tgtgttctca 674

<210> 102
 <211> 151
 15 <212> PRT
 <213> Homo sapiens

<400> 102

20 Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu Val Arg Pro
 1 5 10 15
 Gly Leu Gln Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp
 20 25 30
 25 Val Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln
 35 40 45
 Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln
 50 55 60
 30 Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe
 65 70 75 80
 Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
 85 90 95
 35 Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr
 100 105 110
 Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg
 115 120 125
 40 Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln
 130 135 140
 Thr Thr Leu Ser Leu Ala Ile
 145 150

45 <210> 103
 <211> 7
 <212> PRT
 <213> Artificial Sequence

50 <220>
 <223> Alternative Glu-Glu (CEE) peptide tag without Gly-Ser residue pair

55 <400> 103

Glu Glu Tyr Met Pro Met Glu

1 5

5

<210> 104
 <211> 513
 <212> DNA
 <213> Artificial Sequence

10

<220>
 <223> Mouse zCytos17Lig(m)-CEE polynucleotide

15

<221> CDS
 <222> (1)...(513)

<400> 104

20

atg atc ttc cac aca gga aca acg aag cct acc ctg gtg ctg ctt tgc 48
 Met. Ile Phe His Thr Gly Thr Thr Lys Pro Thr Leu Val Leu Leu Cys
 1 5 10 15

25

tgt ata gga acc tgg ctg gcc acc tgc agc ttg tcc ttc ggt gcc cca 96
 Cys Ile Gly Thr Trp Leu Ala Thr Cys Ser Leu Ser Phe Gly Ala Pro
 20 25 30

30

ata tcg aag gaa gac tta aga act aca att gac ctc ttg aaa caa gag 144
 Ile Ser Lys Glu Asp Leu Arg Thr Thr Ile Asp Leu Leu Lys Gln Glu
 35 40 45

35

tct cag gat ctt tat aac aac tat agc ata aag cag gca tct ggg atg 192
 Ser Gln Asp Leu Tyr Asn Asn Tyr Ser Ile Lys Gln Ala Ser Gly Met
 50 55 60

40

tca gca gac gaa tca ata cag ctg ccg tgt ttc agc ctg gac cgg gaa 240
 Ser Ala Asp Glu Ser Ile Gln Leu Pro Cys Phe Ser Leu Asp Arg Glu
 65 70 75 80

45

gca tta acc aac atc tcg gtc atc ata gca cat ctg gag aaa gtc aaa 288
 Ala Leu Thr Asn Ile Ser Val Ile Ile Ala His Leu Glu Lys Val Lys

50

55

EP 1 476 541 B1

		85		90		95		
5	gtg ttg agc gag aac aca gta gat act tct tgg gtg ata aga tgg cta							336
	Val Leu Ser Glu Asn Thr Val Asp Thr Ser Trp Val Ile Arg Trp Leu	100		105		110		
10	aca aac atc agc tgt ttc aac cca ctg aat tta aac att tct gtg cct							384
	Thr Asn Ile Ser Cys Phe Asn Pro Leu Asn Leu Asn Ile Ser Val Pro	115		120		125		
15	gga aat act gat gaa tcc tat gat tgt aaa gtg ttc gtg ctt acg gtt							432
	Gly Asn Thr Asp Glu Ser Tyr Asp Cys Lys Val Phe Val Leu Thr Val	130		135		140		
20	tta aag cag ttc tca aac tgc atg gca gaa ctg cag gct aag gac aat							480
	Leu Lys Gln Phe Ser Asn Cys Met Ala Glu Leu Gln Ala Lys Asp Asn	145		150		155		160
25	act aca tgc gaa gaa tac atg ccg atg gaa tga							513
	Thr Thr Cys Glu Glu Tyr Met Pro Met Glu *							
		165		170				

<210> 105

<211> 170

30 <212> PRT

<213> Artificial Sequence

<220>

<223> Mouse zCyt17Lig(m)-CEE polypeptide

35

<400> 105

40	Met Ile Phe His Thr Gly Thr Thr Lys Pro Thr Leu Val Leu Leu Cys													
	1		5			10					15			
	Cys Ile Gly Thr Trp Leu Ala Thr Cys Ser Leu Ser Phe Gly Ala Pro													
		20			25				30					
	Ile Ser Lys Glu Asp Leu Arg Thr Thr Ile Asp Leu Leu Lys Gln Glu													
45		35		40		45								
	Ser Gln Asp Leu Tyr Asn Asn Tyr Ser Ile Lys Gln Ala Ser Gly Met													
		50		55		60								
	Ser Ala Asp Glu Ser Ile Gln Leu Pro Cys Phe Ser Leu Asp Arg Glu													
50		65		70		75					80			
	Ala Leu Thr Asn Ile Ser Val Ile Ile Ala His Leu Glu Lys Val Lys													

55

EP 1 476 541 B1

5 Val Leu Ser Glu Asn Thr Val Asp Thr Ser Trp Val Ile Arg Trp Leu
 100 105 110
 Thr Asn Ile Ser Cys Phe Asn Pro Leu Asn Leu Asn Ile Ser Val Pro
 115 120 125
 10 Gly Asn Thr Asp Glu Ser Tyr Asp Cys Lys Val Phe Val Leu Thr Val
 130 135 140
 Leu Lys Gln Phe Ser Asn Cys Met Ala Glu Leu Gln Ala Lys Asp Asn
 145 150 155 160
 15 Thr Thr Cys Glu Glu Tyr Met Pro Met Glu
 165 170

20 <210> 106
 <211> 49
 <212> DNA
 <213> Artificial Sequence

25 <220>
 <223> Oligonucleotide primer ZC41643

<400> 106
 tccaggaat tcatataggc cggccacat gatcttcac acaggaaca 49

30 <210> 107
 <211> 85
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> Oligonucleotide primer ZC41641

<400> 107

40 caaccccaga gctgttttaa ggcgcgctc tagattatca ttccatcggc atgtattctt 60
 cgcatgtagt attgtcctta gcctg 85

45 <210> 108
 <211> 19
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Oligonucleotide primer ZC38,239

<400> 108
 gccgactaag ccagagaac 19

55 <210> 109
 <211> 20
 <212> DNA
 <213> Artificial Sequence

EP 1 476 541 B1

<220>

<223> Oligonucleotide primer ZC38.245

<400> 109

5 ctgttgacag ttctgaaccg 20

<210> 110

<211> 20

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Oligonucleotide primer ZC38,238

<400> 110

15 cgcggtttcc attgtatctg 20

<210> 111

<211> 2748

<212> DNA

20 <213> Mus musculus

<220>

<221> CDS

25 <222> (237)...(2222)

<400> 111

30 gatggggccc tgaatgttga tctgacagaa ttccagacca acctggtggt tattgtcctt 60
ttcatctggt catgctgaat atactctcaa gatgtgctgg agaaggctgct gctgtccggg 120
ctctcagaga aggcagtgct ggaggcgctc ctggcccggg tctcctccta ctgttcctgg 180
tagcccagcc ttctcggggg ggaaggagaa gctggccagg tgagctctga ggaagc atg 239
35 Met
1

40

45

50

55

EP 1 476 541 B1

ctg agc agc cag aag gga tcc tgc agc cag gaa cca ggg gca gcc cac 287
 Leu Ser Ser Gln Lys Gly Ser Cys Ser Gln Glu Pro Gly Ala Ala His
 5 5 10 15

gtc cag cct ctg ggt gtg aac gct gga ata atg tgg acc ttg gca ctg 335
 Val Gln Pro Leu Gly Val Asn Ala Gly Ile Met Trp Thr Leu Ala Leu
 10 20 25 30

tgg gca ttc tct ttc ctc tgc aaa ttc agc ctg gca gtc ctg ccg act 383
 Trp Ala Phe Ser Phe Leu Cys Lys Phe Ser Leu Ala Val Leu Pro Thr
 15 35 40 45

aag cca gag aac att tcc tgc gtc ttt tac ttc gac aga aat ctg act 431
 Lys Pro Glu Asn Ile Ser Cys Val Phe Tyr Phe Asp Arg Asn Leu Thr
 20 50 55 60 65

tgc act tgg aga cca gag aag gaa acc aat gat acc agc tac att gtg 479
 Cys Thr Trp Arg Pro Glu Lys Glu Thr Asn Asp Thr Ser Tyr Ile Val
 25 70 75 80

act ttg act tac tcc tat gga aaa agc aat tat agt gac aat gct aca 527
 Thr Leu Thr Tyr Ser Tyr Gly Lys Ser Asn Tyr Ser Asp Asn Ala Thr
 30 85 90 95

gag gct tca tat tct ttt ccc cgt tcc tgt gca atg ccc cca gac atc 575
 Glu Ala Ser Tyr Ser Phe Pro Arg Ser Cys Ala Met Pro Pro Asp Ile
 35 100 105 110

tgc agt gtt gaa gta caa gct caa aat gga gat ggt aaa gtt aaa tct 623
 Cys Ser Val Glu Val Gln Ala Gln Asn Gly Asp Gly Lys Val Lys Ser
 40 115 120 125

gac atc aca tat tgg cat tta atc tcc ata gca aaa acc gaa cca cct 671
 Asp Ile Thr Tyr Trp His Leu Ile Ser Ile Ala Lys Thr Glu Pro Pro
 45 130 135 140 145

ata att tta agt gtg aat cca att tgt aat aga atg ttc cag ata caa 719
 Ile Ile Leu Ser Val Asn Pro Ile Cys Asn Arg Met Phe Gln Ile Gln
 50 150 155 160

tgg aaa ccg cgt gaa aag act cgt ggg ttt cct tta gta tgc atg ctt 767
 Trp Lys Pro Arg Glu Lys Thr Arg Gly Phe Pro Leu Val Cys Met Leu
 55 165 170 175

EP 1 476 541 B1

5 cgg ttc aga act gtc aac agt agc cgc tgg acg gaa gtc aat ttt gaa 815
 Arg Phe Arg Thr Val Asn Ser Ser Arg Trp Thr Glu Val Asn Phe Glu
 180 185 190

10 aac tgt aaa cag gtc tgc aac ctc aca gga ctt cag gct ttc aca gaa 863
 Asn Cys Lys Gln Val Cys Asn Leu Thr Gly Leu Gln Ala Phe Thr Glu
 195 200 205

15 tat gtc ctg gct cta cga ttc agg ttc aat gac tca aga tat tgg agc 911
 Tyr Val Leu Ala Leu Arg Phe Arg Phe Asn Asp Ser Arg Tyr Trp Ser
 210 215 220 225

20 aag tgg agc aaa gaa gaa acc aga gtg act atg gag gaa gtt cca cat 959
 Lys Trp Ser Lys Glu Glu Thr Arg Val Thr Met Glu Glu Val Pro His
 230 235 240

25 gtc ctg gac ctg tgg aga att ctg gaa cca gca gac atg aac gga gac 1007
 Val Leu Asp Leu Trp Arg Ile Leu Glu Pro Ala Asp Met Asn Gly Asp
 245 250 255

30 agg aag gtg cga ttg ctg tgg aag aag gca aga gga gcc ccc gtc ttg 1055
 Arg Lys Val Arg Leu Leu Trp Lys Lys Ala Arg Gly Ala Pro Val Leu
 260 265 270

35 gag aaa aca ttt ggc tac cac ata cag tac ttt gca gag aac agc act 1103
 Glu Lys Thr Phe Gly Tyr His Ile Gln Tyr Phe Ala Glu Asn Ser Thr
 275 280 285

40 aac ctc aca gag ata aac aac atc acc acc cag cag tat gaa ctg ctt 1151
 Asn Leu Thr Glu Ile Asn Asn Ile Thr Thr Gln Gln Tyr Glu Leu Leu
 290 295 300 305

45 ctg atg agc cag gca cac tct gtg tcc gtg act tct ttt aat tct ctt 1199
 Leu Met Ser Gln Ala His Ser Val Ser Val Thr Ser Phe Asn Ser Leu
 310 315 320

50 ggc aag tcc caa gag acc atc ctg agg atc cca gat gtc cat gag aag 1247
 Gly Lys Ser Gln Glu Thr Ile Leu Arg Ile Pro Asp Val His Glu Lys
 325 330 335

55 acc ttc cag tac att aag agc atg cag gcc tac ata gcc gag ccc ctg 1295
 Thr Phe Gln Tyr Ile Lys Ser Met Gln Ala Tyr Ile Ala Glu Pro Leu

EP 1 476 541 B1

	340		345		350		
5	ttg gtg gtg aac tgg caa agc tcc att cct gcg gtg gac act tgg ata						1343
	Leu Val Val Asn Trp Gln Ser Ser Ile Pro Ala Val Asp Thr Trp Ile						
	355		360		365		
10	gtg gag tgg ctc cca gaa gct gcc atg tcg aag ttc cct gcc ctt tcc						1391
	Val Glu Trp Leu Pro Glu Ala Ala Met Ser Lys Phe Pro Ala Leu Ser						
	370		375		380		385
15	tgg gaa tct gtg tct cag gtc acg aac tgg acc atc gag caa gat aaa						1439
	Trp Glu Ser Val Ser Gln Val Thr Asn Trp Thr Ile Glu Gln Asp Lys						
		390		395		400	
20	cta aaa cct ttc aca tgc tat aat ata tca gtg tat cca gtg ttg gga						1487
	Leu Lys Pro Phe Thr Cys Tyr Asn Ile Ser Val Tyr Pro Val Leu Gly						
		405		410		415	
25	cac cga gtt gga gag ccg tat tca atc caa gct tat gcc aaa gaa gga						1535
	His Arg Val Gly Glu Pro Tyr Ser Ile Gln Ala Tyr Ala Lys Glu Gly						
		420		425		430	
30	act cca tta aaa ggt cct gag acc agg gtg gag aac atc ggt ctg agg						1583
	Thr Pro Leu Lys Gly Pro Glu Thr Arg Val Glu Asn Ile Gly Leu Arg						
		435		440		445	
35	aca gcc acg atc aca tgg aag gag att cct aag agt gct agg aat gga						1631
	Thr Ala Thr Ile Thr Trp Lys Glu Ile Pro Lys Ser Ala Arg Asn Gly						
		450		455		460	465
40	ttt atc aac aat tac act gta ttt tac caa gct gaa ggt gga aaa gaa						1679
	Phe Ile Asn Asn Tyr Thr Val Phe Tyr Gln Ala Glu Gly Gly Lys Glu						
		470		475		480	
45	ctc tcc aag act gtt aac tct cat gcc ctg cag tgt gac ctg gag tct						1727
	Leu Ser Lys Thr Val Asn Ser His Ala Leu Gln Cys Asp Leu Glu Ser						
		485		490		495	
50	ctg aca cga agg acc tct tat act gtt tgg gtc atg gcc agc acc aga						1775
	Leu Thr Arg Arg Thr Ser Tyr Thr Val Trp Val Met Ala Ser Thr Arg						
		500		505		510	
55	gct gga ggt acc aac ggg gtg aga ata aac ttc aag aca ttg tca atc						1823

EP 1 476 541 B1

Ala Gly Gly Thr Asn Gly Val Arg Ile Asn Phe Lys Thr Leu Ser Ile
515 520 525

5
agt gtg ttt gaa att gtc ctt cta aca tct cta gtt gga gga ggc ctt 1871
Ser Val Phe Glu Ile Val Leu Leu Thr Ser Leu Val Gly Gly Gly Leu
530 535 540 545

10
ctt cta ctt agc atc aaa aca gtg act ttt ggc ctc aga aag cca aac 1919
Leu Leu Leu Ser Ile Lys Thr Val Thr Phe Gly Leu Arg Lys Pro Asn
550 555 560

15
cgg ttg act ccc ctg tgt tgt cct gat gtt ccc aac cct gct gaa agt 1967
Arg Leu Thr Pro Leu Cys Cys Pro Asp Val Pro Asn Pro Ala Glu Ser
565 570 575

20
agt tta gcc aca tgg ctc gga gat ggt ttc aag aag tca aat atg aag 2015
Ser Leu Ala Thr Trp Leu Gly Asp Gly Phe Lys Lys Ser Asn Met Lys
580 585 590

25
gag act gga aac tct ggg aac aca gaa gac gtg gtc cta aaa cca tgt 2063
Glu Thr Gly Asn Ser Gly Asn Thr Glu Asp Val Val Leu Lys Pro Cys
595 600 605

30
ccc gtc ccc gcg gat ctc att gac aag ctg gta gtg aac ttt gag aat 2111
Pro Val Pro Ala Asp Leu Ile Asp Lys Leu Val Val Asn Phe Glu Asn
610 615 620 625

35
ttt ctg gaa gta gtt ttg aca gag gaa gct gga aag ggt cag gcg agc 2159
Phe Leu Glu Val Val Leu Thr Glu Glu Ala Gly Lys Gly Gln Ala Ser
630 635 640

40
att ttg gga gga gaa gcg aat gag tat atc tta tcc cag gaa cca agc 2207
Ile Leu Gly Gly Glu Ala Asn Glu Tyr Ile Leu Ser Gln Glu Pro Ser
645 650 655

45
tgt cct ggc cat tgc tgaagctacc ctcagggtcc aggacagctg tcttgttggc 2262
Cys Pro Gly His Cys
660

50
acttgactct ggcaggaacc tgatctctac ttttcttctc cctgtctccg gacactttct 2322
ctccttcatg cagagaccag gactagagcg gattctctcat ggtttgccag gctcctcagt 2382
ccttgctcgg gctcaggatc ttcaacaatg ccctttctgg gacactccat catccactta 2442
tattatattt ttgcaacatt gtggattgaa cccagggact tgtttatgcg cgcaacttca 2502

55

EP 1 476 541 B1

gtaactgtgg cagagactta ggaatggaga tctgaccctt tgcagaaggt ttctggacat 2562
 ccgtcccctgt gtgagcctca gacagcattg tctttacttt gaatcagctt ccaagttaat 2622
 5 aaaagaaaaa cagagaggtg gcataacagc tcctgcttcc tgacctgctt gagttccagt 2682
 tctgacttcc tttggtgatg aacagcaatg tggggaagtgt aagctgaata aaccctttcc 2742
 tcccca 2748

<210> 112
 <211> 662
 <212> PRT
 <213> Mus musculus

<400> 112

Met Leu Ser Ser Gln Lys Gly Ser Cys Ser Gln Glu Pro Gly Ala Ala
 1 5 10 15
 His Val Gln Pro Leu Gly Val Asn Ala Gly Ile Met Trp Thr Leu Ala
 20 20 25 30
 Leu Trp Ala Phe Ser Phe Leu Cys Lys Phe Ser Leu Ala Val Leu Pro
 25 35 40 45
 Thr Lys Pro Glu Asn Ile Ser Cys Val Phe Tyr Phe Asp Arg Asn Leu
 50 55 60
 Thr Cys Thr Trp Arg Pro Glu Lys Glu Thr Asn Asp Thr Ser Tyr Ile
 30 65 70 75 80
 Val Thr Leu Thr Tyr Ser Tyr Gly Lys Ser Asn Tyr Ser Asp Asn Ala
 85 90 95
 Thr Glu Ala Ser Tyr Ser Phe Pro Arg Ser Cys Ala Met Pro Pro Asp
 35 100 105 110
 Ile Cys Ser Val Glu Val Gln Ala Gln Asn Gly Asp Gly Lys Val Lys
 115 120 125
 Ser Asp Ile Thr Tyr Trp His Leu Ile Ser Ile Ala Lys Thr Glu Pro
 40 130 135 140
 Pro Ile Ile Leu Ser Val Asn Pro Ile Cys Asn Arg Met Phe Gln Ile
 145 150 155 160
 Gln Trp Lys Pro Arg Glu Lys Thr Arg Gly Phe Pro Leu Val Cys Met
 45 165 170 175
 Leu Arg Phe Arg Thr Val Asn Ser Ser Arg Trp Thr Glu Val Asn Phe
 180 185 190
 Glu Asn Cys Lys Gln Val Cys Asn Leu Thr Gly Leu Gln Ala Phe Thr
 195 200 205
 50 Glu Tyr Val Leu Ala Leu Arg Phe Arg Phe Asn Asp Ser Arg Tyr Trp
 210 215 220
 Ser Lys Trp Ser Lys Glu Glu Thr Arg Val Thr Met Glu Glu Val Pro
 225 230 235 240
 55 His Val Leu Asp Leu Trp Arg Ile Leu Glu Pro Ala Asp Met Asn Gly

EP 1 476 541 B1

				245					250				255			
	Asp	Arg	Lys	Val	Arg	Leu	Leu	Trp	Lys	Lys	Ala	Arg	Gly	Ala	Pro	Val
5				260					265				270			
	Leu	Glu	Lys	Thr	Phe	Gly	Tyr	His	Ile	Gln	Tyr	Phe	Ala	Glu	Asn	Ser
			275					280				285				
	Thr	Asn	Leu	Thr	Glu	Ile	Asn	Asn	Ile	Thr	Thr	Gln	Gln	Tyr	Glu	Leu
10			290				295					300				
	Leu	Leu	Met	Ser	Gln	Ala	His	Ser	Val	Ser	Val	Thr	Ser	Phe	Asn	Ser
	305				310					315					320	
	Leu	Gly	Lys	Ser	Gln	Glu	Thr	Ile	Leu	Arg	Ile	Pro	Asp	Val	His	Glu
15				325						330				335		
	Lys	Thr	Phe	Gln	Tyr	Ile	Lys	Ser	Met	Gln	Ala	Tyr	Ile	Ala	Glu	Pro
			340					345					350			
	Leu	Leu	Val	Val	Asn	Trp	Gln	Ser	Ser	Ile	Pro	Ala	Val	Asp	Thr	Trp
20			355				360						365			
	Ile	Val	Glu	Trp	Leu	Pro	Glu	Ala	Ala	Met	Ser	Lys	Phe	Pro	Ala	Leu
	370					375						380				
	Ser	Trp	Glu	Ser	Val	Ser	Gln	Val	Thr	Asn	Trp	Thr	Ile	Glu	Gln	Asp
25	385				390					395					400	
	Lys	Leu	Lys	Pro	Phe	Thr	Cys	Tyr	Asn	Ile	Ser	Val	Tyr	Pro	Val	Leu
				405					410					415		
	Gly	His	Arg	Val	Gly	Glu	Pro	Tyr	Ser	Ile	Gln	Ala	Tyr	Ala	Lys	Glu
30			420					425					430			
	Gly	Thr	Pro	Leu	Lys	Gly	Pro	Glu	Thr	Arg	Val	Glu	Asn	Ile	Gly	Leu
			435				440					445				
	Arg	Thr	Ala	Thr	Ile	Thr	Trp	Lys	Glu	Ile	Pro	Lys	Ser	Ala	Arg	Asn
35	450					455					460					
	Gly	Phe	Ile	Asn	Asn	Tyr	Thr	Val	Phe	Tyr	Gln	Ala	Glu	Gly	Gly	Lys
	465				470					475					480	
	Glu	Leu	Ser	Lys	Thr	Val	Asn	Ser	His	Ala	Leu	Gln	Cys	Asp	Leu	Glu
40				485						490				495		
	Ser	Leu	Thr	Arg	Arg	Thr	Ser	Tyr	Thr	Val	Trp	Val	Met	Ala	Ser	Thr
			500					505					510			
	Arg	Ala	Gly	Gly	Thr	Asn	Gly	Val	Arg	Ile	Asn	Phe	Lys	Thr	Leu	Ser
45			515				520						525			
	Ile	Ser	Val	Phe	Glu	Ile	Val	Leu	Leu	Thr	Ser	Leu	Val	Gly	Gly	Gly
	530					535						540				
	Leu	Leu	Leu	Leu	Ser	Ile	Lys	Thr	Val	Thr	Phe	Gly	Leu	Arg	Lys	Pro
50	545					550					555				560	
	Asn	Arg	Leu	Thr	Pro	Leu	Cys	Cys	Pro	Asp	Val	Pro	Asn	Pro	Ala	Glu
				565						570					575	
	Ser	Ser	Leu	Ala	Thr	Trp	Leu	Gly	Asp	Gly	Phe	Lys	Lys	Ser	Asn	Met
55			580					585						590		

Lys Glu Thr Gly Asn Ser Gly Asn Thr Glu Asp Val Val Leu Lys Pro
 595 600 605
 5 Cys Pro Val Pro Ala Asp Leu Ile Asp Lys Leu Val Val Asn Phe Glu
 610 615 620
 Asn Phe Leu Glu Val Val Leu Thr Glu Glu Ala Gly Lys Gly Gln Ala
 10 625 630 635 640
 Ser Ile Leu Gly Gly Glu Ala Asn Glu Tyr Ile Leu Ser Gln Glu Pro
 645 650 655
 Ser Cys Pro Gly His Cys
 15 660

20 <210> 113
 <211> 2728
 <212> DNA
 <213> Mus musculus

25 <220>
 <221> CDS
 <222> (237)...(1877)

<400> 113

30 gatggggccc tgaatgttga tctgacagaa ttccagacca acctggtggt tattgtcctt 60
 ttcattctggt catgctgaat atactctcaa gatgtgctgg agaagggtgct gctgtccggg 120
 ctctcagaga aggcagtgct ggaggcgttc ctggcccggg tctcctccta ctgttctctg 180
 35 tagcccagcc ttctcggggg ggaaggagaa gctggccagg tgagctctga ggaagc atg 239
 Met

40 ctg agc agc cag aag gga tcc tgc agc cag gaa cca ggg gca gcc cac 287
 Leu Ser Ser Gln Lys Gly Ser Cys Ser Gln Glu Pro Gly Ala Ala His
 5 10 15

45 gtc cag cct ctg ggt gtg aac gct gga ata atg tgg acc ttg gca ctg 335
 Val Gln Pro Leu Gly Val Asn Ala Gly Ile Met Trp Thr Leu Ala Leu
 20 25 30

50 tgg gca ttc tct ttc ctc tgc aaa ttc agc ctg gca gtc ctg ccg act 383
 Trp Ala Phe Ser Phe Leu Cys Lys Phe Ser Leu Ala Val Leu Pro Thr
 35 40 45

55 aag cca gag aac att tcc tgc gtc ttt tac ttc gac aga aat ctg act 431
 Lys Pro Glu Asn Ile Ser Cys Val Phe Tyr Phe Asp Arg Asn Leu Thr

EP 1 476 541 B1

	50		55		60		65		
5	tgc act tgg aga cca gag aag gaa acc aat gat acc agc tac att gtg								479
	Cys Thr Trp Arg Pro Glu Lys Glu Thr Asn Asp Thr Ser Tyr Ile Val								
			70		75		80		
10	act ttg act tac tcc tat gga aaa agc aat tat agt gac aat gct aca							527	
	Thr Leu Thr Tyr Ser Tyr Gly Lys Ser Asn Tyr Ser Asp Asn Ala Thr								
		85		90		95			
15	gag gct tca tat tct ttt ccc cgt tcc tgt gca atg ccc cca gac atc							575	
	Glu Ala Ser Tyr Ser Phe Pro Arg Ser Cys Ala Met Pro Pro Asp Ile								
		100		105		110			
20	tgc agt gtt gaa gta caa gct caa aat gga gat ggt aaa gtt aaa tct							623	
	Cys Ser Val Glu Val Gln Ala Gln Asn Gly Asp Gly Lys Val Lys Ser								
		115		120		125			
25	gac atc aca tat tgg cat tta atc tcc ata gca aaa acc gaa cca cct							671	
	Asp Ile Thr Tyr Trp His Leu Ile Ser Ile Ala Lys Thr Glu Pro Pro								
		130		135		140		145	
30	ata att tta agt gtg aat cca att tgt aat aga atg ttc cag ata caa							719	
	Ile Ile Leu Ser Val Asn Pro Ile Cys Asn Arg Met Phe Gln Ile Gln								
			150		155		160		
35	tgg aaa ccg cgt gaa aag act cgt ggg ttt cct tta gta tgc atg ctt							767	
	Trp Lys Pro Arg Glu Lys Thr Arg Gly Phe Pro Leu Val Cys Met Leu								
		165		170		175			
40	cgg ttc aga act gtc aac agt agc cgc tgg acg gaa gtc aat ttt gaa							815	
	Arg Phe Arg Thr Val Asn Ser Ser Arg Trp Thr Glu Val Asn Phe Glu								
		180		185		190			
45	aac tgt aaa cag gtc tgc aac ctc aca gga ctt cag gct ttc aca gaa							863	
	Asn Cys Lys Gln Val Cys Asn Leu Thr Gly Leu Gln Ala Phe Thr Glu								
		195		200		205			
50	tat gtc ctg gct cta cga ttc agg ttc aat gac tca aga tat tgg agc							911	
	Tyr Val Leu Ala Leu Arg Phe Arg Phe Asn Asp Ser Arg Tyr Trp Ser								
		210		215		220		225	
55	aag tgg agc aaa gaa gaa acc aga gtg act atg gag gaa gtt cca cat							959	

EP 1 476 541 B1

5 Lys Trp Ser Lys Glu Glu Thr Arg Val Thr Met Glu Glu Val Pro His
 230 235 240
 gtc ctg gac ctg tgg aga att ctg gaa cca gca gac atg aac gga gac 1007
 Val Leu Asp Leu Trp Arg Ile Leu Glu Pro Ala Asp Met Asn Gly Asp
 245 250 255
 10 agg aag gtg cga ttg ctg tgg aag aag gca aga gga gcc ccc gtc ttg 1055
 Arg Lys Val Arg Leu Leu Trp Lys Lys Ala Arg Gly Ala Pro Val Leu
 260 265 270
 15 gag aaa aca ttt ggc tac cac ata cag tac ttt gca gag aac agc act 1103
 Glu Lys Thr Phe Gly Tyr His Ile Gln Tyr Phe Ala Glu Asn Ser Thr
 275 280 285
 20 aac ctc aca gag ata aac aac atc acc acc cag cag tat gaa ctg ctt 1151
 Asn Leu Thr Glu Ile Asn Asn Ile Thr Thr Gln Gln Tyr Glu Leu Leu
 290 295 300 305
 25 ctg atg agc cag gca cac tct gtg tcc gtg act tct ttt aat tct ctt 1199
 Leu Met Ser Gln Ala His Ser Val Ser Val Thr Ser Phe Asn Ser Leu
 310 315 320
 30 ggc aag tcc caa gag acc atc ctg agg atc cca gat gtc cat gag aag 1247
 Gly Lys Ser Gln Glu Thr Ile Leu Arg Ile Pro Asp Val His Glu Lys
 325 330 335
 35 acc ttc cag tac att aag agc atg cag gcc tac ata gcc gag ccc ctg 1295
 Thr Phe Gln Tyr Ile Lys Ser Met Gln Ala Tyr Ile Ala Glu Pro Leu
 340 345 350
 40 ttg gtg gtg aac tgg caa agc tcc att cct gcg gtg gac act tgg ata 1343
 Leu Val Val Asn Trp Gln Ser Ser Ile Pro Ala Val Asp Thr Trp Ile
 355 360 365
 45 gtg gag tgg ctc cca gaa gct gcc atg tcg aag ttc cct gcc ctt tcc 1391
 Val Glu Trp Leu Pro Glu Ala Ala Met Ser Lys Phe Pro Ala Leu Ser
 370 375 380 385
 50 tgg gaa tct gtg tct cag gtc acg aac tgg acc atc gag caa gat aaa 1439
 Trp Glu Ser Val Ser Gln Val Thr Asn Trp Thr Ile Glu Gln Asp Lys
 390 395 400
 55

EP 1 476 541 B1

5 cta aaa cct ttc aca tgc tat aat ata tca gtg tat cca gtg ttg gga 1487
 Leu Lys Pro Phe Thr Cys Tyr Asn Ile Ser Val Tyr Pro Val Leu Gly
 405 410 415

10 cac cga gtt gga gag ccg tat tca atc caa gct tat gcc aaa gaa gga 1535
 His Arg Val Gly Glu Pro Tyr Ser Ile Gln Ala Tyr Ala Lys Glu Gly
 420 425 430

15 act cca tta aaa ggt cct gag acc agg gtg gag aac atc ggt ctg agg 1583
 Thr Pro Leu Lys Gly Pro Glu Thr Arg Val Glu Asn Ile Gly Leu Arg
 435 440 445

20 aca gcc acg atc aca tgg aag gag att cct aag agt gct agg aat gga 1631
 Thr Ala Thr Ile Thr Trp Lys Glu Ile Pro Lys Ser Ala Arg Asn Gly
 450 455 460 465

25 ttt atc aac aat tac act gta ttt tac caa gct gaa ggt gga aaa gaa 1679
 Phe Ile Asn Asn Tyr Thr Val Phe Tyr Gln Ala Glu Gly Gly Lys Glu
 470 475 480

30 ctc tcc aag act gtt aac tct cat gcc ctg cag tgt gac ctg gag tct 1727
 Leu Ser Lys Thr Val Asn Ser His Ala Leu Gln Cys Asp Leu Glu Ser
 485 490 495

35 ctg aca cga agg acc tct tat act gtt tgg gtc atg gcc agc acc aga 1775
 Leu Thr Arg Arg Thr Ser Tyr Thr Val Trp Val Met Ala Ser Thr Arg
 500 505 510

40 gct gga ggt acc aac ggg gtg aga ata aac ttc aag aca ttg tca atc 1823
 Ala Gly Gly Thr Asn Gly Val Arg Ile Asn Phe Lys Thr Leu Ser Ile
 515 520 525

45 agt gag tac tgg ctt cag gcc tca ttc tgg agt tta ctt cgg gtt gga 1871
 Ser Glu Tyr Trp Leu Gln Ala Ser Phe Trp Ser Leu Leu Arg Val Gly
 530 535 540 545

50 aat gtt tgacaggagc aaggagagcc agcagagggc agcagagcat ggcttctct 1927
 Asn Val

55 gctctctctg gctcactcac ctcccaggag ttactgagga gctggcaaag ggagggtga 1987
 gttagacc aa caggccattt tgatccttgc tggtaagcag ccacaaataa tcttaagatg 2047
 aagcaagcaa catccacttc agcctcagcc acgtcaaagg ctgttgctg agctcact 2107

EP 1 476 541 B1

5 ggccagtcc taaatgtcag gagttgtgca atagaacctg ggaaggaaca actggttgat 2167
 cagaggtcac tgacaagga cttaatgtta ccatctgcgg tggggctttt gtttcgtttt 2227
 gtttgttgt tatgtgtatt caacttatca gcttttacgt tgaaaacatg aaaagcaaga 2287
 caaatgtgt agatatacaca tataatgtga aatataatag ttttaataatt gagtaggaaa 2347
 gctgaggcca tgtaatagac agagggaaaa gaagaggaaa gccagtctgg tctacaaagt 2407
 10 gagttccagg acagccagg ctacatggag aaaccctgtc tcaatcaatc aatcaatcaa 2467
 tcaatcagtc aatcaatcaa aattcaagca gcattgacaa gttttgcaat aactactata 2527
 aacaaaaaa gtcacttga tgtatctcag aagccccttg ttatttatgt tcctgaagac 2587
 taaagtagac cgtggctctg agaaccatga gcaagataac acgttctgtc ctgcagccta 2647
 15 acaatgcctt cttggtattc ttttgatac aacttctaaa ataactttt ttttaaaaaa 2707
 ataaaaatca tgttacagct a 2728

20 <210> 114
 <211> 547
 <212> PRT
 <213> Mus musculus

25 <400> 114

Met Leu Ser Ser Gln Lys Gly Ser Cys Ser Gln Glu Pro Gly Ala Ala
 1 5 10 15
 30 His Val Gln Pro Leu Gly Val Asn Ala Gly Ile Met Trp Thr Leu Ala
 20 25 30
 Leu Trp Ala Phe Ser Phe Leu Cys Lys Phe Ser Leu Ala Val Leu Pro
 35 35 40 45
 Thr Lys Pro Glu Asn Ile Ser Cys Val Phe Tyr Phe Asp Arg Asn Leu
 50 55 60
 Thr Cys Thr Trp Arg Pro Glu Lys Glu Thr Asn Asp Thr Ser Tyr Ile
 65 70 75 80
 40 Val Thr Leu Thr Tyr Ser Tyr Gly Lys Ser Asn Tyr Ser Asp Asn Ala
 85 90 95
 Thr Glu Ala Ser Tyr Ser Phe Pro Arg Ser Cys Ala Met Pro Pro Asp
 100 105 110
 45 Ile Cys Ser Val Glu Val Gln Ala Gln Asn Gly Asp Gly Lys Val Lys
 115 120 125
 Ser Asp Ile Thr Tyr Trp His Leu Ile Ser Ile Ala Lys Thr Glu Pro
 130 135 140
 50 Pro Ile Ile Leu Ser Val Asn Pro Ile Cys Asn Arg Met Phe Gln Ile
 145 150 155 160
 Gln Trp Lys Pro Arg Glu Lys Thr Arg Gly Phe Pro Leu Val Cys Met
 165 170 175
 55 Leu Arg Phe Arg Thr Val Asn Ser Ser Arg Trp Thr Glu Val Asn Phe
 180 185 190
 Glu Asn Cys Lys Gln Val Cys Asn Leu Thr Gly Leu Gln Ala Phe Thr

Gly Asn Val
545

5

<210> 115

<211> 30

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Primer ZC41.764

15

<400> 115

atcgaattca gaccaatggc tttctctgtg 30

<210> 116

<211> 24

20 <212> DNA

<213> Artificial Sequence

<220>

<223> Primer ZC41,598

25

<400> 116

acagtagtgt tctgactcag ttgg 24

<210> 117

<211> 21

30 <212> DNA

<213> Artificial Sequence

<220>

35 <223> Primer ZC41,948

<400> 117

ggtactgttc tctttgtctc g 21

40

<210> 118

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

45 <223> Primer ZC41.766

<400> 118

atctctagat gtttactgtt caccttg 27

50

<210> 119

<211> 4026

<212> DNA

<213> Mus musculus

55

<220>

<221> CDS

<222> (780)...(3692)

EP 1 476 541 B1

<400> 119

```

5   ctgtggacat tttaccatgc agccataaag agaggtcaaa aatgtctttc aagtgcccg 60
   ttagtaaaga tctgatggcg ttctaaggag agaaaggaac ttggatcttc gtggacaaaag 120
   aattcaggtc tgtagctgaa ggaggcgtgg ccacacaggg cgtttcagg tcctgtagag 180
   gaagcacagt tcatagatct ctgttctaac acgtctgtct tgctctgaac gccgaaagtc 240
   aactcgatca caagtttgat ccaacagttt gacatttcag gtaattttca gacggagcgc 300
10  tggggttga tctccaagc aacacaattg gctctgtgca ggacacctgg cacggggcac 360
   tgggtcgcag ctgtcccct ctccctccag gaacaacgat gctcaaggac cagcttttcc 420
   tcccaggcct ctcccacttc cttctcacc ggtgctgcc gcccggtccc ggaaccgcg 480
   cccgtcgcag ggtcccgatc gttccccta catccttg gaccaggagc aaattcctgt 540
   gggcccagg agtgccaaaa gtgctcagcg agacgggaaa ttgcaacagt acttggccct 600
15  tcggccctcc cccggcgctt tcccgtaact cccgccctg gacacttgtc ccgtagttga 660
   ttcatagctg gggcgcgggg ccgcctccac acgcctggac agacgtccgc gcccgttccc 720
   ctgtgaggcc gaggaccggc aaggctccgg agcaggtcgc caggcgggta atcagacca 779
   atg gct ttc tct gtg gtc ctt cat cca gcc ttc ctc ctg gca gtg ctg 827
20  Met Ala Phe Ser Val Val Leu His Pro Ala Phe Leu Leu Ala Val Leu
   1       5       10      15

   tcc ctg agg gca tcc cga agc gaa gtc ttg gag gag cct tta cca ttg 875
25  Ser Leu Arg Ala Ser Arg Ser Glu Val Leu Glu Glu Pro Leu Pro Leu
   20      25      30

   act cct gag ata cat aaa gtt tct ttt caa ttg aaa ctt caa gaa gtg 923
30  Thr Pro Glu Ile His Lys Val Ser Phe Gln Leu Lys Leu Gln Glu Val
   35      40      45

   aat tta gaa tgg act gtc cca gcc ctt act cat gaa gaa tta aac atg 971
35  Asn Leu Glu Trp Thr Val Pro Ala Leu Thr His Glu Glu Leu Asn Met
   50      55      60

```

40

45

50

55

EP 1 476 541 B1

5 ata ttt cag ata gag atc agt aga ctg aac ata tcc aac acc atc tgg 1019
 Ile Phe Gln Ile Glu Ile Ser Arg Leu Asn Ile Ser Asn Thr Ile Trp
 65 70 75 80

10 gtg gag aat tat agc acc act gtg aag cgt gaa gaa gct gtg cgt tgg 1067
 Val Glu Asn Tyr Ser Thr Thr Val Lys Arg Glu Glu Ala Val Arg Trp
 85 90 95

15 aac tgg acg tct gat atc cct ttg gag tgt gtc aaa cat ttc ata aga 1115
 Asn Trp Thr Ser Asp Ile Pro Leu Glu Cys Val Lys His Phe Ile Arg
 100 105 110

20 atc agg gct ctg gta gat gac acc aag tcc ctt cca cag agt tcc tgg 1163
 Ile Arg Ala Leu Val Asp Asp Thr Lys Ser Leu Pro Gln Ser Ser Trp
 115 120 125

25 ggc aac tgg agt tcc tgg aaa gaa gtt aat gca aag gtt tcc gtt gaa 1211
 Gly Asn Trp Ser Ser Trp Lys Glu Val Asn Ala Lys Val Ser Val Glu
 130 135 140

30 cct gat aaa tca tta ata ttt cct aaa gac aaa gtg ttg gaa gaa ggc 1259
 Pro Asp Lys Ser Leu Ile Phe Pro Lys Asp Lys Val Leu Glu Glu Gly
 145 150 155 160

35 tcc aat gtc acc atc tgt ctg atg tat ggg cag aat gta tat aat gta 1307
 Ser Asn Val Thr Ile Cys Leu Met Tyr Gly Gln Asn Val Tyr Asn Val
 165 170 175

40 tcc tgt aag ttg caa gat gag cca atc cat gga gaa caa ctt gat tcc 1355
 Ser Cys Lys Leu Gln Asp Glu Pro Ile His Gly Glu Gln Leu Asp Ser
 180 185 190

45 cac gtg tca tta tta aaa ttg aac aat gta gtt ttc ctt agt gac aca 1403
 His Val Ser Leu Leu Lys Leu Asn Asn Val Val Phe Leu Ser Asp Thr
 195 200 205

50 ggg aca aac atc aat tgt caa gcc acg aag ggt cct aaa aga ata ttt 1451
 Gly Thr Asn Ile Asn Cys Gln Ala Thr Lys Gly Pro Lys Arg Ile Phe
 210 215 220

55 ggg act gtt ctc ttt gtc tcg aaa gtg ctc gag gaa cct aag aat gtt 1499
 Gly Thr Val Leu Phe Val Ser Lys Val Leu Glu Glu Pro Lys Asn Val

EP 1 476 541 B1

	225		230		235		240	
5	tcc tgt gaa acc cga gac ttt aag act ttg gac tgt tca tgg gaa cct							1547
	Ser Cys Glu Thr Arg Asp Phe Lys Thr Leu Asp Cys Ser Trp Glu Pro							
			245		250		255	
10	ggg gta gat acg act ttg act tgg cgt aaa caa aga ttc caa aac tac							1595
	Gly Val Asp Thr Thr Leu Thr Trp Arg Lys Gln Arg Phe Gln Asn Tyr							
		260		265		270		
15	act tta tgt gaa tcg ttc tct aag aga tgt gag gtt tct aac tac agg							1643
	Thr Leu Cys Glu Ser Phe Ser Lys Arg Cys Glu Val Ser Asn Tyr Arg							
		275		280		285		
20	aac tcc tat acc tgg caa atc act gaa ggc tca cag gaa atg tat aac							1691
	Asn Ser Tyr Thr Trp Gln Ile Thr Glu Gly Ser Gln Glu Met Tyr Asn							
		290		295		300		
25	ttt act ctc aca gct gaa aac caa cta agg aaa aga agt gtc aac att							1739
	Phe Thr Leu Thr Ala Glu Asn Gln Leu Arg Lys Arg Ser Val Asn Ile							
		305		310		315		320
30	aat ttt aac ctg acc cat aga gtt cat cca aag gct ccg cag gac gtc							1787
	Asn Phe Asn Leu Thr His Arg Val His Pro Lys Ala Pro Gln Asp Val							
		325		330		335		
35	acc ctt aaa att ata ggt gct aca aaa gcc aac atg act tgg aag gtt							1835
	Thr Leu Lys Ile Ile Gly Ala Thr Lys Ala Asn Met Thr Trp Lys Val							
		340		345		350		
40	cac tcc cat gga aac aac tac aca ctt ttg tgt cag gtt aaa ctc caa							1883
	His Ser His Gly Asn Asn Tyr Thr Leu Leu Cys Gln Val Lys Leu Gln							
		355		360		365		
45	tat gga gaa gtg att cat gag cac aat gtt tct gtc cac atg agc gca							1931
	Tyr Gly Glu Val Ile His Glu His Asn Val Ser Val His Met Ser Ala							
		370		375		380		
50	aac tac ctc ttc agt gat ctg gat cca gac aca aag tac aag gct ttt							1979
	Asn Tyr Leu Phe Ser Asp Leu Asp Pro Asp Thr Lys Tyr Lys Ala Phe							
		385		390		395		400
55	gtg cgc tgt gca agt gcc aac cac ttc tgg aaa tgg agc gac tgg acc							2027

EP 1 476 541 B1

5 Val Arg Cys Ala Ser Ala Asn His Phe Trp Lys Trp Ser Asp Trp Thr
405 410 415

caa aaa gag ttc agc aca ccc gag act gct ccc tca cag gct ctt gat 2075
Gln Lys Glu Phe Ser Thr Pro Glu Thr Ala Pro Ser Gln Ala Leu Asp
420 425 430

10 gta tgg aga caa gtg tgg tcg gag aat gga aga cgc att gtg act tta 2123
Val Trp Arg Gln Val Trp Ser Glu Asn Gly Arg Arg Ile Val Thr Leu
435 440 445

15 ttc tgg aag cca cta tta aaa tca cag gcc aat ggc aaa atc ata tcc 2171
Phe Trp Lys Pro Leu Leu Lys Ser Gln Ala Asn Gly Lys Ile Ile Ser
450 455 460

20 tat aat ata gtt gta gaa aat gaa gcc aaa cca act gag tca gaa cac 2219
Tyr Asn Ile Val Val Glu Asn Glu Ala Lys Pro Thr Glu Ser Glu His
465 470 475 480

25 tac tgt gtc tgg gca cca gcc ctc agc aca aac ctg agc ctt gac ctg 2267
Tyr Cys Val Trp Ala Pro Ala Leu Ser Thr Asn Leu Ser Leu Asp Leu
485 490 495

30 caa cct tac aag att cgc atc aca gcc aac aac agc atg ggg gca tct 2315
Gln Pro Tyr Lys Ile Arg Ile Thr Ala Asn Asn Ser Met Gly Ala Ser
500 505 510

35 cct gag tcc ttg atg gtc ctt tct aat gat tct gga cac gag gtc aag 2363
Pro Glu Ser Leu Met Val Leu Ser Asn Asp Ser Gly His Glu Val Lys
515 520 525

40 gaa aag aca att aaa ggt ata aag gat gca ttc aat att tct tgg gag 2411
Glu Lys Thr Ile Lys Gly Ile Lys Asp Ala Phe Asn Ile Ser Trp Glu
530 535 540

45 ccc gta tct gga gac acg atg ggc tat gtt gtg gac tgg tgt gca cat 2459
Pro Val Ser Gly Asp Thr Met Gly Tyr Val Val Asp Trp Cys Ala His
545 550 555 560

50 tcc cag gac caa cgc tgt gat ttg cag tgg aag aac ctt ggt ccc aat 2507
Ser Gln Asp Gln Arg Cys Asp Leu Gln Trp Lys Asn Leu Gly Pro Asn
565 570 575

55

EP 1 476 541 B1

5 acc aca agc acc acc atc acc tca gat gat ttt aaa cca ggc gtc cgt 2555
 Thr Thr Ser Thr Thr Ile Thr Ser Asp Asp Phe Lys Pro Gly Val Arg
 580 585 590

10 tac aac ttc aga att ttt gaa agg tct gtg gaa cac aaa gct cgg tta 2603
 Tyr Asn Phe Arg Ile Phe Glu Arg Ser Val Glu His Lys Ala Arg Leu
 595 600 605

15 gta gag aaa caa aga gga tac acc cag gaa ctg gct cct ttg gtg aat 2651
 Val Glu Lys Gln Arg Gly Tyr Thr Gln Glu Leu Ala Pro Leu Val Asn
 610 615 620

20 cca aaa gtg gag att cct tac tcg acc cct aac tcc ttc gtt cta aga 2699
 Pro Lys Val Glu Ile Pro Tyr Ser Thr Pro Asn Ser Phe Val Leu Arg
 625 630 635 640

25 tgg cca gat tat gac agc gac ttc cag gct ggt ttt ata aaa ggg tac 2747
 Trp Pro Asp Tyr Asp Ser Asp Phe Gln Ala Gly Phe Ile Lys Gly Tyr
 645 650 655

30 ctc gtg tat gtg aaa tcc aag gag atg cag tgc aac caa ccc tgg gaa 2795
 Leu Val Tyr Val Lys Ser Lys Glu Met Gln Cys Asn Gln Pro Trp Glu
 660 665 670

35 agg acc ctc ctt cca gat aat tca gtc ctc tgt aaa tac gac atc aat 2843
 Arg Thr Leu Leu Pro Asp Asn Ser Val Leu Cys Lys Tyr Asp Ile Asn
 675 680 685

40 ggc tca gag aca aag aca ctc acc gtg gaa aac ctt cag cca gag tcc 2891
 Gly Ser Glu Thr Lys Thr Leu Thr Val Glu Asn Leu Gln Pro Glu Ser
 690 695 700

45 ctc tat gag ttt ttc gtc act ccg tac acc agc gct ggc cca gga ccc 2939
 Leu Tyr Glu Phe Phe Val Thr Pro Tyr Thr Ser Ala Gly Pro Gly Pro
 705 710 715 720

50 aat gaa acg ttc aca aag gtc aca act cca gat gca cgc tcc cac atg 2987
 Asn Glu Thr Phe Thr Lys Val Thr Thr Pro Asp Ala Arg Ser His Met
 725 730 735

55 ctg ctg cag atc ata cta ccc atg acc ctc tgc gtc ttg ctc agc atc 3035
 Leu Leu Gln Ile Ile Leu Pro Met Thr Leu Cys Val Leu Leu Ser Ile
 740 745 750

EP 1 476 541 B1

5 att gtc tgc tac tgg aaa agt cag tgg gtg aag gag aag tgc tac cct 3083
 Ile Val Cys Tyr Trp Lys Ser Gln Trp Val Lys Glu Lys Cys Tyr Pro
 755 760 765

10 gac att ccc aat ccg tac aag agc agc att ctg tca ctc ata aaa tcc 3131
 Asp Ile Pro Asn Pro Tyr Lys Ser Ser Ile Leu Ser Leu Ile Lys Ser
 770 775 780

15 aag aag aat cct cac tta ata atg aat gtc aaa gac tgc att cca gat 3179
 Lys Lys Asn Pro His Leu Ile Met Asn Val Lys Asp Cys Ile Pro Asp
 785 790 795 800

20 gtc ctt gaa gtg ata aac aaa gca gaa ggc agc aag aca cag tgt gta 3227
 Val Leu Glu Val Ile Asn Lys Ala Glu Gly Ser Lys Thr Gln Cys Val
 805 810 815

25 ggc tct ggg aaa ctt cac att gaa gat gta ccc act aag ccg cca atc 3275
 Gly Ser Gly Lys Leu His Ile Glu Asp Val Pro Thr Lys Pro Pro Ile
 820 825 830

30 gtg cca aca gaa aag gat tcc tca ggg cct gtg ccc tgc atc ttc ttt 3323
 Val Pro Thr Glu Lys Asp Ser Ser Gly Pro Val Pro Cys Ile Phe Phe
 835 840 845

35 gag aat ttt act tac gat cag tca gct ttt gac tct ggt tcc cat ggc 3371
 Glu Asn Phe Thr Tyr Asp Gln Ser Ala Phe Asp Ser Gly Ser His Gly
 850 855 860

40 ctc att cca ggt ccc cta aaa gac aca gca cac caa ctt gga cta ttg 3419
 Leu Ile Pro Gly Pro Leu Lys Asp Thr Ala His Gln Leu Gly Leu Leu
 865 870 875 880

45 gct cca cct aac aag ttc cag aac gta tta aaa aat gac tac atg aag 3467
 Ala Pro Pro Asn Lys Phe Gln Asn Val Leu Lys Asn Asp Tyr Met Lys
 885 890 895

50 ccc ctg gtc gaa agt cca act gaa gaa act agc ttg att tat gtg tca 3515
 Pro Leu Val Glu Ser Pro Thr Glu Glu Thr Ser Leu Ile Tyr Val Ser
 900 905 910

55 cag ctg gct tca ccc atg tgc gga gac aag gac acg ctt gcc aca gaa 3563
 Gln Leu Ala Ser Pro Met Cys Gly Asp Lys Asp Thr Leu Ala Thr Glu

EP 1 476 541 B1

	915	920	925	
5	cca ccc gtg cca gtg cat ggt tca gag tat aaa agg caa atg gta gtt			3611
	Pro Pro Val Pro Val His Gly Ser Glu Tyr Lys Arg Gln Met Val Val			
	930	935	940	
10	ccc ggg agc ctc gca tca cct tct ctg aag gag gat aac agc ttg acc			3659
	Pro Gly Ser Leu Ala Ser Pro Ser Leu Lys Glu Asp Asn Ser Leu Thr			
	945	950	955	960
15	tca acg gtc ctc tta ggc caa ggt gaa cag taa acaccacgca gcacaaataa			3712
	Ser Thr Val Leu Leu Gly Gln Gly Glu Gln *			
	965	970		
20	atgcactcca cacactatag gcactttggg agatgtagct gttaccatgc caacaccacg			3772
	tgccctgggt ggttccaggg gtggggggtg aggggagact cattatctgc agtgctgatt			3832
	tatcaacgat cactacagac caacagactt aaggaccata taatatggtg ttcaccctga			3892
	aggcgtccc tagaaatggc agatccgaga gcatgctgac cttgctatta tttggtccag			3952
25	gctcaccctt attgcagtag cttgacatag ggtgtacacc agtcatttcg cagagcctac			4012
	ctactcaaaa ctac			4026
30	<210> 120			
	<211> 970			
	<212> PRT			
	<213> Mus musculus			
35	<400> 120			
	Met Ala Phe Ser Val Val Leu His Pro Ala Phe Leu Leu Ala Val Leu			
	1 5 10 15			
	Ser Leu Arg Ala Ser Arg Ser Glu Val Leu Glu Glu Pro Leu Pro Leu			
40	20 25 30			
	Thr Pro Glu Ile His Lys Val Ser Phe Gln Leu Lys Leu Gln Glu Val			
	35 40 45			
	Asn Leu Glu Trp Thr Val Pro Ala Leu Thr His Glu Glu Leu Asn Met			
45	50 55 60			
	Ile Phe Gln Ile Glu Ile Ser Arg Leu Asn Ile Ser Asn Thr Ile Trp			
	65 70 75 80			
	Val Glu Asn Tyr Ser Thr Thr Val Lys Arg Glu Glu Ala Val Arg Trp			
50	85 90 95			
	Asn Trp Thr Ser Asp Ile Pro Leu Glu Cys Val Lys His Phe Ile Arg			
	100 105 110			
	Ile Arg Ala Leu Val Asp Asp Thr Lys Ser Leu Pro Gln Ser Ser Trp			
55	115 120 125			

Gly Asn Trp Ser Ser Trp Lys Glu Val Asn Ala Lys Val Ser Val Glu
 130 135 140
 5 Pro Asp Lys Ser Leu Ile Phe Pro Lys Asp Lys Val Leu Glu Glu Gly
 145 150 155 160
 Ser Asn Val Thr Ile Cys Leu Met Tyr Gly Gln Asn Val Tyr Asn Val
 165 170 175
 10 Ser Cys Lys Leu Gln Asp Glu Pro Ile His Gly Glu Gln Leu Asp Ser
 180 185 190
 His Val Ser Leu Leu Lys Leu Asn Asn Val Val Phe Leu Ser Asp Thr
 195 200 205
 15 Gly Thr Asn Ile Asn Cys Gln Ala Thr Lys Gly Pro Lys Arg Ile Phe
 210 215 220
 Gly Thr Val Leu Phe Val Ser Lys Val Leu Glu Glu Pro Lys Asn Val
 225 230 235 240
 20 Ser Cys Glu Thr Arg Asp Phe Lys Thr Leu Asp Cys Ser Trp Glu Pro
 245 250 255
 Gly Val Asp Thr Thr Leu Thr Trp Arg Lys Gln Arg Phe Gln Asn Tyr
 260 265 270
 25 Thr Leu Cys Glu Ser Phe Ser Lys Arg Cys Glu Val Ser Asn Tyr Arg
 275 280 285
 Asn Ser Tyr Thr Trp Gln Ile Thr Glu Gly Ser Gln Glu Met Tyr Asn
 290 295 300
 30 Phe Thr Leu Thr Ala Glu Asn Gln Leu Arg Lys Arg Ser Val Asn Ile
 305 310 315 320
 Asn Phe Asn Leu Thr His Arg Val His Pro Lys Ala Pro Gln Asp Val
 325 330 335
 35 Thr Leu Lys Ile Ile Gly Ala Thr Lys Ala Asn Met Thr Trp Lys Val
 340 345 350
 His Ser His Gly Asn Asn Tyr Thr Leu Leu Cys Gln Val Lys Leu Gln
 355 360 365
 40 Tyr Gly Glu Val Ile His Glu His Asn Val Ser Val His Met Ser Ala
 370 375 380
 Asn Tyr Leu Phe Ser Asp Leu Asp Pro Asp Thr Lys Tyr Lys Ala Phe
 385 390 395 400
 45 Val Arg Cys Ala Ser Ala Asn His Phe Trp Lys Trp Ser Asp Trp Thr
 405 410 415
 Gln Lys Glu Phe Ser Thr Pro Glu Thr Ala Pro Ser Gln Ala Leu Asp
 420 425 430
 50 Val Trp Arg Gln Val Trp Ser Glu Asn Gly Arg Arg Ile Val Thr Leu
 435 440 445
 Phe Trp Lys Pro Leu Leu Lys Ser Gln Ala Asn Gly Lys Ile Ile Ser
 450 455 460
 55 Tyr Asn Ile Val Val Glu Asn Glu Ala Lys Pro Thr Glu Ser Glu His

	465				470					475				480		
	Tyr	Cys	Val	Trp	Ala	Pro	Ala	Leu	Ser	Thr	Asn	Leu	Ser	Leu	Asp	Leu
5					485					490				495		
	Gln	Pro	Tyr	Lys	Ile	Arg	Ile	Thr	Ala	Asn	Asn	Ser	Met	Gly	Ala	Ser
				500					505					510		
10	Pro	Glu	Ser	Leu	Met	Val	Leu	Ser	Asn	Asp	Ser	Gly	His	Glu	Val	Lys
				515					520					525		
	Glu	Lys	Thr	Ile	Lys	Gly	Ile	Lys	Asp	Ala	Phe	Asn	Ile	Ser	Trp	Glu
				530					535					540		
15	Pro	Val	Ser	Gly	Asp	Thr	Met	Gly	Tyr	Val	Val	Asp	Trp	Cys	Ala	His
	545						550					555				560
	Ser	Gln	Asp	Gln	Arg	Cys	Asp	Leu	Gln	Trp	Lys	Asn	Leu	Gly	Pro	Asn
				565								570				575
20	Thr	Thr	Ser	Thr	Thr	Ile	Thr	Ser	Asp	Asp	Phe	Lys	Pro	Gly	Val	Arg
				580										590		
	Tyr	Asn	Phe	Arg	Ile	Phe	Glu	Arg	Ser	Val	Glu	His	Lys	Ala	Arg	Leu
				595					600					605		
25	Val	Glu	Lys	Gln	Arg	Gly	Tyr	Thr	Gln	Glu	Leu	Ala	Pro	Leu	Val	Asn
				610					615					620		
	Pro	Lys	Val	Glu	Ile	Pro	Tyr	Ser	Thr	Pro	Asn	Ser	Phe	Val	Leu	Arg
	625															640
30	Trp	Pro	Asp	Tyr	Asp	Ser	Asp	Phe	Gln	Ala	Gly	Phe	Ile	Lys	Gly	Tyr
				645												655
	Leu	Val	Tyr	Val	Lys	Ser	Lys	Glu	Met	Gln	Cys	Asn	Gln	Pro	Trp	Glu
				660												670
35	Arg	Thr	Leu	Leu	Pro	Asp	Asn	Ser	Val	Leu	Cys	Lys	Tyr	Asp	Ile	Asn
				675												685
	Gly	Ser	Glu	Thr	Lys	Thr	Leu	Thr	Val	Glu	Asn	Leu	Gln	Pro	Glu	Ser
				690												700
40	Leu	Tyr	Glu	Phe	Phe	Val	Thr	Pro	Tyr	Thr	Ser	Ala	Gly	Pro	Gly	Pro
	705															720
	Asn	Glu	Thr	Phe	Thr	Lys	Val	Thr	Thr	Pro	Asp	Ala	Arg	Ser	His	Met
				725												735
45	Leu	Leu	Gln	Ile	Ile	Leu	Pro	Met	Thr	Leu	Cys	Val	Leu	Leu	Ser	Ile
				740												750
	Ile	Val	Cys	Tyr	Trp	Lys	Ser	Gln	Trp	Val	Lys	Glu	Lys	Cys	Tyr	Pro
				755												765
50	Asp	Ile	Pro	Asn	Pro	Tyr	Lys	Ser	Ser	Ile	Leu	Ser	Leu	Ile	Lys	Ser
				770												780
	Lys	Lys	Asn	Pro	His	Leu	Ile	Met	Asn	Val	Lys	Asp	Cys	Ile	Pro	Asp
	785															800
55	Val	Leu	Glu	Val	Ile	Asn	Lys	Ala	Glu	Gly	Ser	Lys	Thr	Gln	Cys	Val
				805												815

Gly Ser Gly Lys Leu His Ile Glu Asp Val Pro Thr Lys Pro Pro Ile
 820 825 830
 Val Pro Thr Glu Lys Asp Ser Ser Gly Pro Val Pro Cys Ile Phe Phe
 835 840 845
 Glu Asn Phe Thr Tyr Asp Gln Ser Ala Phe Asp Ser Gly Ser His Gly
 850 855 860
 Leu Ile Pro Gly Pro Leu Lys Asp Thr Ala His Gln Leu Gly Leu Leu
 865 870 875 880
 Ala Pro Pro Asn Lys Phe Gln Asn Val Leu Lys Asn Asp Tyr Met Lys
 885 890 895
 Pro Leu Val Glu Ser Pro Thr Glu Glu Thr Ser Leu Ile Tyr Val Ser
 900 905 910
 Gln Leu Ala Ser Pro Met Cys Gly Asp Lys Asp Thr Leu Ala Thr Glu
 915 920 925
 Pro Pro Val Pro Val His Gly Ser Glu Tyr Lys Arg Gln Met Val Val
 930 935 940
 Pro Gly Ser Leu Ala Ser Pro Ser Leu Lys Glu Asp Asn Ser Leu Thr
 945 950 955 960
 Ser Thr Val Leu Leu Gly Gln Gly Glu Gln
 965 970

30 <210> 121
 <211> 2910
 <212> DNA
 <213> Artificial Sequence

35 <220>
 <223> Degenerate polynucleotide encoding the polypeptide of SEQ ID NO:120.

<221> misc_feature
 <222> (1)...(2910)
 40 <223> N = A, T, G, or C

<221> misc_feature
 <222> (1)...(2910)
 <223> n =A.T.C or G

45 <400> 121

50 atggcnttyw sngtngtnyt ncayccngcn ttyytntyng cngtnyt nws nytnmgngcn 60
 wsnmgngwsng argtnytnga rgarccnytn ccnytnacnc cngarathca yaargtnwsn 120
 ttycarytna arytncarga rgtnaayytn gartggacng tncngcnytn nacncaygar 180

55

	garytnaaya	tgathttyca	rathgarath	wsmgnytna	ayathwsnaa	yacnathtgg	240
	gtngaraayt	aywsnacnac	ngtnaarmgn	gargargcng	tnmgntggaa	ytggacnwsn	300
5	gayathccny	tngartgygt	naarcaytty	athmgnathm	gngcnytngt	ngaygayacn	360
	aarwsnytn	cncarwsnws	ntggggnaay	tggwsnwsnt	ggaargargt	naaygcnaar	420
	gtnwsngtng	arccngayaa	rwsnytnath	ttyccnaarg	ayaargtnyt	ngargarggn	480
	wsnaaygtna	cnathtgyyt	natgtayggn	caraaygtnt	ayaaygtnws	ntgyaarytn	540
10	cargaygarc	cnathcaygg	ngarcarytn	gaywsncayg	tnwsnytnyt	naarytnaay	600
	aaygtngtnt	tyytnwsnga	yacnggnacn	aayathaayt	gycargcnac	naarggnccn	660
	aarmgnatht	tyggnacngt	nytnnttygtn	wsnaargtny	tngargarcc	naaraaygtn	720
	wsntgygara	cnmgngaytt	yaaracnytn	gaytgywsnt	gggarccngg	ngtngayacn	780
15	acnytnacnt	ggmgnaarca	rmgnttycar	aaytayacny	tntgygarws	nttywsnaar	840
	mgntgygarg	tnwsnaayta	ymgnaaywsn	tayacntggc	arathacnga	rggnwsncar	900
	garatgtaya	ayttyacny	nacngcngar	aaycarytnm	gnaarmgnws	ngtnaayath	960
	aayttyaayy	tnacncaymg	ngtncaayccn	aargcncnc	argaygtnac	nytnaarath	1020
20	athggngcna	cnaargcnaa	yatgacntgg	aargtncayw	sncayggnaa	yaaytayacn	1080
	ytnytntgyc	argtnaaryt	ncartayggn	gargtnathc	aygarcaayaa	ygtnwsngtn	1140
	cayatgwsng	cnaaytayyt	nttywsngay	ytngayccng	ayacnaarta	yaargcntty	1200
	gtnmgntgyg	cnwsngcnaa	ycayttypg	aartggwsng	aytggacnca	raargartty	1260
25	wsnacnccng	aracngcnc	nwsncargcn	ytngaygtnt	ggmgncargt	ntggwsngar	1320
	aayggnmgnm	gnathgtnac	nytnnttygg	aarccnytny	tnaarwsnca	rgcnaayggn	1380
	aarathathw	sntayaayat	hgtngtngar	aaygargcna	arccnacnga	rwsngarcay	1440
	taytgygtnt	gggcncngc	nytnwsnacn	aayytwnsny	tngayytnc	rcntayaar	1500
30	athmgnatha	cngcnaayaa	ywsnatgggn	gcnwsnccng	arwsnytnat	ggtnytnwsn	1560
	aaygaywsng	gncaygargt	naargaraar	acnathaarg	gnathaarga	ygcnttyaay	1620
	athwsntggg	arccngtnws	nggngayacn	atgggntayg	tngtngaytg	gtgygcncay	1680
	wsncargayc	armgntgyga	yytncartgg	aaraaytng	gncnaayac	nacnwsnacn	1740
35	acnathacnw	sngaygaytt	yaarccnggn	gtnmgntaya	ayttymgnat	httygarmgn	1800
	wsngtngarc	ayaargcnmg	nytngtngar	aarcarmgng	gntayacnca	rgarytnagn	1860
	ccnytngtna	ayccnaargt	ngarathccn	taywsnacnc	cnaaywsntt	ygtnytnmgn	1920
	tggccngayt	aygaywsnga	yttycargcn	ggnttyatha	arggntayyt	ngtntaygtn	1980
40	aarwsnaarg	aratgcartg	yaaycarccn	tgggarmgna	cnytnytnc	ngayaaywsn	2040
	gtnytntgya	artaygayat	haayggnwsn	garacnaara	cnytnacngt	ngaraaaytn	2100
	carccngarw	snytnayga	rttytygtn	acncntaya	cnwsngcngg	nccnggnccn	2160
	aaygaracnt	tyacnaargt	nacnacncn	gaygcnmgnw	sncayatgyt	nytnarath	2220
	athytnccna	tgacnytn	ygtnytnyt	wsnathathg	tntgytaytg	gaarwsncar	2280
45	tgggtnaarg	araartgyta	yccngayath	ccnaayccnt	ayaarwsnws	nathytnwsn	2340
	ytnathaarw	snaaraaraa	yccncayytn	athatgaayg	tnaargaytg	yathccngay	2400
	gtnytngarg	tnathaayaa	rgcngarggn	wsnaaracnc	artgygtngg	nwsnggnaar	2460
	ytncaayathg	argaygtnc	nacnaarccn	ccnathgtnc	cnacngaraa	rgaywsnwsn	2520
50	ggncngtnc	cntgyathtt	ytyygaray	tyacntayg	aycarwsngc	nttygaywsn	2580
	ggnwsncayg	gnytnathcc	nggnccnytn	aargayacng	cncaycaryt	nggnytnyt	2640
	gcncncnca	ayaarttyca	raaygtnytn	aaraaygayt	ayatgaarcc	nytngtngar	2700
	wsncnacng	argaracnws	nytnathtay	gtnwsncary	tngcnwsncc	natgtgyggn	2760

55

EP 1 476 541 B1

gayaargaya cnytnqcnac ngarccnccn gtnccngtnc ayggnewsnga rtayaarmgn 2820
caratggtnq tncnqgnws nytngcnwsn ccwnsnytna argargayaa ywsnytnacn 2880
5 wsnacngtny tnytnqgnca rggngarcar 2910

10 <210> 122
<211> 24
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Primer ZC43891

<400> 122
gggcagtagg atatgaatca gcat 24

20 <210> 123
<211> 19
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Primer ZC43900

<400> 123
gaaggcccca gtgctacgt 19

30 <210> 124
<211> 24
<212> DNA
<213> Artificial Sequence

35 <220>
<223> OSMRbeta probe ZC43896

<400> 124
tcatccggag tcgtgacctt cgtg 24

40 <210> 125
<211> 20
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Primer ZC43280

<400> 125
gagcagccc ttcttctct 20

50 <210> 126
<211> 20
<212> DNA
55 <213> Artificial Sequence

<220>
<223> Primer ZC43281

EP 1 476 541 B1

<400> 126
cgttgcccggt cgtttacta 20

5 <210> 127
<211> 40
<212> DNA
<213> qArtificial Sequence

10 <220>
<223> zcytor17lig probe ZC43275

<400> 127
ctgtaattcc tcgactattt tctgtacatc atcacttggt 40

15 <210> 128
<211> 22
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Primer ZC40574

<400> 128
ctcatttggga atttgcccga tt 22

25 <210> 129
<211> 22
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Primer ZC40575

<400> 129
ccgagtgaag atcccctttt ta 22

35 <210> 130
<211> 26
<212> DNA
<213> Artificial Sequence

40 <220>
<223> GUS probe ZC43017

45 <400> 130
tgaacagtca ccgacgagag tgctgg 26

50 <210> 131
<211> 24
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Primer ZC28480

<400> 131
cgattcagga cagtcaacag tacc 24

EP 1 476 541 B1

<210> 132
<211> 21
<212> DNA
<213> Artificial Sequence
5

<220>
<223> Primer ZC41653

<400> 132
10 ccttctgtgaa cgtagcactg g 21

<210> 133
<211> 19
<212> DNA
15 <213> Artificial Sequence

<220>
<223> Primer ZC41655

20 <400> 133
ctgaaatcca aggcgaggc 19

<210> 134
<211> 20
25 <212> DNA
<213> Artificial Sequence

<220>
<223> Primer ZC41703
30

<400> 134
tgaagctggc cttgctct 20

<210> 135
35 <211> 19
<212> DNA
<213> Artificial Sequence

<220>
40 <223> Primer ZC41704

<400> 135
gagatatgcc cggatggct 19

45 <210> 136
<211> 24
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Primer ZC43272

<400> 136
55 gctggatca ttggttct tctc 24

<210> 137
<211> 24
<212> DNA

EP 1 476 541 B1

<213> Artificial Sequence

<220>
<223> Primer ZC43273

5

<400> 137
cattctctt cctctgcaaa ttca 24

<210> 138
<211> 34
<212> DNA
<213> Artificial Sequence

10

<220>
<223> zcytor17 probe ZC43478

15

<400> 138
tagagaacat ttctgcgctc tttactctg acag 34

20

<210> 139
<211> 30
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Primer ZC43278

<400> 139
aaacaagagt ctcaggatct ttataacaac 30

30

<210> 140
<211> 21
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Primer ZC43279

<400> 140
acggcagctg tattgattcg t 21

40

<210> 141
<211> 26
<212> DNA
<213> Artificial Sequence

45

<220>
<223> zcytor17lig probe ZC43276

<400> 141
taaagcaggc atctgggatg tcagca 26

50

<210> 142
<211> 33
<212> DNA
<213> Artificial Sequence

55

<220>

EP 1 476 541 B1

<223> Primer ZC43045

<400> 142
aaacatgata tttcagatag agatcagtag act 33

5

<210> 143
<211> 26
<212> DNA
<213> Artificial Sequence

10

<220>
<223> Primer ZC43046

<400> 143
cttatgaaat gttgacaca ctccaa 26

15

<210> 144
<211> 29
<212> DNA
<213> Artificial Sequence

20

<220>
<223> OSMRbeta probe ZC43141

<400> 144
ctgtgcgttg gaactggacg tctgatatc 29

25

<210> 145
<211> 21
<212> DNA
<213> Artificial Sequence

30

<220>
<223> Primer ZC43004

35

<400> 145
gaaacccgcc gcatattact t 21

40

<210> 146
<211> 19
<212> DNA
<213> Artificial Sequence

45

<220>
<223> Primer ZC43005

<400> 146
tggcgttgct cacaaaggt 19

50

<210> 147
<211> 24
<212> DNA
<213> Artificial Sequence

55

<220>
<223> Murine GUS probe ZC43018 .

<400> 147

EP 1 476 541 B1

5 acccacacca aagccctgga cctc 24

 <210> 148
 <211> 23
 <212> DNA
 <213> Artificial Sequence

10 <220>
 <223> Primer ZC40269

 <400> 148
 gccagttca cacactcctc ttt 23

15 <210> 149
 <211> 26
 <212> DNA
 <213> Artificial Sequence

20 <220>
 <223> Primer ZC40268

 <400> 149
 gcagctattg cactagtcat ttctt 26

25 <210> 150
 <211> 29
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Transferrin receptor probe ZC40298

 <400> 150
 cccaggtagc cactcatgaa tccaatcaa 29

35 <210> 151
 <211> 20
 <212> DNA
 <213> Artificial Sequence

40 <220>
 <223> Primer ZC43140

 <400> 151
 ttctccaca gcaatcgcac 20

45 <210> 152
 <211> 21
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Primer ZC43139

55 <400> 152
 atgcatgctt cggttcagaa c 21

 <210> 153

EP 1 476 541 B1

<211> 24
<212> DNA
<213> Artificial Sequence

5 <220>
<223> Primer ZC41608

<400> 153
gcagacaatg atgctgagca agac 24

10 <210> 154
<211> 24
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Primer ZC41609

<400> 154
caacgctgtg attgcagtg gaag 24

20 <210> 155
<211> 18
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Primer ZC41502

<400> 155
agcgggcctt cctcactc 18

30 <210> 156
<211> 24
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Primer ZC41500

40 <400> 156
ggacaaaata aaaacataaa taac 24

45 <210> 157
<211> 40
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Linker

<400> 157
tgtcgatgaa gcctgaaag acgcgagac taattcgagc 40

55 <210> 158
<211> 60
<212> DNA
<213> Artificial Sequence

EP 1 476 541 B1

<220>
<223> Linker

5 <400> 158
acgcgagac taattcgagc tcccaccatc accatcacca cgcgaattcg gtaccgctgg 60

<210> 159
<211> 60
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Linker
15 <400> 159
actcactata gggcgaattg cccgggggat ccacgaggaa ccagcggtag cgaattcgcg 60

<210> 160
<211> 42
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Linker
25 <400> 160
acggccagtg aattgtaata cgactcacta tagggcgaat tg 42

<210> 161
30 <211> 825
<212> DNA
<213> Homo sapiens

<220>
35 <221> CDS
<222> (48)...(518)

<400> 161

40

45

50

55

EP 1 476 541 B1

	atcactctct ttaatcacta ctcaattaa cctcaactcc tgccaca atg tac agg	56
		Met Tyr Arg
		1
5		
	atg caa ctc ctg tct tgc att gca cta att ctt gca ctt gtc aca aac	104
	Met Gln Leu Leu Ser Cys Ile Ala Leu Ile Leu Ala Leu Val Thr Asn	
	5 10 15	
10		
	agt gca cct act tca agt tcg aca aag aaa aca aag aaa aca cag cta	152
	Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Lys Lys Thr Gln Leu	
	20 25 30 35	
15		
	caa ctg gag cat tta ctg ctg gat tta cag atg att ttg aat gga att	200
	Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile	
	40 45 50	
20		
	aat aat tac aag aat ccc aaa ctc acc agg atg ctc aca ttt aag ttt	248
	Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe	
	55 60 65	
25		
	tac atg ccc aag aag gcc aca gaa ctg aaa cag ctt cag tgt cta gaa	296
	Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys Gln Leu Gln Cys Leu Glu	
	70 75 80	
30		
	gaa gaa ctc aaa cct ctg gag gaa gtg ctg aat tta gct caa agc aaa	344
	Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys	
	85 90 95	
35		
40		
45		
50		
55		

EP 1 476 541 B1

5 aac ttt cac tta aga ccc agg gac tta atc agc aat atc aac gta ata 392
 Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile
 100 105 110 115

10 gtt ctg gaa cta aag gga tct gaa aca aca ttc atg tgt gaa tat gca 440
 Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
 120 125 130

15 gat gag aca gca acc att gta gaa ttt ctg aac aga tgg att acc ttt 488
 Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
 135 140 145

20 tgt caa agc atc atc tca aca cta act tga taattaagtg cttcccactt 538
 Cys Gln Ser Ile Ile Ser Thr Leu Thr *
 150 155

25 aaaacatatc aggccttcta tttatttatt taaatattta aattttatat ttattgttga 598
 atgtatgggtt gctacctatt gtaactatta ttcttaatct taaaactata aatatggatc 658
 ttttatgatt ctttttgtaa gccctagggg ctctaaaatg gttacctta tttatcccaa 718
 aatattttat tattatgttg aatgttaa atagtatcta tgtagattgg ttagtaaaac 778
 tattaataa atttgataaa tataaaaaaa aaaaacaaaa aaaaaaa 825

30 <210> 162
 <211> 156
 <212> PRT
 <213> Homo sapiens

35 <400> 162

40 Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ile Leu Ala Leu
 1 5 10 15
 Val Thr Asn Ser Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Lys Lys
 20 25 30
 Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu
 35 40 45
 45 Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
 50 55 60
 Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys Gln Leu Gln
 65 70 75 80
 50 Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala
 85 90 95
 Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile
 100 105 110
 55 Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys

EP 1 476 541 B1

		115		120		125														
	Glu	Tyr	Ala	Asp	Glu	Thr	Ala	Thr	Ile	Val	Glu	Phe	Leu	Asn	Arg	Trp				
5			130				135				140									
	Ile	Thr	Phe	Cys	Gln	Ser	Ile	Ile	Ser	Thr	Leu	Thr								
	145					150					155									
10	<210> 163																			
	<211> 614																			
	<212> DNA																			
	<213> Homo sapiens																			
15	<220>																			
	<221> CDS																			
	<222> (64)...(525)																			
20	<400> 163																			
	gatcgttagc ttctcctgat aaactaattg cctcacattg tcaactgcaaa tcgacaccta 60																			
	tta	atg	ggt	ctc	acc	tcc	caa	ctg	ctt	ccc	cct	ctg	ttc	ttc	ctg	cta				108
25		Met	Gly	Leu	Thr	Ser	Gln	Leu	Leu	Pro	Pro	Leu	Phe	Phe	Leu	Leu				
		1				5					10					15				
	gca tgt gcc ggc aac ttt gtc cac gga cac aag tgc gat atc acc tta 156																			
30	Ala	Cys	Ala	Gly	Asn	Phe	Val	His	Gly	His	Lys	Cys	Asp	Ile	Thr	Leu				
					20					25					30					
	cag gag atc atc aaa act ttg aac agc ctc aca gag cag aag act ctg 204																			
35	Gln	Glu	Ile	Ile	Lys	Thr	Leu	Asn	Ser	Leu	Thr	Glu	Gln	Lys	Thr	Leu				
				35					40					45						
	tgc acc gag ttg acc gta aca gac atc ttt gct gcc tcc aag aac aca 252																			
40	Cys	Thr	Glu	Leu	Thr	Val	Thr	Asp	Ile	Phe	Ala	Ala	Ser	Lys	Asn	Thr				
			50					55					60							
	act gag aag gaa acc ttc tgc agg gct gcg act gtg ctc cgg cag ttc 300																			
45	Thr	Glu	Lys	Glu	Thr	Phe	Cys	Arg	Ala	Ala	Thr	Val	Leu	Arg	Gln	Phe				
		65					70				75									
	tac agc cac cat gag aag gac act cgc tgc ctg ggt gcg act gca cag 348																			
50	Tyr	Ser	His	His	Glu	Lys	Asp	Thr	Arg	Cys	Leu	Gly	Ala	Thr	Ala	Gln				
	80					85					90				95					
	cag ttc cac agg cac aag cag ctg atc cga ttc ctg aaa cgg ctc gac 396																			
55																				

EP 1 476 541 B1

Gln Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys Arg Leu Asp
 100 105 110

5
 agg aac ctc tgg ggc ctg gcg ggc ttg aat tcc tgt cct gtg aag gaa 444
 Arg Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro Val Lys Glu
 115 120 125

10
 gcc aac cag agt acg ttg gaa aac ttc ttg gaa agg cta aag acg atc 492
 Ala Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu Lys Thr Ile
 130 135 140

15
 atg aga gag aaa tat tca aag tgt tcg agc tga atattttaat ttatgagttt 545
 Met Arg Glu Lys Tyr Ser Lys Cys Ser Ser *
 145 150

20
 ttgatagctt tattttttaa gtatttatat attataact catcataaaa taaagtatat 605
 atagaatct 614

25
 <210> 164
 <211> 153
 <212> PRT
 <213> Homo sapiens

30
 <400> 164

Met Gly Leu Thr Ser Gln Leu Leu Pro Pro Leu Phe Phe Leu Leu Ala
 1 5 10 15
 35 Cys Ala Gly Asn Phe Val His Gly His Lys Cys Asp Ile Thr Leu Gln
 20 25 30
 Glu Ile Ile Lys Thr Leu Asn Ser Leu Thr Glu Gln Lys Thr Leu Cys
 35 40 45
 40 Thr Glu Leu Thr Val Thr Asp Ile Phe Ala Ala Ser Lys Asn Thr Thr
 50 55 60
 Glu Lys Glu Thr Phe Cys Arg Ala Ala Thr Val Leu Arg Gln Phe Tyr
 65 70 75 80
 45 Ser His His Glu Lys Asp Thr Arg Cys Leu Gly Ala Thr Ala Gln Gln
 85 90 95
 Phe His Arg His Lys Gln Leu Ile Arg Phe Leu Lys Arg Leu Asp Arg
 100 105 110
 50 Asn Leu Trp Gly Leu Ala Gly Leu Asn Ser Cys Pro Val Lys Glu Ala
 115 120 125
 Asn Gln Ser Thr Leu Glu Asn Phe Leu Glu Arg Leu Lys Thr Ile Met
 130 135 140
 55 Arg Glu Lys Tyr Ser Lys Cys Ser Ser

145

150

5 <210> 165
 <211> 756
 <212> DNA
 <213> Homo sapiens,

10 <220>
 <221> CDS
 <222> (9)...(443)

15 <400> 165

gctggagg atg tgg ctg cag agc ctg ctg ctc ttg ggc act gtg gcc tgc 50
 Met Trp Leu Gln Ser Leu Leu Leu Leu Gly Thr Val Ala Cys
 1 5 10

20 agc atc tct gca ccc gcc cgc tcg ccc agc ccc agc acg cag ccc tgg 98
 Ser Ile Ser Ala Pro Ala Arg Ser Pro Ser Pro Ser Thr Gln Pro Trp
 15 20 25 30

25 gag cat gtg aat gcc atc cag gag gcc cgg cgt ctc ctg aac ctg agt 146
 Glu His Val Asn Ala Ile Gln Glu Ala Arg Arg Leu Leu Asn Leu Ser
 35 40 45

30 aga gac act gct gct gag atg aat gaa aca gta gaa gtc atc tca gaa 194
 Arg Asp Thr Ala Ala Glu Met Asn Glu Thr Val Glu Val Ile Ser Glu
 35 50 55 60

40 atg ttt gac ctc cag gag ccg acc tgc cta cag acc cgc ctg gag ctg 242
 Met Phe Asp Leu Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Glu Leu
 40 65 70 75

45 tac aag cag ggc ctg cgg ggc agc ctc acc aag ctc aag ggc ccc ttg 290
 Tyr Lys Gln Gly Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu
 45 80 85 90

50 acc atg atg gcc agc cac tac aag cag cac tgc cct cca acc ccg gaa 338
 Thr Met Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro Glu
 50 95 100 105 110

55 act tcc tgt gca acc cag act atc acc ttt gaa agt ttc aaa gag aac 386
 Thr Ser Cys Ala Thr Gln Thr Ile Thr Phe Glu Ser Phe Lys Glu Asn

EP 1 476 541 B1

115 120 125
 5 ctg aag gac ttt ctg ctt gtc atc ccc ttt gac tgc tgg gag cca gtc 434
 Leu Lys Asp Phe Leu Leu Val Ile Pro Phe Asp Cys Trp Glu Pro Val
 130 135 140

10 cag gag tga gaccggccag atgaggctgg ccaagccggg gagctgctct 483
 Gln Glu *

15 ctc atg aac aag agc tag aactcaggat ggatccttg gagggaccaa ggggtgggcc 543
 acagccatgg tgggagtggc ctggacctgc cctgggccac actgaccctg atacagggcat 603
 ggcagaagaa tgggaatatt ttatactgac agaaatcagt aatatttata tatttatatt 663
 tttaaaatat ttatttattt atttatttaa gtcatattc catatttatt caagatgttt 723
 taccgtaata attattatta aaaatatgct tct 756

20
 <210> 166
 <211> 144
 <212> PRT
 25 <213> Homo sapiens
 <400> 166

30 Met Trp Leu Gln Ser Leu Leu Leu Leu Gly Thr Val Ala Cys Ser Ile
 1 5 10 15
 Ser Ala Pro Ala Arg Ser Pro Ser Pro Ser Thr Gln Pro Trp Glu His
 20 25 30
 35 Val Asn Ala Ile Gln Glu Ala Arg Arg Leu Leu Asn Leu Ser Arg Asp
 35 40 45
 Thr Ala Ala Glu Met Asn Glu Thr Val Glu Val Ile Ser Glu Met Phe
 50 55 60
 40 Asp Leu Gln Glu Pro Thr Cys Leu Gln Thr Arg Leu Glu Leu Tyr Lys
 65 70 75 80
 Gln Gly Leu Arg Gly Ser Leu Thr Lys Leu Lys Gly Pro Leu Thr Met
 85 90 95
 45 Met Ala Ser His Tyr Lys Gln His Cys Pro Pro Thr Pro Glu Thr Ser
 100 105 110
 Cys Ala Thr Gln Thr Ile Thr Phe Glu Ser Phe Lys Glu Asn Leu Lys
 115 120 125
 50 Asp Phe Leu Leu Val Ile Pro Phe Asp Cys Trp Glu Pro Val Gln Glu
 130 135 140

55 <210> 167
 <211> 60
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)...(60)

5 <221> variation
 <222> (25)...(30)
 <223> n = A, G, C, or T

10 <221> misc_feature
 <222> (1)...(60)
 <223> n = A, T, C or G

<400> 167

15 gcc aca gaa ctg aaa cag ctt cag nnn nnn gaa gaa gaa ctc aaa cct 48
 Ala Thr Glu Leu Lys Gln Leu Gln Xaa Xaa Glu Glu Glu Leu Lys Pro
 1 5 10 15

20 ctg gag gaa gtg 60
 Leu Glu Glu Val
 20

25 <210> 168
 <211> 20
 <212> PRT
 <213> Homo sapiens

30 <220>
 <221> VARIANT
 <222> (9)...(10)
 <223> Any amino acid

35 <221> VARIANT
 <222> (1)...(20)
 <223> Xaa = Any Amino Acid

40 <400> 168

45 Ala Thr Glu Leu Lys Gln Leu Gln Xaa Xaa Glu Glu Glu Leu Lys Pro
 1 5 10 15

50 Leu Glu Glu Val
 20

Claims

- 55 1. An isolated polypeptide comprising a sequence of amino acid residues that is at least 90% identical to the sequence of amino acid residues selected from the group of:

EP 1 476 541 B1

- (a) the polypeptide shown from residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO:2;
- (b) the polypeptide shown from residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2;
- (c) the polypeptide shown from residues 24 (Ser) to 164 (Thr) as shown in SEQ ID NO:2; and
- (d) the polypeptide shown from residues 1 (Met) to 164 (Thr) as shown in SEQ ID NO:2.

- 5
2. An isolated polypeptide according to Claim 1, wherein amino acid residues 72, 133 and 147 are cysteine.
3. An isolated polypeptide according Claim 1, wherein the polypeptide binds the Zcytor17 receptor as shown in SEQ ID NO:5 or SEQ ID NO:71.
- 10
4. An isolated polypeptide comprising an amino acid sequence selected from the group of:

- (a) amino acid residues 38-52 of SEQ ID NO:2;
- (b) amino acid residues 83-98 of SEQ ID NO:2;
- (c) amino acid residues 104-117 of SEQ ID NO:2;
- (d) amino acid residues 137-152 of SEQ ID NO:2;
- (e) amino acid residues 38-52 of SEQ ID NO:11;
- (f) amino acid residues 33-38 of SEQ ID NO:2;
- (g) amino acid residues 35-40 of SEQ ID NO:2;
- (h) amino acid residues 53-58 of SEQ ID NO:2;
- (i) amino acid residues 54-59 of SEQ ID NO:2;
- (j) amino acid residues 129-134 of SEQ ID NO:2;
- (k) amino acid residues 34-39 of SEQ ID NO: 11;
- (l) amino acid residues 46-51 of SEQ ID NO:11;
- (m) amino acid residues 101-105 of SEQ ID NO:2;
- (n) amino acid residues 113-118 of SEQ ID NO2;
- (o) amino acid residues 114-119 of SEQ ID NO:2;
- (p) amino acid residues 126-131 of SEQ ID NO:2;
- (q) amino acid residues 158-162 of SEQ ID NO:2;

or consisting of an amino acid sequence selected from amino acids 85-98, 104-118, 131-136, 141-157, 157-162 or 158-163 of SEQ ID NO:11.

- 25
5. A fusion protein comprising at least four polypeptides, wherein the order of polypeptides from N-terminus to C-terminus are:
- 35

a first polypeptide that comprises amino acid residues 38-52 of SEQ ID NO:2;

a first spacer of 6-27 amino acid residues;

a second polypeptide that comprises a sequence of amino acid residues selected from the group of:

- (a) IL-2 helix B amino acid residues of SEQ ID NO:168;
- (b) IL-4 helix B residues 65-83 of SEQ ID NO:164;
- (c) IL-3 helix B residues 73-86 of SEQ ID NO:102;
- (d) GM-CSF helix 8 residues 72-81 of SEQ ID NO:166; and
- (e) amino acid residues 83-98 of SEQ ID NO:2;

a second spacer of 5-11 amino acid residues;

a third polypeptide that comprises a sequence of amino acid residues selected from the group of:

- (a) IL-2 helix C residues 102-116 of SEQ ID NO:162;
- (b) IL-4 helix C residues 94-118 of SEQ ID NO:164;
- (c) IL-3 helix C residues 91-103 of SEQ ID NO:102;
- (d) GM-CSF helix C residues 85-103 of SEQ ID NO:166; and
- (e) amino acid residues 104-117 of SEQ ID NO:2;

a third spacer of 3-29 amino acid residues; and

a fourth polypeptide that comprises a sequence of amino acid residues selected from the group of:

EP 1 476 541 B1

- (a) IL-2 helix D residues 134-149 of SEQ ID NO:162 ;
(b) IL-3 helix D residues 123-141 of SEQ ID NO:102;
(c) IL-4 helix D residues 133-151 of SEQ ID NO:164;
(d) GM-CSF helix D residues 120-131 of SEQ ID NO:166; and
(e) amino acid residues 137-152 of SEQ ID NO:2.

6. A fusion protein comprising at least four polypeptides, wherein the order of polypeptides from N-terminus to C-terminus are:

a first polypeptide that comprises a sequence of amino acid residues selected from a group consisting of:

- (a) IL-2 helix A residues 27-48 of SEQ ID NO:162;
(b) IL-4 helix A residues 30-42 of SEQ ID NO:164;
(c) IL-3 helix A residues 35-45 of SEQ ID NO:102;
(d) GM-CSF helix A residues 30-44 of SEQ ID NO:166; and
(e) amino acids residues 38-52 of SEQ ID NO:2;

a first spacer of 6-27 amino acid residues;

a second polypeptide that comprises a sequence of amino acid residues selected from the group of:

- (a) IL-2 helix B residues of SEQ ID NO:168;
(b); IL-4 helix B residues 65-83 of SEQ ID NO:164;
(c) IL-3 helix B residues 73-86 of SEQ ID NO:102;
(d) GM-CSF helix B residues 72-81 of SEQ ID NO:166; and
(e) amino acid residues 83-98 of SEQ ID NO:2;

a second spacer of 5-11 amino acid residues;

a third polypeptide that comprises a sequence of amino acid residues selected from the group of:

- (a) IL-2 helix C residues 102-116 of SEQ ID NO:162;
(b) IL-4 helix C residues 94-118 of SEQ ID NO:164;
(c) IL-3 helix C residues 91-103 of SEQ ID NO:102;
(d) GM-CSF helix C residues 85-103 of SEQ ID NO:166; and
(e) amino acid residues 104-117 of SEQ ID NO:2;

a third spacer of 3-29 amino acid residues; and

a fourth polypeptide that comprises amino acid residues 137-152 of SEQ ID NO:2.

7. A fusion protein according to claim 6, wherein the fourth polypeptide comprises amino acid residues 137-152 of SEQ ID NO:2.

8. An isolated polynucleotide molecule consisting of a sequence of nucleotides that encode a polypeptide consisting of a sequence of amino acid residues that is at least 90% identical to a sequence of amino acids selected from the group of:

- (a) the polypeptide shown from residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO:2;
(b) the polypeptide shown from residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2;
(c) the polypeptide shown from residues 24 (Ser) to 164 (Thr) as shown in SEQ ID NO:2; and
(d) the polypeptide shown from residues 1 (Met) to 164 (Thr) as shown in SEQ ID NO:2.

9. An isolated polynucleotide molecule according to Claim 8, wherein the nucleotides are selected from the group of:

- (a) a polynucleotide as shown in SEQ ID NO: 1 from nucleotide 139 to nucleotide 483;
(b) a polynucleotide as shown in SEQ ID NO: 1 from nucleotide 106 to nucleotide 519;
(c) a polynucleotide as shown in SEQ ID NO: 1 from nucleotide 97 to nucleotide 519; and
(d) a polynucleotide as shown in SEQ ID NO: 1 from nucleotide 28 to nucleotide 519, or

wherein said nucleotides encode a polypeptide according to Claim 4.

10. An expression vector comprising the following operably linked elements:

- (a) a transcription promoter;
(b) a DNA segment encoding a polypeptide consisting of a sequence of amino acid residues selected from the group of:

- (i) amino acid residues 38-52 of SEQ ID NO:2;
(ii) amino acid residues 83-98 of SEQ ID NO:2;
(iii) amino acid residues 10A-117 of SEQ ID NO:2;
(iv) amino acid residues 137-152 of SEQ ID NO:2;

or consisting of an isolated polynucleotide according to Claim 8; and (c) a transcription terminator.

11. A cultured cell comprising an expression vector according to Claim 10.

12. A method of producing a polypeptide, comprising culturing a cell according to Claim 11 under conditions wherein the DNA segment is expressed; and recovering the polypeptide encoded by the DNA segment.

13. A method of producing an antibody that binds a polypeptide according to Claim 1, wherein the inoculated polypeptide is selected from the group of:

- (a) a polypeptide consisting of 9 to 141 amino acids, wherein the polypeptide is identical to a contiguous sequence of amino acid residues in SEQ ID NO:2 from amino acid number 24 (Ser) to amino acid number 164 (Thr);
(b) a polypeptide according to claim 1;
(c) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 38-52;
(d) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 83-98;
(e) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 104-117;
(f) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 137-152;
(g) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 38-152;
(h) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 24-164;
(i) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 from amino acid number 27-164;
(j) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 38-52;
(k) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 85-98;
(l) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 104-118;
(m) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 141-157;
(n) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 38-157;
(o) a polypeptide comprising the amino acid sequence of SEQ ID NO:11 from amino acid number 24-163;
(p) a polypeptide comprising amino acid residues 54-59, 129-134, 53-58, 35-40 or 33-38 of SEQ ID NO: 2 or amino acid residues 34-39, 46-51, 131-136, 158-163 or 157-162 of SEQ ID NO 11, wherein buried G, S, and T residues and exposed H, Y, and W residues are ignored; and

wherein the polypeptide elicits an immune response to produce the antibody; and isolating the antibody from the animal.

14. An antibody obtainable by the method of Claim 13, wherein the antibody binds to a polypeptide of SEQ ID NO: 2 or SEQ 10 NO:11.

15. An antibody or antibody fragment which specifically binds to a polypeptide shown in SEQ ID NO:2 or SEQ ID NO: 11. or to a polypeptide comprising a sequence of amino acid residues selected from the group of:

- (a) the polypeptide shown from residues 38 (Val) to 152 (Leu) as shown in SEQ ID NO:2;
(b) the polypeptide shown from residues 27 (Leu) to 164 (Thr) as shown in SEQ ID NO:2;
(c) the polypeptide shown from residues 24 (Ser) to 164 (Thr) as shown in SEQ ID NO:2; and
(d) the polypeptide shown from residues 1 (Met) to 164 (Thr) as shown in SEQ ID NO:2.

16. An antibody according to Claim 15, wherein the antibody is selected from the group of: (a) a polyclonal antibody, (b) a murine monoclonal antibody, (c) a humanized antibody derived from (b), (d) an antibody fragment, and (e) a

human monoclonal antibody.

5 17. An antibody according to Claim 15, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

18. An antibody according to Claim 15 for reducing inflammation induced by a polypeptide according to any of Claims 1-4.

10 19. Use of an antibody according to Claim 15 for the manufacture of a medicament for use in a method of suppressing an inflammatory response in a mammal with inflammation, said method comprising:

- 15 (1) determining a level of an inflammatory molecule;
(2) administering said medicament;
(3) determining a post administration level of the inflammatory molecule;
(4) comparing the level of the inflammatory molecule in step (1) to the level of the inflammatory molecule in step (3), wherein a lack of increase or a decrease in the inflammatory molecule level is indicative of suppressing an inflammatory response.

20 20. A method of detecting the presence of a polypeptide according to any of Claims 1-4 in a biological sample, comprising the steps of:

- 25 (a) contacting the biological sample with an antibody, or an antibody fragment, according to Claim 15, wherein the contacting is performed under conditions that allow the binding of the antibody or antibody fragment to the biological sample, and
(b) detecting any of the bound antibody or bound antibody fragment.

30 21. A method for inhibiting proliferation or differentiation of hematopoietic cells and hematopoietic cell progenitors induced by a polypeptide according to any of Claims 1-4 comprising culturing bone marrow or peripheral blood cells with a composition comprising an amount of an antibody according to Claim 15 sufficient to reduce proliferation or differentiation of the hematopoietic cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of soluble cytokine receptor.

22. A method according to Claim 21, wherein the hematopoietic cells and hematopoietic progenitor cells are lymphoid cells.

35 23. A method according to Claim 22, wherein the lymphoid cells are macrophages or T cells.

40 24. Use of a polypeptide according to any of Claims 1-4 for the manufacture of a medicament for use in a method of stimulating an immune response in a mammal exposed to an antigen or pathogen, said method comprising the steps of:

- 45 (1) determining directly or indirectly the level of antigen or pathogen present in said mammal;
(2) administering said medicament;
(3) determining directly or indirectly the level of antigen or pathogen in said mammal; and
(4) comparing the level of the antigen or pathogen in step 1 to the antigen or pathogen level in step 3, wherein a change in the level is indicative of stimulating an immune response.

25. Use according to Claim 24, wherein said method further comprises:

- 50 (5) re-administering said medicament;
(6) determining directly or indirectly the level of antigen or pathogen in said mammal; and
(7) comparing the number of comparing the antigen or pathogen level in step 1 to the antigen level in step 6, wherein a change in the level is indicative of stimulating an immune response.

55 26. A method for expansion of hematopoietic cells and hematopoietic cell progenitors comprising culturing bone marrow or peripheral blood cells with a composition comprising an amount of a polypeptide according to any of Claims 1-4 sufficient to produce an increase in the number of lymphoid cells in the bone marrow or peripheral blood cells as compared to bone marrow or peripheral blood cells cultured in the absence of said polypeptide.

27. A method according to Claim 26, wherein the hematopoietic cells and hemopoietic progenitor cells are lymphoid cells.

28. A method according to Claim 27, wherein the lymphoid cells are monocytic cells, macrophages or T cells.

5 29. Use of a polypeptide according to any of Claims 1-4 for the manufacture of a medicament for use in a method of stimulating an immune response in a mammal exposed to an antigen or pathogen, said method comprising:

- 10 (1) determining a level of an antigen- or pathogen-specific antibody;
(2) administering said medicament;
10 (3) determining a post administration level of antigen- or pathogen-specific antibody;
(4) comparing the level of antibody in step (1) to the level of antibody in step (3),

wherein an increase in antibody level is indicative of stimulating an immune response.

15 30. A method of detecting the presence of RNA encoding a polypeptide according to any of Claims 1-4 in a biological sample, comprising the steps of :

- 20 (a) contacting a nucleic acid probe under hybridizing conditions with either (i) test RNA molecules isolated from the biological sample, or (ii) nucleic acid molecules synthesized from the isolated RNA molecules, wherein the probe has a nucleotide sequence comprising either a portion of the nucleotide sequence of the nucleic acid molecule of Claim 9, or its complement, and
(b) detecting the formation of hybrids of the nucleic acid probe and either the test RNA molecules or the synthesized nucleic acid molecules, wherein the presence of the hybrids indicates the presence of RNA encoding a polypeptide according to any of Claims 1-4 in the biological sample.

25 31. An *in vitro* or *ex vivo* method for killing cancer cells, comprising producing a polypeptide by a method according to Claim 12: and formulating the polypeptide in a pharmaceutically acceptable vehicle; and exposing a tissue sample or biological sample containing cancer cells to the polypeptide; wherein the polypeptide kills the cells.

30 32. Use of a polypeptide produced by a method according to Claim 12 for the manufacture of a medicament for killing cancer cells.

33. A method according to Claim 31 or a use according to Claim 32, wherein the polypeptide is further conjugated to a toxin.

35 34. Use of an antagonist of a polypeptide according to any of Claims 1-4 for the manufacture of a medicament for treating a mammal afflicted with an inflammatory disease wherein the antagonist is an antibody that specifically binds a polypeptide according to any of Claims 1-4, or an antibody or antibody fragment according to Claim 15.

40 35. Use according to Claim 34, wherein the disease is a chronic inflammatory disease.

36. Use according to Claim 35, wherein the chronic inflammatory disease is selected from the group of:

- 45 (a) inflammatory bowel disease;
(b) ulcerative colitis;
(c) Crohn's disease;
(d) atopic dermatitis;
(e) eczema; and
50 (f) psoriasis.

37. Use according to Claim 34, wherein the disease is an acute inflammatory disease.

38. Use according to Claim 37, wherein the acute inflammatory disease is selected from the group of:

- 55 (a) endotoxemia;
(b) septicemia;
(c) toxic shock syndrome; and
(d) infectious disease.

39. Use according to Claim 34, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.

5 40. A method for detecting inflammation in a patient, comprising:

10 incubating a tissue sample or biological sample from a patient with an antibody according to Claim 15 under conditions wherein the antibody binds to its complementary polypeptide in the tissue or biological sample; visualizing the antibody bound in the tissue or biological sample, and comparing levels of antibody bound in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the level of antibody bound to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of inflammation in the patient.

15 41. A method for detecting inflammation in a patient, comprising:

20 labeling a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1; incubating a tissue sample or biological sample from a patient with said labeled polynucleotide under conditions wherein the polynucleotide will hybridize to complementary polynucleotide sequence; visualizing the labeled polynucleotide in the tissue or biological sample; and comparing the level of labeled polynucleotide hybridization in the tissue or biological sample from the patient to a normal control tissue or biological sample, wherein an increase in the labeled polynucleotide hybridization to the patient tissue or biological sample relative to the normal control tissue or biological sample is indicative of inflammation in the patient.

25 **Patentansprüche**

30 1. Isoliertes Polypeptid, umfassend eine Sequenz von Aminosäureresten, die zu mindestens 90% mit der Sequenz von Aminosäureresten, ausgewählt aus der folgenden Gruppe, identisch ist:

- 35 (a) in SEQ ID NO:2 von Rest 38 (Val) bis 152 (Leu) dargestelltes Polypeptid;
(b) in SEQ ID NO:2 von Rest 27 (Leu) bis 164 (Thr) dargestelltes Polypeptid;
(c) in SEQ ID NO:2 von Rest 24 (Ser) bis 164 (Thr) dargestelltes Polypeptid; und
(d) in SEQ ID NO:2 von Rest 1 (Met) bis 164 (Thr) dargestelltes Polypeptid.

2. Isoliertes Polypeptid gemäß Anspruch 1, wobei die Aminosäurereste 72, 133 und 147 Cystein sind.

40 3. Isoliertes Polypeptid gemäß Anspruch 1, wobei das Polypeptid an den in SEQ ID NO:5 oder SEQ ID NO:71 dargestellten Zcytor17-Rezeptor bindet.

4. Isoliertes Polypeptid, umfassend eine Aminosäuresequenz, ausgewählt aus der Gruppe:

- 45 (a) Aminosäurereste 38-52 von SEQ ID NO:2;
(b) Aminosäurereste 83-98 von SEQ ID NO:2;
(c) Aminosäurereste 104-117 von SEQ ID NO:2;
(d) Aminosäurereste 137-152 von SEQ ID NO:2;
(e) Aminosäurereste 38-52 von SEQ ID NO:11;
(f) Aminosäurereste 33-38 von SEQ ID NO:2;
50 (g) Aminosäurereste 35-40 von SEQ ID NO:2;
(h) Aminosäurereste 53-58 von SEQ ID NO:2;
(i) Aminosäurereste 54-59 von SEQ ID NO:2;
(j) Aminosäurereste 129-134 von SEQ ID NO:2;
(k) Aminosäurereste 34-39 von SEQ ID NO:11;
55 (l) Aminosäurereste 46-51 von SEQ ID NO:11;
(m) Aminosäurereste 101-105 von SEQ ID NO:2;
(n) Aminosäurereste 113-118 von SEQ ID NO:2;
(o) Aminosäurereste 114-119 von SEQ ID NO:2;

EP 1 476 541 B1

(p) Aminosäurereste 126-131 von SEQ ID NO:2;

(q) Aminosäurereste 158-162 von SEQ ID NO:2;

oder bestehend aus einer Aminosäuresequenz, ausgewählt aus den Aminosäuren 85-98, 104-118, 131-136, 141-157, 157-162 oder 158-163 von SEQ ID NO:11.

- 5
5. Fusionsprotein, umfassend mindestens vier Polypeptide, wobei die Reihenfolge der Polypeptide vom N-Terminus zum C-Terminus ist:

10 ein erstes Polypeptid, das die Aminosäurereste 38-52 von SEQ ID NO:2 umfasst;

ein erster Spacer aus 6-27 Aminosäureresten;

ein zweites Polypeptid, das eine Sequenz von Aminosäureresten umfasst, ausgewählt aus der Gruppe:

15 (a) Aminosäurereste von SEQ ID NO:168 der Helix B von IL-2;

(b) Reste 65-83 von SEQ ID NO:164 der Helix B von IL-4;

(c) Reste 73-86 von SEQ ID NO:102 der Helix B von IL-3;

(d) Reste 72-81 von SEQ ID NO:166 der Helix B von GM-CSF; und

(e) Aminosäurereste 83-98 von SEQ ID NO:2;

20 ein zweiter Spacer aus 5-11 Aminosäureresten;

ein drittes Polypeptid, das eine Sequenz von Aminosäureresten umfasst, ausgewählt aus der Gruppe:

25 (a) Reste 102-116 von SEQ ID NO:162 der Helix C von IL-2;

(b) Reste 94-118 von SEQ ID NO:164 der Helix C von IL-4;

(c) Reste 91-103 von SEQ ID NO:102 der Helix C von IL-3;

(d) Reste 85-103 von SEQ ID NO:166 der Helix C von GM-CSF; und

(e) Aminosäurereste 104-117 von SEQ ID NO:2;

30 ein dritter Spacer aus 3-29 Aminosäureresten; und

ein viertes Polypeptid, das eine Sequenz von Aminosäureresten umfasst, ausgewählt aus der Gruppe:

35 (a) Reste 134-149 von SEQ ID NO:162 der Helix D von IL-2;

(b) Reste 123-141 von SEQ ID NO:102 der Helix D von IL-3;

(c) Reste 133-151 von SEQ ID NO:164 der Helix D von IL-4;

(d) Reste 120-131 von SEQ ID NO:166 der Helix D von GM-CSF; und

(e) Aminosäurereste 137-152 von SEQ ID NO:2.

6. Fusionsprotein, umfassend mindestens vier Polypeptide, wobei die Reihenfolge der Polypeptide vom N-Terminus zum C-Terminus ist:

40 ein erstes Polypeptid, das eine Sequenz von Aminosäureresten umfasst, ausgewählt aus der Gruppe, bestehend aus:

45 (a) Resten 27-48 von SEQ ID NO:162 der Helix A von IL-2;

(b) Resten 30-42 von SEQ ID NO:164 der Helix A von IL-4;

(c) Resten 35-45 von SEQ ID NO:102 der Helix A von IL-3;

(d) Resten 30-44 von SEQ ID NO:166 der Helix A von GM-CSF; und

(e) Aminosäureresten 38-52 von SEQ ID NO:2;

50 ein erster Spacer aus 6-27 Aminosäureresten;

ein zweites Polypeptid, das eine Sequenz von Aminosäureresten umfasst, ausgewählt aus der Gruppe:

55 (a) Reste von SEQ ID NO:168 der Helix B von IL-2;

(b) Reste 65-83 von SEQ ID NO:164 der Helix B von IL-4;

(c) Reste 73-86 von SEQ ID NO:102 der Helix B von IL-3;

(d) Reste 72-81 von SEQ ID NO:166 der Helix B von GM-CSF; und

(e) Aminosäurereste 83-98 von SEQ ID NO:2;

EP 1 476 541 B1

ein zweiter Spacer aus 5-11 Aminosäureresten;

ein drittes Polypeptid, das eine Sequenz von Aminosäureresten umfasst, ausgewählt aus der Gruppe:

- (a) Reste 102-116 von SEQ ID NO:162 der Helix C von IL-2;
- (b) Reste 94-118 von SEQ ID NO: 164 der Helix C von IL-4;
- (c) Reste 91-103 von SEQ ID NO:102 der Helix C von IL-3;
- (d) Reste 85-103 von SEQ ID NO:166 der Helix C von GM-CSF; und
- (e) Aminosäurereste 104-117 von SEQ ID NO:2;

ein dritter Spacer aus 3-29 Aminosäureresten; und

ein viertes Polypeptid, das die Aminosäurereste 137-152 von SEQ ID NO:2 umfasst.

7. Fusionsprotein gemäß Anspruch 6, wobei das vierte Polypeptid Aminosäurereste 137-152 von SEQ ID NO:2 umfasst.

8. Isoliertes Polynukleotidmolekül, bestehend aus einer Sequenz von Nukleotiden, die für ein Polypeptid kodieren, bestehend aus einer Sequenz von Aminosäureresten, die zu mindestens 90% mit einer Sequenz von Aminosäuren, ausgewählt aus der folgenden Gruppe, identisch ist:

- (a) in SEQ ID NO:2 von Rest 38 (Val) bis 152 (Leu) dargestelltes Polypeptid;
- (b) in SEQ ID NO:2 von Rest 27 (Leu) bis 164 (Thr) dargestelltes Polypeptid;
- (c) in SEQ ID NO:2 von Rest 24 (Ser) bis 164 (Thr) dargestelltes Polypeptid; und
- (d) in SEQ ID NO:2 von Rest 1 (Met) bis 164 (Thr) dargestelltes Polypeptid.

9. Isoliertes Polynukleotidmolekül gemäß Anspruch 8, wobei die Nukleotide ausgewählt sind, aus der Gruppe:

- (a) in SEQ ID NO:1 von Nukleotid 139 bis Nukleotid 483 dargestelltes Polynukleotid;
- (b) in SEQ ID NO:1 von Nukleotid 106 bis Nukleotid 519 dargestelltes Polynukleotid;
- (c) in SEQ ID NO:1 von Nukleotid 97 bis Nukleotid 519 dargestelltes Polynukleotid; und
- (d) in SEQ ID NO:1 von Nukleotid 28 bis Nukleotid 519 dargestelltes Polynukleotid, oder

wobei die Nukleotide für ein Polypeptid gemäß Anspruch 4 kodieren.

10. Expressionsvektor, umfassend die folgenden operabel miteinander verknüpften Elemente:

- (a) einen Transkriptionspromotor;
- (b) ein DNA-Segment, kodierend für ein Polypeptid, bestehend aus einer Sequenz von Aminosäureresten, ausgewählt aus der Gruppe:

- (i) Aminosäurereste 38-52 von SEQ ID NO:2;
- (ii) Aminosäurereste 83-98 von SEQ ID NO:2;
- (iii) Aminosäurereste 104-117 von SEQ ID NO:2;
- (iv) Aminosäurereste 137-152 von SEQ ID NO:2;

oder bestehend aus einem isolierten Polynukleotid gemäß Anspruch 8; und

(c) einen Transkriptionsterminator.

11. Kultivierte Zelle, umfassend einen Expressionsvektor gemäß Anspruch 10.

12. Verfahren zur Herstellung eines Polypeptids, umfassend das Kultivieren einer Zelle gemäß Anspruch 11 unter Bedingungen, bei denen das DNA-Segment exprimiert wird; und Gewinnen des Polypeptids, das durch das DNA-Segment kodiert wird.

13. Verfahren zur Herstellung eines Antikörpers, der an ein Polypeptid gemäß Anspruch 1 bindet, wobei das inokulierte Polypeptid ausgewählt ist aus der Gruppe:

- (a) Polypeptid, bestehend aus 9 bis 141 Aminosäuren, wobei das Polypeptid mit einer zusammenhängenden Sequenz von Aminosäureresten in SEQ ID NO:2 von Aminosäurenummer 24 (Ser) bis Aminosäurenummer 164 (Thr) identisch ist;

- (b) Polypeptid gemäß Anspruch 1;
(c) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:2 von Aminosäurenummer 38-52;
(d) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:2 von Aminosäurenummer 83-98;
(e) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:2 von Aminosäurenummer 104-117;
(f) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:2 von Aminosäurenummer 137-152;
(g) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:2 von Aminosäurenummer 38-152;
(h) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:2 von Aminosäurenummer 24-164;
(i) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:2 von Aminosäurenummer 27-164;
(j) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:11 von Aminosäurenummer 38-52;
(k) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:11 von Aminosäurenummer 85-98;
(l) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:11 von Aminosäurenummer 104-118;
(m) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:11 von Aminosäurenummer 141-157;
(n) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:11 von Aminosäurenummer 38-157;
(o) Polypeptid, umfassend die Aminosäuresequenz von SEQ ID NO:11 von Aminosäurenummer 24-163;
(p) Polypeptid, umfassend die Aminosäurereste 54-59, 129-134, 53-58, 35-40 oder 33-38 von SEQ ID NO:2 oder Aminosäurereste 34-39, 46-51, 131-136, 158-163 oder 157-162 von SEQ ID NO:11, wobei die verborgenen G-, S- und T-Reste und die exponierten H-, Y- und W-Reste vernachlässigt werden; und

wobei das Polypeptid eine Immunantwort zur Herstellung von Antikörpern auslöst; und Isolieren des Antikörpers aus dem Lebewesen.

14. Antikörper, erhältlich durch das Verfahren nach Anspruch 13, wobei der Antikörper an ein Polypeptid von SEQ ID NO:2 oder SEQ ID NO:11 bindet.

15. Antikörper oder Antikörperfragment, der/das an ein in SEQ ID NO:2 oder SEQ ID NO:11 dargestelltes Polypeptid oder ein Polypeptid, umfassend eine Sequenz von Aminosäureresten, ausgewählt aus der folgenden Gruppe, spezifisch bindet:

- (a) in SEQ ID NO:2 von Rest 38 (Val) bis 152 (Leu) dargestelltes Polypeptid;
(b) in SEQ ID NO:2 von Rest 27 (Leu) bis 164 (Thr) dargestelltes Polypeptid;
(c) in SEQ ID NO:2 von Rest 24 (Ser) bis 164 (Thr) dargestelltes Polypeptid; und
(d) in SEQ ID NO:2 von Rest 1 (Met) bis 164 (Thr) dargestelltes Polypeptid.

16. Antikörper gemäß Anspruch 15, wobei der Antikörper ausgewählt ist aus der Gruppe: (a) polyklonaler Antikörper, (b) muriner monoklonaler Antikörper, (c) humanisierter, von (b) stammender Antikörper, (d) Antikörperfragment und (e) humaner monoklonaler Antikörper.

17. Antikörper gemäß Anspruch 15, wobei der Antikörper weiterhin ein(en) Radionuklid, Enzym, Substrat, Cofaktor, Fluoreszenzmarker, Chemilumineszenzmarker, Peptidtag, magnetisches Partikel, Wirkstoff oder Toxin umfasst.

18. Antikörper gemäß Anspruch 15 zur Reduzierung einer durch ein Polypeptid gemäß einem beliebigen der Ansprüche 1-4 induzierten Entzündung.

19. Verwendung eines Antikörpers gemäß Anspruch 15 zur Herstellung eines Medikaments zur Verwendung in einem Verfahren zur Unterdrückung einer Entzündungsantwort in einem Säugetier mit Entzündung, wobei das Verfahren umfasst:

- (1) Bestimmung eines Niveaus eines Entzündungsmoleküls;
(2) Verabreichung des Medikaments;
(3) Bestimmung eines Niveaus des Entzündungsmoleküls nach der Verabreichung;
(4) Vergleich des Niveaus des Entzündungsmoleküls in Schritt (1) mit dem Niveau des Entzündungsmoleküls in Schritt (3), wobei ein Fehlen der Erhöhung oder Erniedrigung des Entzündungsmolekül-Niveaus ein Indiz für die Unterdrückung einer Entzündungsantwort ist.

20. Verfahren zur Detektion der Anwesenheit eines Polypeptids gemäß einem beliebigen der Ansprüche 1-4 in einer biologischen Probe, umfassend die Schritte:

- (a) In-Kontakt-Bringen der biologischen Probe mit einem Antikörper oder einem Antikörperfragment gemäß

EP 1 476 541 B1

Anspruch 15, wobei das In-Kontakt-Bringen unter Bedingungen durchgeführt wird, die die Bindung des Antikörpers oder Antikörperfragments an die biologische Probe ermöglichen, und

(b) Detektieren entweder des gebundenen Antikörpers oder des gebundenen Antikörperfragments.

5 **21.** Verfahren zur Inhibierung der Proliferation oder Differenzierung hämatopoietischer Zellen und hämatopoietischer Vorläuferzellen, die durch ein Polypeptid gemäß jedem beliebigen der Ansprüche 1-4 induziert werden, umfassend das Kultivieren von Knochenmark oder peripheren Blutzellen mit einer Zusammensetzung, umfassend eine Menge eines Antikörpers gemäß Anspruch 15, die ausreichend ist, um die Proliferation und Differenzierung hämatopoietischer Zellen im Knochenmark oder in peripheren Blutzellen im Vergleich zum Knochenmark oder peripheren Blutzellen, welche in Abwesenheit des löslichen Cytokin-Rezeptors kultiviert wurden, zu reduzieren.

10 **22.** Verfahren gemäß Anspruch 21, wobei die hämatopoietischen Zellen und hämatopoietischen Vorläuferzellen Lymphzellen sind.

15 **23.** Verfahren gemäß Anspruch 22, wobei die Lymphzellen Makrophagen oder T-Zellen sind.

24. Verwendung eines Polypeptids gemäß jedem beliebigen der Ansprüche 1-4 zur Herstellung eines Medikaments zur Verwendung in einem Verfahren zur Stimulierung einer Immunantwort in einem Säugetier, das einem Antigen oder Pathogen ausgesetzt wurde, wobei das Verfahren die Schritte umfasst:

- 20
- (1) Direkte oder indirekte Bestimmung des Antigen- oder Pathogen-Niveaus in dem Säugetier;
 - (2) Verabreichung des Medikaments;
 - (3) Direkte oder indirekte Bestimmung des Antigen- oder Pathogen-Niveaus in dem Säugetier; und
 - (4) Vergleich des Antigen- oder Pathogen-Niveaus in Schritt (1) mit dem Antigen- oder Pathogen-Niveau in Schritt (3), wobei eine Änderung des Niveaus ein Indiz für die Stimulierung einer Immunantwort ist.
- 25

25. Verwendung gemäß Anspruch 24, wobei das Verfahren weiterhin umfasst:

- 30
- (5) Wiederverabreichung des Medikaments;
 - (6) Direkte oder indirekte Bestimmung des Antigen- oder Pathogen-Niveaus in dem Säugetier; und
 - (7) Vergleich der Anzahl der Vergleiche des Antigen- oder Pathogen-Niveaus in Schritt (1) mit dem Antigen- oder Pathogen-Niveau in Schritt (6), wobei eine Änderung des Niveaus ein Indiz für die Stimulierung einer Immunantwort ist.

35 **26.** Verfahren zur Expansion hämatopoietischer Zellen und hämatopoietischer Vorläuferzellen, umfassend das Kultivieren von Knochenmark oder peripheren Blutzellen mit einer Zusammensetzung, umfassend eine Menge eines Polypeptids gemäß jedem beliebigen der Ansprüche 1-4, die ausreichend ist, um eine Erhöhung der Lymphzell-Anzahl im Knochenmark oder in den peripheren Blutzellen im Vergleich zum Knochenmark oder peripheren Blutzellen, welche in Abwesenheit des Polypeptids kultiviert wurden, zu bewirken.

40 **27.** Verfahren gemäß Anspruch 26, wobei die hämatopoietischen Zellen und hämatopoietischen Vorläuferzellen Lymphzellen sind.

28. Verfahren gemäß Anspruch 27, wobei die Lymphzellen monocytische Zellen, Makrophagen oder T-Zellen sind.

45 **29.** Verwendung eines Polypeptids gemäß jedem beliebigen der Ansprüche 1-4 zur Herstellung eines Medikaments zur Verwendung in einem Verfahren zur Stimulierung einer Immunantwort in einem Säugetier, das einem Antigen oder Pathogen ausgesetzt wurde, wobei das Verfahren umfasst:

- 50
- (1) Bestimmung des Niveaus eines Antigen- oder Pathogen-spezifischen Antikörpers;
 - (2) Verabreichung des Medikaments;
 - (3) Bestimmung des Niveaus des Antigen- oder Pathogen-spezifischen Antikörpers nach der Verabreichung; und
 - (4) Vergleich des Antikörper-Niveaus in Schritt (1) mit dem Antikörper-Niveau in Schritt (3),
- 55

wobei eine Erhöhung des Antikörper-Niveaus ein Indiz für die Stimulierung einer Immunantwort ist.

30. Verfahren zur Detektion der Anwesenheit von RNA, die für ein Polypeptid gemäß jedem beliebigen der Ansprüche

1-4 kodiert, in einer biologischen Probe, umfassend die Schritte:

5 (a) In-Kontakt-Bringen einer Nukleinsäure-Sonde unter hybridisierenden Bedingungen entweder mit (i) Test-RNA-Molekülen, die aus der biologischen Probe isoliert wurden, oder (ii) Nukleinsäuremolekülen, die ausgehend von den isolierten RNA-Molekülen synthetisiert wurden, wobei die Sonde eine Nukleotidsequenz aufweist, umfassend entweder einen Teil der Nukleotidsequenz des Nukleinsäuremoleküls nach Anspruch 9 oder sein Komplement, und

10 (b) Detektieren der Bildung von Hybriden der Nukleinsäure-Sonde und entweder der Test-RNA-Moleküle oder der synthetisierten Nukleinsäuremoleküle, wobei die Anwesenheit der Hybride ein Indiz für die Anwesenheit der RNA, die für das Polypeptid gemäß jedem beliebigen der Ansprüche 1-4 kodiert, in der biologischen Probe ist.

15 **31.** *In-vitro*- oder *Ex-vivo*-Verfahren zur Abtötung von Krebszellen, umfassend die Herstellung eines Polypeptids durch ein Verfahren gemäß Anspruch 12; und Formulierung des Polypeptids in einem pharmazeutisch akzeptablen Vehikel; und Aussetzen einer Gewebeprobe oder einer biologischen Probe, enthaltend Krebszellen, dem Polypeptid; wobei das Polypeptid die Zellen abtötet.

32. Verwendung eines Polypeptids, das nach einem Verfahren gemäß Anspruch 12 hergestellt wurde, zur Herstellung eines Medikaments zur Abtötung von Krebszellen.

20 **33.** Verfahren gemäß Anspruch 31 oder Verwendung gemäß Anspruch 32, wobei das Polypeptid weiterhin an ein Toxin konjugiert ist.

25 **34.** Verwendung eines Antagonisten eines Polypeptids gemäß jedem beliebigen der Ansprüche 1-4 zur Herstellung eines Medikaments zur Behandlung eines Säugetiers, das von einer Entzündungserkrankung befallen ist, wobei der Antagonist ein Antikörper, der an ein Polypeptid gemäß jedem beliebigen der Ansprüche 1-4 spezifisch bindet, oder ein Antikörper oder Antikörperfragment gemäß Anspruch 15 ist.

35. Verwendung gemäß Anspruch 34, wobei die Erkrankung eine chronische Entzündungserkrankung ist.

30 **36.** Verwendung gemäß Anspruch 35, wobei die chronische Entzündungserkrankung ausgewählt ist aus der Gruppe:

- 35 (a) entzündliche Darmerkrankung;
(b) ulzerative Kolitis;
(c) Crohnsche Erkrankung;
(c) atopische Dermatitis;
(d) Ekzem; und
(e) Psoriasis.

40 **37.** Verwendung gemäß Anspruch 34, wobei die Erkrankung eine akute Entzündungserkrankung ist.

38. Verwendung gemäß Anspruch 37, wobei die akute Entzündungserkrankung ausgewählt ist aus der Gruppe:

- 45 (a) Endotoxämie;
(b) Sepsis;
(c) toxischer Schock-Syndrom; und
(d) infektiöse Erkrankung.

50 **39.** Verwendung gemäß Anspruch 34, wobei der Antikörper weiterhin ein(en) Radionuklid, Enzym, Substrat, Cofaktor, Fluoreszenzmarker, Chemilumineszenzmarker, Peptidtag, magnetisches Partikel, Wirkstoff oder Toxin umfasst.

40. Verfahren zur Detektion einer Entzündung bei einem Patienten, umfassend:

55 Inkubieren einer Gewebeprobe oder einer biologischen Probe eines Patienten mit einem Antikörper gemäß Anspruch 15 unter Bedingungen, bei denen der Antikörper an sein komplementäres Polypeptid in der Gewebe- oder der biologischen Probe bindet;
Visualisierung des Antikörpers, der in der Gewebe- oder der biologischen Probe gebunden ist; und
Vergleich der Niveaus des Antikörpers, der in der Gewebe- oder der biologischen Probe des Patienten gebunden ist, mit dem einer normalen Gewebe- oder einer normalen biologischen Kontroll-Probe,

EP 1 476 541 B1

wobei eine Erhöhung des Niveaus des Antikörpers, der an die Gewebe- oder die biologische Probe des Patienten gebunden ist, gegenüber dem der normalen Gewebe- oder der normalen biologischen Kontroll-Probe ein Indiz für die Entzündung bei einem Patienten ist.

5 41. Verfahren zur Detektion von Entzündung bei einem Patienten, umfassend:

Markieren eines Polynukleotids, umfassend mindestens 14 zusammenhängende Nukleotide von SEQ ID NO: 1 oder des Komplements von SEQ ID NO:1;

10 Inkubieren einer Gewebeprobe oder einer biologischen Probe eines Patienten mit dem markierten Polynukleotid unter Bedingungen, bei denen das Polynukleotid an die komplementäre Polynukleotidsequenz hybridisieren wird;

Visualisierung des markierten Polynukleotids in der Gewebe- oder der biologischen Probe; und

Vergleich des Niveaus der Hybridisierung des markierten Polynukleotids in der Gewebe- oder der biologischen Probe des Patienten mit dem einer normalen Gewebe- oder einer normalen biologischen Kontroll-Probe,

15 wobei eine Erhöhung der Hybridisierung des markierten Polynukleotids an die Gewebe- oder die biologische Probe des Patienten gegenüber der der normalen Gewebe- oder der normalen biologischen Kontroll-Probe ein Indiz für die Entzündung bei einem Patienten ist.

20 Revendications

1. Polypeptide isolé comprenant une séquence de résidus d'acide aminé qui est identique à au moins 90 % à la séquence de résidus d'acide aminé sélectionnée dans le groupe :

- 25 (a) du polypeptide représenté des résidus 38 (Val) à 152 (Leu), ainsi qu'indiqué dans le SEQ ID NO : 2 ;
(b) du polypeptide représenté des résidus 27 (Leu) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2 ;
(c) du polypeptide représenté des résidus 24 (Ser) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2 ; et
(d) du polypeptide représenté des résidus 1 (Met) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2.

30 2. Polypeptide isolé selon la revendication 1, dans lequel les résidus d'acide aminé 72, 133 et 147 sont des cystéines.

3. Polypeptide isolé selon la revendication 1, dans lequel le polypeptide se lie au récepteur zcytor17, comme indiqué dans le SEQ ID NO : 5 ou le SEQ ID NO : 71.

35 4. Polypeptide isolé comprenant une séquence d'acides aminés sélectionnée dans le groupe des :

- (a) résidus d'acide aminé 38-52 du SEQ ID NO : 2 ;
(b) résidus d'acide aminé 83-98 du SEQ ID NO : 2 ;
(c) résidus d'acide aminé 104-117 du SEQ ID NO : 2 ;
40 (d) résidus d'acide aminé 137-152 du SEQ ID NO : 2 ;
(e) résidus d'acide aminé 38-52 du SEQ ID NO : 11 ;
(f) résidus d'acide aminé 33-38 du SEQ ID NO : 2 ;
(g) résidus d'acide aminé 35-40 du SEQ ID NO : 2 ;
(h) résidus d'acide aminé 53-58 du SEQ ID NO : 2 ;
45 (i) résidus d'acide aminé 54-59 du SEQ ID NO : 2 ;
(j) résidus d'acide aminé 129-134 du SEQ ID NO : 2 ;
(k) résidus d'acide aminé 34-39 du SEQ ID NO : 11 ;
(l) résidus d'acide aminé 46-51 du SEQ ID NO : 11 ;
(m) résidus d'acide aminé 101-105 du SEQ ID NO : 2 ;
50 (n) résidus d'acide aminé 113-118 du SEQ ID NO : 2 ;
(o) résidus d'acide aminé 114-119 du SEQ ID NO : 2 ;
(p) résidus d'acide aminé 126-131 du SEQ ID NO : 2 ;
(q) résidus d'acide aminé 158-162 du SEQ ID NO : 2 ;

55 ou consistant en une séquence d'acides aminés sélectionnée parmi les acides aminés 85-98, 104-118, 131-136, 141-157, 157-162 ou 158-163 du SEQ ID NO : 11.

5. Protéine de fusion comprenant au moins quatre polypeptides, dans laquelle l'ordre des polypeptides de l'extrémité

EP 1 476 541 B1

N-terminale à l'extrémité C-terminale est le suivant :

un premier polypeptide qui comprend les résidus d'acide aminé 38-52 du SEQ ID NO:2;

un premier espaceur de 6-27 résidus d'acide aminé ;

un deuxième polypeptide qui comprend une séquence de résidus d'acide aminé sélectionnée dans le groupe de :

(a) résidus d'acide aminé d'hélice B d'IL-2 du SEQ ID NO : 168 ;

(b) résidus 65-83 d'hélice B d'IL-4 du SEQ ID NO : 164 ;

(c) résidus 73-86 d'hélice B d'IL-3 du SEQ ID NO : 102 ;

(d) résidus 72-81 d'hélice B de GM-CSF du SEQ ID NO : 166 ; et

(e) résidus d'acide aminé 83-98 du SEQ ID NO : 2 ;

un deuxième espaceur de 5-11 résidus d'acide aminé ;

un troisième polypeptide qui comprend une séquence de résidus d'acide aminé sélectionnée dans le groupe de :

(a) résidus 102-116 d'hélice C d'IL-2 du SEQ ID NO : 162 ;

(b) résidus 94-118 d'hélice C d'IL-4 du SEQ ID NO : 164 ;

(c) résidus 91-103 d'hélice C d'IL-3 du SEQ ID NO : 102 ;

(d) résidus 85-103 d'hélice C de GM-CSF du SEQ ID NO : 166 ; et

(e) résidus d'acide aminé 104-117 du SEQ ID NO : 2 ;

un troisième espaceur de 3-29 résidus d'acide aminé ; et

un quatrième polypeptide qui comprend une séquence de résidus d'acide aminé sélectionnée dans le groupe de :

(a) résidus 134-149 d'hélice D d'IL-2 du SEQ ID NO : 162 ;

(b) résidus 123-141 d'hélice D d'IL-3 du SEQ ID NO : 102 ;

(c) résidus 133-151 d'hélice D d'IL-4 du SEQ ID NO : 164 ;

(d) résidus 120-131 d'hélice D de GM-CSF du SEQ ID NO : 166 ; et

(e) résidus d'acide aminé 137-152 du SEQ ID NO : 2.

6. Protéine de fusion comprenant au moins quatre polypeptides, dans laquelle l'ordre des polypeptides de l'extrémité N-terminale à l'extrémité C-terminale est :

un premier polypeptide qui comprend une séquence de résidus d'acide aminé sélectionnée dans un groupe constitué de :

(a) résidus 27-48 d'hélice A d'IL-2 du SEQ ID NO : 162 ;

(b) résidus 30-42 d'hélice A d'IL-4 du SEQ ID NO : 164 ;

(c) résidus 35-45 d'hélice A d'IL-3 du SEQ ID NO : 102 ;

(d) résidus 30-44 d'hélice A de GM-CSF du SEQ ID NO : 166 ; et

(e) résidus d'acide aminé 38-52 du SEQ ID NO : 2 ;

un premier espaceur de 6-27 résidus d'acide aminé ;

un deuxième polypeptide qui comprend une séquence de résidus d'acide aminé sélectionnée dans le groupe de :

(a) résidus d'hélice B d'IL-2 du SEQ ID NO : 168 ;

(b) résidus 65-83 d'hélice B d'IL-4 du SEQ ID NO : 164 ;

(c) résidus 73-86 d'hélice B d'IL-3 du SEQ ID NO : 102 ;

(d) résidus 72-81 d'hélice B de GM-CSF du SEQ ID NO : 166 ; et

(e) résidus d'acide aminé 83-98 du SEQ ID NO : 2 ;

un deuxième espaceur de 5-11 résidus d'acide aminé ;

un troisième polypeptide qui comprend une séquence de résidus d'acide aminé sélectionnée dans le groupe de :

(a) résidus 102-116 d'hélice C d'IL-2 du SEQ ID NO : 162 ;

(b) résidus 94-118 d'hélice C d'IL-4 du SEQ ID NO : 164 ;

(c) résidus 91-103 d'hélice C d'IL-3 du SEQ ID NO : 102 ;

(d) résidus 85-103 d'hélice C de GM-CSF du SEQ ID NO : 166 ; et

EP 1 476 541 B1

(e) résidus d'acide aminé 104-117 du SEQ ID NO : 2 ;

un troisième espaceur de 3-29 résidus d'acide aminé ; et
un quatrième polypeptide qui comprend des résidus d'acide aminé 137-152 du SEQ ID NO : 2.

- 5
7. Protéine de fusion selon la revendication 6, dans laquelle le quatrième polypeptide comprend des résidus d'acide aminé 137-152 du SEQ ID NO : 2.
- 10
8. Molécule de polynucléotide isolée consistant en une séquence de nucléotides qui code pour un polypeptide consistant en une séquence de résidus d'acide aminé qui est identique à au moins 90 % à une séquence d'acides aminés sélectionnée dans le groupe :
- 15
- (a) du polypeptide représenté des résidus 38 (Val) à 152 (Leu), ainsi qu'indiqué dans le SEQ ID NO : 2 ;
(b) du polypeptide représenté des résidus 27 (Leu) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2 ;
(c) du polypeptide représenté des résidus 24 (Ser) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2 ; et
(d) du polypeptide représenté des résidus 1 (Met) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2.
- 20
9. Molécule de polynucléotide isolée selon la revendication 8, dans laquelle les nucléotides sont sélectionnés dans le groupe de :
- 25
- (a) un polynucléotide tel que représenté dans le SEQ ID NO : 1 du nucléotide 139 au nucléotide 483 ;
(b) un polynucléotide tel que représenté dans le SEQ ID NO : 1 du nucléotide 106 au nucléotide 519 ;
(c) un polynucléotide tel que représenté dans le SEQ ID NO : 1 du nucléotide 97 au nucléotide 519 ; et
(d) un polynucléotide tel que représenté dans le SEQ ID NO : 1 du nucléotide 28 au nucléotide 519, ou
- 30
- dans laquelle lesdits nucléotides codent pour un polypeptide selon la revendication 4.
10. Vecteur d'expression comprenant les éléments liés de manière fonctionnelle suivants :
- 35
- (a) un promoteur de transcription ;
(b) un segment d'ADN codant pour un polypeptide consistant en une séquence de résidus d'acide aminé sélectionnée dans le groupe de :
- 40
- (i) résidus d'acide aminé 38-52 du SEQ ID NO : 2 ;
(ii) résidus d'acide aminé 83-98 du SEQ ID NO : 2 ;
(iii) résidus d'acide aminé 104-117 du SEQ ID NO : 2 ;
(iv) résidus d'acide aminé 137-152 du SEQ ID NO : 2 ;
- ou consistant en un polynucléotide isolé selon la revendication 8 ; et
(c) un signal de terminaison de transcription.
- 45
11. Cellule en culture comprenant un vecteur d'expression selon la revendication 10.
12. Procédé de production d'un polypeptide comprenant la culture d'une cellule selon la revendication 11 dans des conditions dans lesquelles le segment d'ADN est exprimé et la récupération du polypeptide codé par le segment d'ADN.
- 50
13. Procédé de production d'un anticorps qui se lie à un polypeptide selon la revendication 1, dans lequel le polypeptide inoculé est sélectionné dans le groupe de :
- 55
- (a) un polypeptide consistant en 9 à 141 acides aminés, où le polypeptide est identique à une séquence de résidus d'acide aminé contiguë dans le SEQ ID NO : 2 de l'acide aminé 24 (Ser) à l'acide aminé 164 (Thr) ;
(b) un polypeptide selon la revendication 1 ;
(c) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 2 des acides aminés 38-52 ;
(d) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 2 des acides aminés 83-98 ;
(e) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 2 des acides aminés 104-117 ;
(f) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 2 des acides aminés 137-152 ;
(g) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 2 des acides aminés 38-152 ;

(h) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 2 des acides aminés 24-164 ;
 (i) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 2 des acides aminés 27-164 ;
 (j) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 11 des acides aminés 38-52 ;
 (k) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 11 des acides aminés 85-98 ;
 (l) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 11 des acides aminés 104-118 ;
 (m) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 11 des acides aminés 141-157 ;
 (n) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 11 des acides aminés 38-157 ;
 (o) un polypeptide comprenant la séquence d'acides aminés du SEQ ID NO : 11 des acides aminés 24-163 ;
 (p) un polypeptide comprenant des résidus d'acide aminé 54-59, 129-134, 53-58, 35-40 ou 33-38 du SEQ ID
 NO : 2 ou des résidus d'acide aminé 34-39, 46-51, 131-136, 158-163 ou 157-162 du SEQ ID NO : 11, où les
 résidus G, S et T enterrés et les résidus H, Y et W exposés sont ignorés ; et

où le polypeptide provoque une réponse immune afin de produire l'anticorps ; et d'isolation de l'anticorps de l'animal.

14. Anticorps susceptible d'être obtenu par le procédé de la revendication 13, dans lequel l'anticorps se lie à un polypeptide du SEQ ID NO : 2 ou du SEQ ID NO : 11.

15. Anticorps ou fragment d'anticorps qui se lie spécifiquement à un polypeptide représenté dans le SEQ ID NO : 2 ou le SEQ ID NO : 11 ou à un polypeptide comprenant une séquence de résidus d'acide aminé sélectionnée dans le groupe de :

- (a) le polypeptide représenté des résidus 38 (Val) à 152 (Leu), ainsi qu'indiqué dans le SEQ ID NO : 2 ;
- (b) le polypeptide représenté des résidus 27 (Leu) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2 ;
- (c) le polypeptide représenté des résidus 24 (Ser) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2 ; et
- (d) le polypeptide représenté des résidus 1 (Met) à 164 (Thr), ainsi qu'indiqué dans le SEQ ID NO : 2.

16. Anticorps selon la revendication 15, dans lequel l'anticorps est sélectionné dans le groupe de : (a) un anticorps polyclonal, (b) un anticorps monoclonal murin, (c) un anticorps humanisé dérivé de (b), (d) un fragment d'anticorps et (e) un anticorps monoclonal humain.

17. Anticorps selon la revendication 15, dans lequel l'anticorps comprend en plus un radionucléide, une enzyme, un substrat, un cofacteur, un marqueur fluorescent, un marqueur à chimioluminescence, une étiquette peptidique, une particule magnétique, un médicament ou une toxine.

18. Anticorps selon la revendication 15 destiné à réduire l'inflammation induite par un polypeptide selon l'une quelconque des revendications 1-4.

19. Utilisation d'un anticorps selon la revendication 15 pour la fabrication d'un médicament destiné à être utilisé dans un procédé de suppression d'une réponse inflammatoire chez un mammifère souffrant d'inflammation, ledit procédé comprenant :

- (1) la détermination du niveau d'une molécule inflammatoire ;
- (2) l'administration dudit médicament ;
- (3) la détermination d'un niveau post-administration de la molécule inflammatoire ;
- (4) la comparaison du niveau de la molécule inflammatoire à l'étape (1) au niveau de la molécule inflammatoire à l'étape (3), où une absence d'augmentation ou de diminution du niveau de la molécule inflammatoire indique la suppression d'une réponse inflammatoire.

20. Procédé de détection de la présence d'un polypeptide selon l'une quelconque des revendications 1-4 dans un échantillon biologique, comprenant les étapes de :

- (a) mise en contact de l'échantillon biologique avec un anticorps, ou un fragment d'anticorps, selon la revendication 15, où la mise en contact est effectuée dans des conditions qui permettent la liaison de l'anticorps ou du fragment d'anticorps à l'échantillon biologique, et de
- (b) détection des anticorps liés ou fragments d'anticorps liés.

21. Procédé d'inhibition de la prolifération ou de la différenciation des cellules hématopoïétiques et des progéniteurs de cellules hématopoïétiques induite par un polypeptide selon l'une quelconque des revendications 1-4 comprenant

EP 1 476 541 B1

la culture de cellules de moelle osseuse ou de sang périphérique avec une composition comprenant une quantité d'un anticorps selon la revendication 15 suffisante pour réduire la prolifération ou la différenciation des cellules hématopoïétiques dans les cellules de moelle osseuse ou de sang périphérique comparé aux cellules de moelle osseuse ou de sang périphérique cultivées en l'absence de récepteur de cytokine soluble.

- 5
22. Procédé selon la revendication 21, dans lequel les cellules hématopoïétiques et les cellules de progéniteur hématopoïétique sont des cellules lymphoïdes.
- 10
23. Procédé selon la revendication 22, dans lequel les cellules lymphoïdes sont des macrophages ou des lymphocytes T.
24. Utilisation d'un polypeptide selon l'une quelconque des revendications 1-4 pour la fabrication d'un médicament destiné à être utilisé dans un procédé de stimulation d'une réponse immune chez un mammifère exposé à un antigène ou un pathogène, ledit procédé comprenant les étapes de :
- 15
- (1) détermination, directement ou indirectement, du niveau d'antigène ou de pathogène présent chez ledit mammifère ;
- (2) d'administration dudit médicament ;
- (3) de détermination, directement ou indirectement, du niveau d'antigène ou de pathogène chez ledit mammifère ; et
- 20
- (4) de comparaison du niveau de l'antigène ou du pathogène dans l'étape 1 au niveau d'antigène ou de pathogène dans l'étape 3, où un changement de niveau indique la stimulation d'une réponse immune.
25. Utilisation selon la revendication 24, dans laquelle ledit procédé comprend en plus :
- 25
- (5) la ré-administration dudit médicament ;
- (6) la détermination, directement ou indirectement, du niveau d'antigène ou de pathogène chez ledit mammifère ; et
- (7) la comparaison du niveau d'antigène ou de pathogène à l'étape 1 au niveau d'antigène à l'étape 6, où un changement de niveau indique la stimulation d'une réponse immune.
- 30
26. Procédé d'expansion de cellules hématopoïétiques et de progéniteurs de cellules hématopoïétiques comprenant la culture de cellules de moelle osseuse ou de sang périphérique avec une composition comprenant une quantité d'un polypeptide selon l'une quelconque des revendications 1-4 suffisante pour produire une augmentation du nombre de cellules lymphoïdes dans les cellules de moelle osseuse ou de sang périphérique comparé aux cellules de moelle osseuse ou de sang périphérique cultivées en l'absence dudit polypeptide.
- 35
27. Procédé selon la revendication 26, dans lequel les cellules hématopoïétiques et les cellules de progéniteurs hématopoïétiques sont des cellules lymphoïdes.
- 40
28. Procédé selon la revendication 27, dans lequel les cellules lymphoïdes sont des cellules monocytaires, des macrophages ou des lymphocytes T.
29. Utilisation d'un polypeptide selon l'une quelconque des revendications 1-4 pour la fabrication d'un médicament destiné à être utilisé dans un procédé de stimulation d'une réponse immune chez un mammifère exposé à un antigène ou un pathogène, ledit procédé comprenant :
- 45
- (1) la détermination du niveau d'un anticorps spécifique de l'antigène ou du pathogène ;
- (2) l'administration dudit médicament ;
- (3) la détermination d'un niveau post-administration de l'anticorps spécifique de l'antigène ou du pathogène ;
- 50
- (4) la comparaison du niveau d'anticorps à l'étape (1) au niveau d'anticorps à l'étape (3), où une augmentation du niveau d'anticorps indique la stimulation d'une réponse immune.
30. Procédé de détection de la présence d'ARN codant pour un polypeptide selon l'une quelconque des revendications 1-4 dans un échantillon biologique, comprenant les étapes de :
- 55
- (a) mise en contact d'une sonde d'acide nucléique dans des conditions d'hybridation avec soit (i) des molécules d'ARN test isolées à partir de l'échantillon biologique, soit (ii) des molécules d'acide nucléique synthétisées à partir des molécules d'ARN isolées, où la sonde possède une séquence de nucléotides comprenant soit une

EP 1 476 541 B1

partie de la séquence de nucléotides de la molécule d'acide nucléique selon la revendication 9, soit son complémentaire, et de

(b) détection de la formation d'hybrides de la sonde d'acide nucléique et soit des molécules d'ARN test, soit des molécules d'acide nucléique synthétisées, où la présence des hybrides indique la présence d'ARN codant pour un polypeptide selon l'une quelconque des revendications 1-4 dans l'échantillon biologique.

- 5
- 10
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
31. Procédé *in vitro* ou *ex vivo* destiné à tuer des cellules cancéreuses, comprenant la production d'un polypeptide par un procédé selon la revendication 12 ; la formulation du polypeptide dans un véhicule pharmaceutiquement acceptable ; et l'exposition d'un échantillon de tissu ou d'un échantillon biologique contenant des cellules cancéreuses au polypeptide; dans lequel le polypeptide tue les cellules.
 32. Utilisation d'un polypeptide produit par un procédé selon la revendication 12 pour la fabrication d'un médicament destiné à tuer les cellules cancéreuses.
 33. Procédé selon la revendication 31 ou utilisation selon la revendication 32, où le polypeptide est en outre conjugué à une toxine.
 34. Utilisation d'un antagoniste d'un polypeptide selon l'une quelconque des revendications 1-4 pour la fabrication d'un médicament destiné à traiter un mammifère atteint d'une maladie inflammatoire, dans laquelle l'antagoniste est un anticorps qui se lie spécifiquement à un polypeptide selon l'une quelconque des revendications 1-4, ou un anticorps ou fragment d'anticorps selon la revendication 15.
 35. Utilisation selon la revendication 34, dans laquelle la maladie est une maladie inflammatoire chronique.
 36. Utilisation selon la revendication 35, dans laquelle la maladie inflammatoire chronique est sélectionnée dans le groupe de :
 - (a) affection abdominale inflammatoire ;
 - (b) recto-colite hémorragique ;
 - (c) maladie de Crohn ;
 - (d) dermite atopique ;
 - (e) eczéma ; et
 - (f) psoriasis.
 37. Utilisation selon la revendication 34, dans laquelle la maladie est une maladie inflammatoire aiguë.
 38. Utilisation selon la revendication 37, dans laquelle la maladie inflammatoire aiguë est sélectionnée dans le groupe de :
 - (a) endotoxémie ;
 - (b) septicémie ;
 - (c) choc toxique staphylococcique ; et
 - (d) maladie infectieuse.
 39. Utilisation selon la revendication 34, dans laquelle l'anticorps comprend en outre un radionucléide, une enzyme, un substrat, un cofacteur, un marqueur fluorescent, un marqueur à chimioluminescence, une étiquette peptidique, une particule magnétique, un médicament ou une toxine.
 40. Procédé de détection d'une inflammation chez un patient, comprenant :
 - l'incubation d'un échantillon de tissu ou d'un échantillon biologique d'un patient avec un anticorps selon la revendication 15 dans des conditions dans lesquelles l'anticorps se lie à son polypeptide complémentaire dans l'échantillon de tissu ou l'échantillon biologique ;
 - la visualisation de l'anticorps lié dans l'échantillon de tissu ou l'échantillon biologique; et
 - la comparaison des niveaux d'anticorps lié dans l'échantillon de tissu ou l'échantillon biologique du patient à un échantillon de tissu ou un échantillon biologique témoin normal,où une augmentation du niveau d'anticorps lié à l'échantillon de tissu ou l'échantillon biologique du patient par rapport à l'échantillon de tissu ou l'échantillon biologique témoin normal indique une inflammation chez le patient.

EP 1 476 541 B1

41. Procédé de détection d'une inflammation chez un patient, comprenant :

le marquage d'un polynucléotide comprenant au moins 14 nucléotides contigus du SEQ ID NO : 1 ou du complémentaire du SEQ ID NO : 1 ;

5 l'incubation d'un échantillon de tissu ou d'un échantillon biologique d'un patient avec ledit polynucléotide marqué dans des conditions dans lesquelles le polynucléotide s'hybridera à la séquence de polynucléotide complémentaire ;

10 la visualisation du polynucléotide marqué dans l'échantillon de tissu ou l'échantillon biologique; et la comparaison du niveau d'hybridation du polynucléotide marqué dans l'échantillon de tissu ou l'échantillon biologique du patient à un échantillon de tissu ou un échantillon biologique témoin normal,

où une augmentation de l'hybridation du polynucléotide marqué avec l'échantillon de tissu ou l'échantillon biologique du patient par rapport à l'échantillon de tissu ou l'échantillon biologique témoin normal indique une inflammation chez le patient.

15

20

25

30

35

40

45

50

55

	1	15 16	30 31	45	
1 zcytor17lig	---ASHTLPVRLLRP	SDDVQKIVEELQSL	KMLLKD--VEEEKGV		40
2 mzytor17lig	---ATCSLSFGAPIS	KEDLRTTIDLLKQES	QDLYNNYSIKQASGM		42
3 mIL-3	ASISGRDTHRLRTL	NCS-SIVKEIIGKL-	--PEP----ELKT--		35
4 hIL-3	APMTQTTPKTSW-V	NCS-NMIDEIITHLK	QPPLP--LLDFNNLN		41
	46	60 61	75 76	90	
1 zcytor17lig	LVSQNYTLPCLSPDA	QPPNNIHSPAIRAYL	KTIRQLDNKSVIDEI		85
2 mzytor17lig	SADESIQLPCFSLDR	EALTNISVIIAHLEK	VKVLSE-NTVDTSWV		86
3 mIL-3	DDEGPSLRNKS----	-----FRRVNLKSFV	ESQGEVDPEDRYVIK		71
4 hIL-3	GEDQDILMENN----	-----LRRPNLEAFN	RAVKSL--QNASAIE		75
	91	105 106	120 121	135	
1 zcytor17lig	IEHLDKLIFQDAPET	NISVPTDHE---CK	RFILTISQQFSECMD		127
2 mzytor17lig	IRWLTNISCFNPLNL	NISVPGNTDESYDCK	VFVLTVLKQFSNCMA		131
3 mIL-3	SNLQKLNCCLPSTAN	DSALPGVFIRDLD--	DFRKKLRFYMVH-LN		113
4 hIL-3	SILKNLLPCLPLATA	APTRHPIHIKGDWN	EFRRKLTFY----LK		116
	136	150 151	165 166	180	
1 zcytor17lig	LALKSLTSGAQQATT				142
2 mzytor17lig	ELQAKDNTTC				141
3 mIL-3	DLETVLTSRPPQPAS	GSVSPNRTGVEC			140
4 hIL-3	TLENA----QAQQT	LSLAIF			133

FIG. 1

	10	20	30	40	50	
ZCYTOR	MASHSGPSTSVLFLFCCLGGWLASHTLPVRLLRPSDDVQKIVEELQSLSKMLLKD--VEE					
	:	:	:	:	:	:
M17RL-	MIFHTGTTKPTLVLLCCIGTWLATCSLSFGAPISKEDLRTTIDLLKQESQDLYNNYSIKQ					
	10	20	30	40	50	60
	60	70	80	90	100	110
ZCYTOR	EKGLVLSQNYTLPCLSPDAQPPNNIHSPAIRAYLKTIRQLDNKSVIDE-II EHLDKLIFQ					
	:	:	:	:	:	:
M17RL-	ASGMSADESIQLPCFSLDREALTNI--SVIIAHLEKVKVLSENTVDTSWIRWLTNISCF					
	70	80	90	100	110	
	120	130	140	150	160	
ZCYTOR	DAPETNISVPTDHE---CKRFILTISQQFSECM-DLALKSLTSGAQQATT					
	:	:	X:	:	:	:
M17RL-	NPLNLSVPGNTDESYDCKVFVLTVLKQFSNCMAELQAKDNTTC					
	120	130	140	150	160	

FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 3E

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 0120484 W [0041]
- WO 0200721 A [0041]
- US 5925735 A [0041] [0279]
- US 5641670 A [0062]
- US 4683202 A, Mullis [0063]
- US 5223409 A, Ladner [0097]
- WO 9206204 A, Huse [0097]
- WO 9720078 A [0098]
- US 5155027 A [0110] [0139]
- US 5567584 A [0110] [0139]
- US 5037743 A, Welch [0114] [0120]
- US 5143830 A, Holland [0114]
- US 4713339 A, Levinson [0116]
- US 4784950 A, Hagen [0116]
- US 4579821 A, Palmiter [0116] [0116]
- US 4656134 A, Ringold [0116]
- US 4956288 A [0116]
- US 4601978 A [0116]
- US 5162222 A, Guarino [0118]
- WO 9406463 A [0118]
- US 5300435 A [0119]
- US 4599311 A, Kawasaki [0120] [0120]
- US 4931373 A, Kawasaki [0120] [0120]
- US 4870008 A, Brake [0120]
- US 4845075 A, Murray [0120]
- US 4615974 A, Kingsman [0120]
- US 4977092 A, Bitter [0120]
- US 4990446 A [0120]
- US 5063154 A [0120]
- US 5139936 A [0120]
- US 4661454 A [0120]
- US 4882279 A, Cregg [0120]
- US 4935349 A, McKnight [0120]
- US 5162228 A, Sumino [0120]
- US 4486533 A, Lambowitz [0120]
- WO 9717450 A [0121]
- WO 9717451 A [0121]
- WO 9802536 A [0121]
- WO 9802565 A [0121]
- WO 9824893 A [0146]
- US 5399346 A, Anderson [0214]
- US 4650764 A, Temin [0214]
- US 4980289 A, Temin [0214]
- US 5124263 A, Temin [0214]
- WO 9507358 A, Dougherty [0214]
- JP 4244018 A, Hayakawa [0232]
- US 4603044 A, Geho [0233]
- US 60350325 A [0560]
- US 60375323 B [0560]
- US 60435315 B [0560]

Non-patent literature cited in the description

- **KELSO, A.** *Immun. Cell Biol.*, 1998, vol. 76, 300-317 [0004]
- **NILSSON et al.** *EMBO J.*, 1985, vol. 4, 1075 [0016]
- **NILSSON et al.** *Methods Enzymol.*, 1991, vol. 198, 3 [0016]
- **SMITH ; JOHNSON.** *Gene*, 1988, vol. 67, 31 [0016]
- **GRUSSENMEYER et al.** *Proc. Natl. Acad. Sci. USA*, 1985, vol. 82, 7952-4 [0016]
- **HOPP et al.** *Biotechnology*, 1988, vol. 6, 1204-10 [0016]
- **FORD.** *Protein Expression and Purification*, 1991, vol. 2, 95-107 [0016]
- **DYNAN ; TIJAN.** *Nature*, 1985, vol. 316, 774-78 [0024]
- **PALACIOS ; STEINMETZ.** *Cell*, 1985, vol. 41, 727-734 [0040] [0131] [0272]
- **MATHEY-PREVOT et al.** *Mol. Cell. Biol.*, 1986, vol. 6, 4133-4135 [0040] [0272]
- **HAPPEL et al.** *Blood*, 1984, vol. 64, 786-790 [0040] [0131]
- **KISS et al.** *Leukemia*, 1993, vol. 7, 235-240 [0040] [0131]
- **COSMAN.** The Hematopoietin Receptor Superfamily. *Cytokine*, 1993, vol. 5 (2), 95-106 [0041]
- **NICOLA et al.** *Advances in Protein Chemistry*, 1999, vol. 52, 1-65 [0042]
- **KELSO, A.** *Immunol. Cell Biol.*, 1998, vol. 76, 300-317 [0042]
- **MOSMAN.** *J. Immunol. Meth.*, 1983, vol. 65, 55-63 [0045]
- **FRESHNEY.** *Culture of Animal Cells: A Manual of Basic Technique.* Wiley-Liss, 1994 [0045]
- **KALLEN et al.** *J. Biol. Chem.*, 1999, vol. 274, 11859-11867 [0051]
- **GRANTHAM et al.** *Nuc. Acids Res.*, 1980, vol. 8, 1893-912 [0059]
- **HAAS et al.** *Curr. Biol.*, 1996, vol. 6, 315-24 [0059]
- **WAIN-HOBSON et al.** *Gene*, 1981, vol. 13, 355-64 [0059]

- **GROSJEAN ; FIERS.** *Gene*, 1982, vol. 18, 199-209 [0059]
- **HOLM.** *Nuc. Acids Res.*, 1986, vol. 14, 3075-87 [0059]
- **IKEMURA.** *J. Mol. Biol.*, 1982, vol. 158, 573-97 [0059]
- **THOMAS.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 5201 [0060]
- **CHIRGWIN et al.** *Biochemistry*, 1979, vol. 18, 52-94 [0060]
- **AVIV ; LEDER.** *Proc. Natl. Acad. Sci. USA*, 1972, vol. 69, 1408-12 [0060]
- **SAMBROOK et al.** *CHEST* [0066]
- **AUSUBEL.** *CHEST* [0066]
- **MARIAN.** *Chest*, 1995, vol. 108, 255-65 [0066]
- **YAMAGATA et al.** *Cancer Genet Cytogenet*, 1997, vol. 97, 90-93 [0068]
- **DUNPHY ; BATANIAN.** *Cancer Genet Cytogenet*, 1999, vol. 114, 51-57 [0068]
- **BONOMI et al.** *Cancer Genet Cytogenet*, 1999, vol. 108, 75-78 [0068]
- **ICHIKAWA et al.** *Asian J Androl*, 2000, vol. 2, 167-171 [0068]
- Protocols in Human Molecular Genetics. Humana Press, Inc, 1991 [0072] [0073]
- PCR Protocols: Current Methods and Applications. Humana Press, Inc, 1993 [0072]
- Molecular Diagnosis of Cancer. Humana Press, Inc, 1996 [0072]
- Tumor Marker Protocols. Humana Press, Inc, 1998 [0072]
- Clinical Applications of PCR. Humana Press, Inc, 1998 [0072]
- PCR in Bioanalysis. Humana Press, Inc, 1998 [0072]
- **MARIAN.** *Chest*, 1995, vol. 108, 255 [0073]
- **COLEMAN ; TSONGALIS.** Molecular Diagnostics. Human Press, Inc, 1996 [0073]
- Molecular Diagnosis of Genetic Diseases. Humana Press, Inc, 1996 [0073]
- Laboratory Protocols for Mutation Detection. Oxford University Press, 1996 [0073]
- Genome Analysis. Detecting Genes. Cold Spring Harbor Laboratory Press, 1998, vol. 2 [0073]
- Current Protocols in Human Genetics. John Wiley & Sons, 1998 [0073]
- Molecular Diagnostic Testing. **RICHARDS ; WARD.** Principles of Molecular Medicine. Humana Press, Inc, 1998, 83-88 [0073]
- Current Protocols in Human Genetics. John Wiley & Sons, 1998, 7.1.6, 7.1.7 [0073]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, 1989 [0077]
- Current Protocols in Molecular Biology. John Wiley and Sons, Inc, 1987 [0077] [0112]
- Guide to Molecular Cloning Techniques. Academic Press, Inc, 1987 [0077]
- **WETMUR.** *Crit. Rev. Biochem. Mol. Biol.*, 1990, vol. 26, 227 [0077]
- **ALTSCHUL et al.** *Bull. Math. Bio.*, 1986, vol. 48, 603 [0082]
- **HENIKOFF ; HENIKOFF.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 10915 [0082]
- **PEARSON ; LIPMAN.** *Proc. Nat'l Acad. Sci. USA*, 1988, vol. 85, 2444 [0083]
- **PEARSON.** *Meth. Enzymol.*, 1990, vol. 183, 63 [0083] [0084]
- **NEEDLEMAN ; WUNSCH.** *J. Mol. Biol.*, 1970, vol. 48, 444 [0084]
- **SELLERS.** *SIAM J. Appl. Math.*, 1974, vol. 26, 787 [0084]
- **BARTON.** *Current Opin. Struct. Biol.*, 1995, vol. 5, 372-376 [0087]
- **CORDES et al.** *Current Opin. Struct. Biol.*, 1996, vol. 6, 3-10 [0087]
- **LAPTHOM et al.** *Nat. Struct. Biol.*, 1995, vol. 2, 266-268 [0088]
- **BEAN et al.** *Anal. Biochem.*, 1992, vol. 201, 216-226 [0088]
- **GRAY.** *Protein Sci.*, 1993, vol. 2, 1732-1748 [0088]
- **PATTERSON et al.** *Anal. Chem.*, 1994, vol. 66, 3727-3732 [0088]
- **JOHNSON.** *Proteins*, 1990, vol. 7, 205-214 [0088]
- **SCHAANAN et al.** *Science*, 1992, vol. 257, 961-964 [0088]
- **HOPP et al.** *Proc. Natl. Acad. Sci.*, 1981, vol. 78, 3824-3828 [0089]
- **HOPP.** *J. Immun. Meth.*, 1986, vol. 88, 1-18 [0089]
- **TRIQUEUR et al.** *Protein Engineering*, 1998, vol. 11, 153-169 [0089]
- **CUNNINGHAM ; WELLS.** *Science*, 1989, vol. 244, 1081 [0092]
- **BASS et al.** *Proc. Natl Acad. Sci. USA*, 1991, vol. 88, 4498 [0092]
- Site-Directed Mutagenesis and Protein Engineering. **COOMBS ; COREY.** Proteins: Analysis and Design. Academic Press, Inc, 1998, 259-311 [0092]
- **HILTON et al.** *J. Biol. Chem.*, 1996, vol. 271, 4699 [0092]
- **HORISBERGER ; DI MARCO.** *Pharmac. Ther.*, 1995, vol. 66, 507 [0096]
- **TREUTER et al.** *Molec. Gen. Genet.*, 1993, vol. 240, 113 [0096]
- Expression and preliminary deletion analysis of the 42 kDa 2-5A synthetase induced by human interferon. **CONTENT ; NIJHOFF et al.** Biological Interferon Systems, Proceedings of ISIR-TNO Meeting on Interferon Systems. 1987, 65-72 [0096]
- The EGF Receptor. **HERSCHMAN et al.** Control of Animal Cell Proliferation. Academic Press, 1985, vol. 1, 169-199 [0096]
- **COUMAILLEAU et al.** *J. Biol. Chem.*, 1995, vol. 270, 29270 [0096]
- **FUKUNAGA et al.** *J. Biol. Chem.*, 1995, vol. 270, 25291 [0096]
- **YAMAGUCHI et al.** *Biochem. Pharmacol.*, 1995, vol. 50, 1295 [0096]

- **MEISEL et al.** *Plant Molec. Biol.*, 1996, vol. 30, 1 [0096]
- **REIDHAAR-OLSON ; SAUER.** *Science*, 1988, vol. 241, 53 [0097]
- **BOWIE ; SAUER.** *Proc. Nat'l Acad. Sci. USA*, 1989, vol. 86, 2152 [0097]
- **LOWMAN et al.** *Biochem.*, 1991, vol. 30, 10832 [0097]
- **DERBYSHIRE et al.** *Gene*, 1986, vol. 46, 145 [0097]
- **NER et al.** *DNA*, 1988, vol. 7, 127 [0097]
- **STEMMER.** *Nature*, 1994, vol. 370, 389 [0098]
- **STEMMER.** *Proc. Natl Acad. Sci. USA*, 1994, vol. 91, 10747 [0098]
- **ROBERTSON et al.** *J. Am. Chem. Soc.*, 1991, vol. 113, 2722 [0102]
- **ELLMAN et al.** *Methods Enzymol.*, 1991, vol. 202, 301 [0102]
- **CHUNG et al.** *Science*, 1993, vol. 259, 806 [0102]
- **CHUNG et al.** *Proc. Nat'l Acad. Sci. USA*, 1993, vol. 90, 10145 [0102]
- **TURCATTI et al.** *J. Biol. Chem.*, 1996, vol. 271, 19991 [0103]
- **KOIDE et al.** *Biochem.*, 1994, vol. 33, 7470 [0103]
- **WYNN ; RICHARDS.** *Protein Sci.*, 1993, vol. 2, 395 [0103]
- **NUCCI et al.** *Advanced Drug Delivery Reviews*, 1991, vol. 6, 133-155 [0103]
- **LU et al.** *Int. J. Peptide Protein Res.*, 1994, vol. 43, 127-138 [0103]
- **GEYSEN et al.** *Proc. Nat'l Acad. Sci. USA*, 1983, vol. 81, 3998 [0105]
- **SUTCLIFFE et al.** *Science*, 1983, vol. 219, 660 [0106]
- **HOPP et al.** *SCIENCE*, 1981 [0106]
- **HOPP.** *SCIENCE*, 1986 [0106]
- **LANE ; STEPHEN.** *Curr. Opin. Immunol.*, 1993, vol. 5, 268 [0107]
- **CORTESE et al.** *Curr. Opin. Biotechnol.*, 1996, vol. 7, 616 [0107]
- Epitope Mapping. **MOLE.** *Methods in Molecular Biology.* The Humana Press, Inc, 1992, vol. 10, 105-116 [0107]
- Production and Characterization of Synthetic Peptide-Derived Antibodies. **PRICE.** *Monoclonal Antibodies: Production, Engineering, and Clinical Application.* Cambridge University Press, 1995, 60-84 [0107]
- Current Protocols in Immunology. John Wiley & Sons, 1997, 9.3.1-9.3.59.4.1-9.4.11 [0107]
- **TUAN et al.** *Connective Tissue Research*, 1996, vol. 34, 1-9 [0110]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 1989 [0112]
- **WIGLER et al.** *Cell*, 1978, vol. 14, 725 [0116]
- **CORSARO ; PEARSON.** *Somatic Cell Genetics*, 1981, vol. 7, 603 [0116]
- **GRAHAM ; VAN DER EB.** *Virology*, 1982, vol. 52, 456 [0116]
- **NEUMANN et al.** *EMBO J.*, 1982, vol. 1, 841-5 [0116]
- **HAWLEY-NELSON et al.** *Focus*, 1993, vol. 15, 73 [0116]
- **CICCARONE et al.** *Focus*, 1993, vol. 15, 80 [0116]
- **MILLER ; ROSMAN.** *BioTechniques*, 1989, vol. 7, 980-90 [0116]
- **WANG ; FINER.** *Nature Med.*, 1996, vol. 2, 714-6 [0116]
- **GRAHAM et al.** *J. Gen. Virol.*, 1977, vol. 36, 59-72 [0116]
- **SINKAR et al.** *J. Biosci. (Bangalore)*, 1987, vol. 11, 47-58 [0118]
- **KING, L.A. ; POSSEE, R.D.** *The Baculovirus Expression System: A Laboratory Guide*, London. Chapman & Hall [0118]
- **O'REILLY, D.R. et al.** *Baculovirus Expression Vectors: A Laboratory Manual.* Oxford University Press, 1994 [0118]
- *Baculovirus Expression Protocols. Methods in Molecular Biology.* Humana Press, 1995 [0118]
- **LUCKOW, V.A et al.** *J Virol*, 1993, vol. 67, 4566-79 [0118]
- **HILL-PERKINS, M.S. ; POSSEE, R.D.** *J. Gen. Virol.*, 1990, vol. 71, 971-6 [0118]
- **BONNING, B.C. et al.** *J. Gen. Virol.*, 1994, vol. 75, 1551-6 [0118]
- **CHAZENBALK, G.D. ; RAPOPORT, B.** *J. Biol. Chem.*, 1995, vol. 270, 1543-9 [0118]
- **GRUSSENMEYER, T. et al.** *Proc. Natl. Acad. Sci.*, 1985, vol. 82, 7952-4 [0118]
- **GLICK ; PASTERNAK.** *Molecular Biotechnology: Principles and Applications of Recombinant DNA.* ASM Press, 1994 [0119]
- **GLEESON et al.** *J. Gen. Microbiol.*, 1986, vol. 132, 3459-65 [0120]
- *Affinity Chromatography: Principles & Methods.* Pharmacia LKB Biotechnology. 1988 [0125]
- **SULKOWSKI.** *Trends in Biochem.*, 1985, vol. 3, 1-7 [0126]
- *Guide to Protein Purification. Methods in Enzymol. Acad. Press*, 1990, vol. 182, 529-39 [0126]
- **PICARD.** *Cur. Opin. Biology*, 1994, vol. 5, 511-5 [0127]
- **MERRIFIELD.** *J. Am. Chem. Soc.*, 1963, vol. 85, 2149 [0130]
- **PREVOT et al.** *Mol. Cell. Biol.*, 1986, vol. 6, 4133-4135 [0131]
- **GREENBERGER et al.** *Leukemia Res.*, 1984, vol. 8, 363-375 [0131]
- *Experimental Hematology Today. 8th Ann. Mtg. Int. Soc. Exp. Hematol.* 1979, 145-156 [0131]
- **CAVANAUGH et al.** *Investigational New Drugs*, 1990, vol. 8, 347-354 [0132]
- **COOK et al.** *Analytical Biochem.*, 1989, vol. 179, 1-7 [0132]

- **PORSTMANN et al.** *J. Immunol. Methods*, 1985, vol. 82, 169-179 [0132]
- **MOSMANN.** *J. Immunol. Methods*, 1983, vol. 65, 55-63 [0132]
- **ALLEY et al.** *Cancer Res.*, 1988, vol. 48, 589-601 [0132]
- **MARSHALL et al.** *Growth Reg.*, 1995, vol. 5, 69-84 [0132]
- **SCUDIERO et al.** *Cancer Res.*, 1988, vol. 48, 4827-4833 [0132]
- **WATT.** *FASEB*, 1991, vol. 5, 281-284 [0132] [0176]
- **FRANCIS.** *Differentiation*, 1994, vol. 57, 63-75 [0132] [0176]
- **RAES.** *Adv. Anim. Cell Biol. Technol. Bioprocesses*, 1989, 161-171 [0132] [0176]
- **T.C. BECKER et al.** *Meth. Cell Biol.*, 1994, vol. 43, 161-89 [0133]
- **J.T. DOUGLAS ; D.T. CURIEL.** *Science & Medicine*, 1997, vol. 4, 44-53 [0133]
- **MCCONNELL, H.M. et al.** *Science*, 1992, vol. 257, 1906-1912 [0134]
- **PITCHFORD, S. et al.** *Meth. Enzymol.*, 1997, vol. 228, 84-108 [0134]
- **ARIMILLI, S. et al.** *J. Immunol. Meth.*, 1998, vol. 212, 49-59 [0134]
- **VAN LIEFDE, I. et al.** *Eur. J. Pharmacol.*, 1998, vol. 346, 87-95 [0134]
- **KARLSSON.** *J. Immunol. Methods*, 1991, vol. 145, 229-40 [0141]
- **CUNNINGHAM ; WELLS.** *J. Mol. Biol.*, 1993, vol. 234, 554-63 [0141]
- **SCATCHARD.** *Ann. NY Acad. Sci.*, 1949, vol. 51, 660-72 [0142]
- **CUNNINGHAM et al.** *Science*, 1991, vol. 253, 545-48 [0142]
- **CUNNINGHAM et al.** *Science*, 1991, vol. 245, 821-25 [0142]
- *Current Protocols in Immunology.* John Wiley and Sons, Inc, 1995 [0144] [0148]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor, 1989 [0144]
- *Monoclonal Hybridoma Antibodies: Techniques and Applications.* CRC Press, Inc, 1982 [0144]
- **SCATCHARD, G.** *Ann. NY Acad. Sci.*, 1949, vol. 51, 660-672 [0147]
- *Antibodies: A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 1988 [0148] [0149]
- *Fundamental Immunology.* Raven Press, 1993 [0148]
- **GETZOFF et al.** *Adv. in Immunol.*, 1988, vol. 43, 1-98 [0148]
- *Monoclonal Antibodies: Principles and Practice.* Academic Press Ltd, 1996 [0148]
- **BENJAMIN et al.** *Ann. Rev. Immunol.*, 1984, vol. 2, 67-101 [0148]
- **HORNICK et al.** *Blood*, 1997, vol. 89, 4437-47 [0154]
- **GABAY.** *Expert. Opin. Biol. Ther.*, 2002, vol. 2 (2), 135-149 [0159]
- **WOOLEY.** *Curr. Opin. Rheum.*, 1999, vol. 3, 407-20 [0160]
- **WILLIAMS et al.** *Immunol.*, 1992, vol. 89, 9784-788 [0160]
- **MYERS et al.** *Life Sci.*, 1997, vol. 61, 1861-78 [0160]
- **WANG et al.** *Immunol.*, 1995, vol. 92, 8955-959 [0160]
- **GLAUSNER et al.** *Lancet*, 1991, vol. 338, 732 [0163]
- **DUMITRU et al.** *Cell*, 2000, vol. 103, 1071-1083 [0163]
- **BEUTLER et al.** *Science*, 1985, vol. 229, 869 [0164] [0164]
- **NEURATH et al.** *Intern. Rev. Immunol.*, 2000, vol. 19, 51-62 [0168]
- **MRÓZEK et al.** *Blood*, 1996, vol. 87, 2632-2640 [0175]
- **ROBERTSON.** *Blood*, 1990, vol. 76, 2451-2438 [0175]
- **BANYARD, J. ; ZETTER, B.R.** *Cancer and Metast. Rev.*, 1999, vol. 17, 449-458 [0177]
- **O'REILLY MS et al.** *Cell*, 1994, vol. 79, 315-328 [0178] [0178]
- **RUSCIANO D et al.** *Murine Models of Liver Metastasis. Invasion Metastasis*, 1995, vol. 14, 349-361 [0178]
- **WHITESIDE.** *Curr. Top. Microbiol. Immunol.*, 1998, vol. 230, 221-244 [0180]
- **TSUCHIYA et al.** *Int. J. Cancer*, 1980, vol. 26, 171-176 [0186]
- **SUNDSTROM et al.** *Int. J. Cancer*, 1976, vol. 17, 565-577 [0186]
- **MOSLEY et al.** *JBC*, 1996, vol. 271, 32635-32643 [0188]
- **HEANEY et al.** *Blood*, 1996, vol. 87, 847-857 [0194]
- **JOHNSTON, RB.** *New Eng. J. Med.*, 1998, vol. 318, 747-752 [0195]
- **DUMOUTIER, L. et al.** *Proc. Nat'l. Acad. Sci.*, 2000, vol. 97, 10144-10149 [0200]
- **UHLAR, CM ; WHITEHEAD, AS.** *Eur. J. Biochem.*, 1999, vol. 265, 501-523 [0200]
- **BAUMANN H. ; GAULDIE, J.** *Immunology Today*, 1994, vol. 15, 74-80 [0200]
- **HUGHES C et al.** *J. Immunol*, 1994, vol. 153, 3319-3325 [0203]
- **HOLLIGER P ; HOOGENBOOM, H.** *Nature Biotech.*, 1998, vol. 16, 1015-1016 [0203]
- **SMITH JA et al.** *J. Immunol.*, 1998, vol. 160, 4841-4849 [0203]
- **TUTT, AL et al.** *J Immunol.*, 1998, vol. 161, 3175-3185 [0203]
- **COSMAN, D.** *Cytokine*, 1993, vol. 5, 95-106 [0205]
- **FERNANDEZ-BOTRAN, R.** *Exp. Opin. Invest. Drugs*, 2000, vol. 9, 497-513 [0205]
- **HIROTA H. et al.** *Proc. Nat'l. Acad. Sci.*, 1995, vol. 92, 4862-4866 [0206]
- *The Cytokine Handbook.* 208-209 [0206]
- **KAPLITT et al.** *Molec. Cell. Neurosci.*, 1991, vol. 2, 320-30 [0213]

- **STRATFORD-PERRICAUDET et al.** *J. Clin. Invest.*, 1992, vol. 90, 626-30 [0213]
- **SAMULSKI et al.** *J. Virol.*, 1987, vol. 61, 3096-101 [0213]
- **SAMULSKI et al.** *J. Virol.*, 1989, vol. 63, 3822-8 [0213]
- **MANN et al.** *Cell*, 1983, vol. 33, 153 [0214]
- **MARKOWITZ et al.** *J. Virol.*, 1988, vol. 62, 1120 [0214]
- **KUO et al.** *Blood*, 1993, vol. 82, 845 [0214]
- **FELGNER et al.** *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, 7413-7 [0214]
- **MACKEY et al.** *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 8027-31 [0214]
- **WU et al.** *J. Biol. Chem.*, 1992, vol. 267, 963-7 [0215]
- **WU et al.** *J. Biol. Chem.*, 1988, vol. 263, 14621-4 [0215]
- **SNOUWAERT et al.** *Science*, 1992, vol. 257, 1083 [0217]
- **LOWELL et al.** *Nature*, 1993, vol. 366, 740-42 [0217]
- **CAPECCHI, M.R.** *Science*, 1989, vol. 244, 1288-1292 [0217]
- **PALMITER, R.D. et al.** *Annu Rev Genet.*, 1986, vol. 20, 465-499 [0217]
- Oral Delivery of Microencapsulated Proteins. **DIBASE ; MORREL.** Protein Delivery: Physical Systems. Plenum Press, 1997, 255-288 [0225]
- **HINCHCLIFFE ; ILLUM.** *Adv. Drug Deliv. Rev.*, 1999, vol. 35, 199 [0225]
- **PETTIT ; GOMBOTZ. TIBTECH, 1998, vol. 16, 343 [0225]**
- **PATTON et al.** *Adv. Drug Deliv. Rev.*, 1999, vol. 35, 235 [0225]
- **MITRAGOTRI et al.** *Science*, 1995, vol. 269, 850 [0225]
- **POTTS et al.** *Pharm. Biotechnol.*, 1997, vol. 10, 213 [0225]
- Remington's Pharmaceutical Sciences. Mack Publishing Company, 1995 [0226] [0238]
- **BREMER et al.** *Pharm. Biotechnol.*, 1997, vol. 10, 239 [0228]
- Implants in Drug Delivery. **RANADE.** Drug Delivery Systems. CRC Press, 1995, 95-123 [0228]
- Protein Delivery with Infusion Pumps. **BREMER et al.** Protein Delivery: Physical Systems. Plenum Press, 1997, 239-254 [0228]
- Delivery of Proteins from a Controlled Release Injectable Implant. **YEWEY et al.** Protein Delivery: Physical Systems. Plenum Press, 1997, 93-117 [0228]
- **BAKKER-WOUDENBERG et al.** *Eur. J. Clin. Microbiol. Infect. Dis.*, 1993, vol. 12 (1), S61 [0229]
- **KIM.** *Drugs*, 1993, vol. 46, 618 [0229]
- Site-Specific Drug Delivery Using Liposomes as Carriers. **RANADE.** Drug Delivery Systems. CRC Press, 1995, 3-24 [0229]
- **MACHY et al.** Liposomes In Cell Biology And Pharmacology. John Libbey, 1987 [0229]
- **OSTRO et al.** *American J. Hosp. Pharm.*, 1989, vol. 46, 1576 [0229]
- **SCHERPHOF et al.** *Ann. N.Y. Acad. Sci.*, 1985, vol. 446, 368 [0230]
- **CLAASSEN et al.** *Biochim. Biophys. Acta*, 1984, vol. 802, 428 [0231]
- **ALLEN et al.** *Biochim. Biophys. Acta*, 1991, vol. 1068, 133 [0231]
- **ALLEN et al.** *Biochim. Biophys. Acta*, 1993, vol. 1150, 9 [0231] [0235]
- **KATO et al.** *Biol. Pharm. Bull.*, 1993, vol. 16, 960 [0232]
- **SHIMIZU et al.** *Biol. Pharm. Bull.*, 1997, vol. 20, 881 [0232]
- **KATO ; SUGIYAMA.** *Crit. Rev. Ther. Drug Carrier Syst.*, 1997, vol. 14, 287 [0233]
- **MURAHASHI et al.** *Biol. Pharm. Bull.*, 1997, vol. 20, 259 [0233] [0233]
- **WU et al.** *Hepatology*, 1998, vol. 27, 772 [0233]
- **KAMPS et al.** *Proc. Nat'l Acad. Sci. USA*, 1997, vol. 94, 11681 [0233]
- **HARASYM et al.** *Adv. Drug Deliv. Rev.*, 1998, vol. 32, 99 [0234] [0234]
- **ANDERSON et al.** *Infect. Immun.*, 1981, vol. 31, 1099 [0235]
- **ANDERSON et al.** *Cancer Res.*, 1990, vol. 50, 1853 [0235]
- **COHEN et al.** *Biochim. Biophys. Acta*, 1991, vol. 1063, 95 [0235]
- Preparation and Use of Liposomes in Immunological Studies. **ALVING et al.** Liposome Technology. CRC Press, 1993, vol. III, 317 [0235]
- **WASSEF et al.** *Meth. Enzymol.*, 1987, vol. 149, 124 [0235]
- **GOMBOTZ ; PETTIT.** *Bioconjugate Chem.*, 1995, vol. 6, 332 [0236]
- Role of Polymers in Drug Delivery. **RANADE.** Drug Delivery Systems. CRC Press, 1995, 51-93 [0236]
- Degradable Controlled Release Systems Useful for Protein Delivery. **ROSKOS ; MASKIEWICZ.** Protein Delivery: Physical Systems. Plenum Press, 1997, 45-92 [0236]
- **BARTUS et al.** *Science*, 1998, vol. 281, 1161 [0236]
- **PUTNEY ; BURKE.** *Nature Biotechnology*, 1998, vol. 16, 153 [0236]
- **PUTNEY.** *Curr. Opin. Chem. Biol.*, 1998, vol. 2, 548 [0236]
- **GRAF et al.** *Pharm. Biotechnol.*, 1997, vol. 10, 167 [0236]
- **ANSEL ; POPOVICH.** Pharmaceutical Dosage Forms and Drug Delivery Systems. Lea & Febiger, 1990 [0238]
- **RANADE ; HOLLINGER.** Drug Delivery Systems. CRC Press, 1996 [0238]

EP 1 476 541 B1

- **G. URLAUB ; J. MITCHELL ; E. KAS ; L.A. CHASIN ; V.L. FUNANAGE ; T.T. MYODA ; J.L. HAMLIN.** The Effect Of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions. *Somatic Cell and Molec. Genet.*, 1986, vol. 12, 555-566 [0323]
- **SADOWSKI, H. et al.** *Science*, 1993, vol. 261, 1739-1744 [0369]
- **CHIN, Y. et al.** *Science*, 1996, vol. 272, 719-722 [0369]
- **SCHMITT-NEY, M. et al.** *Mol. Cell. Biol.*, 1991, vol. 11, 3745-3755 [0369]
- **SEIDEL, H. et al.** *Proc. Natl. Acad. Sci.*, 1995, vol. 92, 3041-3045 [0369]
- **POULSEN, L.K. et al.** *J. Biol. Chem.*, 1998, vol. 273, 6229-6232 [0369]
- **HOGAN, B. et al.** Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory Press, 1994 [0381]
- **IRITANI, B.M. et al.** *EMBO J.*, 1997, vol. 16, 7019-31 [0383]
- **IRITANI, B.M. et al.** *EMBO J*, 1997, vol. 16, 7019-31 [0389]
- **HIETER P. ; SIKORSKI, R.** *Genetics*, 1989, vol. 122, 19-27 [0398]
- **CASADABAN. J. Mol. Biol.**, vol. 138, 179-207 [0400] [0547]
- **PRYOR ; LEITING.** *Protein Expression and Purification*, 1997, vol. 10, 309-319 [0400] [0547]
- **HEID, C.A. et al.** *Genome Research*, 1996, vol. 6, 986-994 [0413]
- **GIBSON, U.E.M. et al.** *Genome Research*, 1996, vol. 6, 995-1001 [0413]
- **SUNDARESAN, S. et al.** *Endocrinology*, 1998, vol. 139, 4756-4764 [0413]
- **MOSLEY B.** *JBC*, 20 December 1996, vol. 271 (50), 32635-32643 [0448]
- **FARRELL, RE.** RNA Methodologies. Academic Press [0468]
- **BLOBEL et al.** *Virchows Arch B Cell Pathol Incl Mol Pathol.*, 1984, vol. 45 (4), 407-29 [0519]
- **LIN et al.** *J Pharm Pharmacol.*, September 2002, vol. 54 (9), 1271-8 [0519]
- **MARTINEZ et al.** *Toxicol Sci.*, October 2002, vol. 69 (2), 409-23 [0519]
- **WILLS-KARP et al.** *Science*, 1998, vol. 282, 2258-2261 [0520]
- **GRUNIG et al.** *Science*, 1998, vol. 282, 2261-2263 [0520]
- **KIMM et al.** *Acta Otolaryngol.*, September 2002, vol. 122 (6), 638-643 [0520]
- **SEONG et al.** *Acta Otolaryngol.*, June 2002, vol. 122 (4), 401-407 [0520] [0520]
- **DAINES ; HERSHEY.** *J Biol Chem.*, 2002, vol. 22 (12), 10387-10393 [0521] [0521] [0521]

专利名称(译)	细胞因子 (zcytor17配体)		
公开(公告)号	EP1476541B1	公开(公告)日	2008-07-16
申请号	EP2003729693	申请日	2003-01-21
[标]申请(专利权)人(译)	津莫吉尼蒂克斯公司		
申请(专利权)人(译)	ZymoGenetics公司 , INC.		
当前申请(专利权)人(译)	ZymoGenetics公司 , INC.		
[标]发明人	SPRECHER CINDY A KUIJPER JOSEPH L DASOVICH MARIA M GRANT FRANCIS J HAMMOND ANGELA K NOVAK JULIA E GROSS JANE A DILLON STACEY R		
发明人	SPRECHER, CINDY A. KUIJPER, JOSEPH, L. DASOVICH, MARIA M. GRANT, FRANCIS, J. HAMMOND, ANGELA K. NOVAK, JULIA, E. GROSS, JANE A. DILLON, STACEY, R.		
IPC分类号	C12N5/10 C12N15/19 C12N15/62 C12N15/63 C07K14/52 C07K16/24 G01N33/53 G01N33/567 A61K38/19 A61K39/395 C07K14/54 C07K14/00 A61K A61K38/00 A61P1/02 A61P1/04 A61P7/00 A61P11/06 A61P15/08 A61P17/06 A61P19/02 A61P29/00 A61P31/04 A61P35/00 A61P37/02 A61P37 /08 A61P43/00 C07K C07K14/47 C07K16/18 C07K19/00 C12N C12N5/078 C12N15/09 C12N15/12 C12P21/00 C12P21/02 C12P21/08 C12Q1/68 G01N G01N33/566		
CPC分类号	A01K2217/05 A61K38/00 A61P1/02 A61P1/04 A61P11/00 A61P11/06 A61P15/08 A61P17/06 A61P19 /02 A61P29/00 C07K14/47 C07K14/52 C07K16/24 C07K2317/24		
优先权	60/350325 2002-01-18 US 60/375323 2002-04-25 US 60/435315 2002-12-19 US		
其他公开文献	EP1476541A4 EP1476541A2		
外部链接	Espacenet		

摘要(译)

提供了多肽在制备用于上调哺乳动物中IL-13RA2基因表达的药物中的用途, 其中所述多肽包含与氨基酸序列至少90%相同的氨基酸残基序列。多肽残基选自: (a) 包含SEQ ID NO : 2所示残基38 (Val) 至152 (Leu) 的氨基酸序列的多肽; (b) 多肽, 其包含SEQ ID NO : 2所示的残基27 (Leu) 至164 (Thr) 的氨基酸序列; (c) 包含SEQ ID NO : 2所示残基24 (Ser) 至164 (Thr) 的氨基酸序列的多肽; (d) 包含SEQ ID NO : 2所示的残基1 (Met) 至164 (Thr) 的氨基酸序列的多肽。

Total number of identical matches

_____ x 100

[length of the longer sequence plus the

number of gaps introduced into the longer